INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48001, 936, 'Donepezil', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979):  283|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48002, 937, 'Donepezil', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979):  283|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48003, 938, 'Donepezil', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979):  283|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48004, 1231, 'Donepezil', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979):  283|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48005, 1331, 'Donepezil', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979):  283|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48006, 3827, 'Donepezil', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979):  283|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48007, 3828, 'Donepezil', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979):  283|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48008, 3830, 'Donepezil', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979):  283|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48009, 13871, 'Donepezil', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979):  283|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48010, 13874, 'Donepezil', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979):  283|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48011, 13876, 'Donepezil', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979):  283|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48012, 13877, 'Donepezil', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979):  283|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48013, 17817, 'Donepezil', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979):  283|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48014, 17820, 'Donepezil', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979):  283|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48015, 17822, 'Donepezil', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979):  283|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48016, 21799, 'Donepezil', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979):  283|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48017, 23708, 'Donepezil', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979):  283|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48018, 30977, 'Donepezil', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979):  283|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48019, 30978, 'Donepezil', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979):  283|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48020, 472, 'Donepezil', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48021, 935, 'Donepezil', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48022, 936, 'Donepezil', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48023, 937, 'Donepezil', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48024, 938, 'Donepezil', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48025, 1231, 'Donepezil', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48026, 1331, 'Donepezil', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48027, 3827, 'Donepezil', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48028, 3828, 'Donepezil', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48029, 3830, 'Donepezil', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48030, 13871, 'Donepezil', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48031, 13874, 'Donepezil', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48032, 13876, 'Donepezil', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48033, 13877, 'Donepezil', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48034, 17817, 'Donepezil', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48035, 17820, 'Donepezil', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48036, 17822, 'Donepezil', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48037, 21799, 'Donepezil', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48038, 23708, 'Donepezil', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48039, 30977, 'Donepezil', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48040, 30978, 'Donepezil', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48041, 472, 'Donepezil', 'Liver Diseases', 'Donepezil is extensively metabolized by the liver (CYP450-2D6/3A4) to two active and various minor forms.  The clearance of donepezil was decreased 20% in patients with stable alcoholic cirrhosis compared to healthy patients.  Care should be exercised when using donepezil in patients with liver disease.', '2', '"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|Rogers SL, Friedhoff LT "The efficacy and safety of donepezil in patients with Alzheimer''s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial." Dementia 7 (1996):  293-303', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48042, 935, 'Donepezil', 'Liver Diseases', 'Donepezil is extensively metabolized by the liver (CYP450-2D6/3A4) to two active and various minor forms.  The clearance of donepezil was decreased 20% in patients with stable alcoholic cirrhosis compared to healthy patients.  Care should be exercised when using donepezil in patients with liver disease.', '2', '"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|Rogers SL, Friedhoff LT "The efficacy and safety of donepezil in patients with Alzheimer''s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial." Dementia 7 (1996):  293-303', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48043, 936, 'Donepezil', 'Liver Diseases', 'Donepezil is extensively metabolized by the liver (CYP450-2D6/3A4) to two active and various minor forms.  The clearance of donepezil was decreased 20% in patients with stable alcoholic cirrhosis compared to healthy patients.  Care should be exercised when using donepezil in patients with liver disease.', '2', '"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|Rogers SL, Friedhoff LT "The efficacy and safety of donepezil in patients with Alzheimer''s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial." Dementia 7 (1996):  293-303', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48044, 937, 'Donepezil', 'Liver Diseases', 'Donepezil is extensively metabolized by the liver (CYP450-2D6/3A4) to two active and various minor forms.  The clearance of donepezil was decreased 20% in patients with stable alcoholic cirrhosis compared to healthy patients.  Care should be exercised when using donepezil in patients with liver disease.', '2', '"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|Rogers SL, Friedhoff LT "The efficacy and safety of donepezil in patients with Alzheimer''s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial." Dementia 7 (1996):  293-303', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48045, 938, 'Donepezil', 'Liver Diseases', 'Donepezil is extensively metabolized by the liver (CYP450-2D6/3A4) to two active and various minor forms.  The clearance of donepezil was decreased 20% in patients with stable alcoholic cirrhosis compared to healthy patients.  Care should be exercised when using donepezil in patients with liver disease.', '2', '"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|Rogers SL, Friedhoff LT "The efficacy and safety of donepezil in patients with Alzheimer''s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial." Dementia 7 (1996):  293-303', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48046, 1231, 'Donepezil', 'Liver Diseases', 'Donepezil is extensively metabolized by the liver (CYP450-2D6/3A4) to two active and various minor forms.  The clearance of donepezil was decreased 20% in patients with stable alcoholic cirrhosis compared to healthy patients.  Care should be exercised when using donepezil in patients with liver disease.', '2', '"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|Rogers SL, Friedhoff LT "The efficacy and safety of donepezil in patients with Alzheimer''s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial." Dementia 7 (1996):  293-303', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48047, 1331, 'Donepezil', 'Liver Diseases', 'Donepezil is extensively metabolized by the liver (CYP450-2D6/3A4) to two active and various minor forms.  The clearance of donepezil was decreased 20% in patients with stable alcoholic cirrhosis compared to healthy patients.  Care should be exercised when using donepezil in patients with liver disease.', '2', '"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|Rogers SL, Friedhoff LT "The efficacy and safety of donepezil in patients with Alzheimer''s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial." Dementia 7 (1996):  293-303', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48048, 3827, 'Donepezil', 'Liver Diseases', 'Donepezil is extensively metabolized by the liver (CYP450-2D6/3A4) to two active and various minor forms.  The clearance of donepezil was decreased 20% in patients with stable alcoholic cirrhosis compared to healthy patients.  Care should be exercised when using donepezil in patients with liver disease.', '2', '"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|Rogers SL, Friedhoff LT "The efficacy and safety of donepezil in patients with Alzheimer''s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial." Dementia 7 (1996):  293-303', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48049, 3828, 'Donepezil', 'Liver Diseases', 'Donepezil is extensively metabolized by the liver (CYP450-2D6/3A4) to two active and various minor forms.  The clearance of donepezil was decreased 20% in patients with stable alcoholic cirrhosis compared to healthy patients.  Care should be exercised when using donepezil in patients with liver disease.', '2', '"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|Rogers SL, Friedhoff LT "The efficacy and safety of donepezil in patients with Alzheimer''s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial." Dementia 7 (1996):  293-303', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48050, 3830, 'Donepezil', 'Liver Diseases', 'Donepezil is extensively metabolized by the liver (CYP450-2D6/3A4) to two active and various minor forms.  The clearance of donepezil was decreased 20% in patients with stable alcoholic cirrhosis compared to healthy patients.  Care should be exercised when using donepezil in patients with liver disease.', '2', '"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|Rogers SL, Friedhoff LT "The efficacy and safety of donepezil in patients with Alzheimer''s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial." Dementia 7 (1996):  293-303', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48051, 13871, 'Donepezil', 'Liver Diseases', 'Donepezil is extensively metabolized by the liver (CYP450-2D6/3A4) to two active and various minor forms.  The clearance of donepezil was decreased 20% in patients with stable alcoholic cirrhosis compared to healthy patients.  Care should be exercised when using donepezil in patients with liver disease.', '2', '"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|Rogers SL, Friedhoff LT "The efficacy and safety of donepezil in patients with Alzheimer''s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial." Dementia 7 (1996):  293-303', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48052, 13874, 'Donepezil', 'Liver Diseases', 'Donepezil is extensively metabolized by the liver (CYP450-2D6/3A4) to two active and various minor forms.  The clearance of donepezil was decreased 20% in patients with stable alcoholic cirrhosis compared to healthy patients.  Care should be exercised when using donepezil in patients with liver disease.', '2', '"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|Rogers SL, Friedhoff LT "The efficacy and safety of donepezil in patients with Alzheimer''s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial." Dementia 7 (1996):  293-303', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48053, 13876, 'Donepezil', 'Liver Diseases', 'Donepezil is extensively metabolized by the liver (CYP450-2D6/3A4) to two active and various minor forms.  The clearance of donepezil was decreased 20% in patients with stable alcoholic cirrhosis compared to healthy patients.  Care should be exercised when using donepezil in patients with liver disease.', '2', '"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|Rogers SL, Friedhoff LT "The efficacy and safety of donepezil in patients with Alzheimer''s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial." Dementia 7 (1996):  293-303', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48054, 13877, 'Donepezil', 'Liver Diseases', 'Donepezil is extensively metabolized by the liver (CYP450-2D6/3A4) to two active and various minor forms.  The clearance of donepezil was decreased 20% in patients with stable alcoholic cirrhosis compared to healthy patients.  Care should be exercised when using donepezil in patients with liver disease.', '2', '"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|Rogers SL, Friedhoff LT "The efficacy and safety of donepezil in patients with Alzheimer''s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial." Dementia 7 (1996):  293-303', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48055, 17817, 'Donepezil', 'Liver Diseases', 'Donepezil is extensively metabolized by the liver (CYP450-2D6/3A4) to two active and various minor forms.  The clearance of donepezil was decreased 20% in patients with stable alcoholic cirrhosis compared to healthy patients.  Care should be exercised when using donepezil in patients with liver disease.', '2', '"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|Rogers SL, Friedhoff LT "The efficacy and safety of donepezil in patients with Alzheimer''s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial." Dementia 7 (1996):  293-303', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48056, 17820, 'Donepezil', 'Liver Diseases', 'Donepezil is extensively metabolized by the liver (CYP450-2D6/3A4) to two active and various minor forms.  The clearance of donepezil was decreased 20% in patients with stable alcoholic cirrhosis compared to healthy patients.  Care should be exercised when using donepezil in patients with liver disease.', '2', '"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|Rogers SL, Friedhoff LT "The efficacy and safety of donepezil in patients with Alzheimer''s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial." Dementia 7 (1996):  293-303', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48057, 17822, 'Donepezil', 'Liver Diseases', 'Donepezil is extensively metabolized by the liver (CYP450-2D6/3A4) to two active and various minor forms.  The clearance of donepezil was decreased 20% in patients with stable alcoholic cirrhosis compared to healthy patients.  Care should be exercised when using donepezil in patients with liver disease.', '2', '"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|Rogers SL, Friedhoff LT "The efficacy and safety of donepezil in patients with Alzheimer''s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial." Dementia 7 (1996):  293-303', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48058, 21799, 'Donepezil', 'Liver Diseases', 'Donepezil is extensively metabolized by the liver (CYP450-2D6/3A4) to two active and various minor forms.  The clearance of donepezil was decreased 20% in patients with stable alcoholic cirrhosis compared to healthy patients.  Care should be exercised when using donepezil in patients with liver disease.', '2', '"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|Rogers SL, Friedhoff LT "The efficacy and safety of donepezil in patients with Alzheimer''s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial." Dementia 7 (1996):  293-303', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48059, 23708, 'Donepezil', 'Liver Diseases', 'Donepezil is extensively metabolized by the liver (CYP450-2D6/3A4) to two active and various minor forms.  The clearance of donepezil was decreased 20% in patients with stable alcoholic cirrhosis compared to healthy patients.  Care should be exercised when using donepezil in patients with liver disease.', '2', '"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|Rogers SL, Friedhoff LT "The efficacy and safety of donepezil in patients with Alzheimer''s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial." Dementia 7 (1996):  293-303', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48060, 30977, 'Donepezil', 'Liver Diseases', 'Donepezil is extensively metabolized by the liver (CYP450-2D6/3A4) to two active and various minor forms.  The clearance of donepezil was decreased 20% in patients with stable alcoholic cirrhosis compared to healthy patients.  Care should be exercised when using donepezil in patients with liver disease.', '2', '"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|Rogers SL, Friedhoff LT "The efficacy and safety of donepezil in patients with Alzheimer''s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial." Dementia 7 (1996):  293-303', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48061, 30978, 'Donepezil', 'Liver Diseases', 'Donepezil is extensively metabolized by the liver (CYP450-2D6/3A4) to two active and various minor forms.  The clearance of donepezil was decreased 20% in patients with stable alcoholic cirrhosis compared to healthy patients.  Care should be exercised when using donepezil in patients with liver disease.', '2', '"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|Rogers SL, Friedhoff LT "The efficacy and safety of donepezil in patients with Alzheimer''s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial." Dementia 7 (1996):  293-303', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48062, 0, 'Doxepin', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48063, 0, 'Doxepin', 'Anticholinergic Syndrome', 'The use of doxepin is contraindicated in patients with glaucoma, or a tendency to urinary retention.  These disorders should be ruled out before starting treatment, especially in elderly patients.', '3', '"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48064, 0, 'Doxepin', 'Cardiovascular Diseases', 'Tricyclic and tetracyclic antidepressants (TCAs) may cause orthostatic hypotension, reflex tachycardia, syncope, and dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Imipramine appears to have the greatest propensity to induce these effects, while secondary amines such as nortriptyline may do so less frequently.  Tolerance to the hypotensive effects often develops after a few doses to a few weeks.  Rarely, collapse and sudden death have occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include tachycardia, arrhythmias, heart block, hypertension, thrombosis, thrombophlebitis, myocardial infarction, strokes, congestive heart failure, and ECG abnormalities such as PR and QT interval prolongation.  Therapy with TCAs should be avoided during the acute recovery phase following myocardial infarction, and should be administered only with extreme caution in patients with hyperthyroidism, a history of cardiovascular or cerebrovascular disease, or a predisposition to hypotension.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  Many of the newer antidepressants, including bupropion and the selective serotonin reuptake inhibitors (SSRIs), are considerably less or minimally cardiotoxic and may be appropriate alternatives.', '3', 'Robinson DS, Nies A, Corcella J, Cooper TB, Spencer C, Kefover R "Cardiovascular effects of phenelzine and amitriptyline in depressed outpatients." J Clin Psychiatry 43 (1982):  8-15|Veith RC, Bloom V, Bielski R, Friedel RO "ECG effects of comparable plasma concentrations of desipramine and amitriptyline." J Clin Psychopharmacol 2 (1982):  394-8|Dunn FG "Malignant hypertension associated with use of amitriptyline hydrochloride." South Med J 75 (1982):  1124-5|Christensen P, Thomsen HY, Pedersen OL, et al. "Cardiovascular effects of amitriptyline in the treatment of elderly depressed patients." Psychopharmacology (Berl) 87 (1985):  212-5|Pedersen JH, Sorensen JL "Therapeutic effect and side effects in patients with endogenous depression treated with oral nortriptyline once a day." Neuropsychobiology 6 (1980):  42-7|Roose SP, Glassman AH, Siris SG, Walsh BT, Bruno RL, Wright LB "Comparison of imipramine- and nortriptyline-induced orthostatic hypotension: a meaningful difference." J Clin Psychopharmacol 1 (1981):  316-9|Young RC, Alexopoulos GS, Shamoian CA, Dhar AK, Kutt H "Heart failure associated with high plasma 10-hydroxynortriptyline levels." Am J Psychiatry 141 (1984):  432-3|Georgotas A, McCue RE, Hapworth W, et al. "Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly." Biol Psychiatry 21 (1986):  1155-66|Gross JS, Zwerin G "Left bundle branch block developing in a patient with sub-therapeutic nortriptyline levels: a case report." J Am Geriatr Soc 39 (1991):  1006-7|Rudorfer MV, Young RC "Desipramine: cardiovascular effects and plasma levels." Am J Psychiatry 137 (1980):  984-6|Nelson JC, Jatlow PI, Bock J, Quinlan DM, Bowes MB "Major adverse reactions during desipramine treatment." Arch Gen Psychiatry 39 (1982):  1055-61|Carpenter P, Gobel FL, Hulsing DJ "Desipramine cardiac toxicity." Minn Med 65 (1982):  231-4|Luchins DJ "Review of clinical and animal studies comparing the cardiovascular effects of doxepin and other tricyclic antidepressants." Am J Psychiatry 140 (1983):  1006-9|Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EG "Is doxepin a safer tricyclic for the heart?" J Clin Psychiatry 52 (1991):  338-41|Burrows GD, Vohra J, Hunt D, Sloman JG, Scoggins BA, Davies B "Cardiac effects of different tricyclic antidepressant drugs." Br J Psychiatry 129 (1976):  335-41|Linnoila M, Jobson KO, Gilliam JH, Paine RL "Effects of doxepin on blood pressure and heart rate in patients with primary major affective disorder ." J Clin Psychopharmacol 2 (1982):  433-4|Strasberg B, Coelho A, Welch W, Swiryn S, Bauernfeind R, Rosen K "Doxepin induced torsade de pointes." Pacing Clin Electrophysiol 5 (1982):  873-7|Appelbaum PS, Kapoor W "Imipramine-induced vasospasm: a case report." Am J Psychiatry 140 (1983):  913-5|Kantor SJ, Glassman AH, Bigger JT, Jr  Perel JM, Giardina EV "The cardiac effects of therapeutic plasma concentrations of imipramine." Am J Psychiatry 135 (1978):  534-8|Ramanathan KB, Davidson C "Cardiac arrhythmia and imipramine therapy." Br Med J 1 (1975):  661-2|"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993):  89-95|Laird LK, Lydiard RB, Morton WA, Steele TE, Kellner C, Thompson NM, Ballenger JC "Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients." J Clin Psychiatry 54 (1993):  224-8|Feighner JP, Cohn JB, Fabre LF, Jr  Fieve RR, Mendels J, Shrivastava RK, Dunbar GC "A study comparing paroxetine placebo and imipramine in depressed patients." J Affect Disord 28 (1993):  71-9|Van Sweden B "Rebound antidepressant cardiac arrhythmia." Biol Psychiatry 24 (1988):  363-4|Faravelli C, Brat A, Marchetti G, Franchi F, Padeletti L, Michelucci A, Pastorino A "Cardiac effects of clomipramine treatment. ECG and left ventricular systolic time intervals." Neuropsychobiology 9 (1983):  113-8|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|Roos JC "Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine." Br J Clin Pharmacol 15 Suppl 3 (1983):  s439-45|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|Upward JW, Edwards JG, Goldie A, Waller DG "Comparative effects of fluoxetine and amitriptyline on cardiac function." Br J Clin Pharmacol 26 (1988):  399-402', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48065, 0, 'Doxepin', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48066, 0, 'Doxepin', 'Acute Myocardial Infarction Recovery', 'The use of most tricyclic antidepressants is contraindicated in patients that are going through the acute recovery period after a myocardial infarction.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48067, 0, 'Doxepin', 'Epilepsy', 'Tricyclic antidepressants (TCAs), can lower the seizure threshold and trigger seizures.  These drugs should be used with extreme caution in patients with a history of seizures, or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.  Daily dose restrictions might apply for specific antidepressants.  Physicians are encouraged to get additional dosing recommendations on the manufacturer''s prescribing information.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48068, 0, 'Doxepin', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48069, 0, 'Doxepin', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Intermezzo (zolpidem)." Purdue Pharma LP  (2011):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48070, 0, 'Doxepin', 'Bipolar Disorder', 'A major depressive episode can be the initial presentation of bipolar disorder.  Patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder prior to initiating treatment with doxepin.  This screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.  It should be noted that doxepin is not approved for use in treating bipolar depression.', '2', '"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48071, 0, 'Doxepin', 'Bone Marrow Failure Disorders', 'The use of tricyclic and tetracyclic antidepressants (TCAs) has rarely been associated with bone marrow suppression.  Leukopenia, agranulocytosis, thrombocytopenia, anemia, eosinophilia, purpura, and pancytopenia have been reported with some TCAs.  Patients with preexisting bone marrow suppression or blood dyscrasias receiving TCAs should be monitored closely during therapy for further decreases in blood counts.', '2', 'Draper BM, Manoharan A "Neutropenia with cross-intolerance between two tricyclic antidepressant agents." Med J Aust 146 (1987):  452-3|Wolf B, Conradty M, Grohmann R, Ruther E, Witzgall H, Londong V "A case of immune complex hemolytic anemia, thrombocytopenia, and acute renal failure associated with doxepin use." J Clin Psychiatry 50 (1989):  99-100|Albertini RS, Penders TM "Agranulocytosis associated with tricyclics." J Clin Psychiatry 39 (1978):  483-5|"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|Hunt KA, Resnick MP "Clomipramine-induced agranulocytosis and its treatment with G-CSF." Am J Psychiatry 150 (1993):  522-3|Magni G, Urbani A, Silvestro A, Grassetto M "Clomipramine-induced pancytopenia." J Nerv Ment Dis 175 (1987):  309-10|Souhami RL, Ashton CR, Lee-Potter JP "Agranulocytosis and systemic candidiasis following clomipramine therapy." Postgrad Med J 52 (1976):  472-4|Gravenor DS, Leclerc JR, Blake G "Tricyclic antidepressant agranulocytosis." Can J Psychiatry 31 (1986):  661|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48072, 0, 'Doxepin', 'Diabetes Mellitus', 'Both elevation and lowering of blood sugar levels have been reported with the use of some tricyclic antidepressants (TCAs).  Rarely, these effects have also occurred with maprotiline, a tetracyclic antidepressant.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents, particularly during dosage escalation or whenever dosage has been altered.', '2', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|Zogno MG, Tolfo L, Draghi E "Hypoglycemia caused by maprotiline in a patient taking oral antidiabetics." Ann Pharmacother 28 (1994):  406|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48073, 0, 'Doxepin', 'Schizophrenia', 'Tricyclic antidepressants (TCAs) may aggravate symptoms of psychosis in schizophrenic patients, particularly those with paranoid symptomatology.  Depressed patients, usually those with bipolar disorder, may experience a switch from depression to mania or hypomania.  These occurrences have also been reported rarely with the tetracyclic antidepressant, maprotiline.  Therapy with these agents should be administered cautiously in patients with schizophrenia, bipolar disorder, or a history of mania.', '2', 'Hemmingsen R, Rafaelsen OJ "Hypnagogic and hypnopompic hallucinations during amitriptyline treatment." Acta Psychiatr Scand 62 (1980):  364-8|Preskorn SH, Simpson S "Tricyclic-antidepressant-induced delirium and plasma drug concentration." Am J Psychiatry 139 (1982):  822-3|Holmes VF, Fricchione GL "Hypomania in an AIDS patient receiving amitriptyline for neuropathic pain." Neurology 39 (1989):  305|Nelson JC, Jatlow PI, Bock J, Quinlan DM, Bowes MB "Major adverse reactions during desipramine treatment." Arch Gen Psychiatry 39 (1982):  1055-61|Norman TR, Judd F, Holwill BJ, Burrows GD "Doxepin and visual hallucinations." Aust N Z J Psychiatry 16 (1982):  295-6|Hardoby W "Imipramine and suicidal thoughts ." Am J Psychiatry 149 (1992):  412-3|Godwin CD "Case report of tricyclic-induced delirium at a therapeutic drug concentration." Am J Psychiatry 140 (1983):  1517-8|Rampling D "Aggression: a paradoxical response to tricyclic antidepressants." Am J Psychiatry 135 (1978):  117-8|Kupfer DJ, Carpenter LL, Frank E "Possible role of antidepressants in precipitating mania and hypomania in recurrent depression." Am J Psychiatry 145 (1988):  804-8|"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|van Kammen DP, van Scheyen JD, Murphy DL "Platelet monoamine oxidase activity and clomipramine-induced mania in unipolar depressed patients." Biol Psychiatry 15 (1980):  565-73|Vallada HP, Gentil V "Musical hallucinations triggered by clomipramine?" Br J Psychiatry 159 (1991):  888-9|Harper G "Suicidality with clomipramine." J Am Acad Child Adolesc Psychiatry 31 (1992):  369-70|Cruz R "Clomipramine side effects." J Am Acad Child Adolesc Psychiatry 31 (1992):  1168-9|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48074, 0, 'Doxepin', 'Tardive Dyskinesia', 'Tricyclic and tetracyclic antidepressants (TCAs) have anticholinergic activity, to which elderly patients are particularly sensitive.  Tertiary amines such as amitriptyline and trimipramine tend to exhibit greater anticholinergic effects than other agents in the class.  As with other drugs that possess anticholinergic activity, TCAs may aggravate tardive dyskinesia or induce previously suppressed symptoms.  Patients with tardive dyskinesia requiring therapy with TCAs should be monitored for exacerbation of the condition.', '2', 'Woogen S, Graham J, Angrist B "A tardive dyskinesia-like syndrome after amitriptyline treatment." J Clin Psychopharmacol 1 (1981):  34-6|Finder E, Lin K-M, Ananth J "Dystonic reaction to amitriptyline." Am J Psychiatry 139 (1982):  1220|Nelson JC, Jatlow PI, Bock J, Quinlan DM, Bowes MB "Major adverse reactions during desipramine treatment." Arch Gen Psychiatry 39 (1982):  1055-61|Lee HK "Dystonic reactions to amitriptyline and doxepin ." Am J Psychiatry 145 (1988):  649|Gersten SP "Tardive dyskinesia-like syndromes with clomipramine ." Am J Psychiatry 150 (1993):  165-6|Schatzberg AF, Cole JO, Blumer DP "Speech blockage: a tricyclic side effect." Am J Psychiatry 135 (1978):  600-1|Dekret JJ, Maany I, Ramsey TA, Mendels J "A case of oral dyskinesia associated with imipramine treatment." Am J Psychiatry 134 (1977):  1297-8|"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|Sandyk R "Persistent akathisia associated with early dyskinesia." Postgrad Med J 60 (1984):  916|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48075, 0, 'Doxepin', 'Alcoholic Intoxication', 'Tricyclic antidepressants can enhance the response to alcohol.  In patients who may use alcohol excessively, it should be borne in mind that the potentiation may increase the danger inherent in any suicide attempt or overdosage.', '2', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48076, 0, 'Doxepin', 'Neutropenia', 'The use of some tricyclic antidepressants has been associated with neutropenia (ANC < 500/mm3) and agranulocytosis (ANC < 500/mm3).  Leukocyte and differential blood counts should be performed in patients that develop fever and sore throat during treatment.  Therapy should be discontinued if there is evidence of pathologic neutrophil depression.', '2', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48077, 0, 'Doxepin', 'Thyroid Diseases', 'Most tricyclic antidepressants should be administered with caution in hyperthyroid patients or those receiving thyroid medication as they may develop arrhythmias when these drugs are given.', '2', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48078, 0, 'Doxepin', 'Urinary Retention', 'Due to their anticholinergic properties, tricyclic antidepressants should be administered with caution in patients with history of urinary retention.  Particularly doxepin hydrochloride capsules are contraindicated in patients with tendency to urinary retention.', '2', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48079, 0, 'Doxepin (topical)', 'Anticholinergic Syndrome', 'Doxepin possesses anticholinergic activity and is systemically absorbed when applied topically.  Therapy with doxepin should be administered cautiously in patients with conditions adversely affected by anticholinergic activity, such as urinary retention, angle-closure glaucoma or elevated intraocular pressure, gastrointestinal obstructive disorders, or dementia.', '2', '"Product Information. Zonalon (doxepin topical)." Bioglan Pharmaceutical Inc  (2001):|Jones MI, Skaufle ML "Systemic adverse effects from topical doxepin cream." Ann Pharmacother 35 (2001):  505-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48080, 0, 'Doxepin (topical)', 'Liver Failure', 'Doxepin topical is systemically absorbed and metabolized by the liver to an active form.  Parent drug and metabolites are eliminated by the kidney.  Renal and hepatic impairment alter the metabolism and elimination of doxepin and/or its metabolites.', '2', 'Faulkner RD, Senekjian HO, Lee CS "Hemodialysis of doxepin and desmethyldoxepin in uremic patients." Artif Organs 8 (1984):  151-5|Ziegler VE, Biggs JT, Wylie LT, Rosen SH, Hawf DJ, Coryell WH "Doxepin kinetics." Clin Pharmacol Ther 23 (1978):  573-9|"Product Information. Zonalon (doxepin topical)." Bioglan Pharmaceutical Inc  (2001):|Jones MI, Skaufle ML "Systemic adverse effects from topical doxepin cream." Ann Pharmacother 35 (2001):  505-6', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48081, 6921, 'Dorzolamide (ophthalmic)', 'Hematologic Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia,  leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Therapy with topical sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48082, 16355, 'Dorzolamide (ophthalmic)', 'Hematologic Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia,  leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Therapy with topical sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48083, 17844, 'Dorzolamide (ophthalmic)', 'Hematologic Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia,  leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Therapy with topical sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48084, 17845, 'Dorzolamide (ophthalmic)', 'Hematologic Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia,  leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Therapy with topical sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48085, 24431, 'Dorzolamide (ophthalmic)', 'Hematologic Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia,  leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Therapy with topical sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48086, 25533, 'Dorzolamide (ophthalmic)', 'Hematologic Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia,  leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Therapy with topical sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48087, 28590, 'Dorzolamide (ophthalmic)', 'Hematologic Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia,  leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Therapy with topical sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48088, 29767, 'Dorzolamide (ophthalmic)', 'Hematologic Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia,  leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia.  Therapy with topical sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.', '3', 'Barak S, Shaked Y, Bar A, Samra Y "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg 18 (1989):  206-7|Chan M, Beale D, Moorhead J "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract 34 (1980):  87-8|Damergis J, Stoker J, Abadie J "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA 249 (1983):  590-1|Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol 19 (1992):  621-2|Youssef PP, Bertouch JV "Sulphasalazine induced aplastic anaemia." Aust N Z J Med 22 (1992):  391-2|Keisu M, Ekman E "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol 43 (1992):  215-8|Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol 80 (1985):  118-21|Wheelan KR, Cooper B, Stone MJ "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med 97 (1982):  726-7|Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ "Thrombocytopenia and sulfasalazine." Ann Intern Med 102 (1985):  277-8|Davies GE, Palek J "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med 140 (1980):  1122|Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol 16 (1989):  1166-7|Mitrane MP, Singh A, Seibold JR "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol 13 (1986):  969-72|Mechanick JI "Coombs'' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med 52 (1985):  667-70|Betkowski AS, Lubin A "Sulfamethoxazole-related antiplatelet antibody." Blood 82 (1993):  1683|Gales BJ, Gales MA "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother 27 (1993):  1052-4|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48089, 6921, 'Dorzolamide (ophthalmic)', 'Hypersensitivity, Immediate', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with topical sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48090, 16355, 'Dorzolamide (ophthalmic)', 'Hypersensitivity, Immediate', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with topical sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48091, 17844, 'Dorzolamide (ophthalmic)', 'Hypersensitivity, Immediate', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with topical sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48092, 17845, 'Dorzolamide (ophthalmic)', 'Hypersensitivity, Immediate', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with topical sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48093, 24431, 'Dorzolamide (ophthalmic)', 'Hypersensitivity, Immediate', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with topical sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48094, 25533, 'Dorzolamide (ophthalmic)', 'Hypersensitivity, Immediate', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with topical sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48095, 28590, 'Dorzolamide (ophthalmic)', 'Hypersensitivity, Immediate', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with topical sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48096, 29767, 'Dorzolamide (ophthalmic)', 'Hypersensitivity, Immediate', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides is associated with large increases in the risk of Stevens-Johnson syndrome, toxic epidermal necrolysis and other serious dermatologic reactions, although these phenomena are rare as a whole.  Hepatitis, pneumonitis, and interstitial nephritis have also occurred in association with sulfonamide hypersensitivity.  Therapy with topical sulfonamides should be administered cautiously in patients with severe allergies, bronchial asthma or AIDS, since these patients may be at increased risk for potentially severe hypersensitivity reactions.  Patients should be instructed to promptly report signs and symptoms that may precede the onset of cutaneous manifestations of the Stevens-Johnson syndrome, such as high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Sulfonamide therapy should be stopped at once if a rash develops.', '3', 'Johnson M, Goodwin D, Shands J "Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review." Pharmacotherapy 10 (1990):  413-16|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Whittington R "Toxic epidermal necrolysis and co-trimoxazole." Lancet 2 (1989):  574|Kelly W, Dooley D, Lattuada C, Smith C "A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus." Clin Infect Dis 14 (1992):  1034-9|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Gibson J "Recurrent trimethoprim-associated fixed skin eruption." Br Med J 284 (1982):  1529-30|Holdcroft C, Ellison R "Trimethoprim-sulfamethoxazole reaction simulating pneumocystis carinii pneumonia." AIDS 5 (1991):  1029-42|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Ulstad D, Ampel N, Shon B, Galgiani JN, Cutcher AB "Reaction after re-exposure to trimethoprim-sulfamethoxazole." Chest 95 (1989):  937-8|Heer M, Altorfer J, Burger H, Walti M "Bullous esophageal lesions due to co-trimoxazole: an immune-mediated process?" Gastroenterology 88 (1985):  1954-7|Pisanty S, Brayer L "Erythema multiforme-like eruption due to sulfadiazine." J Dent Med 20 (1965):  154-7|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Tenant-Flowers M, Boyle M, Carey D, et al. "Sulphadiazine desenitization in patients with AIDS and cerebral toxoplasmosis." AIDS 5 (1991):  311-5|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Yaffe BH, Korelitz BI "Sulfasalazine pneumonitis." Am J Gastroenterol 78 (1983):  493-4|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y "Sulfasalazine pneumonitis." Am J Gastroenterol 80 (1985):  343-5|Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S, Matsumoto K, Kitagawa T, Yamamoto J "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine." Am J Gastroenterol 87 (1992):  1654-7|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Hamadeh MA, Atkinson J, Smith LJ "Sulfasalazine-induced pulmonary disease." Chest 101 (1992):  1033-7|Williams T, Eidus L, Thomas P "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy." Chest 81 (1982):  766-8|Valcke Y, Pauwels R, Van der Straeten M "Bronchoalveolar lavage in acute hypersensitivity pneumonitis caused by sulfasalazine." Chest 92 (1987):  572-3|Taffet SL, Das KM "Sulfasalazine. Adverse effects and desensitization." Dig Dis Sci 28 (1983):  833-42|Pearl RK, Nelson RL, Prasad ML, Orsay CP, Abcarian H "Serious complications of sulfasalazine." Dis Colon Rectum 29 (1986):  201-2|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Wang KK, Bowyer BA, Fleming CR, Schroeder KW "Pulmonary infiltrates and eosinophilia associated with sulfasalazine." Mayo Clin Proc 59 (1984):  343-6|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Faintuch J, Mott CB, Machado MC "Pancreatitis and pancreatic necrosis during sulfasalazine therapy." Int Surg 70 (1985):  271-2|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Marinac JS, Stanford JF "A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus." Clin Infect Dis 16 (1993):  178-9|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Roujeau JC, Kelly JP, Naldi L, et al. "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis." N Engl J Med 333 (1995):  1600-7|Kawada A, Kobayashi T, Noguchi H, Hiruma M, Ishibashi A, Marshall J "Fixed drug eruption induced by sulfasalazine." Contact Dermatitis 34 (1996):  155-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48097, 6921, 'Dorzolamide (ophthalmic)', 'Porphyrias', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Therapy with topical sulfonamides should be administered cautiously in patients with porphyria, since these drugs can precipitate an acute attack.  The use of oral sulfonamides is considered contraindicated in patients with porphyria.', '3', '"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48098, 16355, 'Dorzolamide (ophthalmic)', 'Porphyrias', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Therapy with topical sulfonamides should be administered cautiously in patients with porphyria, since these drugs can precipitate an acute attack.  The use of oral sulfonamides is considered contraindicated in patients with porphyria.', '3', '"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48099, 17844, 'Dorzolamide (ophthalmic)', 'Porphyrias', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Therapy with topical sulfonamides should be administered cautiously in patients with porphyria, since these drugs can precipitate an acute attack.  The use of oral sulfonamides is considered contraindicated in patients with porphyria.', '3', '"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48100, 17845, 'Dorzolamide (ophthalmic)', 'Porphyrias', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Therapy with topical sulfonamides should be administered cautiously in patients with porphyria, since these drugs can precipitate an acute attack.  The use of oral sulfonamides is considered contraindicated in patients with porphyria.', '3', '"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48101, 24431, 'Dorzolamide (ophthalmic)', 'Porphyrias', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Therapy with topical sulfonamides should be administered cautiously in patients with porphyria, since these drugs can precipitate an acute attack.  The use of oral sulfonamides is considered contraindicated in patients with porphyria.', '3', '"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48102, 25533, 'Dorzolamide (ophthalmic)', 'Porphyrias', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Therapy with topical sulfonamides should be administered cautiously in patients with porphyria, since these drugs can precipitate an acute attack.  The use of oral sulfonamides is considered contraindicated in patients with porphyria.', '3', '"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48103, 28590, 'Dorzolamide (ophthalmic)', 'Porphyrias', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Therapy with topical sulfonamides should be administered cautiously in patients with porphyria, since these drugs can precipitate an acute attack.  The use of oral sulfonamides is considered contraindicated in patients with porphyria.', '3', '"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48104, 29767, 'Dorzolamide (ophthalmic)', 'Porphyrias', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Therapy with topical sulfonamides should be administered cautiously in patients with porphyria, since these drugs can precipitate an acute attack.  The use of oral sulfonamides is considered contraindicated in patients with porphyria.', '3', '"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48105, 6921, 'Dorzolamide (ophthalmic)', 'Crystalluria', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides has been associated with crystalluria due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48106, 16355, 'Dorzolamide (ophthalmic)', 'Crystalluria', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides has been associated with crystalluria due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48107, 17844, 'Dorzolamide (ophthalmic)', 'Crystalluria', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides has been associated with crystalluria due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48108, 17845, 'Dorzolamide (ophthalmic)', 'Crystalluria', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides has been associated with crystalluria due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48109, 24431, 'Dorzolamide (ophthalmic)', 'Crystalluria', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides has been associated with crystalluria due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48110, 25533, 'Dorzolamide (ophthalmic)', 'Crystalluria', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides has been associated with crystalluria due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48111, 28590, 'Dorzolamide (ophthalmic)', 'Crystalluria', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides has been associated with crystalluria due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48112, 29767, 'Dorzolamide (ophthalmic)', 'Crystalluria', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  The use of sulfonamides has been associated with crystalluria due to precipitation of the sulfonamide and/or its N4-acetyl metabolite in the urinary tract.  Renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine has been reported.  Hydration and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of crystalluria and lithiasis and should be encouraged to consume additional amounts of liquid.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).', '2', 'Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48113, 6921, 'Dorzolamide (ophthalmic)', 'Liver Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with topical sulfonamides should be administered cautiously in patients with liver disease.', '2', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48114, 16355, 'Dorzolamide (ophthalmic)', 'Liver Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with topical sulfonamides should be administered cautiously in patients with liver disease.', '2', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48115, 17844, 'Dorzolamide (ophthalmic)', 'Liver Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with topical sulfonamides should be administered cautiously in patients with liver disease.', '2', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48116, 17845, 'Dorzolamide (ophthalmic)', 'Liver Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with topical sulfonamides should be administered cautiously in patients with liver disease.', '2', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48117, 24431, 'Dorzolamide (ophthalmic)', 'Liver Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with topical sulfonamides should be administered cautiously in patients with liver disease.', '2', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48118, 25533, 'Dorzolamide (ophthalmic)', 'Liver Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with topical sulfonamides should be administered cautiously in patients with liver disease.', '2', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48119, 28590, 'Dorzolamide (ophthalmic)', 'Liver Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with topical sulfonamides should be administered cautiously in patients with liver disease.', '2', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48120, 29767, 'Dorzolamide (ophthalmic)', 'Liver Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis and hepatic failure, has rarely been reported in patients receiving sulfonamides.  In addition, sulfonamides are partially metabolized by the liver and may accumulate in patients with hepatic impairment.  Therapy with topical sulfonamides should be administered cautiously in patients with liver disease.', '2', 'Kowdley K, Keeffe E, Fawaz K "Prolonged cholestasis due to trimethoprim-sulfamethoxazole." Gastroenterology 102 (1992):  2148-50|Hofer T, Becker EW, Weigand K, Berg PA "Demonstration of sensititzed lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis." J Hepatol 15 (1992):  262-3|Stevenson D, Christie D, Haas J "Hepatic injury in a child caused by trimethoprim-sulfamethoxazole." Pediatrics 61 (1978):  864-6|Horak J, Mertl L, Hrabal P "Severe liver injuries due to sulfamethoxazole-trimethoprim and sulfamethoxydiazine." Hepatogastroenterology 31 (1984):  199-200|Steinbrecher U, Mishkin S "Sulfamethoxazole-induced hepatic injury." Dig Dis Sci 26 (1981):  756-9|Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L "Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim." Am J Gastroenterol 84 (1989):  1577-9|Ransohoff D, Jacobs G "Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim." Gastroenterology 80 (1981):  816-9|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Khan AK, Truelove SC, Aronson JK "The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man." Br J Clin Pharmacol 13 (1982):  523-8|Klotz U "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid." Clin Pharmacokinet 10 (1985):  285-302|Leroux JL, Ghezail M, Chertok P, Blotman F "Hypersensitivity reactions to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes." Clin Exp Rheumatol 10 (1992):  427|Kanner RS, Tedesco FJ, Kalser MH "Azulfidine- (sulfasalazine-) induced hepatic injury." Am J Dig Dis 23 (1978):  956-8|Losek JD, Werlin SL "Sulfasalazine hepatotoxicity." Am J Dis Child 135 (1981):  1070-2|Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D "Sulfasalazine hepatotoxicity." Am J Gastroenterol 79 (1984):  401-2|Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS "Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine." Am J Gastroenterol 81 (1986):  205-8|Poland GA, Love KR "Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy." Am J Med 81 (1986):  707-8|Sotolongo RP, Neefe LI, Rudzki C, Ishak KG "Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity." Gastroenterology 75 (1978):  95-9|Haines JD, Jr "Hepatotoxicity after treatment with sulfasalazine." Postgrad Med 79 (1986):  193-4,|Marinos G, Riley J, Painter DM, McCaughan GW "Sulfasalazine-induced fulminant hepatic failure." J Clin Gastroenterol 14 (1992):  132-5|Namias A, Bhalotra R, Donowitz M "Reversible sulfasalazine-induced granulomatous hepatitis." J Clin Gastroenterol 3 (1981):  193-8|Gremse DA, Bancroft J, Moyer MS "Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia." J Pediatr Gastroenterol Nutr 9 (1989):  261-3|Rubin R "Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis." Am J Gastroenterol 89 (1994):  789-91|Schroder H, Campbell DE "Absorption, metabolism, and excretion of salicylazosulfapyridine in man." Clin Pharmacol Ther 13 (1972):  539-51|Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, Margreiter R, Vogel W "Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole." Eur J Pediatr 154 (1995):  530-3|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48121, 6921, 'Dorzolamide (ophthalmic)', 'Kidney Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Once absorbed, sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).  Some manufacturers of topical sulfonamide products do not recommend their use in patients with impaired renal function.', '2', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48122, 16355, 'Dorzolamide (ophthalmic)', 'Kidney Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Once absorbed, sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).  Some manufacturers of topical sulfonamide products do not recommend their use in patients with impaired renal function.', '2', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48123, 17844, 'Dorzolamide (ophthalmic)', 'Kidney Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Once absorbed, sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).  Some manufacturers of topical sulfonamide products do not recommend their use in patients with impaired renal function.', '2', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48124, 17845, 'Dorzolamide (ophthalmic)', 'Kidney Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Once absorbed, sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).  Some manufacturers of topical sulfonamide products do not recommend their use in patients with impaired renal function.', '2', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48125, 24431, 'Dorzolamide (ophthalmic)', 'Kidney Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Once absorbed, sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).  Some manufacturers of topical sulfonamide products do not recommend their use in patients with impaired renal function.', '2', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48126, 25533, 'Dorzolamide (ophthalmic)', 'Kidney Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Once absorbed, sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).  Some manufacturers of topical sulfonamide products do not recommend their use in patients with impaired renal function.', '2', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48127, 28590, 'Dorzolamide (ophthalmic)', 'Kidney Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Once absorbed, sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).  Some manufacturers of topical sulfonamide products do not recommend their use in patients with impaired renal function.', '2', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48128, 29767, 'Dorzolamide (ophthalmic)', 'Kidney Diseases', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Once absorbed, sulfonamides and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from sulfonamides due to decreased drug clearance.  Additionally, sulfonamides may cause renal toxicity secondary to crystalluria, including uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  Hydration and adequate urinary output (> 1.5 L/day) should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).  Some manufacturers of topical sulfonamide products do not recommend their use in patients with impaired renal function.', '2', 'Smith E, Light J, Filo R, Yum M "Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients." JAMA 244 (1980):  360-1|Rudra T, Webb D, Evans A "Acute tubular necrosis following co-trimoxazole therapy." Nephron 53 (1989):  85-6|Cryst C, Hammar S "Acute granulomatous interstitial nephritis due to co-trimoxazole." Am J Nephrol 8 (1988):  483-8|Robson M, Levi J, Dolberg L, Rosenfeld J "Acute tubulo-interstitial nephritis following sulfadiazine therapy." Isr J Med Sci 6 (1970):  561-6|Goadsby P, Donaghy A, Lloyd A, Wakefield D "Acquired immunodeficiency syndrome (AIDS) and sulfadiazine-associated acute renal failure." Ann Intern Med 107 (1987):  783-4|Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Christin S, Baumelou A, Bahri S, Ben Hmida M, Deray G, Jacobs C "Acute renal failure due to sulfadiazine in patients with AIDS." Nephron 55 (1990):  233-4|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Hekster C, Vree T "Clinical pharmacokinetics of sulphonamides and their N4-acetyl derivatives." Antibiot Chemother 31 (1982):  22-118|Adam W, Dawborn J "Urinary excretion and plasma levels of sulphonamides in patients with renal impairment." Australas Ann Med 19 (1970):  250-4|Madsen S "A comparative study of the excretion of sulfonamide-metabolites in cases of renal failure and hepatitis." Chemotherapy 11 (1966):  1-9|Andreasen F, Elsborg L, Husted S, Thomsen O "Pharmacokinetics of sulfadiazine and trimethoprim in man." Eur J Clin Pharmacol 14 (1978):  57-67|Bergan T, Brodwall E, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Ortengren B, Fellner H, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part 2: Comparative pharmacokinetics of five sulphonamides." Infection 7 Suppl 4 (1979):  s367-70|Stachowska B, Senczuk W "Studies on kinetics of sulfadiazine and trimethoprim excretion in man." Int J Clin Pharmacol Ther Toxicol 25 (1987):  81-5|Ohnhaus EE, Spring P "Elimination kinetics of sulfadiazine in patients with normal and impaired renal function." J Pharmacokinet Biopharm 3 (1975):  171-9|Ortengren B, Magni L, Bergan T "Development of sulphonamide-trimethoprim combinations for urinary tract infections. part 3: pharmacokinetic characterization of sulphadiazine and sulphamethoxazole." Infection 7 (1979):  s371-81|Bergan T, Brodwall EK "Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination." Acta Med Scand 192 (1972):  483-92|Adam WR, Henning M, Dawborn JK "Excretion of trimethoprim and sulphamethoxazole in patients with renal failure." Aust N Z J Med 3 (1973):  383-7|Kremers P, Duvivier J, Heusghem C "Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses." J Clin Pharmacol 14 (1974):  112-7|Rieder J, Schwartz DE, Fernex M, et al. "Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function." Antibiot Chemother 18 (1974):  148-98|Bergan T, Brodwall EK, Vik-Mo H, Anstad U "Pharmacokinetics of sulphadiazine, sulphamethoxazole and trimethoprim in patients with varying renal function." Infection 7 (1979):  s382-7|Patel RB, Welling PG "Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)." Clin Pharmacokinet 5 (1980):  405-23|Vergin H, Ferber H, Zimmermann I, Neurath GB "Single and multiple dose kinetics of co-tetroxazine and co-trimoxazole in patients." Int J Clin Pharmacol Ther Toxicol 19 (1981):  350-7|Cohen M, Pocelinko R "Renal transport mechanisms for the excretion of sulfisoxazole." J Pharmacol Exp Ther 185 (1973):  703-12|Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S "Pharmacokinetics of sulfisoxazole in renal transplant patients." Antimicrob Agents Chemother 28 (1985):  535-9|Dwarakanath AD, Michael J, Allan RN "Sulphasalazine-induced renal failure." Gut 33 (1992):  1006-7|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Farinas MC, Echevarria S, Sampedro I, Gonzalez A, Perez del Molino A, Gonzalez-Macias J "Renal failure due to sulphadiazine in AIDS patients with cerebral toxoplasmosis." J Intern Med 233 (1993):  365-7|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|Becker K, Jablonowski H, Haussinger D "Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome." Medicine 75 (1996):  185-94|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48129, 6921, 'Dorzolamide (ophthalmic)', 'Urethral Obstruction', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Once absorbed, sulfonamides are excreted and concentrated in the urine.  Therapy with topical sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).', '2', 'Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48130, 16355, 'Dorzolamide (ophthalmic)', 'Urethral Obstruction', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Once absorbed, sulfonamides are excreted and concentrated in the urine.  Therapy with topical sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).', '2', 'Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48131, 17844, 'Dorzolamide (ophthalmic)', 'Urethral Obstruction', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Once absorbed, sulfonamides are excreted and concentrated in the urine.  Therapy with topical sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).', '2', 'Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48132, 17845, 'Dorzolamide (ophthalmic)', 'Urethral Obstruction', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Once absorbed, sulfonamides are excreted and concentrated in the urine.  Therapy with topical sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).', '2', 'Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48133, 24431, 'Dorzolamide (ophthalmic)', 'Urethral Obstruction', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Once absorbed, sulfonamides are excreted and concentrated in the urine.  Therapy with topical sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).', '2', 'Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48134, 25533, 'Dorzolamide (ophthalmic)', 'Urethral Obstruction', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Once absorbed, sulfonamides are excreted and concentrated in the urine.  Therapy with topical sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).', '2', 'Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48135, 28590, 'Dorzolamide (ophthalmic)', 'Urethral Obstruction', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Once absorbed, sulfonamides are excreted and concentrated in the urine.  Therapy with topical sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).', '2', 'Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48136, 29767, 'Dorzolamide (ophthalmic)', 'Urethral Obstruction', 'Sulfonamides may be systemically absorbed when applied to the skin, eye, or mucosal membranes.  Once absorbed, sulfonamides are excreted and concentrated in the urine.  Therapy with topical sulfonamides should be administered cautiously in patients with urinary obstruction or retention, since excessive drug accumulation may occur.  These patients may also be at increased risk for sulfonamide crystalluria, which may be associated with renal toxicity such as uro- and nephrolithiasis, nephritis, toxic nephrosis, hematuria, proteinuria, and elevated BUN and creatinine.  A urinary output of at least 1.5 L/day should be maintained during sulfonamide administration.  Renal function tests and urinalysis should be performed regularly during prolonged therapy (> 2 weeks).', '2', 'Sahai J, Heimberger R, Collins K, Kaplowitz L, Polk R "Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency syndrome: a reminder." Am J Med 84 (1988):  791-2|Carbone L, Bendixen B, Appel G "Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome." Am J Kidney Dis 12 (1988):  72-5|Simon D, Brosius F, Rothstein D "Sulfadiazine crystalluria revisited." Arch Intern Med 150 (1990):  2379-84|Molina J, Belenfant X, Doco-Lecompte T, et al. "Sulfadiazine-induced crystalluria in AIDS patients with toxoplasma encephalitis." AIDS 5 (1991):  587-9|Marques L, Silva M, Madeira E, Santos O "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Marques LP, Silva MT, Madeira EP, Santos OR "Obstructive renal failure due to therapy with sulfadiazine in an AIDS patient." Nephron 62 (1992):  361|Sasson JP, Dratch PL, Shortsleeve MJ "Renal US findings in sulfadiazine-induced crystalluria." Radiology 185 (1992):  739-40|Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE "Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases." Clin Nephrol 39 (1993):  254-6|Erturk E, Casemento JB, Guertin KR, Kende AS "Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy." J Urol 151 (1994):  1605-6|"Product Information. Gantrisin (sulfiSOXAZOLE)." Roche Laboratories  (2022):|"Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc  (2001):|"Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc  (2001):|"Product Information. Klaron (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. Sodium Sulamyd (sulfacetamide sodium ophthalmic)." Schering Corporation|"Product Information. Sultrin Triple Sulfa (triple sulfa topical)." Janssen Pharmaceuticals|"Product Information. Sulfacet-R (sulfacetamide sodium topical)." Dermik Laboratories/Aventis  (2001):|"Product Information. AVC (sulfanilamide topical)." Aventis Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48137, 2086, 'Doxazosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48138, 2087, 'Doxazosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48139, 3865, 'Doxazosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48140, 3866, 'Doxazosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48141, 3911, 'Doxazosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48142, 15865, 'Doxazosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48143, 17013, 'Doxazosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48144, 17078, 'Doxazosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48145, 17847, 'Doxazosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48146, 17848, 'Doxazosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48147, 17849, 'Doxazosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48148, 17866, 'Doxazosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48149, 17867, 'Doxazosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48150, 17869, 'Doxazosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48151, 17872, 'Doxazosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48152, 17965, 'Doxazosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48153, 18142, 'Doxazosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48154, 18143, 'Doxazosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48155, 18360, 'Doxazosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48156, 18805, 'Doxazosin', 'Hypotension', 'Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations.  Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose.  However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days.  Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects.  Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes.  Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs.  Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling.  During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur.  Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized.  If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.', '2', 'Grunstein JA "The problem of postural hypotension." Gerontol Clin (Basel) 16 (1974):  171-4|Glass AR, Ballou R "Pheochromocytoma, prazosin, and hypotension." Ann Intern Med 97 (1982):  455|Melkild A "Prazosin (peripress): a long-term study." Curr Med Res Opin 9 (1984):  219-28|Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS "Prazosin: the first-dose phenomenon." Br Med J 2 (1976):  1293-4|"Prazosin (Minipress) for hypertension." Med Lett Drugs Ther 19 (1977):  1-2|Salim SS, Mtui EP, Makene WJ "An open evaluation of the efficacy and toleration of prazosin in patients with hypertension." East Afr Med J 54 (1977):  429-33|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Hytrin (terazosin)." Abbott Pharmaceutical  (2001):|Troffa C, Manunta P, Dessifulgheri P, Pazzola A, Sabino G, Patteri G, Tonolo G, Pupita G, Glorioso N, Gitti M, Rappelli A "Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension." Curr Ther Res Clin Exp 55 (1994):  22-31|Ahaneku JE, Taylor OG, Walker D, Agbedana OE, Salako LA "Blood pressure and biochemical changes during doxazosin monotherapy in nigerian hypertensive patients." Curr Ther Res Clin Exp 55 (1994):  1067-74|Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M "Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension." Angiology 46 (1995):  11-8|Limbird LE eds., Gilman AG, Hardman JG "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: McGraw-Hill  (1995):|Roehrborn CG, Siegel RL "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." Urology 48 (1996):  406-15|"Product Information. Flomax (tamsulosin)." Boehringer-Ingelheim  (2001):|"Product Information. Uroxatral (alfuzosin)." sanofi-aventis  (2003):|"Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48157, 2086, 'Doxazosin', 'Liver Diseases', 'Doxazosin is metabolized by the liver and subsequently excreted in the bile, primarily as metabolites, some of which are pharmacologically active.  In patients with cirrhosis (Child-Pugh Class A) given a single 2 mg dose, there was a 40% increase in exposure to doxazosin compared to patients with normal hepatic function.  The clearance was reduced by 30%, while elimination half-life was not significantly changed.  Therapy with doxazosin should be administered cautiously in patients with significantly impaired hepatic or biliary function, since drug and/or metabolite accumulation may occur.', '2', 'Elliott HL, Meredith PA, Reid JL "Pharmacokinetic overview of doxazosin." Am J Cardiol 59 (1987):  g78-81|Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL "The metabolism and kinetics of doxazosin in man, mouse, rat and dog." Br J Clin Pharmacol 21 (1986):  s19-25|Young RA, Brogden RN "Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension." Drugs 35 (1988):  525-41|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|Penenberg D, Chung M, Walmsley P, Vashi V "The effects of hepatic impairment on the pharmacokinetics of docazosin." J Clin Pharmacol 40 (2000):  67-73', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48158, 2087, 'Doxazosin', 'Liver Diseases', 'Doxazosin is metabolized by the liver and subsequently excreted in the bile, primarily as metabolites, some of which are pharmacologically active.  In patients with cirrhosis (Child-Pugh Class A) given a single 2 mg dose, there was a 40% increase in exposure to doxazosin compared to patients with normal hepatic function.  The clearance was reduced by 30%, while elimination half-life was not significantly changed.  Therapy with doxazosin should be administered cautiously in patients with significantly impaired hepatic or biliary function, since drug and/or metabolite accumulation may occur.', '2', 'Elliott HL, Meredith PA, Reid JL "Pharmacokinetic overview of doxazosin." Am J Cardiol 59 (1987):  g78-81|Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL "The metabolism and kinetics of doxazosin in man, mouse, rat and dog." Br J Clin Pharmacol 21 (1986):  s19-25|Young RA, Brogden RN "Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension." Drugs 35 (1988):  525-41|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|Penenberg D, Chung M, Walmsley P, Vashi V "The effects of hepatic impairment on the pharmacokinetics of docazosin." J Clin Pharmacol 40 (2000):  67-73', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48159, 3865, 'Doxazosin', 'Liver Diseases', 'Doxazosin is metabolized by the liver and subsequently excreted in the bile, primarily as metabolites, some of which are pharmacologically active.  In patients with cirrhosis (Child-Pugh Class A) given a single 2 mg dose, there was a 40% increase in exposure to doxazosin compared to patients with normal hepatic function.  The clearance was reduced by 30%, while elimination half-life was not significantly changed.  Therapy with doxazosin should be administered cautiously in patients with significantly impaired hepatic or biliary function, since drug and/or metabolite accumulation may occur.', '2', 'Elliott HL, Meredith PA, Reid JL "Pharmacokinetic overview of doxazosin." Am J Cardiol 59 (1987):  g78-81|Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL "The metabolism and kinetics of doxazosin in man, mouse, rat and dog." Br J Clin Pharmacol 21 (1986):  s19-25|Young RA, Brogden RN "Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension." Drugs 35 (1988):  525-41|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|Penenberg D, Chung M, Walmsley P, Vashi V "The effects of hepatic impairment on the pharmacokinetics of docazosin." J Clin Pharmacol 40 (2000):  67-73', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48160, 3866, 'Doxazosin', 'Liver Diseases', 'Doxazosin is metabolized by the liver and subsequently excreted in the bile, primarily as metabolites, some of which are pharmacologically active.  In patients with cirrhosis (Child-Pugh Class A) given a single 2 mg dose, there was a 40% increase in exposure to doxazosin compared to patients with normal hepatic function.  The clearance was reduced by 30%, while elimination half-life was not significantly changed.  Therapy with doxazosin should be administered cautiously in patients with significantly impaired hepatic or biliary function, since drug and/or metabolite accumulation may occur.', '2', 'Elliott HL, Meredith PA, Reid JL "Pharmacokinetic overview of doxazosin." Am J Cardiol 59 (1987):  g78-81|Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL "The metabolism and kinetics of doxazosin in man, mouse, rat and dog." Br J Clin Pharmacol 21 (1986):  s19-25|Young RA, Brogden RN "Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension." Drugs 35 (1988):  525-41|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|Penenberg D, Chung M, Walmsley P, Vashi V "The effects of hepatic impairment on the pharmacokinetics of docazosin." J Clin Pharmacol 40 (2000):  67-73', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48161, 3911, 'Doxazosin', 'Liver Diseases', 'Doxazosin is metabolized by the liver and subsequently excreted in the bile, primarily as metabolites, some of which are pharmacologically active.  In patients with cirrhosis (Child-Pugh Class A) given a single 2 mg dose, there was a 40% increase in exposure to doxazosin compared to patients with normal hepatic function.  The clearance was reduced by 30%, while elimination half-life was not significantly changed.  Therapy with doxazosin should be administered cautiously in patients with significantly impaired hepatic or biliary function, since drug and/or metabolite accumulation may occur.', '2', 'Elliott HL, Meredith PA, Reid JL "Pharmacokinetic overview of doxazosin." Am J Cardiol 59 (1987):  g78-81|Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL "The metabolism and kinetics of doxazosin in man, mouse, rat and dog." Br J Clin Pharmacol 21 (1986):  s19-25|Young RA, Brogden RN "Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension." Drugs 35 (1988):  525-41|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|Penenberg D, Chung M, Walmsley P, Vashi V "The effects of hepatic impairment on the pharmacokinetics of docazosin." J Clin Pharmacol 40 (2000):  67-73', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48162, 15865, 'Doxazosin', 'Liver Diseases', 'Doxazosin is metabolized by the liver and subsequently excreted in the bile, primarily as metabolites, some of which are pharmacologically active.  In patients with cirrhosis (Child-Pugh Class A) given a single 2 mg dose, there was a 40% increase in exposure to doxazosin compared to patients with normal hepatic function.  The clearance was reduced by 30%, while elimination half-life was not significantly changed.  Therapy with doxazosin should be administered cautiously in patients with significantly impaired hepatic or biliary function, since drug and/or metabolite accumulation may occur.', '2', 'Elliott HL, Meredith PA, Reid JL "Pharmacokinetic overview of doxazosin." Am J Cardiol 59 (1987):  g78-81|Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL "The metabolism and kinetics of doxazosin in man, mouse, rat and dog." Br J Clin Pharmacol 21 (1986):  s19-25|Young RA, Brogden RN "Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension." Drugs 35 (1988):  525-41|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|Penenberg D, Chung M, Walmsley P, Vashi V "The effects of hepatic impairment on the pharmacokinetics of docazosin." J Clin Pharmacol 40 (2000):  67-73', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48163, 17013, 'Doxazosin', 'Liver Diseases', 'Doxazosin is metabolized by the liver and subsequently excreted in the bile, primarily as metabolites, some of which are pharmacologically active.  In patients with cirrhosis (Child-Pugh Class A) given a single 2 mg dose, there was a 40% increase in exposure to doxazosin compared to patients with normal hepatic function.  The clearance was reduced by 30%, while elimination half-life was not significantly changed.  Therapy with doxazosin should be administered cautiously in patients with significantly impaired hepatic or biliary function, since drug and/or metabolite accumulation may occur.', '2', 'Elliott HL, Meredith PA, Reid JL "Pharmacokinetic overview of doxazosin." Am J Cardiol 59 (1987):  g78-81|Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL "The metabolism and kinetics of doxazosin in man, mouse, rat and dog." Br J Clin Pharmacol 21 (1986):  s19-25|Young RA, Brogden RN "Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension." Drugs 35 (1988):  525-41|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|Penenberg D, Chung M, Walmsley P, Vashi V "The effects of hepatic impairment on the pharmacokinetics of docazosin." J Clin Pharmacol 40 (2000):  67-73', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48164, 17078, 'Doxazosin', 'Liver Diseases', 'Doxazosin is metabolized by the liver and subsequently excreted in the bile, primarily as metabolites, some of which are pharmacologically active.  In patients with cirrhosis (Child-Pugh Class A) given a single 2 mg dose, there was a 40% increase in exposure to doxazosin compared to patients with normal hepatic function.  The clearance was reduced by 30%, while elimination half-life was not significantly changed.  Therapy with doxazosin should be administered cautiously in patients with significantly impaired hepatic or biliary function, since drug and/or metabolite accumulation may occur.', '2', 'Elliott HL, Meredith PA, Reid JL "Pharmacokinetic overview of doxazosin." Am J Cardiol 59 (1987):  g78-81|Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL "The metabolism and kinetics of doxazosin in man, mouse, rat and dog." Br J Clin Pharmacol 21 (1986):  s19-25|Young RA, Brogden RN "Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension." Drugs 35 (1988):  525-41|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|Penenberg D, Chung M, Walmsley P, Vashi V "The effects of hepatic impairment on the pharmacokinetics of docazosin." J Clin Pharmacol 40 (2000):  67-73', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48165, 17847, 'Doxazosin', 'Liver Diseases', 'Doxazosin is metabolized by the liver and subsequently excreted in the bile, primarily as metabolites, some of which are pharmacologically active.  In patients with cirrhosis (Child-Pugh Class A) given a single 2 mg dose, there was a 40% increase in exposure to doxazosin compared to patients with normal hepatic function.  The clearance was reduced by 30%, while elimination half-life was not significantly changed.  Therapy with doxazosin should be administered cautiously in patients with significantly impaired hepatic or biliary function, since drug and/or metabolite accumulation may occur.', '2', 'Elliott HL, Meredith PA, Reid JL "Pharmacokinetic overview of doxazosin." Am J Cardiol 59 (1987):  g78-81|Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL "The metabolism and kinetics of doxazosin in man, mouse, rat and dog." Br J Clin Pharmacol 21 (1986):  s19-25|Young RA, Brogden RN "Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension." Drugs 35 (1988):  525-41|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|Penenberg D, Chung M, Walmsley P, Vashi V "The effects of hepatic impairment on the pharmacokinetics of docazosin." J Clin Pharmacol 40 (2000):  67-73', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48166, 17848, 'Doxazosin', 'Liver Diseases', 'Doxazosin is metabolized by the liver and subsequently excreted in the bile, primarily as metabolites, some of which are pharmacologically active.  In patients with cirrhosis (Child-Pugh Class A) given a single 2 mg dose, there was a 40% increase in exposure to doxazosin compared to patients with normal hepatic function.  The clearance was reduced by 30%, while elimination half-life was not significantly changed.  Therapy with doxazosin should be administered cautiously in patients with significantly impaired hepatic or biliary function, since drug and/or metabolite accumulation may occur.', '2', 'Elliott HL, Meredith PA, Reid JL "Pharmacokinetic overview of doxazosin." Am J Cardiol 59 (1987):  g78-81|Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL "The metabolism and kinetics of doxazosin in man, mouse, rat and dog." Br J Clin Pharmacol 21 (1986):  s19-25|Young RA, Brogden RN "Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension." Drugs 35 (1988):  525-41|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|Penenberg D, Chung M, Walmsley P, Vashi V "The effects of hepatic impairment on the pharmacokinetics of docazosin." J Clin Pharmacol 40 (2000):  67-73', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48167, 17849, 'Doxazosin', 'Liver Diseases', 'Doxazosin is metabolized by the liver and subsequently excreted in the bile, primarily as metabolites, some of which are pharmacologically active.  In patients with cirrhosis (Child-Pugh Class A) given a single 2 mg dose, there was a 40% increase in exposure to doxazosin compared to patients with normal hepatic function.  The clearance was reduced by 30%, while elimination half-life was not significantly changed.  Therapy with doxazosin should be administered cautiously in patients with significantly impaired hepatic or biliary function, since drug and/or metabolite accumulation may occur.', '2', 'Elliott HL, Meredith PA, Reid JL "Pharmacokinetic overview of doxazosin." Am J Cardiol 59 (1987):  g78-81|Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL "The metabolism and kinetics of doxazosin in man, mouse, rat and dog." Br J Clin Pharmacol 21 (1986):  s19-25|Young RA, Brogden RN "Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension." Drugs 35 (1988):  525-41|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|Penenberg D, Chung M, Walmsley P, Vashi V "The effects of hepatic impairment on the pharmacokinetics of docazosin." J Clin Pharmacol 40 (2000):  67-73', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48168, 17866, 'Doxazosin', 'Liver Diseases', 'Doxazosin is metabolized by the liver and subsequently excreted in the bile, primarily as metabolites, some of which are pharmacologically active.  In patients with cirrhosis (Child-Pugh Class A) given a single 2 mg dose, there was a 40% increase in exposure to doxazosin compared to patients with normal hepatic function.  The clearance was reduced by 30%, while elimination half-life was not significantly changed.  Therapy with doxazosin should be administered cautiously in patients with significantly impaired hepatic or biliary function, since drug and/or metabolite accumulation may occur.', '2', 'Elliott HL, Meredith PA, Reid JL "Pharmacokinetic overview of doxazosin." Am J Cardiol 59 (1987):  g78-81|Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL "The metabolism and kinetics of doxazosin in man, mouse, rat and dog." Br J Clin Pharmacol 21 (1986):  s19-25|Young RA, Brogden RN "Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension." Drugs 35 (1988):  525-41|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|Penenberg D, Chung M, Walmsley P, Vashi V "The effects of hepatic impairment on the pharmacokinetics of docazosin." J Clin Pharmacol 40 (2000):  67-73', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48169, 17867, 'Doxazosin', 'Liver Diseases', 'Doxazosin is metabolized by the liver and subsequently excreted in the bile, primarily as metabolites, some of which are pharmacologically active.  In patients with cirrhosis (Child-Pugh Class A) given a single 2 mg dose, there was a 40% increase in exposure to doxazosin compared to patients with normal hepatic function.  The clearance was reduced by 30%, while elimination half-life was not significantly changed.  Therapy with doxazosin should be administered cautiously in patients with significantly impaired hepatic or biliary function, since drug and/or metabolite accumulation may occur.', '2', 'Elliott HL, Meredith PA, Reid JL "Pharmacokinetic overview of doxazosin." Am J Cardiol 59 (1987):  g78-81|Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL "The metabolism and kinetics of doxazosin in man, mouse, rat and dog." Br J Clin Pharmacol 21 (1986):  s19-25|Young RA, Brogden RN "Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension." Drugs 35 (1988):  525-41|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|Penenberg D, Chung M, Walmsley P, Vashi V "The effects of hepatic impairment on the pharmacokinetics of docazosin." J Clin Pharmacol 40 (2000):  67-73', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48170, 17869, 'Doxazosin', 'Liver Diseases', 'Doxazosin is metabolized by the liver and subsequently excreted in the bile, primarily as metabolites, some of which are pharmacologically active.  In patients with cirrhosis (Child-Pugh Class A) given a single 2 mg dose, there was a 40% increase in exposure to doxazosin compared to patients with normal hepatic function.  The clearance was reduced by 30%, while elimination half-life was not significantly changed.  Therapy with doxazosin should be administered cautiously in patients with significantly impaired hepatic or biliary function, since drug and/or metabolite accumulation may occur.', '2', 'Elliott HL, Meredith PA, Reid JL "Pharmacokinetic overview of doxazosin." Am J Cardiol 59 (1987):  g78-81|Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL "The metabolism and kinetics of doxazosin in man, mouse, rat and dog." Br J Clin Pharmacol 21 (1986):  s19-25|Young RA, Brogden RN "Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension." Drugs 35 (1988):  525-41|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|Penenberg D, Chung M, Walmsley P, Vashi V "The effects of hepatic impairment on the pharmacokinetics of docazosin." J Clin Pharmacol 40 (2000):  67-73', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48171, 17872, 'Doxazosin', 'Liver Diseases', 'Doxazosin is metabolized by the liver and subsequently excreted in the bile, primarily as metabolites, some of which are pharmacologically active.  In patients with cirrhosis (Child-Pugh Class A) given a single 2 mg dose, there was a 40% increase in exposure to doxazosin compared to patients with normal hepatic function.  The clearance was reduced by 30%, while elimination half-life was not significantly changed.  Therapy with doxazosin should be administered cautiously in patients with significantly impaired hepatic or biliary function, since drug and/or metabolite accumulation may occur.', '2', 'Elliott HL, Meredith PA, Reid JL "Pharmacokinetic overview of doxazosin." Am J Cardiol 59 (1987):  g78-81|Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL "The metabolism and kinetics of doxazosin in man, mouse, rat and dog." Br J Clin Pharmacol 21 (1986):  s19-25|Young RA, Brogden RN "Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension." Drugs 35 (1988):  525-41|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|Penenberg D, Chung M, Walmsley P, Vashi V "The effects of hepatic impairment on the pharmacokinetics of docazosin." J Clin Pharmacol 40 (2000):  67-73', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48172, 17965, 'Doxazosin', 'Liver Diseases', 'Doxazosin is metabolized by the liver and subsequently excreted in the bile, primarily as metabolites, some of which are pharmacologically active.  In patients with cirrhosis (Child-Pugh Class A) given a single 2 mg dose, there was a 40% increase in exposure to doxazosin compared to patients with normal hepatic function.  The clearance was reduced by 30%, while elimination half-life was not significantly changed.  Therapy with doxazosin should be administered cautiously in patients with significantly impaired hepatic or biliary function, since drug and/or metabolite accumulation may occur.', '2', 'Elliott HL, Meredith PA, Reid JL "Pharmacokinetic overview of doxazosin." Am J Cardiol 59 (1987):  g78-81|Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL "The metabolism and kinetics of doxazosin in man, mouse, rat and dog." Br J Clin Pharmacol 21 (1986):  s19-25|Young RA, Brogden RN "Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension." Drugs 35 (1988):  525-41|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|Penenberg D, Chung M, Walmsley P, Vashi V "The effects of hepatic impairment on the pharmacokinetics of docazosin." J Clin Pharmacol 40 (2000):  67-73', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48173, 18142, 'Doxazosin', 'Liver Diseases', 'Doxazosin is metabolized by the liver and subsequently excreted in the bile, primarily as metabolites, some of which are pharmacologically active.  In patients with cirrhosis (Child-Pugh Class A) given a single 2 mg dose, there was a 40% increase in exposure to doxazosin compared to patients with normal hepatic function.  The clearance was reduced by 30%, while elimination half-life was not significantly changed.  Therapy with doxazosin should be administered cautiously in patients with significantly impaired hepatic or biliary function, since drug and/or metabolite accumulation may occur.', '2', 'Elliott HL, Meredith PA, Reid JL "Pharmacokinetic overview of doxazosin." Am J Cardiol 59 (1987):  g78-81|Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL "The metabolism and kinetics of doxazosin in man, mouse, rat and dog." Br J Clin Pharmacol 21 (1986):  s19-25|Young RA, Brogden RN "Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension." Drugs 35 (1988):  525-41|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|Penenberg D, Chung M, Walmsley P, Vashi V "The effects of hepatic impairment on the pharmacokinetics of docazosin." J Clin Pharmacol 40 (2000):  67-73', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48174, 18143, 'Doxazosin', 'Liver Diseases', 'Doxazosin is metabolized by the liver and subsequently excreted in the bile, primarily as metabolites, some of which are pharmacologically active.  In patients with cirrhosis (Child-Pugh Class A) given a single 2 mg dose, there was a 40% increase in exposure to doxazosin compared to patients with normal hepatic function.  The clearance was reduced by 30%, while elimination half-life was not significantly changed.  Therapy with doxazosin should be administered cautiously in patients with significantly impaired hepatic or biliary function, since drug and/or metabolite accumulation may occur.', '2', 'Elliott HL, Meredith PA, Reid JL "Pharmacokinetic overview of doxazosin." Am J Cardiol 59 (1987):  g78-81|Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL "The metabolism and kinetics of doxazosin in man, mouse, rat and dog." Br J Clin Pharmacol 21 (1986):  s19-25|Young RA, Brogden RN "Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension." Drugs 35 (1988):  525-41|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|Penenberg D, Chung M, Walmsley P, Vashi V "The effects of hepatic impairment on the pharmacokinetics of docazosin." J Clin Pharmacol 40 (2000):  67-73', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48175, 18360, 'Doxazosin', 'Liver Diseases', 'Doxazosin is metabolized by the liver and subsequently excreted in the bile, primarily as metabolites, some of which are pharmacologically active.  In patients with cirrhosis (Child-Pugh Class A) given a single 2 mg dose, there was a 40% increase in exposure to doxazosin compared to patients with normal hepatic function.  The clearance was reduced by 30%, while elimination half-life was not significantly changed.  Therapy with doxazosin should be administered cautiously in patients with significantly impaired hepatic or biliary function, since drug and/or metabolite accumulation may occur.', '2', 'Elliott HL, Meredith PA, Reid JL "Pharmacokinetic overview of doxazosin." Am J Cardiol 59 (1987):  g78-81|Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL "The metabolism and kinetics of doxazosin in man, mouse, rat and dog." Br J Clin Pharmacol 21 (1986):  s19-25|Young RA, Brogden RN "Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension." Drugs 35 (1988):  525-41|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|Penenberg D, Chung M, Walmsley P, Vashi V "The effects of hepatic impairment on the pharmacokinetics of docazosin." J Clin Pharmacol 40 (2000):  67-73', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48176, 18805, 'Doxazosin', 'Liver Diseases', 'Doxazosin is metabolized by the liver and subsequently excreted in the bile, primarily as metabolites, some of which are pharmacologically active.  In patients with cirrhosis (Child-Pugh Class A) given a single 2 mg dose, there was a 40% increase in exposure to doxazosin compared to patients with normal hepatic function.  The clearance was reduced by 30%, while elimination half-life was not significantly changed.  Therapy with doxazosin should be administered cautiously in patients with significantly impaired hepatic or biliary function, since drug and/or metabolite accumulation may occur.', '2', 'Elliott HL, Meredith PA, Reid JL "Pharmacokinetic overview of doxazosin." Am J Cardiol 59 (1987):  g78-81|Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL "The metabolism and kinetics of doxazosin in man, mouse, rat and dog." Br J Clin Pharmacol 21 (1986):  s19-25|Young RA, Brogden RN "Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension." Drugs 35 (1988):  525-41|"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):|Penenberg D, Chung M, Walmsley P, Vashi V "The effects of hepatic impairment on the pharmacokinetics of docazosin." J Clin Pharmacol 40 (2000):  67-73', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48177, 2086, 'Doxazosin', 'Neutropenia', 'Slight but sometimes clinically significant decreases in white blood cell and neutrophil counts have occurred during treatment with some of the peripheral alpha 1-adrenergic receptor blocking agents (aka alpha 1-blockers), including doxazosin.  Reported cases were generally asymptomatic and reversible.  Patients with preexisting neutropenia or bone marrow depression may require closer monitoring during therapy with alpha 1-blockers.', '2', '"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48178, 2087, 'Doxazosin', 'Neutropenia', 'Slight but sometimes clinically significant decreases in white blood cell and neutrophil counts have occurred during treatment with some of the peripheral alpha 1-adrenergic receptor blocking agents (aka alpha 1-blockers), including doxazosin.  Reported cases were generally asymptomatic and reversible.  Patients with preexisting neutropenia or bone marrow depression may require closer monitoring during therapy with alpha 1-blockers.', '2', '"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48179, 3865, 'Doxazosin', 'Neutropenia', 'Slight but sometimes clinically significant decreases in white blood cell and neutrophil counts have occurred during treatment with some of the peripheral alpha 1-adrenergic receptor blocking agents (aka alpha 1-blockers), including doxazosin.  Reported cases were generally asymptomatic and reversible.  Patients with preexisting neutropenia or bone marrow depression may require closer monitoring during therapy with alpha 1-blockers.', '2', '"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48180, 3866, 'Doxazosin', 'Neutropenia', 'Slight but sometimes clinically significant decreases in white blood cell and neutrophil counts have occurred during treatment with some of the peripheral alpha 1-adrenergic receptor blocking agents (aka alpha 1-blockers), including doxazosin.  Reported cases were generally asymptomatic and reversible.  Patients with preexisting neutropenia or bone marrow depression may require closer monitoring during therapy with alpha 1-blockers.', '2', '"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48181, 3911, 'Doxazosin', 'Neutropenia', 'Slight but sometimes clinically significant decreases in white blood cell and neutrophil counts have occurred during treatment with some of the peripheral alpha 1-adrenergic receptor blocking agents (aka alpha 1-blockers), including doxazosin.  Reported cases were generally asymptomatic and reversible.  Patients with preexisting neutropenia or bone marrow depression may require closer monitoring during therapy with alpha 1-blockers.', '2', '"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48182, 15865, 'Doxazosin', 'Neutropenia', 'Slight but sometimes clinically significant decreases in white blood cell and neutrophil counts have occurred during treatment with some of the peripheral alpha 1-adrenergic receptor blocking agents (aka alpha 1-blockers), including doxazosin.  Reported cases were generally asymptomatic and reversible.  Patients with preexisting neutropenia or bone marrow depression may require closer monitoring during therapy with alpha 1-blockers.', '2', '"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48183, 17013, 'Doxazosin', 'Neutropenia', 'Slight but sometimes clinically significant decreases in white blood cell and neutrophil counts have occurred during treatment with some of the peripheral alpha 1-adrenergic receptor blocking agents (aka alpha 1-blockers), including doxazosin.  Reported cases were generally asymptomatic and reversible.  Patients with preexisting neutropenia or bone marrow depression may require closer monitoring during therapy with alpha 1-blockers.', '2', '"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48184, 17078, 'Doxazosin', 'Neutropenia', 'Slight but sometimes clinically significant decreases in white blood cell and neutrophil counts have occurred during treatment with some of the peripheral alpha 1-adrenergic receptor blocking agents (aka alpha 1-blockers), including doxazosin.  Reported cases were generally asymptomatic and reversible.  Patients with preexisting neutropenia or bone marrow depression may require closer monitoring during therapy with alpha 1-blockers.', '2', '"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48185, 17847, 'Doxazosin', 'Neutropenia', 'Slight but sometimes clinically significant decreases in white blood cell and neutrophil counts have occurred during treatment with some of the peripheral alpha 1-adrenergic receptor blocking agents (aka alpha 1-blockers), including doxazosin.  Reported cases were generally asymptomatic and reversible.  Patients with preexisting neutropenia or bone marrow depression may require closer monitoring during therapy with alpha 1-blockers.', '2', '"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48186, 17848, 'Doxazosin', 'Neutropenia', 'Slight but sometimes clinically significant decreases in white blood cell and neutrophil counts have occurred during treatment with some of the peripheral alpha 1-adrenergic receptor blocking agents (aka alpha 1-blockers), including doxazosin.  Reported cases were generally asymptomatic and reversible.  Patients with preexisting neutropenia or bone marrow depression may require closer monitoring during therapy with alpha 1-blockers.', '2', '"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48187, 17849, 'Doxazosin', 'Neutropenia', 'Slight but sometimes clinically significant decreases in white blood cell and neutrophil counts have occurred during treatment with some of the peripheral alpha 1-adrenergic receptor blocking agents (aka alpha 1-blockers), including doxazosin.  Reported cases were generally asymptomatic and reversible.  Patients with preexisting neutropenia or bone marrow depression may require closer monitoring during therapy with alpha 1-blockers.', '2', '"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48188, 17866, 'Doxazosin', 'Neutropenia', 'Slight but sometimes clinically significant decreases in white blood cell and neutrophil counts have occurred during treatment with some of the peripheral alpha 1-adrenergic receptor blocking agents (aka alpha 1-blockers), including doxazosin.  Reported cases were generally asymptomatic and reversible.  Patients with preexisting neutropenia or bone marrow depression may require closer monitoring during therapy with alpha 1-blockers.', '2', '"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48189, 17867, 'Doxazosin', 'Neutropenia', 'Slight but sometimes clinically significant decreases in white blood cell and neutrophil counts have occurred during treatment with some of the peripheral alpha 1-adrenergic receptor blocking agents (aka alpha 1-blockers), including doxazosin.  Reported cases were generally asymptomatic and reversible.  Patients with preexisting neutropenia or bone marrow depression may require closer monitoring during therapy with alpha 1-blockers.', '2', '"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48190, 17869, 'Doxazosin', 'Neutropenia', 'Slight but sometimes clinically significant decreases in white blood cell and neutrophil counts have occurred during treatment with some of the peripheral alpha 1-adrenergic receptor blocking agents (aka alpha 1-blockers), including doxazosin.  Reported cases were generally asymptomatic and reversible.  Patients with preexisting neutropenia or bone marrow depression may require closer monitoring during therapy with alpha 1-blockers.', '2', '"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48191, 17872, 'Doxazosin', 'Neutropenia', 'Slight but sometimes clinically significant decreases in white blood cell and neutrophil counts have occurred during treatment with some of the peripheral alpha 1-adrenergic receptor blocking agents (aka alpha 1-blockers), including doxazosin.  Reported cases were generally asymptomatic and reversible.  Patients with preexisting neutropenia or bone marrow depression may require closer monitoring during therapy with alpha 1-blockers.', '2', '"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48192, 17965, 'Doxazosin', 'Neutropenia', 'Slight but sometimes clinically significant decreases in white blood cell and neutrophil counts have occurred during treatment with some of the peripheral alpha 1-adrenergic receptor blocking agents (aka alpha 1-blockers), including doxazosin.  Reported cases were generally asymptomatic and reversible.  Patients with preexisting neutropenia or bone marrow depression may require closer monitoring during therapy with alpha 1-blockers.', '2', '"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48193, 18142, 'Doxazosin', 'Neutropenia', 'Slight but sometimes clinically significant decreases in white blood cell and neutrophil counts have occurred during treatment with some of the peripheral alpha 1-adrenergic receptor blocking agents (aka alpha 1-blockers), including doxazosin.  Reported cases were generally asymptomatic and reversible.  Patients with preexisting neutropenia or bone marrow depression may require closer monitoring during therapy with alpha 1-blockers.', '2', '"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48194, 18143, 'Doxazosin', 'Neutropenia', 'Slight but sometimes clinically significant decreases in white blood cell and neutrophil counts have occurred during treatment with some of the peripheral alpha 1-adrenergic receptor blocking agents (aka alpha 1-blockers), including doxazosin.  Reported cases were generally asymptomatic and reversible.  Patients with preexisting neutropenia or bone marrow depression may require closer monitoring during therapy with alpha 1-blockers.', '2', '"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48195, 18360, 'Doxazosin', 'Neutropenia', 'Slight but sometimes clinically significant decreases in white blood cell and neutrophil counts have occurred during treatment with some of the peripheral alpha 1-adrenergic receptor blocking agents (aka alpha 1-blockers), including doxazosin.  Reported cases were generally asymptomatic and reversible.  Patients with preexisting neutropenia or bone marrow depression may require closer monitoring during therapy with alpha 1-blockers.', '2', '"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48196, 18805, 'Doxazosin', 'Neutropenia', 'Slight but sometimes clinically significant decreases in white blood cell and neutrophil counts have occurred during treatment with some of the peripheral alpha 1-adrenergic receptor blocking agents (aka alpha 1-blockers), including doxazosin.  Reported cases were generally asymptomatic and reversible.  Patients with preexisting neutropenia or bone marrow depression may require closer monitoring during therapy with alpha 1-blockers.', '2', '"Product Information. Cardura (doxazosin)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48197, 3876, 'Doxycycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48198, 3879, 'Doxycycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48199, 4657, 'Doxycycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48200, 11132, 'Doxycycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48201, 11489, 'Doxycycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48202, 11490, 'Doxycycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48203, 11491, 'Doxycycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48204, 17889, 'Doxycycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48205, 17890, 'Doxycycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48206, 17891, 'Doxycycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48207, 20052, 'Doxycycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48208, 29237, 'Doxycycline', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48209, 3876, 'Doxycycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984):  1491-2|Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992):  68-71|Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982):  142-6|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996):  1641-3|Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997):  143-6|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48210, 3879, 'Doxycycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984):  1491-2|Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992):  68-71|Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982):  142-6|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996):  1641-3|Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997):  143-6|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48211, 4657, 'Doxycycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984):  1491-2|Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992):  68-71|Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982):  142-6|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996):  1641-3|Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997):  143-6|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48212, 11132, 'Doxycycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984):  1491-2|Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992):  68-71|Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982):  142-6|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996):  1641-3|Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997):  143-6|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48213, 11489, 'Doxycycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984):  1491-2|Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992):  68-71|Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982):  142-6|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996):  1641-3|Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997):  143-6|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48214, 11490, 'Doxycycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984):  1491-2|Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992):  68-71|Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982):  142-6|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996):  1641-3|Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997):  143-6|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48215, 11491, 'Doxycycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984):  1491-2|Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992):  68-71|Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982):  142-6|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996):  1641-3|Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997):  143-6|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48216, 17889, 'Doxycycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984):  1491-2|Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992):  68-71|Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982):  142-6|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996):  1641-3|Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997):  143-6|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48217, 17890, 'Doxycycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984):  1491-2|Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992):  68-71|Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982):  142-6|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996):  1641-3|Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997):  143-6|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48218, 17891, 'Doxycycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984):  1491-2|Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992):  68-71|Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982):  142-6|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996):  1641-3|Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997):  143-6|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48219, 20052, 'Doxycycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984):  1491-2|Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992):  68-71|Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982):  142-6|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996):  1641-3|Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997):  143-6|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48220, 29237, 'Doxycycline', 'Liver Diseases', 'The use of tetracyclines has rarely been associated with hepatotoxicity.  Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs.  Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction.  Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling.  Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.', '2', 'Burette A, Finet C, Prigogine T, De Roy G, Deltenre M "Acute hepatic injury associated with minocycline." Arch Intern Med 144 (1984):  1491-2|Min DI, Burke PA, Lewis D, Jenkins RL "Acute hepatic failure associated with oral minocycline: a case report." Pharmacotherapy 12 (1992):  68-71|Nelis HJ, De Leenheer AP "Metabolism of minocycline in humans." Drug Metab Dispos 10 (1982):  142-6|Brogden RN, Speight TM, Avery GS "Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use." Drugs 9 (1975):  251-91|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Malcolm A, Heap TR, Eckstein RP, Lunzer MR "Minocycline-induced liver injury." Am J Gastroenterol 91 (1996):  1641-3|Golstein PE, Deviere J, Cremer M "Acute hepatitis and drug-related lupus induced by minocycline treatment." Am J Gastroenterol 92 (1997):  143-6|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48221, 3876, 'Doxycycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980):  27|Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984):  223|Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985):  1009-11|Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980):  113-5|Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981):  1359-60|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994):  1185-7|Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996):  547-8|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48222, 3879, 'Doxycycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980):  27|Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984):  223|Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985):  1009-11|Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980):  113-5|Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981):  1359-60|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994):  1185-7|Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996):  547-8|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48223, 4657, 'Doxycycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980):  27|Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984):  223|Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985):  1009-11|Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980):  113-5|Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981):  1359-60|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994):  1185-7|Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996):  547-8|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48224, 11132, 'Doxycycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980):  27|Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984):  223|Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985):  1009-11|Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980):  113-5|Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981):  1359-60|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994):  1185-7|Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996):  547-8|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48225, 11489, 'Doxycycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980):  27|Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984):  223|Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985):  1009-11|Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980):  113-5|Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981):  1359-60|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994):  1185-7|Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996):  547-8|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48226, 11490, 'Doxycycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980):  27|Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984):  223|Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985):  1009-11|Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980):  113-5|Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981):  1359-60|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994):  1185-7|Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996):  547-8|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48227, 11491, 'Doxycycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980):  27|Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984):  223|Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985):  1009-11|Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980):  113-5|Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981):  1359-60|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994):  1185-7|Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996):  547-8|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48228, 17889, 'Doxycycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980):  27|Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984):  223|Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985):  1009-11|Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980):  113-5|Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981):  1359-60|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994):  1185-7|Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996):  547-8|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48229, 17890, 'Doxycycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980):  27|Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984):  223|Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985):  1009-11|Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980):  113-5|Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981):  1359-60|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994):  1185-7|Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996):  547-8|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48230, 17891, 'Doxycycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980):  27|Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984):  223|Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985):  1009-11|Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980):  113-5|Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981):  1359-60|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994):  1185-7|Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996):  547-8|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48231, 20052, 'Doxycycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980):  27|Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984):  223|Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985):  1009-11|Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980):  113-5|Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981):  1359-60|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994):  1185-7|Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996):  547-8|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48232, 29237, 'Doxycycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', 'Aarons B, Bruns BJ "Oesophageal ulceration associated with ingestion of doxycycline." N Z Med J 91 (1980):  27|Geschwind A "Oesophagitis and oesophageal ulceration following ingestion of doxycycline tablets." Med J Aust 140 (1984):  223|Amendola MA, Spera TD "Doxycycline-induced esophagitis." JAMA 253 (1985):  1009-11|Khera DC, Herschman BR, Sosa F "Tetracycline-induced esophageal ulcers." Postgrad Med J 68 (1980):  113-5|Channer KS, Hollanders D "Tetracycline-induced oesophageal ulceration." Br Med J 282 (1981):  1359-60|"Product Information. Vibramycin (doxycycline)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Minocin (minocycline)." Lederle Laboratories  (2002):|"Product Information. Achromycin (tetracycline)." Lederle Laboratories  (2001):|"Product Information. Declomycin (demeclocycline)." Lederle Laboratories  (2001):|Foster JA, Sylvia LM "Doxycyline-induced esophageal ulceration." Ann Pharmacother 28 (1994):  1185-7|Nordt SP "Tetracycline-induced oral mucosal ulceration." Ann Pharmacother 30 (1996):  547-8|"Product Information. Terramycin (oxytetracycline)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48233, 0, 'Doripenem', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48234, 0, 'Doripenem', 'Kidney Diseases', 'Carbapenems are primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from carbapenems, including seizures and other central nervous system disturbances, due to decreased drug clearance.  Dosage adjustments should be considered, with modifications based on degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '3', 'Drusano GL, Standiford HC, Bustamante C, et al. "Multiple-dose pharmacokinetics of imipenem-cilastatin." Antimicrob Agents Chemother 26 (1984):  715-21|Gibson TP, Demetriades JL, Bland JA "Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency." Am J Med 78 (1985):  54-61|Rogers JD, Meisinger AP, Feber F, et al. "Pharmacokinetics of imipenem and cilastatin in volunteers." Rev Infect Dis 7 (1985):  s435-46|Berman SJ, Sugihara JG, Nakamura JM, et al. "Multiple-dose study of imipenem/cilastatin in patients with end-stage renal disease undergoing long-term hemodialysis." Am J Med 78 (1985):  113-6|Somani P, Freimer EH, Gross ML, Higgins JT "Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing continuous ambulatory peritoneal dialysis." Antimicrob Agents Chemother 32 (1988):  530-4|Bax RP, Bastain W, Featherstone A, Wilkinson DM, Hutchison M, Haworth SJ "The pharmacokinetics of meropenem in volunteers." J Antimicrob Chemother 24(suppl a (1989):  311-20|Ljungberg B, Nilsson-Ehle I "Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men." Antimicrob Agents Chemother 36 (1992):  1437-40|Wise R, Logan M, Cooper M, Ashby JP, Andrews JM "Meropenem pharmacokinetics and penetration into an inflammatory exudate." Antimicrob Agents Chemother 34 (1990):  1515-7|Chimata M, Nagase M, Suzuki Y, Shimomura M, Kakuta S "Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease." Antimicrob Agents Chemother 37 (1993):  229-33|Leroy A, Fillastre JP, Borsa-Lebas F, Etienne I, Humbert G "Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment." Antimicrob Agents Chemother 36 (1992):  2794-8|Mouton JW, van den Anker JN "Meropenem clinical pharmacokinetics." Clin Pharmacokinet 28 (1995):  275-86|Leroy A, Fillastre JP, Etienne I, Borsa-Lebas F, Humbert G "Pharmacokinetics of meropenem in subjects with renal insufficiency." Eur J Clin Pharmacol 42 (1992):  535-8|Drusano GL, Hutchison M "The pharmacokinetics of meropenem." Scand J Infect Dis Suppl 96 (1995):  11-6|Christensson BA, Nilsson-Ehle I, Hutchison M, Haworth SJ, Oqvist B, Norrby SR "Pharmacokinetics of meropenem in subjects with various degrees of renal impairment." Antimicrob Agents Chemother 36 (1992):  1532-7|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|Campise M "Neurological complication during imipenem/cilastatin therapy in uraemic patients." Nephrol Dialysis Transplant 13 (1998):  1895-6|"Product Information. Invanz (ertapenem)." Merck & Co., Inc  (2001):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48235, 0, 'Doripenem', 'Central Nervous System Diseases', 'The intravenous use of carbapenems has been associated with central nervous system adverse effects such as seizures (up to 1.5%) and, less frequently, somnolence, encephalopathy, myoclonus, tremor, paresthesia, confusion, agitation, depression, and hallucinations.  Therapy with carbapenems, regardless of route of administration, should be administered cautiously in patients with or predisposed to seizures or other neurologic disturbances.  The normally recommended dosages should not be exceeded in such patients.  In those with a known seizure disorder, anticonvulsant therapy should be continued during carbapenem therapy.', '2', 'Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Wang C, Calandra GB, Aziz MA, Brown KR "Efficacy and safety of imipenem/cilastatin: a review of worldwide clinical experience." Rev Infect Dis 7 (1985):  s528-36|Calandra GB, Brown KR, Grad LC, et al. "Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin." Am J Med 78 (1985):  73-8|Zazgornik J, Schein W, Heimberger K, et al. "Potentiation of neurotoxic side effects by coadministration of imipenem to cyclosporine therapy in a kidney transplant recipient: synergism of side effects or drug." Clin Nephrol 26 (1986):  265-6|Eng RH, Munsif AN, Yangco BG, et al. "Seizure propensity with imipenem." Arch Intern Med 149 (1989):  1881-3|Job ML, Dretler RH "Seizure activity with imipenem therapy: incidence and risk factors." DICP 24 (1990):  467-9|Duque A, Altimiras J, Garcia-Cases C, Vidal P "Vertigo caused by intravenous imipenem/cilastatin." DICP 25 (1991):  1009|Leo RJ, Ballow CH "Seizure activity associated with imipenem use: clinical case reports and review of the literature." DICP 25 (1991):  351-4|"Product Information. Primaxin (imipenem)." Merck & Co., Inc  (2002):|Lane M, Kania D, Rapp RP "Seizures related to use of imipenem-cilastatin." Am J Health Syst Pharm 53 (1996):  1605-6|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|Guglielmo BJ, Jacobs RA "Impact of dosage-monitoring system on frequency of seizures associated with imipenem-cilastatin." Am J Health Syst Pharm 53 (1996):  1097-8|Frucht S, Eidelberg D "Imipenem-induced myoclonus." Mov Disord 12 (1997):  621-2|Campise M "Neurological complication during imipenem/cilastatin therapy in uraemic patients." Nephrol Dialysis Transplant 13 (1998):  1895-6|"Product Information. Invanz (ertapenem)." Merck & Co., Inc  (2001):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48236, 0, 'Doripenem', 'Diseases requiring hemodialysis', 'In patients undergoing hemodialysis, carbapenems are recommended only if the benefit outweighs the potential risk of seizures.  Carbapenems are removed by hemodialysis and should be administered after dialysis to avoid premature removal of the drug.  There is not enough information regarding the use of some carbapenems such as meropenem for injection in patients on dialysis.', '2', '"Product Information. Primaxin (imipenem)." Merck & Co., Inc  (2002):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|Hashimoto S, Honda M, Yamaguchi M, Sekimoto M, Tanaka Y "Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill." Asaio J 43 (1997):  84-8|Thalhammer F, Schenk P, Burgmann H, ElMenyawi I, Hollenstein UM, Rosenkranz AR, SunderPlassmann G, Breyer S, Ratheiser K "Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration." Antimicrob Agents Chemother 42 (1998):  2417-20|Krueger WA, Schroeder TH, Hutchison M, Hoffmann E, Dieterich HJ, Heininger A, Erley C, Wehrle A, Unertl K "Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration." Antimicrob Agents Chemother 42 (1998):  2421-4|Meyer MM, Munar MY, Kohlhepp SJ, Bryant RE "Meropenem pharmacokinetics in a patient with multiorgan failure from meningococcemia undergoing continuous venovenous hemodiafiltration." Am J Kidney Dis 33 (1999):  790-5|Giles LJ, Jennings AC, Thomson AH, Creed G, Beale RJ, McLuckie A "Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration." Crit Care Med 28 (2000):  632-7|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48237, 0, 'Dolasetron', 'Long QT Syndrome', 'Dolasetron may cause acute but usually reversible and self-limiting interval changes in the electrocardiogram, including PR, QTc and JT prolongation and QRS widening.  The incidence and severity of these changes are related to serum levels of the active metabolite, hydrodolasetron.  Cardiovascular morbidity such as heart block and cardiac arrhythmias may occur rarely.  Therapy with dolasetron should be administered cautiously in patients with or predisposed to prolongation of cardiac conduction intervals.  Risk factors include hypokalemia; hypomagnesemia; use of diuretics that may induce electrolyte abnormalities; use of antiarrhythmic agents or other drugs that may cause QTc prolongation; cumulative high-dose anthracycline therapy; significant bradycardia; congestive heart failure; myocardial ischemia; and atrial fibrillation.', '3', '"Product Information. Anzemet (dolasetron)." Hoechst Marion Roussel  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48238, 0, 'Doxercalciferol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48239, 0, 'Doxercalciferol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48240, 0, 'Abciximab', 'Hemorrhagic Disorders', 'The use of gp11b/111a platelet inhibitors is contraindicated in patients with active internal bleeding, recent significant gastrointestinal or genitourinary bleeding (within 6 weeks), recent trauma or major surgery (within 6 weeks), history of bleeding diathesis, recent stroke (within 4 weeks), history of hemorrhage stroke or residual neurologic deficit, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), uncontrolled hypertension (SBP > 180; DBP > 110), or thrombocytopenia (<100,000/mm3).  Thrombocytopenia, serious GI/GU bleeding, hemorrhagic retinopathy, and bleeding at the arterial access have been reported during gp11b/111a platelet inhibitor therapy.  Clinical monitoring of hemoglobin and hematocrit (H/H), platelet count, prothrombin time (PT) and activated partial prothrombin time (aPTT) is recommended prior to initiation of, during and following gp11b/111a platelet inhibitor therapy.', '3', 'Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med 82 (1987):  703-13|Boehrer JD, Kereiakes DJ, Navetta FI, Califf RM, Topol EJ "Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery." Am J Cardiol 74 (1994):  1166-70|Kereiakes DJ, Essell JH, Abbottsmith CW, Broderick TM, Runyon JP "Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion." Am J Cardiol 78 (1996):  1161|"Product Information. Aggrastat (tirofiban)." Merck & Co., Inc  (2001):|Adgey AA "An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors." Am Heart J 135 (1998):  s43-55|Kleiman NS "Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis." Am J Cardiol 80 (1997):  b29-33|The IMPACT-II Investigators "Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II." Lancet 349 (1997):  1422-8|The RESTORE Investigators "Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction..." Circulation 96 (1997):  1445-53|"Product Information. Integrilin (eptifibatide)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48241, 17912, 'Dronedarone', 'Cardiomyopathies', 'Dronedarone has shown to double the risk of death in patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure.  It has also shown to double the risk of stroke and death and hospitalization due to heart failure in patients with atrial fibrillation.  Other patients at risk include patients with second or third degree AV block, or sick sinus syndrome (except when used in conjunction with a functioning pacemaker), patients with bradycardia < 50 bpm, and patients with QT interval prolongation.  The use of dronedarone is contraindicated in these patients.', '3', '"Product Information. Multaq (dronedarone)." sanofi-aventis  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48242, 29021, 'Dronedarone', 'Cardiomyopathies', 'Dronedarone has shown to double the risk of death in patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure.  It has also shown to double the risk of stroke and death and hospitalization due to heart failure in patients with atrial fibrillation.  Other patients at risk include patients with second or third degree AV block, or sick sinus syndrome (except when used in conjunction with a functioning pacemaker), patients with bradycardia < 50 bpm, and patients with QT interval prolongation.  The use of dronedarone is contraindicated in these patients.', '3', '"Product Information. Multaq (dronedarone)." sanofi-aventis  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48243, 29022, 'Dronedarone', 'Cardiomyopathies', 'Dronedarone has shown to double the risk of death in patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure.  It has also shown to double the risk of stroke and death and hospitalization due to heart failure in patients with atrial fibrillation.  Other patients at risk include patients with second or third degree AV block, or sick sinus syndrome (except when used in conjunction with a functioning pacemaker), patients with bradycardia < 50 bpm, and patients with QT interval prolongation.  The use of dronedarone is contraindicated in these patients.', '3', '"Product Information. Multaq (dronedarone)." sanofi-aventis  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48244, 17912, 'Dronedarone', 'Liver Diseases', 'Dronedarone is extensively metabolized by the liver.  There is little clinical experience with moderate hepatic impairment and none in patients with severe hepatic impairment.  No dosage adjustment is recommended for patients with moderate hepatic impairment, however its use is contraindicated in patients with severe hepatic impairment.  Additionally hepatocellular liver injury, including acute liver failure has been reported in patients using dronedarone in the postmarketing setting.  Patients should be advised to report immediately any symptoms suggesting hepatic injury, such as anorexia, nausea, vomiting, fever, malaise, fatigue, right upper quadrant pain, jaundice, dark urine or itching.', '3', '"Product Information. Multaq (dronedarone)." sanofi-aventis  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48245, 29021, 'Dronedarone', 'Liver Diseases', 'Dronedarone is extensively metabolized by the liver.  There is little clinical experience with moderate hepatic impairment and none in patients with severe hepatic impairment.  No dosage adjustment is recommended for patients with moderate hepatic impairment, however its use is contraindicated in patients with severe hepatic impairment.  Additionally hepatocellular liver injury, including acute liver failure has been reported in patients using dronedarone in the postmarketing setting.  Patients should be advised to report immediately any symptoms suggesting hepatic injury, such as anorexia, nausea, vomiting, fever, malaise, fatigue, right upper quadrant pain, jaundice, dark urine or itching.', '3', '"Product Information. Multaq (dronedarone)." sanofi-aventis  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48246, 29022, 'Dronedarone', 'Liver Diseases', 'Dronedarone is extensively metabolized by the liver.  There is little clinical experience with moderate hepatic impairment and none in patients with severe hepatic impairment.  No dosage adjustment is recommended for patients with moderate hepatic impairment, however its use is contraindicated in patients with severe hepatic impairment.  Additionally hepatocellular liver injury, including acute liver failure has been reported in patients using dronedarone in the postmarketing setting.  Patients should be advised to report immediately any symptoms suggesting hepatic injury, such as anorexia, nausea, vomiting, fever, malaise, fatigue, right upper quadrant pain, jaundice, dark urine or itching.', '3', '"Product Information. Multaq (dronedarone)." sanofi-aventis  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48247, 487, 'Amantadine', 'Psychotic Disorders', 'Amantadine may precipitate or exacerbate psychotic symptoms.  Rarely, suicide attempts and suicidal ideation have also been reported, some of which occurred in patients with no prior history of psychiatric illness who were taking short courses of amantadine for influenza.  Therapy with amantadine should be administered cautiously in patients with a history of psychiatric disorders, emotional instability, or substance abuse, and particularly if they are elderly.  It may be prudent to refrain from dispensing large quantities of amantadine to these patients to prevent intentional overdose, which is potentially fatal.', '3', 'Rizzo M, Biandrate P, Tognoni, Morselli PL "Amantadine in depression: relationship between behavioural effects and plasma levels." Eur J Clin Pharmacol 5 (1973):  226-8|Armbruster KF, Rahn AC, Ing TS, Halper IS, Oyama JH, Klawans HL "Amantadine toxicity in a patient with renal insufficiency." Nephron 13 (1974):  183-6|Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975):  212-5|Ing TS, Daugirdas JT, Soung LS, et al. "Toxic effects of amantadine in patients with renal failure." Can Med Assoc J 120 (1979):  695-8|Borison RL "Amantadine-induced psychosis in a geriatric patient with renal disease." Am J Psychiatry 136 (1979):  111-2|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|Hayden FG, Hoffman HE, Spyker DA "Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics." Antimicrob Agents Chemother 23 (1983):  458-64|Nestelbaum Z, Siris SG, Rifkin A, Klar H, Reardon GT "Exacerbation of schizophrenia associated with amantadine." Am J Psychiatry 143 (1986):  1170-1|Degelau J, Somani S, Cooper SL, Irvine PW "Occurrence of adverse effects and high amantadine concentrations with influenza prophylaxis in the nursing home." J Am Geriatr Soc 38 (1990):  428-32|Strange KC, Little DW, Blatnik B "Adverse reactions to amantadine prophylaxis of influenza in a retirement home." J Am Geriatr Soc 33 (1991):  700-5|Somani SK, Degelau J, Cooper SL, Guay DR, Ehresman D, Zaske D "Comparison of pharmacokinetic and safety profiles of amantadine 50- and 100-mg daily doses in elderly nursing home residents." Pharmacotherapy 11 (1991):  460-6|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):|Stroe AE, Hall J, Amin F "Psychotic episode related to phenylpropanolamine and amantadine in a healthy female." Gen Hosp Psychiatry 17 (1995):  457-8|Noveske FG "Breakthrough panic after amantadine treatment in a parkinson''s disease patient." J Clin Psychiatry 57 (1996):  374', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48248, 6469, 'Amantadine', 'Psychotic Disorders', 'Amantadine may precipitate or exacerbate psychotic symptoms.  Rarely, suicide attempts and suicidal ideation have also been reported, some of which occurred in patients with no prior history of psychiatric illness who were taking short courses of amantadine for influenza.  Therapy with amantadine should be administered cautiously in patients with a history of psychiatric disorders, emotional instability, or substance abuse, and particularly if they are elderly.  It may be prudent to refrain from dispensing large quantities of amantadine to these patients to prevent intentional overdose, which is potentially fatal.', '3', 'Rizzo M, Biandrate P, Tognoni, Morselli PL "Amantadine in depression: relationship between behavioural effects and plasma levels." Eur J Clin Pharmacol 5 (1973):  226-8|Armbruster KF, Rahn AC, Ing TS, Halper IS, Oyama JH, Klawans HL "Amantadine toxicity in a patient with renal insufficiency." Nephron 13 (1974):  183-6|Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975):  212-5|Ing TS, Daugirdas JT, Soung LS, et al. "Toxic effects of amantadine in patients with renal failure." Can Med Assoc J 120 (1979):  695-8|Borison RL "Amantadine-induced psychosis in a geriatric patient with renal disease." Am J Psychiatry 136 (1979):  111-2|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|Hayden FG, Hoffman HE, Spyker DA "Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics." Antimicrob Agents Chemother 23 (1983):  458-64|Nestelbaum Z, Siris SG, Rifkin A, Klar H, Reardon GT "Exacerbation of schizophrenia associated with amantadine." Am J Psychiatry 143 (1986):  1170-1|Degelau J, Somani S, Cooper SL, Irvine PW "Occurrence of adverse effects and high amantadine concentrations with influenza prophylaxis in the nursing home." J Am Geriatr Soc 38 (1990):  428-32|Strange KC, Little DW, Blatnik B "Adverse reactions to amantadine prophylaxis of influenza in a retirement home." J Am Geriatr Soc 33 (1991):  700-5|Somani SK, Degelau J, Cooper SL, Guay DR, Ehresman D, Zaske D "Comparison of pharmacokinetic and safety profiles of amantadine 50- and 100-mg daily doses in elderly nursing home residents." Pharmacotherapy 11 (1991):  460-6|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):|Stroe AE, Hall J, Amin F "Psychotic episode related to phenylpropanolamine and amantadine in a healthy female." Gen Hosp Psychiatry 17 (1995):  457-8|Noveske FG "Breakthrough panic after amantadine treatment in a parkinson''s disease patient." J Clin Psychiatry 57 (1996):  374', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48249, 13461, 'Amantadine', 'Psychotic Disorders', 'Amantadine may precipitate or exacerbate psychotic symptoms.  Rarely, suicide attempts and suicidal ideation have also been reported, some of which occurred in patients with no prior history of psychiatric illness who were taking short courses of amantadine for influenza.  Therapy with amantadine should be administered cautiously in patients with a history of psychiatric disorders, emotional instability, or substance abuse, and particularly if they are elderly.  It may be prudent to refrain from dispensing large quantities of amantadine to these patients to prevent intentional overdose, which is potentially fatal.', '3', 'Rizzo M, Biandrate P, Tognoni, Morselli PL "Amantadine in depression: relationship between behavioural effects and plasma levels." Eur J Clin Pharmacol 5 (1973):  226-8|Armbruster KF, Rahn AC, Ing TS, Halper IS, Oyama JH, Klawans HL "Amantadine toxicity in a patient with renal insufficiency." Nephron 13 (1974):  183-6|Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975):  212-5|Ing TS, Daugirdas JT, Soung LS, et al. "Toxic effects of amantadine in patients with renal failure." Can Med Assoc J 120 (1979):  695-8|Borison RL "Amantadine-induced psychosis in a geriatric patient with renal disease." Am J Psychiatry 136 (1979):  111-2|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|Hayden FG, Hoffman HE, Spyker DA "Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics." Antimicrob Agents Chemother 23 (1983):  458-64|Nestelbaum Z, Siris SG, Rifkin A, Klar H, Reardon GT "Exacerbation of schizophrenia associated with amantadine." Am J Psychiatry 143 (1986):  1170-1|Degelau J, Somani S, Cooper SL, Irvine PW "Occurrence of adverse effects and high amantadine concentrations with influenza prophylaxis in the nursing home." J Am Geriatr Soc 38 (1990):  428-32|Strange KC, Little DW, Blatnik B "Adverse reactions to amantadine prophylaxis of influenza in a retirement home." J Am Geriatr Soc 33 (1991):  700-5|Somani SK, Degelau J, Cooper SL, Guay DR, Ehresman D, Zaske D "Comparison of pharmacokinetic and safety profiles of amantadine 50- and 100-mg daily doses in elderly nursing home residents." Pharmacotherapy 11 (1991):  460-6|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):|Stroe AE, Hall J, Amin F "Psychotic episode related to phenylpropanolamine and amantadine in a healthy female." Gen Hosp Psychiatry 17 (1995):  457-8|Noveske FG "Breakthrough panic after amantadine treatment in a parkinson''s disease patient." J Clin Psychiatry 57 (1996):  374', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48250, 13888, 'Amantadine', 'Psychotic Disorders', 'Amantadine may precipitate or exacerbate psychotic symptoms.  Rarely, suicide attempts and suicidal ideation have also been reported, some of which occurred in patients with no prior history of psychiatric illness who were taking short courses of amantadine for influenza.  Therapy with amantadine should be administered cautiously in patients with a history of psychiatric disorders, emotional instability, or substance abuse, and particularly if they are elderly.  It may be prudent to refrain from dispensing large quantities of amantadine to these patients to prevent intentional overdose, which is potentially fatal.', '3', 'Rizzo M, Biandrate P, Tognoni, Morselli PL "Amantadine in depression: relationship between behavioural effects and plasma levels." Eur J Clin Pharmacol 5 (1973):  226-8|Armbruster KF, Rahn AC, Ing TS, Halper IS, Oyama JH, Klawans HL "Amantadine toxicity in a patient with renal insufficiency." Nephron 13 (1974):  183-6|Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975):  212-5|Ing TS, Daugirdas JT, Soung LS, et al. "Toxic effects of amantadine in patients with renal failure." Can Med Assoc J 120 (1979):  695-8|Borison RL "Amantadine-induced psychosis in a geriatric patient with renal disease." Am J Psychiatry 136 (1979):  111-2|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|Hayden FG, Hoffman HE, Spyker DA "Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics." Antimicrob Agents Chemother 23 (1983):  458-64|Nestelbaum Z, Siris SG, Rifkin A, Klar H, Reardon GT "Exacerbation of schizophrenia associated with amantadine." Am J Psychiatry 143 (1986):  1170-1|Degelau J, Somani S, Cooper SL, Irvine PW "Occurrence of adverse effects and high amantadine concentrations with influenza prophylaxis in the nursing home." J Am Geriatr Soc 38 (1990):  428-32|Strange KC, Little DW, Blatnik B "Adverse reactions to amantadine prophylaxis of influenza in a retirement home." J Am Geriatr Soc 33 (1991):  700-5|Somani SK, Degelau J, Cooper SL, Guay DR, Ehresman D, Zaske D "Comparison of pharmacokinetic and safety profiles of amantadine 50- and 100-mg daily doses in elderly nursing home residents." Pharmacotherapy 11 (1991):  460-6|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):|Stroe AE, Hall J, Amin F "Psychotic episode related to phenylpropanolamine and amantadine in a healthy female." Gen Hosp Psychiatry 17 (1995):  457-8|Noveske FG "Breakthrough panic after amantadine treatment in a parkinson''s disease patient." J Clin Psychiatry 57 (1996):  374', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48251, 24976, 'Amantadine', 'Psychotic Disorders', 'Amantadine may precipitate or exacerbate psychotic symptoms.  Rarely, suicide attempts and suicidal ideation have also been reported, some of which occurred in patients with no prior history of psychiatric illness who were taking short courses of amantadine for influenza.  Therapy with amantadine should be administered cautiously in patients with a history of psychiatric disorders, emotional instability, or substance abuse, and particularly if they are elderly.  It may be prudent to refrain from dispensing large quantities of amantadine to these patients to prevent intentional overdose, which is potentially fatal.', '3', 'Rizzo M, Biandrate P, Tognoni, Morselli PL "Amantadine in depression: relationship between behavioural effects and plasma levels." Eur J Clin Pharmacol 5 (1973):  226-8|Armbruster KF, Rahn AC, Ing TS, Halper IS, Oyama JH, Klawans HL "Amantadine toxicity in a patient with renal insufficiency." Nephron 13 (1974):  183-6|Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975):  212-5|Ing TS, Daugirdas JT, Soung LS, et al. "Toxic effects of amantadine in patients with renal failure." Can Med Assoc J 120 (1979):  695-8|Borison RL "Amantadine-induced psychosis in a geriatric patient with renal disease." Am J Psychiatry 136 (1979):  111-2|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|Hayden FG, Hoffman HE, Spyker DA "Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics." Antimicrob Agents Chemother 23 (1983):  458-64|Nestelbaum Z, Siris SG, Rifkin A, Klar H, Reardon GT "Exacerbation of schizophrenia associated with amantadine." Am J Psychiatry 143 (1986):  1170-1|Degelau J, Somani S, Cooper SL, Irvine PW "Occurrence of adverse effects and high amantadine concentrations with influenza prophylaxis in the nursing home." J Am Geriatr Soc 38 (1990):  428-32|Strange KC, Little DW, Blatnik B "Adverse reactions to amantadine prophylaxis of influenza in a retirement home." J Am Geriatr Soc 33 (1991):  700-5|Somani SK, Degelau J, Cooper SL, Guay DR, Ehresman D, Zaske D "Comparison of pharmacokinetic and safety profiles of amantadine 50- and 100-mg daily doses in elderly nursing home residents." Pharmacotherapy 11 (1991):  460-6|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):|Stroe AE, Hall J, Amin F "Psychotic episode related to phenylpropanolamine and amantadine in a healthy female." Gen Hosp Psychiatry 17 (1995):  457-8|Noveske FG "Breakthrough panic after amantadine treatment in a parkinson''s disease patient." J Clin Psychiatry 57 (1996):  374', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48252, 24977, 'Amantadine', 'Psychotic Disorders', 'Amantadine may precipitate or exacerbate psychotic symptoms.  Rarely, suicide attempts and suicidal ideation have also been reported, some of which occurred in patients with no prior history of psychiatric illness who were taking short courses of amantadine for influenza.  Therapy with amantadine should be administered cautiously in patients with a history of psychiatric disorders, emotional instability, or substance abuse, and particularly if they are elderly.  It may be prudent to refrain from dispensing large quantities of amantadine to these patients to prevent intentional overdose, which is potentially fatal.', '3', 'Rizzo M, Biandrate P, Tognoni, Morselli PL "Amantadine in depression: relationship between behavioural effects and plasma levels." Eur J Clin Pharmacol 5 (1973):  226-8|Armbruster KF, Rahn AC, Ing TS, Halper IS, Oyama JH, Klawans HL "Amantadine toxicity in a patient with renal insufficiency." Nephron 13 (1974):  183-6|Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975):  212-5|Ing TS, Daugirdas JT, Soung LS, et al. "Toxic effects of amantadine in patients with renal failure." Can Med Assoc J 120 (1979):  695-8|Borison RL "Amantadine-induced psychosis in a geriatric patient with renal disease." Am J Psychiatry 136 (1979):  111-2|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|Hayden FG, Hoffman HE, Spyker DA "Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics." Antimicrob Agents Chemother 23 (1983):  458-64|Nestelbaum Z, Siris SG, Rifkin A, Klar H, Reardon GT "Exacerbation of schizophrenia associated with amantadine." Am J Psychiatry 143 (1986):  1170-1|Degelau J, Somani S, Cooper SL, Irvine PW "Occurrence of adverse effects and high amantadine concentrations with influenza prophylaxis in the nursing home." J Am Geriatr Soc 38 (1990):  428-32|Strange KC, Little DW, Blatnik B "Adverse reactions to amantadine prophylaxis of influenza in a retirement home." J Am Geriatr Soc 33 (1991):  700-5|Somani SK, Degelau J, Cooper SL, Guay DR, Ehresman D, Zaske D "Comparison of pharmacokinetic and safety profiles of amantadine 50- and 100-mg daily doses in elderly nursing home residents." Pharmacotherapy 11 (1991):  460-6|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):|Stroe AE, Hall J, Amin F "Psychotic episode related to phenylpropanolamine and amantadine in a healthy female." Gen Hosp Psychiatry 17 (1995):  457-8|Noveske FG "Breakthrough panic after amantadine treatment in a parkinson''s disease patient." J Clin Psychiatry 57 (1996):  374', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48253, 29395, 'Amantadine', 'Psychotic Disorders', 'Amantadine may precipitate or exacerbate psychotic symptoms.  Rarely, suicide attempts and suicidal ideation have also been reported, some of which occurred in patients with no prior history of psychiatric illness who were taking short courses of amantadine for influenza.  Therapy with amantadine should be administered cautiously in patients with a history of psychiatric disorders, emotional instability, or substance abuse, and particularly if they are elderly.  It may be prudent to refrain from dispensing large quantities of amantadine to these patients to prevent intentional overdose, which is potentially fatal.', '3', 'Rizzo M, Biandrate P, Tognoni, Morselli PL "Amantadine in depression: relationship between behavioural effects and plasma levels." Eur J Clin Pharmacol 5 (1973):  226-8|Armbruster KF, Rahn AC, Ing TS, Halper IS, Oyama JH, Klawans HL "Amantadine toxicity in a patient with renal insufficiency." Nephron 13 (1974):  183-6|Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975):  212-5|Ing TS, Daugirdas JT, Soung LS, et al. "Toxic effects of amantadine in patients with renal failure." Can Med Assoc J 120 (1979):  695-8|Borison RL "Amantadine-induced psychosis in a geriatric patient with renal disease." Am J Psychiatry 136 (1979):  111-2|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|Hayden FG, Hoffman HE, Spyker DA "Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics." Antimicrob Agents Chemother 23 (1983):  458-64|Nestelbaum Z, Siris SG, Rifkin A, Klar H, Reardon GT "Exacerbation of schizophrenia associated with amantadine." Am J Psychiatry 143 (1986):  1170-1|Degelau J, Somani S, Cooper SL, Irvine PW "Occurrence of adverse effects and high amantadine concentrations with influenza prophylaxis in the nursing home." J Am Geriatr Soc 38 (1990):  428-32|Strange KC, Little DW, Blatnik B "Adverse reactions to amantadine prophylaxis of influenza in a retirement home." J Am Geriatr Soc 33 (1991):  700-5|Somani SK, Degelau J, Cooper SL, Guay DR, Ehresman D, Zaske D "Comparison of pharmacokinetic and safety profiles of amantadine 50- and 100-mg daily doses in elderly nursing home residents." Pharmacotherapy 11 (1991):  460-6|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):|Stroe AE, Hall J, Amin F "Psychotic episode related to phenylpropanolamine and amantadine in a healthy female." Gen Hosp Psychiatry 17 (1995):  457-8|Noveske FG "Breakthrough panic after amantadine treatment in a parkinson''s disease patient." J Clin Psychiatry 57 (1996):  374', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48254, 487, 'Amantadine', 'Kidney Diseases', 'Amantadine is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from amantadine due to decreased drug clearance.  Therapy with amantadine should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended for patients with moderate to severe renal dysfunction.', '3', 'Armbruster KF, Rahn AC, Ing TS, Halper IS, Oyama JH, Klawans HL "Amantadine toxicity in a patient with renal insufficiency." Nephron 13 (1974):  183-6|Ing TS, Daugirdas JT, Soung LS, et al. "Toxic effects of amantadine in patients with renal failure." Can Med Assoc J 120 (1979):  695-8|Borison RL "Amantadine-induced psychosis in a geriatric patient with renal disease." Am J Psychiatry 136 (1979):  111-2|Horadam VW, Sharp JG, Smilack JD, et al. "Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function." Ann Intern Med 94 (1981):  454-8|Wu MJ, Ing TS, Soung LS, Daugirdas JT, Hano JE, Gandhi VC "Amantadine hydrochloride pharmacokinetics in patients with impaired renal function." Clin Nephrol 17 (1982):  19-23|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48255, 6469, 'Amantadine', 'Kidney Diseases', 'Amantadine is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from amantadine due to decreased drug clearance.  Therapy with amantadine should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended for patients with moderate to severe renal dysfunction.', '3', 'Armbruster KF, Rahn AC, Ing TS, Halper IS, Oyama JH, Klawans HL "Amantadine toxicity in a patient with renal insufficiency." Nephron 13 (1974):  183-6|Ing TS, Daugirdas JT, Soung LS, et al. "Toxic effects of amantadine in patients with renal failure." Can Med Assoc J 120 (1979):  695-8|Borison RL "Amantadine-induced psychosis in a geriatric patient with renal disease." Am J Psychiatry 136 (1979):  111-2|Horadam VW, Sharp JG, Smilack JD, et al. "Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function." Ann Intern Med 94 (1981):  454-8|Wu MJ, Ing TS, Soung LS, Daugirdas JT, Hano JE, Gandhi VC "Amantadine hydrochloride pharmacokinetics in patients with impaired renal function." Clin Nephrol 17 (1982):  19-23|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48256, 13461, 'Amantadine', 'Kidney Diseases', 'Amantadine is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from amantadine due to decreased drug clearance.  Therapy with amantadine should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended for patients with moderate to severe renal dysfunction.', '3', 'Armbruster KF, Rahn AC, Ing TS, Halper IS, Oyama JH, Klawans HL "Amantadine toxicity in a patient with renal insufficiency." Nephron 13 (1974):  183-6|Ing TS, Daugirdas JT, Soung LS, et al. "Toxic effects of amantadine in patients with renal failure." Can Med Assoc J 120 (1979):  695-8|Borison RL "Amantadine-induced psychosis in a geriatric patient with renal disease." Am J Psychiatry 136 (1979):  111-2|Horadam VW, Sharp JG, Smilack JD, et al. "Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function." Ann Intern Med 94 (1981):  454-8|Wu MJ, Ing TS, Soung LS, Daugirdas JT, Hano JE, Gandhi VC "Amantadine hydrochloride pharmacokinetics in patients with impaired renal function." Clin Nephrol 17 (1982):  19-23|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48257, 13888, 'Amantadine', 'Kidney Diseases', 'Amantadine is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from amantadine due to decreased drug clearance.  Therapy with amantadine should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended for patients with moderate to severe renal dysfunction.', '3', 'Armbruster KF, Rahn AC, Ing TS, Halper IS, Oyama JH, Klawans HL "Amantadine toxicity in a patient with renal insufficiency." Nephron 13 (1974):  183-6|Ing TS, Daugirdas JT, Soung LS, et al. "Toxic effects of amantadine in patients with renal failure." Can Med Assoc J 120 (1979):  695-8|Borison RL "Amantadine-induced psychosis in a geriatric patient with renal disease." Am J Psychiatry 136 (1979):  111-2|Horadam VW, Sharp JG, Smilack JD, et al. "Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function." Ann Intern Med 94 (1981):  454-8|Wu MJ, Ing TS, Soung LS, Daugirdas JT, Hano JE, Gandhi VC "Amantadine hydrochloride pharmacokinetics in patients with impaired renal function." Clin Nephrol 17 (1982):  19-23|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48258, 24976, 'Amantadine', 'Kidney Diseases', 'Amantadine is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from amantadine due to decreased drug clearance.  Therapy with amantadine should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended for patients with moderate to severe renal dysfunction.', '3', 'Armbruster KF, Rahn AC, Ing TS, Halper IS, Oyama JH, Klawans HL "Amantadine toxicity in a patient with renal insufficiency." Nephron 13 (1974):  183-6|Ing TS, Daugirdas JT, Soung LS, et al. "Toxic effects of amantadine in patients with renal failure." Can Med Assoc J 120 (1979):  695-8|Borison RL "Amantadine-induced psychosis in a geriatric patient with renal disease." Am J Psychiatry 136 (1979):  111-2|Horadam VW, Sharp JG, Smilack JD, et al. "Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function." Ann Intern Med 94 (1981):  454-8|Wu MJ, Ing TS, Soung LS, Daugirdas JT, Hano JE, Gandhi VC "Amantadine hydrochloride pharmacokinetics in patients with impaired renal function." Clin Nephrol 17 (1982):  19-23|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48259, 24977, 'Amantadine', 'Kidney Diseases', 'Amantadine is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from amantadine due to decreased drug clearance.  Therapy with amantadine should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended for patients with moderate to severe renal dysfunction.', '3', 'Armbruster KF, Rahn AC, Ing TS, Halper IS, Oyama JH, Klawans HL "Amantadine toxicity in a patient with renal insufficiency." Nephron 13 (1974):  183-6|Ing TS, Daugirdas JT, Soung LS, et al. "Toxic effects of amantadine in patients with renal failure." Can Med Assoc J 120 (1979):  695-8|Borison RL "Amantadine-induced psychosis in a geriatric patient with renal disease." Am J Psychiatry 136 (1979):  111-2|Horadam VW, Sharp JG, Smilack JD, et al. "Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function." Ann Intern Med 94 (1981):  454-8|Wu MJ, Ing TS, Soung LS, Daugirdas JT, Hano JE, Gandhi VC "Amantadine hydrochloride pharmacokinetics in patients with impaired renal function." Clin Nephrol 17 (1982):  19-23|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48260, 29395, 'Amantadine', 'Kidney Diseases', 'Amantadine is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from amantadine due to decreased drug clearance.  Therapy with amantadine should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended for patients with moderate to severe renal dysfunction.', '3', 'Armbruster KF, Rahn AC, Ing TS, Halper IS, Oyama JH, Klawans HL "Amantadine toxicity in a patient with renal insufficiency." Nephron 13 (1974):  183-6|Ing TS, Daugirdas JT, Soung LS, et al. "Toxic effects of amantadine in patients with renal failure." Can Med Assoc J 120 (1979):  695-8|Borison RL "Amantadine-induced psychosis in a geriatric patient with renal disease." Am J Psychiatry 136 (1979):  111-2|Horadam VW, Sharp JG, Smilack JD, et al. "Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function." Ann Intern Med 94 (1981):  454-8|Wu MJ, Ing TS, Soung LS, Daugirdas JT, Hano JE, Gandhi VC "Amantadine hydrochloride pharmacokinetics in patients with impaired renal function." Clin Nephrol 17 (1982):  19-23|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48261, 487, 'Amantadine', 'Epilepsy', 'Amantadine may rarely precipitate or exacerbate seizure activity.  Patients with epilepsy or predisposed to seizures should be monitored closely for increased seizure activity during therapy with amantadine.', '3', 'Ing TS, Daugirdas JT, Soung LS, et al. "Toxic effects of amantadine in patients with renal failure." Can Med Assoc J 120 (1979):  695-8|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48262, 6469, 'Amantadine', 'Epilepsy', 'Amantadine may rarely precipitate or exacerbate seizure activity.  Patients with epilepsy or predisposed to seizures should be monitored closely for increased seizure activity during therapy with amantadine.', '3', 'Ing TS, Daugirdas JT, Soung LS, et al. "Toxic effects of amantadine in patients with renal failure." Can Med Assoc J 120 (1979):  695-8|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48263, 13461, 'Amantadine', 'Epilepsy', 'Amantadine may rarely precipitate or exacerbate seizure activity.  Patients with epilepsy or predisposed to seizures should be monitored closely for increased seizure activity during therapy with amantadine.', '3', 'Ing TS, Daugirdas JT, Soung LS, et al. "Toxic effects of amantadine in patients with renal failure." Can Med Assoc J 120 (1979):  695-8|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48264, 13888, 'Amantadine', 'Epilepsy', 'Amantadine may rarely precipitate or exacerbate seizure activity.  Patients with epilepsy or predisposed to seizures should be monitored closely for increased seizure activity during therapy with amantadine.', '3', 'Ing TS, Daugirdas JT, Soung LS, et al. "Toxic effects of amantadine in patients with renal failure." Can Med Assoc J 120 (1979):  695-8|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48265, 24976, 'Amantadine', 'Epilepsy', 'Amantadine may rarely precipitate or exacerbate seizure activity.  Patients with epilepsy or predisposed to seizures should be monitored closely for increased seizure activity during therapy with amantadine.', '3', 'Ing TS, Daugirdas JT, Soung LS, et al. "Toxic effects of amantadine in patients with renal failure." Can Med Assoc J 120 (1979):  695-8|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48266, 24977, 'Amantadine', 'Epilepsy', 'Amantadine may rarely precipitate or exacerbate seizure activity.  Patients with epilepsy or predisposed to seizures should be monitored closely for increased seizure activity during therapy with amantadine.', '3', 'Ing TS, Daugirdas JT, Soung LS, et al. "Toxic effects of amantadine in patients with renal failure." Can Med Assoc J 120 (1979):  695-8|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48267, 29395, 'Amantadine', 'Epilepsy', 'Amantadine may rarely precipitate or exacerbate seizure activity.  Patients with epilepsy or predisposed to seizures should be monitored closely for increased seizure activity during therapy with amantadine.', '3', 'Ing TS, Daugirdas JT, Soung LS, et al. "Toxic effects of amantadine in patients with renal failure." Can Med Assoc J 120 (1979):  695-8|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|Millet VM, Dreisbach M, Bryson YJ "Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine." Antimicrob Agents Chemother 21 (1982):  1-4|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48268, 487, 'Amantadine', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48269, 6469, 'Amantadine', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48270, 13461, 'Amantadine', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48271, 13888, 'Amantadine', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48272, 24976, 'Amantadine', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48273, 24977, 'Amantadine', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48274, 29395, 'Amantadine', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48275, 487, 'Amantadine', 'Heart Failure', 'Amantadine may occasionally cause peripheral edema and, rarely, congestive heart failure.  Patients with edema or congestive heart failure should be monitored closely for exacerbation of their condition.  Dosage adjustments may be necessary.', '2', 'Vale JA, Maclfan KS "Amantadine-induced heart-failure." Lancet 1 (1977):  548|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48276, 6469, 'Amantadine', 'Heart Failure', 'Amantadine may occasionally cause peripheral edema and, rarely, congestive heart failure.  Patients with edema or congestive heart failure should be monitored closely for exacerbation of their condition.  Dosage adjustments may be necessary.', '2', 'Vale JA, Maclfan KS "Amantadine-induced heart-failure." Lancet 1 (1977):  548|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48277, 13461, 'Amantadine', 'Heart Failure', 'Amantadine may occasionally cause peripheral edema and, rarely, congestive heart failure.  Patients with edema or congestive heart failure should be monitored closely for exacerbation of their condition.  Dosage adjustments may be necessary.', '2', 'Vale JA, Maclfan KS "Amantadine-induced heart-failure." Lancet 1 (1977):  548|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48278, 13888, 'Amantadine', 'Heart Failure', 'Amantadine may occasionally cause peripheral edema and, rarely, congestive heart failure.  Patients with edema or congestive heart failure should be monitored closely for exacerbation of their condition.  Dosage adjustments may be necessary.', '2', 'Vale JA, Maclfan KS "Amantadine-induced heart-failure." Lancet 1 (1977):  548|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48279, 24976, 'Amantadine', 'Heart Failure', 'Amantadine may occasionally cause peripheral edema and, rarely, congestive heart failure.  Patients with edema or congestive heart failure should be monitored closely for exacerbation of their condition.  Dosage adjustments may be necessary.', '2', 'Vale JA, Maclfan KS "Amantadine-induced heart-failure." Lancet 1 (1977):  548|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48280, 24977, 'Amantadine', 'Heart Failure', 'Amantadine may occasionally cause peripheral edema and, rarely, congestive heart failure.  Patients with edema or congestive heart failure should be monitored closely for exacerbation of their condition.  Dosage adjustments may be necessary.', '2', 'Vale JA, Maclfan KS "Amantadine-induced heart-failure." Lancet 1 (1977):  548|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48281, 29395, 'Amantadine', 'Heart Failure', 'Amantadine may occasionally cause peripheral edema and, rarely, congestive heart failure.  Patients with edema or congestive heart failure should be monitored closely for exacerbation of their condition.  Dosage adjustments may be necessary.', '2', 'Vale JA, Maclfan KS "Amantadine-induced heart-failure." Lancet 1 (1977):  548|"Product Information. Symmetrel (amantadine)." DuPont Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48282, 0, 'Droxidopa', 'Cardiovascular disease', 'Droxidopa is directly metabolized in vivo to norepinephrine via decarboxylation.  As such, it may exacerbate certain cardiovascular conditions by increasing blood pressure and heart rate.  Therapy with droxidopa should be considered cautiously in patients with ischemic heart disease, arrhythmias, or congestive heart failure.  Additionally, droxidopa may exacerbate supine hypertension in patients with neurogenic orthostatic hypotension.  Patients should be advised to elevate the head of the bed while resting or sleeping.  Blood pressure should be monitored both in supine position and the head- elevated sleeping position.  If hypertension persists, then droxidopa dosage should be reduced or discontinued.  If hypertension is not well managed, it can increase the risk of cardiovascular events, especially stroke.', '2', '"Product Information. Northera (droxidopa)." Chelsea Therapeutics Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48283, 0, 'Droxidopa', 'Kidney Diseases', 'Droxidopa and its metabolites is primarily cleared by the kidneys.  Patients with mild and moderate renal impairment did not show adverse reactions in clinical trials.  However, the clinical experience in patients with severe renal function (GFR < 30 mL/min) is limited.  Caution is advised in patients with severe renal impairment.', '2', '"Product Information. Northera (droxidopa)." Chelsea Therapeutics Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48284, 0, 'Dronabinol', 'Seizures', 'Seizures and seizure- like activity have been reported in patients using dronabinol.  Caution is advised in patients with history of a seizure disorder, as dronabinol may lower seizure threshold.  Therapy should be discontinued immediately in patients who develop seizures and medical attention should be sought immediately.', '2', '"Product Information. Marinol (dronabinol)." Roxane Laboratories Inc  (2001):|"Product Information. Syndros (dronabinol)." Insys Therapeutics Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48285, 0, 'Dronabinol', 'Heart Diseases', 'The use of some antiemetics such as dronabinol and nabilone has been associated with occasional hypotension, possible hypertension, syncope or tachycardia.  Therapy with these drugs should be administered cautiously in patients with cardiac disease.', '2', '"Product Information. Marinol (dronabinol)." Roxane Laboratories Inc  (2001):|"Product Information. Cesamet (nabilone)." Valeant Pharmaceuticals  (2006):|"Product Information. Syndros (dronabinol)." Insys Therapeutics Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48286, 0, 'Dronabinol', 'Psychotic Disorders', 'Some antiemetics such as dronabinol and nabilone may precipitate or exacerbate psychotic symptoms or anxiety, depression, hallucinations or psychosis.  Therapy with these drugs should be administered cautiously in patients with a history of psychiatric disorders, emotional instability, or depression, and particularly if they are elderly.  Careful psychiatric monitoring is advised.', '2', '"Product Information. Marinol (dronabinol)." Roxane Laboratories Inc  (2001):|"Product Information. Cesamet (nabilone)." Valeant Pharmaceuticals  (2006):|"Product Information. Syndros (dronabinol)." Insys Therapeutics Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48287, 0, 'Dronabinol', 'Substance-Related Disorders', 'Some antiemetics as dronabinol and nabilone have a significant potential for abuse.  Therapy with these drugs should be administered cautiously in patients with a history of substance abuse.  It may be prudent to refrain from dispensing large quantities of dronabinol to these patients.', '2', '"Product Information. Marinol (dronabinol)." Roxane Laboratories Inc  (2001):|"Product Information. Cesamet (nabilone)." Valeant Pharmaceuticals  (2006):|"Product Information. Syndros (dronabinol)." Insys Therapeutics Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48288, 208, 'Doxylamine', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48289, 208, 'Doxylamine', 'Anticholinergic Syndrome', 'Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects.  In contrast, the newer, relatively nonsedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.', '2', 'Schuller DE, Turkewitz D "Adverse effects of antihistamines." Postgrad Med 79 (1986):  75-86|"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Marezine (cyclizine)." Glaxo Wellcome  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|"Product Information. Semprex-D (acrivastine-pseudoephedrine)." Endo Laboratories LLC  (2001):|"Product Information. Zyrtec (cetirizine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Drixoral (dextromethorphan)." Schering-Plough  (2001):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):|Watemberg NM, Roth KS, Alehan FK, Epstein CE "Central anticholinergic syndrome on therapeutic doses of cyproheptadine." Pediatrics 103 (1999):  158-60|"Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48290, 208, 'Doxylamine', 'Asthma', 'It has been suggested that the anticholinergic effect of antihistamines may reduce the volume and cause thickening of bronchial secretions, resulting in obstruction of respiratory tract.  Some manufacturers and clinicians recommend that therapy with antihistamines be administered cautiously in patients with asthma or chronic obstructive pulmonary disease.', '2', '"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Maddox DE, Reed CE "Clinical pharmacodynamics of antihistamines." Ann Allergy 59 (1987):  43-8|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Marezine (cyclizine)." Glaxo Wellcome  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|"Product Information. Semprex-D (acrivastine-pseudoephedrine)." Endo Laboratories LLC  (2001):|"Product Information. Drixoral (dextromethorphan)." Schering-Plough  (2001):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):|"Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48291, 208, 'Doxylamine', 'Cardiovascular Diseases', 'Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities.  Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported.  Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.', '2', 'Schuller DE, Turkewitz D "Adverse effects of antihistamines." Postgrad Med 79 (1986):  75-86|"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|Smith SJ "Cardiovascular toxicity of antihistamines." Otolaryngol Head Neck Surg 111 Suppl (1994):  348-54|"Product Information. Zyrtec (cetirizine)." Pfizer U.S. Pharmaceuticals  (2001):|Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996):  233-52|"Product Information. Drixoral (dextromethorphan)." Schering-Plough  (2001):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):|"Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48292, 208, 'Doxylamine', 'Liver Diseases', 'Limited pharmacokinetic data are available for the older, first-generation antihistamines.  Many appear to be primarily metabolized by the liver, and both parent drugs and metabolites are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from antihistamines due to drug and metabolite accumulation.  Therapy with antihistamines should be administered cautiously in such patients.  Lower initial dosages may be appropriate.', '2', 'Glazko AJ, Dill WA, Young RM, Smith TC, Ogilvie RI "Metabolic disposition of diphenhydramine." Clin Pharmacol Ther 16 (1974):  1066-76|Paton DM, Webster DR "Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines)." Clin Pharmacokinet 10 (1985):  477-97|Rumore MM "Clinical pharmacokinetics of chlorpheniramine." Drug Intell Clin Pharm 18 (1984):  701-7|Huang SM, Athanikar NK, Sridhar K, Huang YC, Chiou WL "Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults." Eur J Clin Pharmacol 22 (1982):  359-65|Simons KJ, Simons FE, Luciuk GH, Frith EM "Urinary excretion of chlorpheniramine and its metabolites in children." J Pharm Sci 73 (1984):  595-9|Meredith CG, Christian CD Jr, Johnson RF, Madhavan SV, Schenker S "Diphenhydramine disposition in chronic liver disease." Clin Pharmacol Ther 35 (1984):  474-9|Blyden GT, Greenblatt DJ, Scavone JM, Shader RI "Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration." J Clin Pharmacol 26 (1986):  529-33|Albert KS, Hallmark MR, Sakmar E, Weidler DJ, Wagner JG "Pharmacokinetics of diphenhydramine in man." J Pharmacokinet Biopharm 3 (1975):  159-70|Simons FE, Frith EM, Simons KJ "The pharmacokinetics and antihistaminic effects of brompheniramine." J Allergy Clin Immunol 70 (1982):  458-64|Bruce RB, Turnbull LB, Newman JH, Pitts JE "Metabolism of brompheniramine." J Med Chem 11 (1968):  1031-4|Porter CC, Arison BH, Gruber VF, Titus DC, Vandenheuvel WJ "Human metabolism of cyproheptadine." Drug Metab Dispos 3 (1975):  189-97|Hintze KL, Wold JS, Fischer LJ "Disposition of cyproheptadine in rats, mice, and humans and identification of a stable epoxide metabolite." Drug Metab Dispos 3 (1975):  1-9|Maddox DE, Reed CE "Clinical pharmacodynamics of antihistamines." Ann Allergy 59 (1987):  43-8|Simons FE, Simons KJ, Frith EM "The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine." J Allergy Clin Immunol 73 (1984):  69-75|Simons FE, Watson WT, Chen XY, Minuk GY, Simons KJ "The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis." J Clin Pharmacol 29 (1989):  809-15', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48293, 208, 'Doxylamine', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48294, 208, 'Doxylamine', 'Respiratory Insufficiency', 'Oral anxiolytic, sedative, and hypnotic agents may cause respiratory depression and apnea when given in high dosages or following acute overdose.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are recommended.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|Lheureux P, Debailleul G, De Witte O, Askenasi R "Zolpidem intoxication mimicking narcotic overdose: response to flumazenil." Hum Exp Toxicol 9 (1990):  105-7|Murciano D, Aubier M, Palacios S, Parients R "Comparison of zolpidem (Z), triazolam (T), and flunitrazepam (F) effects on arterial blood gases and control of breathing in patients with severe chronic obstructive pulmonary disease (COPD)." Chest 97 Suppl (1990):  s51-2|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|Biban P, Baraldi E, Pettennazzo A, Filippone M, Zacchello F "Adverse effect of chloral hydrate in two young children with obstructive sleep apnea." Pediatrics 92 (1993):  461-3|Greenberg SB, Faerber EN "Respiratory insufficiency following chloral hydrate sedation in two children with Leigh disease (subacute necrotizing encephalomyelopathy)." Pediatr Radiol 20 (1990):  287-8|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48295, 31974, 'Drospirenone', 'Hyperkalemia', 'The progestin drospirenone (DRSP) has antialdosterone activity, including the potential for hyperkalemia in high-risk patients.  The use of DRSP-containing combination hormone is contraindicated in patients with conditions that predispose to hyperkalemia (renal impairment, hepatic impairment, and adrenal insufficiency).  Use caution when prescribing these agents to women who regularly take other medications that can increase potassium, such as nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, angiotensin converting enzyme (ACE) inhibitors, angiotensin-II receptor antagonists, heparin and aldosterone antagonists.  It is recommended to monitor serum potassium concentrations during the first month of dosing in high-risk patients who take strong CYP3A4 inhibitors long-term and concomitantly.', '3', '"Product Information. Yasmin (drospirenone-ethinyl estradiol)." Berlex Laboratories  (2001):|"Product Information. Angeliq (drospirenone-estradiol)." Berlex Laboratories  (2005):|"Product Information. Beyaz (drospirenone/ethinyl estradiol/levomefolate)." Bayer Pharmaceutical Inc  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48296, 31974, 'Drospirenone', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', '"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48297, 0, 'Droperidol', 'Cardiovascular Diseases', 'Cases of QT prolongation and/or torsade de pointes have been reported in patients receiving droperidol at doses at or below recommended doses.  Extreme caution is recommended when using this agent in patients with risk factors for development of prolonged QT syndrome, such as clinically significant bradycardia, any clinically significant cardiac disease, treatment with Class I and Class III antiarrhythmics, treatment with monoamine oxidase inhibitors (MAOI''s), concomitant treatment with other drug products known to prolong the QT interval, and electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs that may cause electrolyte imbalance.  It is advisable that all patients undergo a 12-lead ECG prior to administration to determine if a prolonged QT interval (i.e., QTc greater than 440 msec.  for males or 450 msec.  for females) is present.  If there is a prolonged QT interval, droperidol should not be administered.', '3', '"Product Information. Inapsine (droperidol)." Janssen Pharmaceuticals  (2001):|"Product Information. Droperidol (droperidol)." Abbott Pharmaceutical  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48298, 0, 'Droperidol', 'Long QT Syndrome', 'The use of droperidol is contraindicated in patients with known or suspected QT prolongation (i.e., QTc interval greater than 440 msec.  for males or 450 msec.  for females), including those patients with congenital long QT syndrome.', '3', '"Product Information. Inapsine (droperidol)." Janssen Pharmaceuticals  (2001):|"Product Information. Droperidol (droperidol)." Abbott Pharmaceutical  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48299, 0, 'Droperidol', 'Liver Failure', 'Droperidol should be administered with caution in patients with liver and kidney dysfunction because of the importance of these organs in the metabolism and excretion of drugs.', '2', '"Product Information. Inapsine (droperidol)." Janssen Pharmaceuticals  (2001):|"Product Information. Droperidol (droperidol)." Abbott Pharmaceutical  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48300, 0, 'Droperidol', 'Pheochromocytoma', 'Droperidol should be used with caution in patients with diagnosed or suspected pheochromocytoma as severe hypertension and tachycardia have been observed after its administration.', '2', '"Product Information. Inapsine (droperidol)." Janssen Pharmaceuticals  (2001):|"Product Information. Droperidol (droperidol)." Abbott Pharmaceutical  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48301, 3229, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48302, 3230, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48303, 3231, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48304, 3232, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48305, 3379, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48306, 4147, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48307, 7214, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48308, 7218, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48309, 11264, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48310, 13552, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48311, 13555, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48312, 17005, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48313, 17297, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48314, 17954, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48315, 17955, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48316, 21253, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48317, 21254, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48318, 23430, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48319, 24683, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48320, 30397, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48321, 30398, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48322, 31896, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48323, 32137, 'Duloxetine', 'Liver Diseases', 'Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease.  The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48324, 3229, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48325, 3230, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48326, 3231, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48327, 3232, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48328, 3379, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48329, 4147, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48330, 7214, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48331, 7218, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48332, 11264, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48333, 13552, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48334, 13555, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48335, 17005, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48336, 17297, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48337, 17954, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48338, 17955, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48339, 21253, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48340, 21254, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48341, 23430, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48342, 24683, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48343, 30397, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48344, 30398, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48345, 31896, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48346, 32137, 'Duloxetine', 'Kidney Diseases', 'The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).', '3', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48347, 3229, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48348, 3230, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48349, 3231, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48350, 3232, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48351, 3379, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48352, 4147, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48353, 7214, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48354, 7218, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48355, 11264, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48356, 13552, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48357, 13555, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48358, 17005, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48359, 17297, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48360, 17954, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48361, 17955, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48362, 21253, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48363, 21254, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48364, 23430, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48365, 24683, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48366, 30397, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48367, 30398, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48368, 31896, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48369, 32137, 'Duloxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48370, 3229, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48371, 3230, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48372, 3231, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48373, 3232, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48374, 3379, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48375, 4147, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48376, 7214, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48377, 7218, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48378, 11264, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48379, 13552, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48380, 13555, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48381, 17005, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48382, 17297, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48383, 17954, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48384, 17955, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48385, 21253, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48386, 21254, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48387, 23430, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48388, 24683, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48389, 30397, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48390, 30398, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48391, 31896, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48392, 32137, 'Duloxetine', 'Diabetes Mellitus', 'In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes.  Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.', '2', '"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48393, 3229, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48394, 3230, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48395, 3231, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48396, 3232, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48397, 3379, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48398, 4147, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48399, 7214, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48400, 7218, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48401, 11264, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48402, 13552, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48403, 13555, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48404, 17005, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48405, 17297, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48406, 17954, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48407, 17955, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48408, 21253, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48409, 21254, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48410, 23430, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48411, 24683, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48412, 30397, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48413, 30398, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48414, 31896, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48415, 32137, 'Duloxetine', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48416, 3229, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48417, 3230, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48418, 3231, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48419, 3232, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48420, 3379, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48421, 4147, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48422, 7214, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48423, 7218, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48424, 11264, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48425, 13552, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48426, 13555, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48427, 17005, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48428, 17297, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48429, 17954, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48430, 17955, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48431, 21253, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48432, 21254, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48433, 23430, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48434, 24683, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48435, 30397, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48436, 30398, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48437, 31896, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48438, 32137, 'Duloxetine', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48439, 3229, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48440, 3230, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48441, 3231, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48442, 3232, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48443, 3379, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48444, 4147, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48445, 7214, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48446, 7218, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48447, 11264, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48448, 13552, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48449, 13555, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48450, 17005, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48451, 17297, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48452, 17954, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48453, 17955, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48454, 21253, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48455, 21254, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48456, 23430, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48457, 24683, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48458, 30397, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48459, 30398, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48460, 31896, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48461, 32137, 'Duloxetine', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48462, 3229, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48463, 3230, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48464, 3231, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48465, 3232, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48466, 3379, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48467, 4147, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48468, 7214, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48469, 7218, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48470, 11264, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48471, 13552, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48472, 13555, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48473, 17005, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48474, 17297, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48475, 17954, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48476, 17955, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48477, 21253, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48478, 21254, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48479, 23430, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48480, 24683, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48481, 30397, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48482, 30398, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48483, 31896, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48484, 32137, 'Duloxetine', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48485, 3229, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48486, 3230, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48487, 3231, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48488, 3232, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48489, 3379, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48490, 4147, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48491, 7214, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48492, 7218, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48493, 11264, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48494, 13552, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48495, 13555, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48496, 17005, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48497, 17297, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48498, 17954, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48499, 17955, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48500, 21253, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48501, 21254, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48502, 23430, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48503, 24683, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48504, 30397, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48505, 30398, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48506, 31896, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48507, 32137, 'Duloxetine', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48508, 3229, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48509, 3230, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48510, 3231, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48511, 3232, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48512, 3379, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48513, 4147, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48514, 7214, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48515, 7218, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48516, 11264, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48517, 13552, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48518, 13555, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48519, 17005, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48520, 17297, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48521, 17954, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48522, 17955, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48523, 21253, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48524, 21254, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48525, 23430, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48526, 24683, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48527, 30397, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48528, 30398, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48529, 31896, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48530, 32137, 'Duloxetine', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48531, 28586, 'Dulaglutide', 'Gastroparesis', 'Dulaglutide slows gastric emptying and has not been studied in patients with gastroparesis, therefore it is not recommended in these patients.', '3', '"Product Information. Trulicity (dulaglutide)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48532, 28587, 'Dulaglutide', 'Gastroparesis', 'Dulaglutide slows gastric emptying and has not been studied in patients with gastroparesis, therefore it is not recommended in these patients.', '3', '"Product Information. Trulicity (dulaglutide)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48533, 28586, 'Dulaglutide', 'Pancreatitis', 'The use of GLP-1 receptor agonists has been associated with rare reports of acute pancreatitis.  Other antidiabetic therapies should be considered in patients with a previous history of pancreatitis, although it is not known if they are at increased risk.  Patients receiving treatment with GLP-1 receptor agonists should be observed carefully for signs and symptoms of pancreatitis.  If this diagnosis is suspected, the treatment should be discontinued immediately and appropriate management should be initiated.  Treatment with GLP-1 receptor agonists should be permanently discontinued if pancreatitis is confirmed.', '3', '"Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc  (2005):|"Product Information. Tanzeum (albiglutide)." GlaxoSmithKline  (2014):|"Product Information. Trulicity (dulaglutide)." Eli Lilly and Company  (2014):|"Product Information. Saxenda (liraglutide)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48534, 28587, 'Dulaglutide', 'Pancreatitis', 'The use of GLP-1 receptor agonists has been associated with rare reports of acute pancreatitis.  Other antidiabetic therapies should be considered in patients with a previous history of pancreatitis, although it is not known if they are at increased risk.  Patients receiving treatment with GLP-1 receptor agonists should be observed carefully for signs and symptoms of pancreatitis.  If this diagnosis is suspected, the treatment should be discontinued immediately and appropriate management should be initiated.  Treatment with GLP-1 receptor agonists should be permanently discontinued if pancreatitis is confirmed.', '3', '"Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc  (2005):|"Product Information. Tanzeum (albiglutide)." GlaxoSmithKline  (2014):|"Product Information. Trulicity (dulaglutide)." Eli Lilly and Company  (2014):|"Product Information. Saxenda (liraglutide)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48535, 28586, 'Dulaglutide', 'Thyroid Neoplasms', 'GLP-1 receptor agonist antidiabetic drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).  Carcinogenicity studies in rodents and limited postmarketing data suggest that GLP-1 inhibitors may cause a dose-related and treatment duration-related increase in risk of thyroid C-cell tumors, although a causal relationship has not been established.', '3', '"Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc  (2005):|"Product Information. Victoza (liraglutide)." Novo Nordisk Pharmaceuticals Inc  (2010):|"Product Information. Tanzeum (albiglutide)." GlaxoSmithKline  (2014):|"Product Information. Trulicity (dulaglutide)." Eli Lilly and Company  (2014):|"Product Information. Saxenda (liraglutide)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48536, 28587, 'Dulaglutide', 'Thyroid Neoplasms', 'GLP-1 receptor agonist antidiabetic drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).  Carcinogenicity studies in rodents and limited postmarketing data suggest that GLP-1 inhibitors may cause a dose-related and treatment duration-related increase in risk of thyroid C-cell tumors, although a causal relationship has not been established.', '3', '"Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc  (2005):|"Product Information. Victoza (liraglutide)." Novo Nordisk Pharmaceuticals Inc  (2010):|"Product Information. Tanzeum (albiglutide)." GlaxoSmithKline  (2014):|"Product Information. Trulicity (dulaglutide)." Eli Lilly and Company  (2014):|"Product Information. Saxenda (liraglutide)." Novo Nordisk Pharmaceuticals Inc  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48537, 28586, 'Dulaglutide', 'Kidney Diseases', 'There have been reports of acute renal failure and worsening of chronic renal failure sometimes requiring hemodialysis in patients treated with GLP-1 receptor inhibitors.  Some of these events occurred in patients without known underlying renal disease.  These drugs should be used with caution in patients with renal impairment, especially during treatment initiation or dose escalation.  Patients should be monitored, especially if they report severe gastrointestinal reactions such as nausea, vomiting, diarrhea, or dehydration.  The frequency of gastrointestinal events is increased as renal function declines.  There is limited clinical experience with most of these drugs in patients with severe renal impairment.', '2', '"Product Information. Symlin (pramlintide)." Amphastar Pharmaceuticals Inc  (2005):|"Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc  (2005):|"Product Information. Victoza (liraglutide)." Novo Nordisk Pharmaceuticals Inc  (2010):|"Product Information. Trulicity (dulaglutide)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48538, 28587, 'Dulaglutide', 'Kidney Diseases', 'There have been reports of acute renal failure and worsening of chronic renal failure sometimes requiring hemodialysis in patients treated with GLP-1 receptor inhibitors.  Some of these events occurred in patients without known underlying renal disease.  These drugs should be used with caution in patients with renal impairment, especially during treatment initiation or dose escalation.  Patients should be monitored, especially if they report severe gastrointestinal reactions such as nausea, vomiting, diarrhea, or dehydration.  The frequency of gastrointestinal events is increased as renal function declines.  There is limited clinical experience with most of these drugs in patients with severe renal impairment.', '2', '"Product Information. Symlin (pramlintide)." Amphastar Pharmaceuticals Inc  (2005):|"Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc  (2005):|"Product Information. Victoza (liraglutide)." Novo Nordisk Pharmaceuticals Inc  (2010):|"Product Information. Trulicity (dulaglutide)." Eli Lilly and Company  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48539, 30437, 'Dupilumab', 'Helminthiasis', 'Patients with preexisting-existing helminth infections should be treated prior to therapy with dupilumab.  It is recommended to discontinue treatment with dupilumab if patients become infected while on treatment and if they are not responding to treatment.  Discontinue treatment with dupilumab until the infection resolves.', '2', '"Product Information. Dupixent (dupilumab)." sanofi-aventis  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48540, 30438, 'Dupilumab', 'Helminthiasis', 'Patients with preexisting-existing helminth infections should be treated prior to therapy with dupilumab.  It is recommended to discontinue treatment with dupilumab if patients become infected while on treatment and if they are not responding to treatment.  Discontinue treatment with dupilumab until the infection resolves.', '2', '"Product Information. Dupixent (dupilumab)." sanofi-aventis  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48541, 30437, 'Dupilumab', 'Vision Disorders', 'Conjunctivitis and keratitis may occur while on treatment with dupilumab.  Care should be exercised when using this agent in patients with visual defects.  Patients should be closely monitored for new onset or worsening eye symptoms.', '2', '"Product Information. Dupixent (dupilumab)." sanofi-aventis  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48542, 30438, 'Dupilumab', 'Vision Disorders', 'Conjunctivitis and keratitis may occur while on treatment with dupilumab.  Care should be exercised when using this agent in patients with visual defects.  Patients should be closely monitored for new onset or worsening eye symptoms.', '2', '"Product Information. Dupixent (dupilumab)." sanofi-aventis  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48543, 30670, 'Durvalumab', 'Adrenal Insufficiency', 'Durvalumab can cause immune-mediated adrenal insufficiency.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.  It is recommended to monitor patients for clinical signs and symptoms of adrenal insufficiency and to institute appropriate measures as necessary.  Monitor as clinically indicated prior to and periodically during treatment and withhold, reduce dose, or discontinue therapy with durvalumab as necessary.', '2', '"Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48544, 30671, 'Durvalumab', 'Adrenal Insufficiency', 'Durvalumab can cause immune-mediated adrenal insufficiency.  Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients with prolonged periods of stress due to major surgery, intensive care, etc.  It is recommended to monitor patients for clinical signs and symptoms of adrenal insufficiency and to institute appropriate measures as necessary.  Monitor as clinically indicated prior to and periodically during treatment and withhold, reduce dose, or discontinue therapy with durvalumab as necessary.', '2', '"Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48545, 30670, 'Durvalumab', 'Colitis', 'Immune-mediated colitis has been reported with the use of durvalumab.  Monitor patients for signs and symptoms of diarrhea or colitis.  It is recommended to administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents followed by corticosteroid taper for severe or life-threatening colitis.  It is recommended to interrupt or to permanently discontinue durvalumab for life-threatening or for recurrent colitis.  Care should be taken when using durvalumab in patients with inflammatory bowel disease.', '2', '"Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48546, 30671, 'Durvalumab', 'Colitis', 'Immune-mediated colitis has been reported with the use of durvalumab.  Monitor patients for signs and symptoms of diarrhea or colitis.  It is recommended to administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents followed by corticosteroid taper for severe or life-threatening colitis.  It is recommended to interrupt or to permanently discontinue durvalumab for life-threatening or for recurrent colitis.  Care should be taken when using durvalumab in patients with inflammatory bowel disease.', '2', '"Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48547, 30670, 'Durvalumab', 'Diabetes Mellitus', 'Durvalumab can cause type 1 diabetes mellitus.  Monitor for hyperglycemia or other signs and symptoms of diabetes.  Withhold treatment in cases of severe hyperglycemia until metabolic control is achieved.  Permanently discontinue durvalumab for life-threatening hyperglycemia.  If appropriate interrupt treatment according to manufacturer recommendations.  Care should be exercised when using durvalumab in diabetic patients.', '2', '"Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48548, 30671, 'Durvalumab', 'Diabetes Mellitus', 'Durvalumab can cause type 1 diabetes mellitus.  Monitor for hyperglycemia or other signs and symptoms of diabetes.  Withhold treatment in cases of severe hyperglycemia until metabolic control is achieved.  Permanently discontinue durvalumab for life-threatening hyperglycemia.  If appropriate interrupt treatment according to manufacturer recommendations.  Care should be exercised when using durvalumab in diabetic patients.', '2', '"Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48549, 30670, 'Durvalumab', 'Infections', 'Durvalumab may alter the normal immune response and increase susceptibility to infections.  Monitor patients for signs and symptoms of infection and withhold durvalumab treatment for Grade 3 or higher infections, particularly in patients with urinary tract infections.  Resume once clinically stable.', '2', '"Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48550, 30671, 'Durvalumab', 'Infections', 'Durvalumab may alter the normal immune response and increase susceptibility to infections.  Monitor patients for signs and symptoms of infection and withhold durvalumab treatment for Grade 3 or higher infections, particularly in patients with urinary tract infections.  Resume once clinically stable.', '2', '"Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48551, 30670, 'Durvalumab', 'Liver Diseases', 'Durvalumab can cause immune-mediated hepatitis.  Caution is recommended when using durvalumab in patients with moderate or severe hepatic impairment as this agent has not been studied in these patients.  Monitor patients for signs and symptoms of hepatitis during and after treatment discontinuation.  Periodic hepatic function test should be performed according to medical practices.  Administer corticosteroids as appropriate according to manufacturer recommendations.  It is recommended to interrupt or permanently discontinue treatment with durvalumab for severe or life-threatening transaminase or total bilirubin elevation.  Care should be taken when using durvalumab in patients with liver disease.', '2', '"Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48552, 30671, 'Durvalumab', 'Liver Diseases', 'Durvalumab can cause immune-mediated hepatitis.  Caution is recommended when using durvalumab in patients with moderate or severe hepatic impairment as this agent has not been studied in these patients.  Monitor patients for signs and symptoms of hepatitis during and after treatment discontinuation.  Periodic hepatic function test should be performed according to medical practices.  Administer corticosteroids as appropriate according to manufacturer recommendations.  It is recommended to interrupt or permanently discontinue treatment with durvalumab for severe or life-threatening transaminase or total bilirubin elevation.  Care should be taken when using durvalumab in patients with liver disease.', '2', '"Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48553, 30670, 'Durvalumab', 'Kidney Diseases', 'Durvalumab can cause immune-mediated nephritis.  Monitor patients for abnormal renal function tests prior to and periodically during treatment.  It is recommended to administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents followed by corticosteroid taper for life-threatening increased serum creatinine.  Withhold or permanently discontinue durvalumab based on severity.  If appropriate modify the dose according to manufacturer recommendations.  Care should be taken when using durvalumab in patients with renal dysfunction.', '2', '"Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48554, 30671, 'Durvalumab', 'Kidney Diseases', 'Durvalumab can cause immune-mediated nephritis.  Monitor patients for abnormal renal function tests prior to and periodically during treatment.  It is recommended to administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents followed by corticosteroid taper for life-threatening increased serum creatinine.  Withhold or permanently discontinue durvalumab based on severity.  If appropriate modify the dose according to manufacturer recommendations.  Care should be taken when using durvalumab in patients with renal dysfunction.', '2', '"Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48555, 30670, 'Durvalumab', 'Thyroid Diseases', 'Durvalumab can cause immune-mediated thyroid disorders.  Monitor thyroid function prior to and periodically during treatment.  Administer hormone-replacement therapy for hypothyroidism or initiate medical management for control of hyperthyroidism.  Continue durvalumab for hypothyroidism and interrupt for hyperthyroidism based on the manufacturer recommendation.  Care should be taken when using this agent in patients with thyroid disease.', '2', '"Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48556, 30671, 'Durvalumab', 'Thyroid Diseases', 'Durvalumab can cause immune-mediated thyroid disorders.  Monitor thyroid function prior to and periodically during treatment.  Administer hormone-replacement therapy for hypothyroidism or initiate medical management for control of hyperthyroidism.  Continue durvalumab for hypothyroidism and interrupt for hyperthyroidism based on the manufacturer recommendation.  Care should be taken when using this agent in patients with thyroid disease.', '2', '"Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48557, 30670, 'Durvalumab', 'Pneumonia', 'Durvalumab can cause immune-mediated pneumonitis.  Monitor patients for signs and symptoms of pneumonitis.  Evaluate patients with suspected pneumonitis with radiographic imaging.  It is recommended to administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents for moderate pneumonitis or 1 to 4 mg per kg per day or equivalent corticosteroid for more severe pneumonitis, followed by a taper.  It is recommended to interrupt or permanently discontinue durvalumab based on the severity of symptoms.  Care should be exercised when using this agent in patients with suspected pneumonitis.', '2', '"Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48558, 30671, 'Durvalumab', 'Pneumonia', 'Durvalumab can cause immune-mediated pneumonitis.  Monitor patients for signs and symptoms of pneumonitis.  Evaluate patients with suspected pneumonitis with radiographic imaging.  It is recommended to administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents for moderate pneumonitis or 1 to 4 mg per kg per day or equivalent corticosteroid for more severe pneumonitis, followed by a taper.  It is recommended to interrupt or permanently discontinue durvalumab based on the severity of symptoms.  Care should be exercised when using this agent in patients with suspected pneumonitis.', '2', '"Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48559, 14774, 'Dutasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48560, 15070, 'Dutasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48561, 25402, 'Dutasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48562, 26931, 'Dutasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', '"Product Information. Proscar (finasteride)." Merck & Co., Inc  (2002):|"Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48563, 29123, 'Dyphylline', 'Kidney Diseases', 'Dyphylline is eliminated almost entirely by the kidney.  Drug accumulation may occur in patients with impaired renal function.  Like other methylxanthines, high plasma levels of the drug may be associated with severe cardio- and neurotoxicity, sometimes without any previous warning.  Therapy with dyphylline should be administered cautiously in patients with renal impairment.  Dosage adjustments may be necessary.  The relationship between plasma dyphylline levels and therapeutic as well as toxic effects has not been determined.', '3', '"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48564, 29124, 'Dyphylline', 'Kidney Diseases', 'Dyphylline is eliminated almost entirely by the kidney.  Drug accumulation may occur in patients with impaired renal function.  Like other methylxanthines, high plasma levels of the drug may be associated with severe cardio- and neurotoxicity, sometimes without any previous warning.  Therapy with dyphylline should be administered cautiously in patients with renal impairment.  Dosage adjustments may be necessary.  The relationship between plasma dyphylline levels and therapeutic as well as toxic effects has not been determined.', '3', '"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48565, 29123, 'Dyphylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48566, 29124, 'Dyphylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48567, 29123, 'Dyphylline', 'Cardiotoxicity', 'Like other methylxanthines, dyphylline at high dosages may be associated with positive inotropic and chronotropic effects on the heart.  Therapy with dyphylline and products containing dyphylline should be administered cautiously in patients with severe cardiac disease, hypertension, hyperthyroidism, or recent myocardial infarction.  The relationship between plasma dyphylline levels and therapeutic as well as toxic effects has not been determined.', '2', '"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48568, 29124, 'Dyphylline', 'Cardiotoxicity', 'Like other methylxanthines, dyphylline at high dosages may be associated with positive inotropic and chronotropic effects on the heart.  Therapy with dyphylline and products containing dyphylline should be administered cautiously in patients with severe cardiac disease, hypertension, hyperthyroidism, or recent myocardial infarction.  The relationship between plasma dyphylline levels and therapeutic as well as toxic effects has not been determined.', '2', '"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48569, 29123, 'Dyphylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48570, 29124, 'Dyphylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48571, 18307, 'Ambrisentan', 'Liver Failure', 'Endothelin receptor antagonists (ERAs) have been associated with aminotransferase elevations, hepatotoxicity, and cases of liver failure.  Hepatic function should be assessed before treatment initiation and closely monitored during treatment.  Therapy should be discontinued if aminotransferase elevations are accompanied by increases in bilirubin, or clinical symptoms of hepatotoxicity such as nausea, vomiting, fever, abdominal pain or jaundice.  Treatment should be avoided in patients with elevated aminotransferases at baseline as monitoring for hepatotoxicity may be more difficult.  In general, the use of ERAs is not recommended for patients with moderate to severe hepatic impairment.', '3', '"Product Information. Tracleer (bosentan)." Actelion Pharmaceuticals US Inc  (2001):|"Product Information. Letairis (ambrisentan)." Gilead Sciences  (2007):|"Product Information. Opsumit (macitentan)." Actelion Pharmaceuticals US Inc  (2013):|"Product Information. Filspari (sparsentan)." Travere Therapeutics Inc.  (2023):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48572, 18309, 'Ambrisentan', 'Liver Failure', 'Endothelin receptor antagonists (ERAs) have been associated with aminotransferase elevations, hepatotoxicity, and cases of liver failure.  Hepatic function should be assessed before treatment initiation and closely monitored during treatment.  Therapy should be discontinued if aminotransferase elevations are accompanied by increases in bilirubin, or clinical symptoms of hepatotoxicity such as nausea, vomiting, fever, abdominal pain or jaundice.  Treatment should be avoided in patients with elevated aminotransferases at baseline as monitoring for hepatotoxicity may be more difficult.  In general, the use of ERAs is not recommended for patients with moderate to severe hepatic impairment.', '3', '"Product Information. Tracleer (bosentan)." Actelion Pharmaceuticals US Inc  (2001):|"Product Information. Letairis (ambrisentan)." Gilead Sciences  (2007):|"Product Information. Opsumit (macitentan)." Actelion Pharmaceuticals US Inc  (2013):|"Product Information. Filspari (sparsentan)." Travere Therapeutics Inc.  (2023):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48573, 19573, 'Ambrisentan', 'Liver Failure', 'Endothelin receptor antagonists (ERAs) have been associated with aminotransferase elevations, hepatotoxicity, and cases of liver failure.  Hepatic function should be assessed before treatment initiation and closely monitored during treatment.  Therapy should be discontinued if aminotransferase elevations are accompanied by increases in bilirubin, or clinical symptoms of hepatotoxicity such as nausea, vomiting, fever, abdominal pain or jaundice.  Treatment should be avoided in patients with elevated aminotransferases at baseline as monitoring for hepatotoxicity may be more difficult.  In general, the use of ERAs is not recommended for patients with moderate to severe hepatic impairment.', '3', '"Product Information. Tracleer (bosentan)." Actelion Pharmaceuticals US Inc  (2001):|"Product Information. Letairis (ambrisentan)." Gilead Sciences  (2007):|"Product Information. Opsumit (macitentan)." Actelion Pharmaceuticals US Inc  (2013):|"Product Information. Filspari (sparsentan)." Travere Therapeutics Inc.  (2023):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48574, 18307, 'Ambrisentan', 'Kidney Diseases', 'There is no information on the exposure to ambrisentan in patients with severe renal impairment.  Additionally, the impact of hemodialysis on the disposition of ambrisentan has not been studied, hence caution is advised.  No dosage adjustment is required in patients with mild or moderate renal impairment.', '2', '"Product Information. Letairis (ambrisentan)." Gilead Sciences  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48575, 18309, 'Ambrisentan', 'Kidney Diseases', 'There is no information on the exposure to ambrisentan in patients with severe renal impairment.  Additionally, the impact of hemodialysis on the disposition of ambrisentan has not been studied, hence caution is advised.  No dosage adjustment is required in patients with mild or moderate renal impairment.', '2', '"Product Information. Letairis (ambrisentan)." Gilead Sciences  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48576, 19573, 'Ambrisentan', 'Kidney Diseases', 'There is no information on the exposure to ambrisentan in patients with severe renal impairment.  Additionally, the impact of hemodialysis on the disposition of ambrisentan has not been studied, hence caution is advised.  No dosage adjustment is required in patients with mild or moderate renal impairment.', '2', '"Product Information. Letairis (ambrisentan)." Gilead Sciences  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48577, 18307, 'Ambrisentan', 'Anemia', 'Clinical studies have shown that most endothelin receptor antagonists decrease hemoglobin concentration and hematocrit levels.  There are some postmarketing reports of anemia cases which needed blood transfusion.  Hemoglobin and hematocrit levels should be measured prior to treatment initiation and should be monitored periodically thereafter.  Initiation of therapy is not recommended in patients with clinically significant anemia.', '2', '"Product Information. Tracleer (bosentan)." Actelion Pharmaceuticals US Inc  (2001):|"Product Information. Letairis (ambrisentan)." Gilead Sciences  (2007):|"Product Information. Opsumit (macitentan)." Actelion Pharmaceuticals US Inc  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48578, 18309, 'Ambrisentan', 'Anemia', 'Clinical studies have shown that most endothelin receptor antagonists decrease hemoglobin concentration and hematocrit levels.  There are some postmarketing reports of anemia cases which needed blood transfusion.  Hemoglobin and hematocrit levels should be measured prior to treatment initiation and should be monitored periodically thereafter.  Initiation of therapy is not recommended in patients with clinically significant anemia.', '2', '"Product Information. Tracleer (bosentan)." Actelion Pharmaceuticals US Inc  (2001):|"Product Information. Letairis (ambrisentan)." Gilead Sciences  (2007):|"Product Information. Opsumit (macitentan)." Actelion Pharmaceuticals US Inc  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48579, 19573, 'Ambrisentan', 'Anemia', 'Clinical studies have shown that most endothelin receptor antagonists decrease hemoglobin concentration and hematocrit levels.  There are some postmarketing reports of anemia cases which needed blood transfusion.  Hemoglobin and hematocrit levels should be measured prior to treatment initiation and should be monitored periodically thereafter.  Initiation of therapy is not recommended in patients with clinically significant anemia.', '2', '"Product Information. Tracleer (bosentan)." Actelion Pharmaceuticals US Inc  (2001):|"Product Information. Letairis (ambrisentan)." Gilead Sciences  (2007):|"Product Information. Opsumit (macitentan)." Actelion Pharmaceuticals US Inc  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48580, 18307, 'Ambrisentan', 'Water-Electrolyte Imbalance', 'Peripheral edema and fluid retention are known clinical consequences of pulmonary hypertension and also known effects of endothelin receptor antagonists.  Caution and monitoring is recommended if these agents are used in patients with underlying left ventricular dysfunction or underlying heart failure, as they have an increased risk for developing significant fluid retention that may need treatment or require discontinuation.', '2', '"Product Information. Tracleer (bosentan)." Actelion Pharmaceuticals US Inc  (2001):|"Product Information. Letairis (ambrisentan)." Gilead Sciences  (2007):|"Product Information. Opsumit (macitentan)." Actelion Pharmaceuticals US Inc  (2013):|"Product Information. Filspari (sparsentan)." Travere Therapeutics Inc.  (2023):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48581, 18309, 'Ambrisentan', 'Water-Electrolyte Imbalance', 'Peripheral edema and fluid retention are known clinical consequences of pulmonary hypertension and also known effects of endothelin receptor antagonists.  Caution and monitoring is recommended if these agents are used in patients with underlying left ventricular dysfunction or underlying heart failure, as they have an increased risk for developing significant fluid retention that may need treatment or require discontinuation.', '2', '"Product Information. Tracleer (bosentan)." Actelion Pharmaceuticals US Inc  (2001):|"Product Information. Letairis (ambrisentan)." Gilead Sciences  (2007):|"Product Information. Opsumit (macitentan)." Actelion Pharmaceuticals US Inc  (2013):|"Product Information. Filspari (sparsentan)." Travere Therapeutics Inc.  (2023):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48582, 19573, 'Ambrisentan', 'Water-Electrolyte Imbalance', 'Peripheral edema and fluid retention are known clinical consequences of pulmonary hypertension and also known effects of endothelin receptor antagonists.  Caution and monitoring is recommended if these agents are used in patients with underlying left ventricular dysfunction or underlying heart failure, as they have an increased risk for developing significant fluid retention that may need treatment or require discontinuation.', '2', '"Product Information. Tracleer (bosentan)." Actelion Pharmaceuticals US Inc  (2001):|"Product Information. Letairis (ambrisentan)." Gilead Sciences  (2007):|"Product Information. Opsumit (macitentan)." Actelion Pharmaceuticals US Inc  (2013):|"Product Information. Filspari (sparsentan)." Travere Therapeutics Inc.  (2023):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48583, 18155, 'Eletriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48584, 25845, 'Eletriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48585, 18155, 'Eletriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48586, 25845, 'Eletriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992):  1415|Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993):  1185|Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992):  d713-4|Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993):  861-2|MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993):  1092|Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994):  1105-6|"Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):|Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994):  622-51|Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994):  1704-5|Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994):  305-9|Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995):  1211-3|Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996):  329-31|Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996):  46-51|Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996):  554-9|"Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Amerge (naratriptan)." Glaxo Wellcome  (2001):|"Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):|Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999):  704-11|Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999):  699-723|Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000):  275|"Product Information. Axert (almotriptan)." Pharmacia and Upjohn  (2001):|"Product Information. Frova (frovatriptan)." Endo Laboratories LLC  (2001):|"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48587, 18155, 'Eletriptan', 'Liver Diseases', 'Eletriptan is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, increases of 18% in the peak plasma concentration (Cmax) and 34% in the systemic exposure (AUC) of eletriptan were observed.  Dosage adjustments should not be necessary in this patient population.  There are no data concerning the use of eletriptan in patients with severe hepatic impairment, thus it is not recommended.', '2', '"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48588, 25845, 'Eletriptan', 'Liver Diseases', 'Eletriptan is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, increases of 18% in the peak plasma concentration (Cmax) and 34% in the systemic exposure (AUC) of eletriptan were observed.  Dosage adjustments should not be necessary in this patient population.  There are no data concerning the use of eletriptan in patients with severe hepatic impairment, thus it is not recommended.', '2', '"Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48589, 14247, 'Efavirenz', 'Hypercholesterolemia', 'Increases in total cholesterol and triglycerides have resulted during treatment with efavirenz.  Lipid levels monitoring should be performed before starting treatment and at periodic intervals during therapy.', '2', '"Product Information. Sustiva (efavirenz)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48590, 14247, 'Efavirenz', 'Liver Diseases', 'Efavirenz is primarily metabolized by the liver.  Patients with liver disease may be at greater risk for adverse effects from efavirenz due to decreased drug clearance.  Therapy with efavirenz should be administered cautiously in patients with liver disease.  In addition, elevations in serum transaminases to greater than five times the upper limit of normal as well as acute liver failure requiring transplantation have occurred during therapy with efavirenz, most often in patients with a prior history of Hepatitis B and/or C.  Monitoring of liver function tests is recommended in these patients.', '2', '"Product Information. Sustiva (efavirenz)." DuPont Pharmaceuticals  (2001):|Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013):  331-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48591, 14247, 'Efavirenz', 'Mental Disorders', 'During clinical trials, there have been infrequent reports of delusions and inappropriate behavior associated with the use of efavirenz, predominantly in patients with a history of mental illness or substance abuse.  Severe acute depression, including suicide attempts and suicidal ideation, has also been reported but was not limited to efavirenz treated patients.  Therapy with efavirenz should be administered cautiously in patients with a current or past history of psychiatric illness, emotional instability, or substance abuse.  If symptoms develop or worsen during treatment, discontinuation of efavirenz may be necessary.', '2', '"Product Information. Sustiva (efavirenz)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48592, 14247, 'Efavirenz', 'Long QT Syndrome', 'QTc prolongation has been observed with the use of efavirenz.  Alternatives to efavirenz should be considered when administered to patients at higher risk of torsade de pointes or when coadministered with a medication with known risk of torsade de pointes.', '2', '"Product Information. Sustiva (efavirenz)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48593, 14247, 'Efavirenz', 'Seizures', 'Convulsions have been observed in adult and pediatric patients receiving efavirenz, generally in the presence of known medical history of seizures.  Caution should be taken with any patient with a history of seizures.  Anticonvulsant medication such as phenytoin and phenobarbital may require periodic monitoring of plasma levels.', '2', '"Product Information. Sustiva (efavirenz)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48594, 0, 'Eliglustat', 'Kidney Diseases', 'The use of drugs eliglustat should be avoided in patients with end-stage renal disease (estimated creatinine clearance (eCrCl) less than 15 mL/min not on dialysis or requiring dialysis).  No dosage adjustment is recommended in patients with mild, moderate, or severe renal impairment (eCrCl at least 15 mL/min).  In the case of CYP450 2D6 intermediate metabolizers, or poor metabolizers, eliglustat should be avoided in those patients with any degree of renal impairment.', '3', '"Product Information. Cerdelga (eliglustat)." Genzyme Corporation  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48595, 0, 'Eliglustat', 'Liver Diseases', 'The use of drugs eliglustat is contraindicated in patients with moderate or severe hepatic impairment and in those patients, who are CYP450 2D6 extensive metabolizers with mild hepatic impairment and taking a strong or moderate CYP450 2D6 inhibitor due to the risk of cardiac arrhythmias from prolongation of the PR, QTc, and/or QRS cardiac intervals.  This agent is contraindicated in patients who are CYP450 2D6 extensive metabolizers, intermediate metabolizers and taking a strong or moderate CYP450 2D6 inhibitor concomitantly with a strong or moderate CYP450 3A inhibitor.  In the case of CYP450 2D6 intermediate metabolizers, or poor metabolizers, eliglustat is contraindicated in those patients with any degree of hepatic impairment or those taking a strong CYP450 3A inhibitor.', '3', '"Product Information. Cerdelga (eliglustat)." Genzyme Corporation  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48596, 0, 'Eliglustat', 'Heart Diseases', 'The use of eliglustat is contraindicated in patients who are CYP2D6 extensive metabolizers or intermediate metabolizers taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor or those who are intermediate metabolizers or poor metabolizers taking a strong CYP3A inhibitor due to the risk of a significant increase in drug plasma concentrations.  Eliglustat is predicted to cause increases in EKG intervals (PR, QTc, and QRS) at high plasma concentrations and could result in arrhythmias; therefore, its use is not recommended in patients with preexisting cardiac disease (congestive heart failure, recent myocardial infarction, heart block, arrhythmias), or long QT syndrome.', '3', '"Product Information. Cerdelga (eliglustat)." Genzyme Corporation  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48597, 16585, 'Edoxaban', 'Hemorrhage', 'The use of factor Xa inhibitors is contraindicated in patients with active pathological bleeding as these agents increase the risk of bleeding and can cause serious or fatal hemorrhages.  Caution is recommended when prescribing factor Xa inhibitors to patients at increased risk of bleeding, including patients undergoing procedures where bleeding may cause serious complications.  Such patients include those undergoing spinal/epidural anesthesia or spinal puncture; these patients are at high risk of an epidural or spinal hematoma, which can result in long-term or permanent paralysis.  In general, when using factor Xa inhibitors, the risk of thrombotic events should be weighed against the risk of bleeding.', '3', '"Product Information. Xarelto (rivaroxaban)." Janssen Pharmaceuticals  (2022):|"Product Information. Arixtra (fondaparinux)." Mylan Institutional LLC  (2020):|"Product Information. Eliquis (apixaban)." Bristol-Myers Squibb  (2021):|"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48598, 16586, 'Edoxaban', 'Hemorrhage', 'The use of factor Xa inhibitors is contraindicated in patients with active pathological bleeding as these agents increase the risk of bleeding and can cause serious or fatal hemorrhages.  Caution is recommended when prescribing factor Xa inhibitors to patients at increased risk of bleeding, including patients undergoing procedures where bleeding may cause serious complications.  Such patients include those undergoing spinal/epidural anesthesia or spinal puncture; these patients are at high risk of an epidural or spinal hematoma, which can result in long-term or permanent paralysis.  In general, when using factor Xa inhibitors, the risk of thrombotic events should be weighed against the risk of bleeding.', '3', '"Product Information. Xarelto (rivaroxaban)." Janssen Pharmaceuticals  (2022):|"Product Information. Arixtra (fondaparinux)." Mylan Institutional LLC  (2020):|"Product Information. Eliquis (apixaban)." Bristol-Myers Squibb  (2021):|"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48599, 16587, 'Edoxaban', 'Hemorrhage', 'The use of factor Xa inhibitors is contraindicated in patients with active pathological bleeding as these agents increase the risk of bleeding and can cause serious or fatal hemorrhages.  Caution is recommended when prescribing factor Xa inhibitors to patients at increased risk of bleeding, including patients undergoing procedures where bleeding may cause serious complications.  Such patients include those undergoing spinal/epidural anesthesia or spinal puncture; these patients are at high risk of an epidural or spinal hematoma, which can result in long-term or permanent paralysis.  In general, when using factor Xa inhibitors, the risk of thrombotic events should be weighed against the risk of bleeding.', '3', '"Product Information. Xarelto (rivaroxaban)." Janssen Pharmaceuticals  (2022):|"Product Information. Arixtra (fondaparinux)." Mylan Institutional LLC  (2020):|"Product Information. Eliquis (apixaban)." Bristol-Myers Squibb  (2021):|"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48600, 18080, 'Edoxaban', 'Hemorrhage', 'The use of factor Xa inhibitors is contraindicated in patients with active pathological bleeding as these agents increase the risk of bleeding and can cause serious or fatal hemorrhages.  Caution is recommended when prescribing factor Xa inhibitors to patients at increased risk of bleeding, including patients undergoing procedures where bleeding may cause serious complications.  Such patients include those undergoing spinal/epidural anesthesia or spinal puncture; these patients are at high risk of an epidural or spinal hematoma, which can result in long-term or permanent paralysis.  In general, when using factor Xa inhibitors, the risk of thrombotic events should be weighed against the risk of bleeding.', '3', '"Product Information. Xarelto (rivaroxaban)." Janssen Pharmaceuticals  (2022):|"Product Information. Arixtra (fondaparinux)." Mylan Institutional LLC  (2020):|"Product Information. Eliquis (apixaban)." Bristol-Myers Squibb  (2021):|"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48601, 18081, 'Edoxaban', 'Hemorrhage', 'The use of factor Xa inhibitors is contraindicated in patients with active pathological bleeding as these agents increase the risk of bleeding and can cause serious or fatal hemorrhages.  Caution is recommended when prescribing factor Xa inhibitors to patients at increased risk of bleeding, including patients undergoing procedures where bleeding may cause serious complications.  Such patients include those undergoing spinal/epidural anesthesia or spinal puncture; these patients are at high risk of an epidural or spinal hematoma, which can result in long-term or permanent paralysis.  In general, when using factor Xa inhibitors, the risk of thrombotic events should be weighed against the risk of bleeding.', '3', '"Product Information. Xarelto (rivaroxaban)." Janssen Pharmaceuticals  (2022):|"Product Information. Arixtra (fondaparinux)." Mylan Institutional LLC  (2020):|"Product Information. Eliquis (apixaban)." Bristol-Myers Squibb  (2021):|"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48602, 16585, 'Edoxaban', 'Kidney Diseases', 'Edoxaban is eliminated primarily as unchanged drug in the urine.  Blood levels of edoxaban are increased in patients with renal dysfunction.  The use of edoxaban is not recommended in patients with CrCl < 15 mL/min.  It is recommended to reduce the dose to 30 mg once daily in these patients.  The clearance of edoxaban is not significantly affected by hemodialysis.  Care should be exercised when using this agent in patients with renal dysfunction.', '2', '"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48603, 16586, 'Edoxaban', 'Kidney Diseases', 'Edoxaban is eliminated primarily as unchanged drug in the urine.  Blood levels of edoxaban are increased in patients with renal dysfunction.  The use of edoxaban is not recommended in patients with CrCl < 15 mL/min.  It is recommended to reduce the dose to 30 mg once daily in these patients.  The clearance of edoxaban is not significantly affected by hemodialysis.  Care should be exercised when using this agent in patients with renal dysfunction.', '2', '"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48604, 16587, 'Edoxaban', 'Kidney Diseases', 'Edoxaban is eliminated primarily as unchanged drug in the urine.  Blood levels of edoxaban are increased in patients with renal dysfunction.  The use of edoxaban is not recommended in patients with CrCl < 15 mL/min.  It is recommended to reduce the dose to 30 mg once daily in these patients.  The clearance of edoxaban is not significantly affected by hemodialysis.  Care should be exercised when using this agent in patients with renal dysfunction.', '2', '"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48605, 18080, 'Edoxaban', 'Kidney Diseases', 'Edoxaban is eliminated primarily as unchanged drug in the urine.  Blood levels of edoxaban are increased in patients with renal dysfunction.  The use of edoxaban is not recommended in patients with CrCl < 15 mL/min.  It is recommended to reduce the dose to 30 mg once daily in these patients.  The clearance of edoxaban is not significantly affected by hemodialysis.  Care should be exercised when using this agent in patients with renal dysfunction.', '2', '"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48606, 18081, 'Edoxaban', 'Kidney Diseases', 'Edoxaban is eliminated primarily as unchanged drug in the urine.  Blood levels of edoxaban are increased in patients with renal dysfunction.  The use of edoxaban is not recommended in patients with CrCl < 15 mL/min.  It is recommended to reduce the dose to 30 mg once daily in these patients.  The clearance of edoxaban is not significantly affected by hemodialysis.  Care should be exercised when using this agent in patients with renal dysfunction.', '2', '"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48607, 16585, 'Edoxaban', 'Hepatic Insufficiency', 'The use of factor Xa inhibitors (including apixaban and edoxaban) is not recommended in patients with moderate or severe liver dysfunction (Child-Pugh B or C) as these patients may have intrinsic coagulation abnormalities.', '2', '"Product Information. Eliquis (apixaban)." Bristol-Myers Squibb  (2021):|"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48608, 16586, 'Edoxaban', 'Hepatic Insufficiency', 'The use of factor Xa inhibitors (including apixaban and edoxaban) is not recommended in patients with moderate or severe liver dysfunction (Child-Pugh B or C) as these patients may have intrinsic coagulation abnormalities.', '2', '"Product Information. Eliquis (apixaban)." Bristol-Myers Squibb  (2021):|"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48609, 16587, 'Edoxaban', 'Hepatic Insufficiency', 'The use of factor Xa inhibitors (including apixaban and edoxaban) is not recommended in patients with moderate or severe liver dysfunction (Child-Pugh B or C) as these patients may have intrinsic coagulation abnormalities.', '2', '"Product Information. Eliquis (apixaban)." Bristol-Myers Squibb  (2021):|"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48610, 18080, 'Edoxaban', 'Hepatic Insufficiency', 'The use of factor Xa inhibitors (including apixaban and edoxaban) is not recommended in patients with moderate or severe liver dysfunction (Child-Pugh B or C) as these patients may have intrinsic coagulation abnormalities.', '2', '"Product Information. Eliquis (apixaban)." Bristol-Myers Squibb  (2021):|"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48611, 18081, 'Edoxaban', 'Hepatic Insufficiency', 'The use of factor Xa inhibitors (including apixaban and edoxaban) is not recommended in patients with moderate or severe liver dysfunction (Child-Pugh B or C) as these patients may have intrinsic coagulation abnormalities.', '2', '"Product Information. Eliquis (apixaban)." Bristol-Myers Squibb  (2021):|"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48612, 16585, 'Edoxaban', 'Heart Valve Diseases', 'The use of some factor Xa inhibitors (including apixaban, edoxaban, and rivaroxaban) is not recommended in patients with prosthetic heart valves; safety and efficacy have not been established in such patients.', '2', '"Product Information. Xarelto (rivaroxaban)." Janssen Pharmaceuticals  (2022):|"Product Information. Eliquis (apixaban)." Bristol-Myers Squibb  (2021):|"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48613, 16586, 'Edoxaban', 'Heart Valve Diseases', 'The use of some factor Xa inhibitors (including apixaban, edoxaban, and rivaroxaban) is not recommended in patients with prosthetic heart valves; safety and efficacy have not been established in such patients.', '2', '"Product Information. Xarelto (rivaroxaban)." Janssen Pharmaceuticals  (2022):|"Product Information. Eliquis (apixaban)." Bristol-Myers Squibb  (2021):|"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48614, 16587, 'Edoxaban', 'Heart Valve Diseases', 'The use of some factor Xa inhibitors (including apixaban, edoxaban, and rivaroxaban) is not recommended in patients with prosthetic heart valves; safety and efficacy have not been established in such patients.', '2', '"Product Information. Xarelto (rivaroxaban)." Janssen Pharmaceuticals  (2022):|"Product Information. Eliquis (apixaban)." Bristol-Myers Squibb  (2021):|"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48615, 18080, 'Edoxaban', 'Heart Valve Diseases', 'The use of some factor Xa inhibitors (including apixaban, edoxaban, and rivaroxaban) is not recommended in patients with prosthetic heart valves; safety and efficacy have not been established in such patients.', '2', '"Product Information. Xarelto (rivaroxaban)." Janssen Pharmaceuticals  (2022):|"Product Information. Eliquis (apixaban)." Bristol-Myers Squibb  (2021):|"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48616, 18081, 'Edoxaban', 'Heart Valve Diseases', 'The use of some factor Xa inhibitors (including apixaban, edoxaban, and rivaroxaban) is not recommended in patients with prosthetic heart valves; safety and efficacy have not been established in such patients.', '2', '"Product Information. Xarelto (rivaroxaban)." Janssen Pharmaceuticals  (2022):|"Product Information. Eliquis (apixaban)." Bristol-Myers Squibb  (2021):|"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48617, 16585, 'Edoxaban', 'Antiphospholipid Syndrome', 'Direct acting oral anticoagulants including factor Xa inhibitors and some thrombin inhibitors as dabigatran, are not recommended for use in patients with antiphospholipid syndrome (APS).  Treatment with these drugs has been associated with increased rates of recurrent thrombotic events, especially in patients with triple positive APS.', '2', '"Product Information. Pradaxa (dabigatran)." Boehringer-Ingelheim  (2010):|"Product Information. Xarelto (rivaroxaban)." Janssen Pharmaceuticals  (2022):|"Product Information. Eliquis (apixaban)." Bristol-Myers Squibb  (2021):|"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48618, 16586, 'Edoxaban', 'Antiphospholipid Syndrome', 'Direct acting oral anticoagulants including factor Xa inhibitors and some thrombin inhibitors as dabigatran, are not recommended for use in patients with antiphospholipid syndrome (APS).  Treatment with these drugs has been associated with increased rates of recurrent thrombotic events, especially in patients with triple positive APS.', '2', '"Product Information. Pradaxa (dabigatran)." Boehringer-Ingelheim  (2010):|"Product Information. Xarelto (rivaroxaban)." Janssen Pharmaceuticals  (2022):|"Product Information. Eliquis (apixaban)." Bristol-Myers Squibb  (2021):|"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48619, 16587, 'Edoxaban', 'Antiphospholipid Syndrome', 'Direct acting oral anticoagulants including factor Xa inhibitors and some thrombin inhibitors as dabigatran, are not recommended for use in patients with antiphospholipid syndrome (APS).  Treatment with these drugs has been associated with increased rates of recurrent thrombotic events, especially in patients with triple positive APS.', '2', '"Product Information. Pradaxa (dabigatran)." Boehringer-Ingelheim  (2010):|"Product Information. Xarelto (rivaroxaban)." Janssen Pharmaceuticals  (2022):|"Product Information. Eliquis (apixaban)." Bristol-Myers Squibb  (2021):|"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48620, 18080, 'Edoxaban', 'Antiphospholipid Syndrome', 'Direct acting oral anticoagulants including factor Xa inhibitors and some thrombin inhibitors as dabigatran, are not recommended for use in patients with antiphospholipid syndrome (APS).  Treatment with these drugs has been associated with increased rates of recurrent thrombotic events, especially in patients with triple positive APS.', '2', '"Product Information. Pradaxa (dabigatran)." Boehringer-Ingelheim  (2010):|"Product Information. Xarelto (rivaroxaban)." Janssen Pharmaceuticals  (2022):|"Product Information. Eliquis (apixaban)." Bristol-Myers Squibb  (2021):|"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48621, 18081, 'Edoxaban', 'Antiphospholipid Syndrome', 'Direct acting oral anticoagulants including factor Xa inhibitors and some thrombin inhibitors as dabigatran, are not recommended for use in patients with antiphospholipid syndrome (APS).  Treatment with these drugs has been associated with increased rates of recurrent thrombotic events, especially in patients with triple positive APS.', '2', '"Product Information. Pradaxa (dabigatran)." Boehringer-Ingelheim  (2010):|"Product Information. Xarelto (rivaroxaban)." Janssen Pharmaceuticals  (2022):|"Product Information. Eliquis (apixaban)." Bristol-Myers Squibb  (2021):|"Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48622, 25974, 'Eltrombopag', 'Hepatitis C', 'Eltrombopag has shown to increase the risk of hepatic decompensation in patients with chronic hepatitis C in treatment with interferon and ribavirin.  Clinical trials reported that ascites and encephalopathy occurred more frequently on these patients than in the placebo arm.  Patients with chronic hepatitis and receiving antiviral treatment should be closely monitored.  The manufacturers also recommend to discontinue eltrombopag if the antiviral therapy is discontinued.', '3', '"Product Information. Promacta (eltrombopag)." GlaxoSmithKline  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48623, 25975, 'Eltrombopag', 'Hepatitis C', 'Eltrombopag has shown to increase the risk of hepatic decompensation in patients with chronic hepatitis C in treatment with interferon and ribavirin.  Clinical trials reported that ascites and encephalopathy occurred more frequently on these patients than in the placebo arm.  Patients with chronic hepatitis and receiving antiviral treatment should be closely monitored.  The manufacturers also recommend to discontinue eltrombopag if the antiviral therapy is discontinued.', '3', '"Product Information. Promacta (eltrombopag)." GlaxoSmithKline  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48624, 29183, 'Eltrombopag', 'Hepatitis C', 'Eltrombopag has shown to increase the risk of hepatic decompensation in patients with chronic hepatitis C in treatment with interferon and ribavirin.  Clinical trials reported that ascites and encephalopathy occurred more frequently on these patients than in the placebo arm.  Patients with chronic hepatitis and receiving antiviral treatment should be closely monitored.  The manufacturers also recommend to discontinue eltrombopag if the antiviral therapy is discontinued.', '3', '"Product Information. Promacta (eltrombopag)." GlaxoSmithKline  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48625, 25974, 'Eltrombopag', 'Hepatic Insufficiency', 'Eltrombopag can cause liver enzyme elevations.  Monitor ALT, AST and bilirubin prior to treatment initiation, and every 2 weeks during dose adjustment phase and then monthly.  If abnormalities are confirmed, monitor serum liver tests weekly until resolved or stabilized.  Treatment should be discontinued if ALT levels increase to greater than or equal to 3 x ULN in patients with normal liver function, or greater or equal to 3 x baseline in patients with pretreatment transaminase elevations that are progressively increasing, persist for 4 weeks or more, also have an increase in bilirubin, or also have clinical symptoms of liver injury or hepatic decompensation.  Hepatic impairment influences the exposure to eltrombopag.  The initial dose should be reduced in patients with chronic ITP or severe aplastic anemia who have hepatic impairment.  No dose adjustment is required on patients with chronic hepatitis C and hepatic impairment.', '3', '"Product Information. Promacta (eltrombopag)." GlaxoSmithKline  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48626, 25975, 'Eltrombopag', 'Hepatic Insufficiency', 'Eltrombopag can cause liver enzyme elevations.  Monitor ALT, AST and bilirubin prior to treatment initiation, and every 2 weeks during dose adjustment phase and then monthly.  If abnormalities are confirmed, monitor serum liver tests weekly until resolved or stabilized.  Treatment should be discontinued if ALT levels increase to greater than or equal to 3 x ULN in patients with normal liver function, or greater or equal to 3 x baseline in patients with pretreatment transaminase elevations that are progressively increasing, persist for 4 weeks or more, also have an increase in bilirubin, or also have clinical symptoms of liver injury or hepatic decompensation.  Hepatic impairment influences the exposure to eltrombopag.  The initial dose should be reduced in patients with chronic ITP or severe aplastic anemia who have hepatic impairment.  No dose adjustment is required on patients with chronic hepatitis C and hepatic impairment.', '3', '"Product Information. Promacta (eltrombopag)." GlaxoSmithKline  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48627, 29183, 'Eltrombopag', 'Hepatic Insufficiency', 'Eltrombopag can cause liver enzyme elevations.  Monitor ALT, AST and bilirubin prior to treatment initiation, and every 2 weeks during dose adjustment phase and then monthly.  If abnormalities are confirmed, monitor serum liver tests weekly until resolved or stabilized.  Treatment should be discontinued if ALT levels increase to greater than or equal to 3 x ULN in patients with normal liver function, or greater or equal to 3 x baseline in patients with pretreatment transaminase elevations that are progressively increasing, persist for 4 weeks or more, also have an increase in bilirubin, or also have clinical symptoms of liver injury or hepatic decompensation.  Hepatic impairment influences the exposure to eltrombopag.  The initial dose should be reduced in patients with chronic ITP or severe aplastic anemia who have hepatic impairment.  No dose adjustment is required on patients with chronic hepatitis C and hepatic impairment.', '3', '"Product Information. Promacta (eltrombopag)." GlaxoSmithKline  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48628, 25974, 'Eltrombopag', 'Cataract', 'In clinical trials, eltrombopag developed or worsened cataracts in 7% of the patients receiving treatment.  A baseline ocular examination prior to administration of eltrombopag is recommended, and regular monitoring for signs and symptoms of cataracts should be performed regularly during treatment.', '2', '"Product Information. Promacta (eltrombopag)." GlaxoSmithKline  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48629, 25975, 'Eltrombopag', 'Cataract', 'In clinical trials, eltrombopag developed or worsened cataracts in 7% of the patients receiving treatment.  A baseline ocular examination prior to administration of eltrombopag is recommended, and regular monitoring for signs and symptoms of cataracts should be performed regularly during treatment.', '2', '"Product Information. Promacta (eltrombopag)." GlaxoSmithKline  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48630, 29183, 'Eltrombopag', 'Cataract', 'In clinical trials, eltrombopag developed or worsened cataracts in 7% of the patients receiving treatment.  A baseline ocular examination prior to administration of eltrombopag is recommended, and regular monitoring for signs and symptoms of cataracts should be performed regularly during treatment.', '2', '"Product Information. Promacta (eltrombopag)." GlaxoSmithKline  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48631, 25974, 'Eltrombopag', 'Thromboembolism', 'Thromboembolic complications may result from increases in platelet counts with TPO receptor agonists such as avatrombopag, lusutrombopag, and eltrombopag.  Consider the potential for increased risk of thromboembolism when administering these medications to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210 A, Antithrombin deficiency or Protein C or S deficiency).', '2', '"Product Information. Promacta (eltrombopag)." GlaxoSmithKline  (2008):|"Product Information. Doptelet (avatrombopag)." Dova Pharmaceuticals  (2018):|"Product Information. Mulpleta (lusutrombopag)." Shionogi USA Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48632, 25975, 'Eltrombopag', 'Thromboembolism', 'Thromboembolic complications may result from increases in platelet counts with TPO receptor agonists such as avatrombopag, lusutrombopag, and eltrombopag.  Consider the potential for increased risk of thromboembolism when administering these medications to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210 A, Antithrombin deficiency or Protein C or S deficiency).', '2', '"Product Information. Promacta (eltrombopag)." GlaxoSmithKline  (2008):|"Product Information. Doptelet (avatrombopag)." Dova Pharmaceuticals  (2018):|"Product Information. Mulpleta (lusutrombopag)." Shionogi USA Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48633, 29183, 'Eltrombopag', 'Thromboembolism', 'Thromboembolic complications may result from increases in platelet counts with TPO receptor agonists such as avatrombopag, lusutrombopag, and eltrombopag.  Consider the potential for increased risk of thromboembolism when administering these medications to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210 A, Antithrombin deficiency or Protein C or S deficiency).', '2', '"Product Information. Promacta (eltrombopag)." GlaxoSmithKline  (2008):|"Product Information. Doptelet (avatrombopag)." Dova Pharmaceuticals  (2018):|"Product Information. Mulpleta (lusutrombopag)." Shionogi USA Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48634, 0, 'Eculizumab', 'Meningococcal Infections', 'Eculizumab is contraindicated in patients with unresolved serious Neisseria meningitidis infection, in those who are not currently vaccinated against Neisseria meningitidis, unless the risks of delaying treatment outweigh the risks of developing a meningococcal infection.  Life-threatening and fatal meningococcal infections have occurred in patients treated with eculizumab.  The use of eculizumab increases a patient''s susceptibility to serious meningococcal infections (septicemia and/or meningitis).  Closely monitor patients for early signs and symptoms of meningococcal infection and evaluate patients immediately if an infection is suspected.  Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early.  It is recommended to discontinue eculizumab in patients who are undergoing treatment for serious meningococcal infections.', '3', '"Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48635, 0, 'Eculizumab', 'Infections', 'Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents.  Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reactivated viral infections including opportunistic infections.  Caution should be exercised when considering their use in patients with severe or chronic infections.  It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.', '3', '"Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc  (2007):|"Product Information. BENLYSTA (belimumab)." GlaxoSmithKline  (2011):|"Product Information. Nulojix (belatacept)." Bristol-Myers Squibb  (2011):|"Product Information. Aubagio (teriflunomide)." Genzyme Corporation  (2012):|"Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America  (2014):|"Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation  (2017):|"Product Information. Gamifant (emapalumab)." Sobi Inc  (2018):|"Product Information. Lupkynis (voclosporin)." Aurinia Pharma  (2021):|"Product Information. Saphnelo (anifrolumab)." Astra-Zeneca Pharmaceuticals  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48636, 0, 'Eculizumab', 'Leukoencephalopathy, Progressive Multifocal', 'Immunosuppressive agents may increase the risk of progressive multifocal leukoencephalopathy (PML).  Certain agents are contraindicated in patients who have or have had PML.  Patients receiving chronic immunosuppressant or immunomodulatory therapy or who have systemic medical conditions resulting in significantly compromised immune system function should not be treated with these agents.  Healthcare professionals should monitor patients for any new sign or symptom suggestive of PML.  Withhold therapy dosing immediately and perform an appropriate diagnostic evaluation at the first sign or symptom suggestive of PML.', '3', '"Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tysabri (natalizumab)." Elan Pharmaceutical/Athena Neurosciences Inc  (2004):|"Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc  (2007):|"Product Information. BENLYSTA (belimumab)." GlaxoSmithKline  (2011):|"Product Information. Nulojix (belatacept)." Bristol-Myers Squibb  (2011):|"Product Information. Aubagio (teriflunomide)." Genzyme Corporation  (2012):|"Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America  (2014):|"Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48637, 0, 'Eculizumab', 'Thrombotic Microangiopathies', 'Thrombotic microangiopathy (TMA) complications have occurred after treatment discontinuation or after a missed dose of eculizumab.  It is recommended to monitor patients with atypical hemolytic uremic syndrome for signs and symptoms of thrombotic microangiopathy (TMA) complications for at least 12 weeks.  If TMA complications occur after eculizumab discontinuation, consider reinstitution of treatment, plasma therapy or appropriate organ-specific supportive measures.', '2', '"Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48638, 0, 'Elotuzumab', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48639, 0, 'Elotuzumab', 'Cardiovascular Diseases', 'The use of monoclonal antibodies administered via IV infusion may cause serious infusion reactions, including bronchospasm, hypoxia, dyspnea, fluctuations in blood pressure, laryngeal edema and pulmonary edema.  Caution should be taken in patients with a history of cardiopulmonary disease as they may require additional post-infusion medications to manage respiratory complications.  It is recommended to administer required intravenous hydration and premedication with antihistamines, analgesics, and antipyretics before administration.  Monitor closely for signs and symptoms of infusion reactions during and for at least 4 hours following completion of each infusion in a setting where cardiopulmonary resuscitation medication and equipment are available.  Immediately interrupt or permanently discontinue treatment and institute supportive management for severe or prolonged infusion reactions as appropriate.', '3', '"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48640, 0, 'Elotuzumab', 'Tumor Lysis Syndrome', 'Tumor lysis syndrome (TLS) has occurred in patients receiving certain monoclonal antibodies.  Patients with high tumor burden and those with high circulating lymphocyte counts of greater than 25 X 10^9/L have a higher risk of developing TLS.  Consider tumor lysis prophylaxis prior to the infusion with anti-hyperuricemics and hydration beginning 12 to 24 hours prior to infusion.  It is recommended to correct electrolytes abnormalities, and monitor renal function in patients who develop TLS.  Monitor for signs and symptoms of TLS and temporary interruption or discontinuation of therapy might be required.', '3', '"Product Information. Arzerra (ofatumumab)." GlaxoSmithKline  (2009):|"Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc  (2011):|"Product Information. Gazyva (obinutuzumab)." Genentech  (2013):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48641, 0, 'Elotuzumab', 'Liver Diseases', 'The use of elotuzumab has been associated with elevations in liver enzymes.  Care should be exercised when using this agent in patients with liver impairment.  It is recommended to monitor liver enzymes before the start of therapy and periodically as clinically appropriate.  Interrupt treatment upon Grade 3 or higher elevation of liver enzymes.  After return to baseline values, continuation of treatment may be considered.', '2', '"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48642, 0, 'Amcinonide', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48643, 0, 'Amcinonide', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979):  362-3|Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993):  501-3|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987):  422-4|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983):  59-71|Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977):  1196-202|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995):  950-5|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48644, 0, 'Amcinonide', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990):  107-11|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48645, 0, 'Amcinonide', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48646, 0, 'Amcinonide', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976):  492-5|Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983):  878-81|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993):  664-6|Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976):  207-8|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48647, 0, 'Edetate calcium disodium anhydrous', 'Hepatitis', 'Edetate calcium disodium should not be given to patients with active hepatitis.', '3', '"Product Information. Calcium Disodium Versenate (edetate calcium disodium)." 3M Pharmaceuticals', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48648, 0, 'Edetate calcium disodium anhydrous', 'Kidney Diseases', 'The use of calcium EDTA is contraindicated in patients with anuria and active renal disease.  Dose-related nephrotoxicity (usually reversible) associated with EDTA has included dysuria, oliguria, proteinuria, large renal epithelial cells in urine, renal insufficiency/failure, and acute tubular necrosis.  Impaired renal function decreases the elimination of EDTA and may increase its nephrotoxicity.  Adequate hydration (avoid excess hydration in patients with lead encephalopathy) and established urine flow prior to initiation of EDTA therapy is necessary.  Clinical monitoring of renal function and calcium, phosphorus, and zinc levels is recommended.', '3', '"Product Information. Calcium Disodium Versenate (edetate calcium disodium)." 3M Pharmaceuticals', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48649, 0, 'Edetate calcium disodium anhydrous', 'Diabetes Mellitus', 'EDTA may chelate zinc present in exogenous insulin and alter glucose concentrations and insulin requirements in patients with diabetes.  Insulin dosages may need to be adjusted in diabetic patients administered EDTA.', '2', '"Product Information. Calcium Disodium Versenate (edetate calcium disodium)." 3M Pharmaceuticals|"Product Information. Disotate (edetate disodium)." Abbott Pharmaceutical', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48650, 0, 'Edrophonium', 'Bradycardia', 'Due to their pharmacological action, cholinesterase inhibitors can have a vagotonic effect on the sinoatrial and atrioventricular nodes producing bradycardia or heart block.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with preexisting bradycardia or underlying cardiac conduction abnormalities.  Syncopal episodes have been reported in patients with and without cardiac abnormalities.  Atropine may be used to reverse bradycardia produced by cholinesterase inhibitors.', '3', 'Wilcock GK, Surmon D, Forsyth D, Morgan R "Cholinergic side-effects of tetrahydroaminoacridine." Lancet 2 (1988):  1305|"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Baldessarini RJ, Gelenberg AJ "Using physostigmine safely." Am J Psychiatry 136 (1979):  1608-9|Janowsky DS, Risch SC, Huey LY, Kennedy B, Ziegler M "Effects of physostigmine on pulse, blood pressure, and serum epinephrine levels." Am J Psychiatry 142 (1985):  738-40|Dysken MW, Janowsky DS "Dose-related physostigmine-induced ventricular arrhythmia: case report." J Clin Psychiatry 46 (1985):  446-7|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):|"Product Information. Reminyl (galantamine)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48651, 0, 'Edrophonium', 'Bronchial Spasm', 'Cholinesterase inhibitors inhibit the hydrolysis of acetylcholine.  The enhanced effect of acetylcholine produces constriction of the bronchi, increased bronchial secretions, and bronchospasm.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with respiratory dysfunction, history of asthma or obstructive pulmonary disease.  Monitoring respiratory function during dosage initiation and adjustment is recommended.  Use of atropine along with discontinuation of the cholinesterase inhibitor may be required for serious respiratory distress.  Neostigmine may produce more severe muscarinic side effects than does pyridostigmine and ambenonium.  However, the duration of action is longest for ambenonium and shortest for edrophonium.  Echothiophate iodide ophthalmic may be systemically absorbed and cautious use is recommended in these patients.', '3', 'Wilcock GK, Surmon D, Forsyth D, Morgan R "Cholinergic side-effects of tetrahydroaminoacridine." Lancet 2 (1988):  1305|"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):|"Product Information. Reminyl (galantamine)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48652, 0, 'Edrophonium', 'Coronary Artery Disease', 'The use of cholinesterase inhibitors  has been associated with a constriction of coronary arteries.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with coronary artery disease.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48653, 0, 'Edrophonium', 'Parkinsonian Disorders', 'Cholinesterase inhibitors should be used with caution in patients with parkinsonism.  Some of these drugs might be contraindicated in these patients (refer to specific prescribing information).  Symptoms of Parkinson''s disease may be exacerbated with the increase in cholinergic activity.  Caregivers and patients should be advised.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|el-Yousef MK, Janowsky D, Davis JM, Sekerke HJ "Reversal of antiparkinsonian drug toxicity by physostigmine: a controlled study." Am J Psychiatry 130 (1973):  141-5|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48654, 0, 'Edrophonium', 'Peptic Ulcer', 'The use of cholinesterase inhibitors is associated with an increase in gastric acid secretion and gastric contractions.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with peptic ulcer disease.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):|"Product Information. Reminyl (galantamine)." Janssen Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48655, 0, 'Edrophonium', 'Seizures', 'Cholinesterase inhibitors have been associated with convulsions and tremor.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders.', '3', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Stewart GO "Convulsions after physostigmine." Anaesth Intensive Care 7 (1979):  283|"Product Information. Phospholine Iodide (echothiophate iodide ophthalmic)." Wyeth-Ayerst Laboratories|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Humorsol Ocumeter (demecarium bromide ophthalmic)." Merck & Co., Inc|"Product Information. Eserine Sulfate Ophthalmic (PHYSostigmine ophthalmic)." Ciba Vision Ophthalmics|"Product Information. Exelon (rivastigmine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48656, 0, 'Edrophonium', 'Hyperthyroidism', 'Many of the manifestations of hyperthyroidism may be exacerbated by increased levels of acetylcholine produced by cholinesterase inhibitors.  Therapy with cholinesterase inhibitors should be administered cautiously to patients with hyperthyroidism.  Monitoring of thyroid levels is recommended.', '2', '"Product Information. Cognex (tacrine)." Parke-Davis  (2001):|Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979):  199-255|"Product Information. Mestinon (pyridostigmine)." ICN Pharmaceuticals Inc  (2001):|"Product Information. Prostigman (neostigmine)." ICN Pharmaceuticals Inc, Cost Mesa, CA.|"Product Information. Aricept (donepezil)." Pfizer U.S. Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48657, 0, 'Elagolix', 'Hepatic Insufficiency', 'Compared to women with normal liver function, those with moderate hepatic impairment had approximately 3-fold higher elagolix exposures and those with severe hepatic impairment had approximately 7-fold higher elagolix exposures.  Because of these increased exposures and risk for bone loss, the use of elagolix is contraindicated in women with severe hepatic impairment (Child-Pugh C).  In women with moderate hepatic impairment (Child-Pugh B) elagolix 150 mg is recommended once daily with the duration of treatment limited to 6 months.  No dose adjustment is needed for women with mild hepatic impairment (Child-Pugh A).', '3', '"Product Information. Orilissa (elagolix)." AbbVie US LLC  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48658, 0, 'Elagolix', 'Osteoporosis', 'Elagolix is contraindicated in women with known osteoporosis because of the risk of further bone loss.  Elagolix causes a dose-dependent decrease in bone mineral density (BMD), which is greater with increasing duration of use and may not be completely reversible after stopping treatment.', '3', '"Product Information. Orilissa (elagolix)." AbbVie US LLC  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48659, 0, 'Elagolix', 'Mental Disorders', 'Suicidal ideation and behavior, has been reported in women treated with elagolix in the endometriosis clinical trials.  Women with a history of suicidality or depression had a higher incidence of depression compared to women without such a history.  Promptly evaluate patients with depressive symptoms to determine whether the risks of continued therapy outweigh the benefits.  Patients with new or worsening depression, anxiety or other mood changes should be referred to a mental health professional.  Advise patients to seek immediate medical attention for suicidal ideation and behavior.  Reevaluate the benefits and risks of continuing elagolix if such events occur.', '2', '"Product Information. Orilissa (elagolix)." AbbVie US LLC  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48660, 0, 'Eluxadoline', 'Constipation', 'The use of eluxadoline is contraindicated in patients with history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction.  These patients may be at risk for severe complications of bowel obstruction.', '3', '"Product Information. Viberzi (eluxadoline)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48661, 0, 'Eluxadoline', 'Pancreatitis', 'Pancreatitis, with or without sphincter of Oddi spasm has been reported in patients taking either the 75 mg or 100 mg dosage of eluxadoline, including serious cases resulting in hospitalization, primarily in patients without a gallbladder.  Fatal cases have also been reported.  The use of eluxadoline is contraindicated in patients without a gallbladder and in other patients at risk of pancreatitis such as patients with alcoholism, patients with known or suspected bile duct obstruction, history of pancreatitis or structural disease of the pancreas.  In patients with a gallbladder, the alcohol intake of the patient should be evaluated before starting treatment.  Patients should be monitored for any signs or symptoms suggestive of pancreatitis.  Patients should be instructed to stop treatment immediately and seek medical attention.', '3', '"Product Information. Viberzi (eluxadoline)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48662, 0, 'Eluxadoline', 'Hepatic Insufficiency', 'Eluxadoline is contraindicated in patients with severe hepatic impairment, as these patients are at risk for significantly increased plasma concentrations (16- fold), and there is no information to support the safety on these patients.  In patients with mild to moderate hepatic impairment the plasma concentrations are increased to a lesser extent.  It is recommended to decrease the dose to 75 mg twice a day on these patients and monitor regularly for impaired mental or physical abilities and for any other eluxadoline related adverse reactions.', '3', '"Product Information. Viberzi (eluxadoline)." Actavis Pharma, Inc.  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48663, 0, 'Elvitegravir', 'Liver Diseases', 'The use of elvitegravir is not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C).  No dosage adjustment is required in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.', '3', '"Product Information. Vitekta (elvitegravir)." Gilead Sciences  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48664, 0, 'Elvitegravir', 'Kidney Diseases', 'The use of elvitegravir is not recommended in patients with severe renal impairment (estimated creatinine clearance below 30 mL per minute).  No dosage adjustment is recommended in patients with estimated creatinine clearance greater than or equal to 30 mL per minute.', '3', '"Product Information. Vitekta (elvitegravir)." Gilead Sciences  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48665, 4962, 'Emtricitabine', 'Hepatitis B', 'Severe acute exacerbations of HBV have been reported in HBV-infected patients who have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (DF) and may occur with discontinuation of tenofovir alafenamide-containing products.  It is recommended that all patients with HIV-1 infection be tested for the presence of chronic HBV before or when initiating products containing emtricitabine, tenofovir DF, or tenofovir alafenamide.  Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in HBV-infected patients who discontinue antihepatitis B therapy.  If appropriate, initiation or resumption of antihepatitis B therapy may be warranted, especially in patients with advanced liver disease or cirrhosis, since posttreatment exacerbation of hepatitis may lead to hepatic decompensation and liver failure.', '3', '"Product Information. Truvada (emtricitabine-tenofovir)." Gilead Sciences  (2020):|"Product Information. Descovy (emtricitabine-tenofovir)." Gilead Sciences  (2022):|"Product Information. Emtriva (emtricitabine)." Gilead Sciences  (2018):|"Product Information. Vemlidy (tenofovir)." Gilead Sciences  (2022):|"Product Information. Viread (tenofovir)." Gilead Sciences  (2019):|"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir)." Gilead Sciences  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48666, 4962, 'Emtricitabine', 'Diseases requiring hemodialysis', 'Emtricitabine is removed by hemodialysis.  When started within 1.5 hours of emtricitabine dosing, about 30% of the dose was removed over a 3-hour hemodialysis session (blood flow rate of 400 mL/min and a dialysate flow rate of 600 mL/min).  If dosing on day of hemodialysis, emtricitabine should be administered after hemodialysis.', '2', '"Product Information. Emtriva (emtricitabine)." Gilead Sciences  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48667, 4962, 'Emtricitabine', 'Kidney Diseases', 'Emtricitabine is primarily eliminated by the kidney.  Dosage adjustment of emtricitabine is recommended for patients with CrCl below 50 mL/min or in patients with ESRD requiring dialysis, in accordance with the manufacturer product information.  Clinical response to treatment and renal function should be closely monitored.', '2', '"Product Information. Emtriva (emtricitabine)." Gilead Sciences  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48668, 0, 'Emapalumab', 'Infections', 'Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents.  Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reactivated viral infections including opportunistic infections.  Caution should be exercised when considering their use in patients with severe or chronic infections.  It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.', '3', '"Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc  (2007):|"Product Information. BENLYSTA (belimumab)." GlaxoSmithKline  (2011):|"Product Information. Nulojix (belatacept)." Bristol-Myers Squibb  (2011):|"Product Information. Aubagio (teriflunomide)." Genzyme Corporation  (2012):|"Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America  (2014):|"Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation  (2017):|"Product Information. Gamifant (emapalumab)." Sobi Inc  (2018):|"Product Information. Lupkynis (voclosporin)." Aurinia Pharma  (2021):|"Product Information. Saphnelo (anifrolumab)." Astra-Zeneca Pharmaceuticals  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48669, 5950, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48670, 5951, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48671, 13589, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48672, 15125, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48673, 16503, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48674, 17527, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48675, 17548, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48676, 17549, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48677, 18278, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48678, 18279, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48679, 18286, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48680, 19565, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48681, 19847, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48682, 19848, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48683, 20077, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48684, 21143, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48685, 21144, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48686, 22496, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48687, 22497, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48688, 26749, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48689, 28541, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48690, 30597, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48691, 30598, 'Empagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48692, 5950, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48693, 5951, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48694, 13589, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48695, 15125, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48696, 16503, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48697, 17527, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48698, 17548, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48699, 17549, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48700, 18278, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48701, 18279, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48702, 18286, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48703, 19565, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48704, 19847, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48705, 19848, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48706, 20077, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48707, 21143, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48708, 21144, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48709, 22496, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48710, 22497, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48711, 26749, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48712, 28541, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48713, 30597, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48714, 30598, 'Empagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48715, 5950, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48716, 5951, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48717, 13589, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48718, 15125, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48719, 16503, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48720, 17527, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48721, 17548, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48722, 17549, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48723, 18278, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48724, 18279, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48725, 18286, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48726, 19565, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48727, 19847, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48728, 19848, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48729, 20077, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48730, 21143, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48731, 21144, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48732, 22496, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48733, 22497, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48734, 26749, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48735, 28541, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48736, 30597, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48737, 30598, 'Empagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48738, 0, 'Amifampridine', 'Seizures', 'Amifampridine is contraindicated in patients with a history of seizures.  Seizures have been observed in patients without a history of seizures at the recommended doses.  Seizures may be dose-dependent.  Consider discontinuation or dose-reduction in patients who have a seizure while on treatment.', '3', '"Product Information. Firdapse (amifampridine)." Catalyst Pharmaceuticals, Inc.  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48739, 0, 'Amifampridine', 'Liver Diseases', 'Amifampridine is extensively metabolized by N-acetyltransferase 2 (NAT2) and hepatic impairment may cause an increase in exposure.  The effects of amifampridine have not been studied in patients with hepatic impairment.  It is recommended to start treatment with amifampridine in patients with any degree of hepatic impairment at the lowest recommended starting dosage (15 mg/day) and monitor for adverse reactions.  Consider dosage modification or discontinuation in patients with hepatic impairment as clinically appropriate.', '2', '"Product Information. Firdapse (amifampridine)." Catalyst Pharmaceuticals, Inc.  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48740, 0, 'Amifampridine', 'Kidney Diseases', 'Renal clearance is an elimination pathway for amifampridine and the inactive metabolite, 3-N-acetyl amifampridine, and exposure of amifampridine is higher in subjects with renal impairment.  Patients with renal impairment should be initiated at the lowest recommended starting dosage (15 mg/day), and patients should be closely monitored for adverse reactions.  Consider dosage modification or discontinuation in patients with renal impairment as clinically appropriate.  Caution is recommended as the safety, efficacy, and pharmacokinetics of amifampridine have not been studied in patients with end-stage renal disease.  No dosage recommendation can be made for patients with end-stage renal disease.', '2', '"Product Information. Firdapse (amifampridine)." Catalyst Pharmaceuticals, Inc.  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48741, 35, 'Enalapril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Roberts JR, Wuerz RC "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema." Ann Emerg Med 20 (1991):  555-8|Jett GK "Captopril-induced angioedema ." Ann Emerg Med 13 (1984):  489-90|McElligott S, Perlroth M, Raish L "Angioedema after substituting lisinopril for captopril ." Ann Intern Med 116 (1992):  426-7|Hedner T, Samuelsson O, Lunde H, et al. "Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors." Br Med J 304 (1992):  941-6|Wood SM, Mann RD, Rawlins MD "Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors." Br Med J 294 (1987):  91-2|Seidman MD, Lewandowski CA, Sarpa JR, et al. "Angioedema related to angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 102 (1990):  727-31|Werber JL, Pincus RL "Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 101 (1989):  96-8|Jason DR "Fatal angioedema associated with captopril." J Forensic Sci 37 (1992):  1418-21|Gianos ME, Klaustermeyer WB, Kurohara M, et al. "Enalapril induced angioedema." Am J Emerg Med 8 (1990):  124-6|Gonnering RS, Hirsch SR "Delayed drug-induced periorbital angioedema ." Am J Ophthalmol 110 (1990):  566-8|Chin HL, Buchan DA "Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor ." Ann Intern Med 112 (1990):  312-3|Abidin MR, Eisele DW "Angioedema after long-term use of angiotensin-converting enzyme inhibitor ." Arch Otolaryngol Head Neck Surg 117 (1991):  1059|Orfan N, Patterson R, Dykewicz MS "Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema." JAMA 264 (1990):  1287-9|Gannon TH, Eby TL "Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction." Laryngoscope 100 (1990):  1156-60|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Soo Hoo GW, Dao HT, Klaustermeyer WB "Severe angioedema and respiratory distress associated with lisinopril use." West J Med 158 (1993):  412-7|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Frontera Y, Piecuch JF "Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor." J Am Dent Assoc 126 (1995):  217-20|Gimenez JC "Angioneurotic edema produced by enalapril." Ann Pharmacother 29 (1995):  317|Gonzalo FE, Montagut LB, Vecina ST "Angioedema caused by ramipril." Ann Pharmacother 29 (1995):  431-2|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Forslund T, Tohmo H, Weckstrom G, Stenborg M, Jarvinen S "Angio-oedema induced by enalapril." J Intern Med 238 (1995):  179-81|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Gunkel AR, Thurner KH, Kanonier G, Sprinzl GM, Thumfart WF "Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors." Am J Otolaryngol 17 (1996):  87-91|O''Mara NB, O''Mara EM Jr "Delayed onset of andioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature." Pharmacotherapy 16 (1996):  675-9|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48742, 36, 'Enalapril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Roberts JR, Wuerz RC "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema." Ann Emerg Med 20 (1991):  555-8|Jett GK "Captopril-induced angioedema ." Ann Emerg Med 13 (1984):  489-90|McElligott S, Perlroth M, Raish L "Angioedema after substituting lisinopril for captopril ." Ann Intern Med 116 (1992):  426-7|Hedner T, Samuelsson O, Lunde H, et al. "Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors." Br Med J 304 (1992):  941-6|Wood SM, Mann RD, Rawlins MD "Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors." Br Med J 294 (1987):  91-2|Seidman MD, Lewandowski CA, Sarpa JR, et al. "Angioedema related to angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 102 (1990):  727-31|Werber JL, Pincus RL "Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 101 (1989):  96-8|Jason DR "Fatal angioedema associated with captopril." J Forensic Sci 37 (1992):  1418-21|Gianos ME, Klaustermeyer WB, Kurohara M, et al. "Enalapril induced angioedema." Am J Emerg Med 8 (1990):  124-6|Gonnering RS, Hirsch SR "Delayed drug-induced periorbital angioedema ." Am J Ophthalmol 110 (1990):  566-8|Chin HL, Buchan DA "Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor ." Ann Intern Med 112 (1990):  312-3|Abidin MR, Eisele DW "Angioedema after long-term use of angiotensin-converting enzyme inhibitor ." Arch Otolaryngol Head Neck Surg 117 (1991):  1059|Orfan N, Patterson R, Dykewicz MS "Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema." JAMA 264 (1990):  1287-9|Gannon TH, Eby TL "Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction." Laryngoscope 100 (1990):  1156-60|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Soo Hoo GW, Dao HT, Klaustermeyer WB "Severe angioedema and respiratory distress associated with lisinopril use." West J Med 158 (1993):  412-7|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Frontera Y, Piecuch JF "Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor." J Am Dent Assoc 126 (1995):  217-20|Gimenez JC "Angioneurotic edema produced by enalapril." Ann Pharmacother 29 (1995):  317|Gonzalo FE, Montagut LB, Vecina ST "Angioedema caused by ramipril." Ann Pharmacother 29 (1995):  431-2|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Forslund T, Tohmo H, Weckstrom G, Stenborg M, Jarvinen S "Angio-oedema induced by enalapril." J Intern Med 238 (1995):  179-81|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Gunkel AR, Thurner KH, Kanonier G, Sprinzl GM, Thumfart WF "Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors." Am J Otolaryngol 17 (1996):  87-91|O''Mara NB, O''Mara EM Jr "Delayed onset of andioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature." Pharmacotherapy 16 (1996):  675-9|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48743, 4167, 'Enalapril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Roberts JR, Wuerz RC "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema." Ann Emerg Med 20 (1991):  555-8|Jett GK "Captopril-induced angioedema ." Ann Emerg Med 13 (1984):  489-90|McElligott S, Perlroth M, Raish L "Angioedema after substituting lisinopril for captopril ." Ann Intern Med 116 (1992):  426-7|Hedner T, Samuelsson O, Lunde H, et al. "Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors." Br Med J 304 (1992):  941-6|Wood SM, Mann RD, Rawlins MD "Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors." Br Med J 294 (1987):  91-2|Seidman MD, Lewandowski CA, Sarpa JR, et al. "Angioedema related to angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 102 (1990):  727-31|Werber JL, Pincus RL "Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 101 (1989):  96-8|Jason DR "Fatal angioedema associated with captopril." J Forensic Sci 37 (1992):  1418-21|Gianos ME, Klaustermeyer WB, Kurohara M, et al. "Enalapril induced angioedema." Am J Emerg Med 8 (1990):  124-6|Gonnering RS, Hirsch SR "Delayed drug-induced periorbital angioedema ." Am J Ophthalmol 110 (1990):  566-8|Chin HL, Buchan DA "Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor ." Ann Intern Med 112 (1990):  312-3|Abidin MR, Eisele DW "Angioedema after long-term use of angiotensin-converting enzyme inhibitor ." Arch Otolaryngol Head Neck Surg 117 (1991):  1059|Orfan N, Patterson R, Dykewicz MS "Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema." JAMA 264 (1990):  1287-9|Gannon TH, Eby TL "Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction." Laryngoscope 100 (1990):  1156-60|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Soo Hoo GW, Dao HT, Klaustermeyer WB "Severe angioedema and respiratory distress associated with lisinopril use." West J Med 158 (1993):  412-7|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Frontera Y, Piecuch JF "Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor." J Am Dent Assoc 126 (1995):  217-20|Gimenez JC "Angioneurotic edema produced by enalapril." Ann Pharmacother 29 (1995):  317|Gonzalo FE, Montagut LB, Vecina ST "Angioedema caused by ramipril." Ann Pharmacother 29 (1995):  431-2|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Forslund T, Tohmo H, Weckstrom G, Stenborg M, Jarvinen S "Angio-oedema induced by enalapril." J Intern Med 238 (1995):  179-81|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Gunkel AR, Thurner KH, Kanonier G, Sprinzl GM, Thumfart WF "Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors." Am J Otolaryngol 17 (1996):  87-91|O''Mara NB, O''Mara EM Jr "Delayed onset of andioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature." Pharmacotherapy 16 (1996):  675-9|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48744, 4588, 'Enalapril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Roberts JR, Wuerz RC "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema." Ann Emerg Med 20 (1991):  555-8|Jett GK "Captopril-induced angioedema ." Ann Emerg Med 13 (1984):  489-90|McElligott S, Perlroth M, Raish L "Angioedema after substituting lisinopril for captopril ." Ann Intern Med 116 (1992):  426-7|Hedner T, Samuelsson O, Lunde H, et al. "Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors." Br Med J 304 (1992):  941-6|Wood SM, Mann RD, Rawlins MD "Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors." Br Med J 294 (1987):  91-2|Seidman MD, Lewandowski CA, Sarpa JR, et al. "Angioedema related to angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 102 (1990):  727-31|Werber JL, Pincus RL "Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 101 (1989):  96-8|Jason DR "Fatal angioedema associated with captopril." J Forensic Sci 37 (1992):  1418-21|Gianos ME, Klaustermeyer WB, Kurohara M, et al. "Enalapril induced angioedema." Am J Emerg Med 8 (1990):  124-6|Gonnering RS, Hirsch SR "Delayed drug-induced periorbital angioedema ." Am J Ophthalmol 110 (1990):  566-8|Chin HL, Buchan DA "Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor ." Ann Intern Med 112 (1990):  312-3|Abidin MR, Eisele DW "Angioedema after long-term use of angiotensin-converting enzyme inhibitor ." Arch Otolaryngol Head Neck Surg 117 (1991):  1059|Orfan N, Patterson R, Dykewicz MS "Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema." JAMA 264 (1990):  1287-9|Gannon TH, Eby TL "Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction." Laryngoscope 100 (1990):  1156-60|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Soo Hoo GW, Dao HT, Klaustermeyer WB "Severe angioedema and respiratory distress associated with lisinopril use." West J Med 158 (1993):  412-7|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Frontera Y, Piecuch JF "Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor." J Am Dent Assoc 126 (1995):  217-20|Gimenez JC "Angioneurotic edema produced by enalapril." Ann Pharmacother 29 (1995):  317|Gonzalo FE, Montagut LB, Vecina ST "Angioedema caused by ramipril." Ann Pharmacother 29 (1995):  431-2|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Forslund T, Tohmo H, Weckstrom G, Stenborg M, Jarvinen S "Angio-oedema induced by enalapril." J Intern Med 238 (1995):  179-81|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Gunkel AR, Thurner KH, Kanonier G, Sprinzl GM, Thumfart WF "Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors." Am J Otolaryngol 17 (1996):  87-91|O''Mara NB, O''Mara EM Jr "Delayed onset of andioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature." Pharmacotherapy 16 (1996):  675-9|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48745, 4591, 'Enalapril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Roberts JR, Wuerz RC "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema." Ann Emerg Med 20 (1991):  555-8|Jett GK "Captopril-induced angioedema ." Ann Emerg Med 13 (1984):  489-90|McElligott S, Perlroth M, Raish L "Angioedema after substituting lisinopril for captopril ." Ann Intern Med 116 (1992):  426-7|Hedner T, Samuelsson O, Lunde H, et al. "Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors." Br Med J 304 (1992):  941-6|Wood SM, Mann RD, Rawlins MD "Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors." Br Med J 294 (1987):  91-2|Seidman MD, Lewandowski CA, Sarpa JR, et al. "Angioedema related to angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 102 (1990):  727-31|Werber JL, Pincus RL "Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 101 (1989):  96-8|Jason DR "Fatal angioedema associated with captopril." J Forensic Sci 37 (1992):  1418-21|Gianos ME, Klaustermeyer WB, Kurohara M, et al. "Enalapril induced angioedema." Am J Emerg Med 8 (1990):  124-6|Gonnering RS, Hirsch SR "Delayed drug-induced periorbital angioedema ." Am J Ophthalmol 110 (1990):  566-8|Chin HL, Buchan DA "Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor ." Ann Intern Med 112 (1990):  312-3|Abidin MR, Eisele DW "Angioedema after long-term use of angiotensin-converting enzyme inhibitor ." Arch Otolaryngol Head Neck Surg 117 (1991):  1059|Orfan N, Patterson R, Dykewicz MS "Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema." JAMA 264 (1990):  1287-9|Gannon TH, Eby TL "Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction." Laryngoscope 100 (1990):  1156-60|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Soo Hoo GW, Dao HT, Klaustermeyer WB "Severe angioedema and respiratory distress associated with lisinopril use." West J Med 158 (1993):  412-7|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Frontera Y, Piecuch JF "Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor." J Am Dent Assoc 126 (1995):  217-20|Gimenez JC "Angioneurotic edema produced by enalapril." Ann Pharmacother 29 (1995):  317|Gonzalo FE, Montagut LB, Vecina ST "Angioedema caused by ramipril." Ann Pharmacother 29 (1995):  431-2|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Forslund T, Tohmo H, Weckstrom G, Stenborg M, Jarvinen S "Angio-oedema induced by enalapril." J Intern Med 238 (1995):  179-81|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Gunkel AR, Thurner KH, Kanonier G, Sprinzl GM, Thumfart WF "Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors." Am J Otolaryngol 17 (1996):  87-91|O''Mara NB, O''Mara EM Jr "Delayed onset of andioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature." Pharmacotherapy 16 (1996):  675-9|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48746, 4605, 'Enalapril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Roberts JR, Wuerz RC "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema." Ann Emerg Med 20 (1991):  555-8|Jett GK "Captopril-induced angioedema ." Ann Emerg Med 13 (1984):  489-90|McElligott S, Perlroth M, Raish L "Angioedema after substituting lisinopril for captopril ." Ann Intern Med 116 (1992):  426-7|Hedner T, Samuelsson O, Lunde H, et al. "Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors." Br Med J 304 (1992):  941-6|Wood SM, Mann RD, Rawlins MD "Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors." Br Med J 294 (1987):  91-2|Seidman MD, Lewandowski CA, Sarpa JR, et al. "Angioedema related to angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 102 (1990):  727-31|Werber JL, Pincus RL "Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 101 (1989):  96-8|Jason DR "Fatal angioedema associated with captopril." J Forensic Sci 37 (1992):  1418-21|Gianos ME, Klaustermeyer WB, Kurohara M, et al. "Enalapril induced angioedema." Am J Emerg Med 8 (1990):  124-6|Gonnering RS, Hirsch SR "Delayed drug-induced periorbital angioedema ." Am J Ophthalmol 110 (1990):  566-8|Chin HL, Buchan DA "Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor ." Ann Intern Med 112 (1990):  312-3|Abidin MR, Eisele DW "Angioedema after long-term use of angiotensin-converting enzyme inhibitor ." Arch Otolaryngol Head Neck Surg 117 (1991):  1059|Orfan N, Patterson R, Dykewicz MS "Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema." JAMA 264 (1990):  1287-9|Gannon TH, Eby TL "Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction." Laryngoscope 100 (1990):  1156-60|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Soo Hoo GW, Dao HT, Klaustermeyer WB "Severe angioedema and respiratory distress associated with lisinopril use." West J Med 158 (1993):  412-7|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Frontera Y, Piecuch JF "Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor." J Am Dent Assoc 126 (1995):  217-20|Gimenez JC "Angioneurotic edema produced by enalapril." Ann Pharmacother 29 (1995):  317|Gonzalo FE, Montagut LB, Vecina ST "Angioedema caused by ramipril." Ann Pharmacother 29 (1995):  431-2|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Forslund T, Tohmo H, Weckstrom G, Stenborg M, Jarvinen S "Angio-oedema induced by enalapril." J Intern Med 238 (1995):  179-81|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Gunkel AR, Thurner KH, Kanonier G, Sprinzl GM, Thumfart WF "Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors." Am J Otolaryngol 17 (1996):  87-91|O''Mara NB, O''Mara EM Jr "Delayed onset of andioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature." Pharmacotherapy 16 (1996):  675-9|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48747, 8030, 'Enalapril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Roberts JR, Wuerz RC "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema." Ann Emerg Med 20 (1991):  555-8|Jett GK "Captopril-induced angioedema ." Ann Emerg Med 13 (1984):  489-90|McElligott S, Perlroth M, Raish L "Angioedema after substituting lisinopril for captopril ." Ann Intern Med 116 (1992):  426-7|Hedner T, Samuelsson O, Lunde H, et al. "Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors." Br Med J 304 (1992):  941-6|Wood SM, Mann RD, Rawlins MD "Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors." Br Med J 294 (1987):  91-2|Seidman MD, Lewandowski CA, Sarpa JR, et al. "Angioedema related to angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 102 (1990):  727-31|Werber JL, Pincus RL "Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 101 (1989):  96-8|Jason DR "Fatal angioedema associated with captopril." J Forensic Sci 37 (1992):  1418-21|Gianos ME, Klaustermeyer WB, Kurohara M, et al. "Enalapril induced angioedema." Am J Emerg Med 8 (1990):  124-6|Gonnering RS, Hirsch SR "Delayed drug-induced periorbital angioedema ." Am J Ophthalmol 110 (1990):  566-8|Chin HL, Buchan DA "Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor ." Ann Intern Med 112 (1990):  312-3|Abidin MR, Eisele DW "Angioedema after long-term use of angiotensin-converting enzyme inhibitor ." Arch Otolaryngol Head Neck Surg 117 (1991):  1059|Orfan N, Patterson R, Dykewicz MS "Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema." JAMA 264 (1990):  1287-9|Gannon TH, Eby TL "Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction." Laryngoscope 100 (1990):  1156-60|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Soo Hoo GW, Dao HT, Klaustermeyer WB "Severe angioedema and respiratory distress associated with lisinopril use." West J Med 158 (1993):  412-7|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Frontera Y, Piecuch JF "Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor." J Am Dent Assoc 126 (1995):  217-20|Gimenez JC "Angioneurotic edema produced by enalapril." Ann Pharmacother 29 (1995):  317|Gonzalo FE, Montagut LB, Vecina ST "Angioedema caused by ramipril." Ann Pharmacother 29 (1995):  431-2|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Forslund T, Tohmo H, Weckstrom G, Stenborg M, Jarvinen S "Angio-oedema induced by enalapril." J Intern Med 238 (1995):  179-81|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Gunkel AR, Thurner KH, Kanonier G, Sprinzl GM, Thumfart WF "Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors." Am J Otolaryngol 17 (1996):  87-91|O''Mara NB, O''Mara EM Jr "Delayed onset of andioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature." Pharmacotherapy 16 (1996):  675-9|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48748, 18295, 'Enalapril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Roberts JR, Wuerz RC "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema." Ann Emerg Med 20 (1991):  555-8|Jett GK "Captopril-induced angioedema ." Ann Emerg Med 13 (1984):  489-90|McElligott S, Perlroth M, Raish L "Angioedema after substituting lisinopril for captopril ." Ann Intern Med 116 (1992):  426-7|Hedner T, Samuelsson O, Lunde H, et al. "Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors." Br Med J 304 (1992):  941-6|Wood SM, Mann RD, Rawlins MD "Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors." Br Med J 294 (1987):  91-2|Seidman MD, Lewandowski CA, Sarpa JR, et al. "Angioedema related to angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 102 (1990):  727-31|Werber JL, Pincus RL "Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 101 (1989):  96-8|Jason DR "Fatal angioedema associated with captopril." J Forensic Sci 37 (1992):  1418-21|Gianos ME, Klaustermeyer WB, Kurohara M, et al. "Enalapril induced angioedema." Am J Emerg Med 8 (1990):  124-6|Gonnering RS, Hirsch SR "Delayed drug-induced periorbital angioedema ." Am J Ophthalmol 110 (1990):  566-8|Chin HL, Buchan DA "Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor ." Ann Intern Med 112 (1990):  312-3|Abidin MR, Eisele DW "Angioedema after long-term use of angiotensin-converting enzyme inhibitor ." Arch Otolaryngol Head Neck Surg 117 (1991):  1059|Orfan N, Patterson R, Dykewicz MS "Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema." JAMA 264 (1990):  1287-9|Gannon TH, Eby TL "Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction." Laryngoscope 100 (1990):  1156-60|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Soo Hoo GW, Dao HT, Klaustermeyer WB "Severe angioedema and respiratory distress associated with lisinopril use." West J Med 158 (1993):  412-7|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Frontera Y, Piecuch JF "Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor." J Am Dent Assoc 126 (1995):  217-20|Gimenez JC "Angioneurotic edema produced by enalapril." Ann Pharmacother 29 (1995):  317|Gonzalo FE, Montagut LB, Vecina ST "Angioedema caused by ramipril." Ann Pharmacother 29 (1995):  431-2|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Forslund T, Tohmo H, Weckstrom G, Stenborg M, Jarvinen S "Angio-oedema induced by enalapril." J Intern Med 238 (1995):  179-81|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Gunkel AR, Thurner KH, Kanonier G, Sprinzl GM, Thumfart WF "Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors." Am J Otolaryngol 17 (1996):  87-91|O''Mara NB, O''Mara EM Jr "Delayed onset of andioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature." Pharmacotherapy 16 (1996):  675-9|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48749, 25189, 'Enalapril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Roberts JR, Wuerz RC "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema." Ann Emerg Med 20 (1991):  555-8|Jett GK "Captopril-induced angioedema ." Ann Emerg Med 13 (1984):  489-90|McElligott S, Perlroth M, Raish L "Angioedema after substituting lisinopril for captopril ." Ann Intern Med 116 (1992):  426-7|Hedner T, Samuelsson O, Lunde H, et al. "Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors." Br Med J 304 (1992):  941-6|Wood SM, Mann RD, Rawlins MD "Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors." Br Med J 294 (1987):  91-2|Seidman MD, Lewandowski CA, Sarpa JR, et al. "Angioedema related to angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 102 (1990):  727-31|Werber JL, Pincus RL "Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 101 (1989):  96-8|Jason DR "Fatal angioedema associated with captopril." J Forensic Sci 37 (1992):  1418-21|Gianos ME, Klaustermeyer WB, Kurohara M, et al. "Enalapril induced angioedema." Am J Emerg Med 8 (1990):  124-6|Gonnering RS, Hirsch SR "Delayed drug-induced periorbital angioedema ." Am J Ophthalmol 110 (1990):  566-8|Chin HL, Buchan DA "Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor ." Ann Intern Med 112 (1990):  312-3|Abidin MR, Eisele DW "Angioedema after long-term use of angiotensin-converting enzyme inhibitor ." Arch Otolaryngol Head Neck Surg 117 (1991):  1059|Orfan N, Patterson R, Dykewicz MS "Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema." JAMA 264 (1990):  1287-9|Gannon TH, Eby TL "Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction." Laryngoscope 100 (1990):  1156-60|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Soo Hoo GW, Dao HT, Klaustermeyer WB "Severe angioedema and respiratory distress associated with lisinopril use." West J Med 158 (1993):  412-7|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Frontera Y, Piecuch JF "Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor." J Am Dent Assoc 126 (1995):  217-20|Gimenez JC "Angioneurotic edema produced by enalapril." Ann Pharmacother 29 (1995):  317|Gonzalo FE, Montagut LB, Vecina ST "Angioedema caused by ramipril." Ann Pharmacother 29 (1995):  431-2|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Forslund T, Tohmo H, Weckstrom G, Stenborg M, Jarvinen S "Angio-oedema induced by enalapril." J Intern Med 238 (1995):  179-81|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Gunkel AR, Thurner KH, Kanonier G, Sprinzl GM, Thumfart WF "Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors." Am J Otolaryngol 17 (1996):  87-91|O''Mara NB, O''Mara EM Jr "Delayed onset of andioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature." Pharmacotherapy 16 (1996):  675-9|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48750, 25190, 'Enalapril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Roberts JR, Wuerz RC "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema." Ann Emerg Med 20 (1991):  555-8|Jett GK "Captopril-induced angioedema ." Ann Emerg Med 13 (1984):  489-90|McElligott S, Perlroth M, Raish L "Angioedema after substituting lisinopril for captopril ." Ann Intern Med 116 (1992):  426-7|Hedner T, Samuelsson O, Lunde H, et al. "Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors." Br Med J 304 (1992):  941-6|Wood SM, Mann RD, Rawlins MD "Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors." Br Med J 294 (1987):  91-2|Seidman MD, Lewandowski CA, Sarpa JR, et al. "Angioedema related to angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 102 (1990):  727-31|Werber JL, Pincus RL "Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 101 (1989):  96-8|Jason DR "Fatal angioedema associated with captopril." J Forensic Sci 37 (1992):  1418-21|Gianos ME, Klaustermeyer WB, Kurohara M, et al. "Enalapril induced angioedema." Am J Emerg Med 8 (1990):  124-6|Gonnering RS, Hirsch SR "Delayed drug-induced periorbital angioedema ." Am J Ophthalmol 110 (1990):  566-8|Chin HL, Buchan DA "Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor ." Ann Intern Med 112 (1990):  312-3|Abidin MR, Eisele DW "Angioedema after long-term use of angiotensin-converting enzyme inhibitor ." Arch Otolaryngol Head Neck Surg 117 (1991):  1059|Orfan N, Patterson R, Dykewicz MS "Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema." JAMA 264 (1990):  1287-9|Gannon TH, Eby TL "Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction." Laryngoscope 100 (1990):  1156-60|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Soo Hoo GW, Dao HT, Klaustermeyer WB "Severe angioedema and respiratory distress associated with lisinopril use." West J Med 158 (1993):  412-7|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Frontera Y, Piecuch JF "Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor." J Am Dent Assoc 126 (1995):  217-20|Gimenez JC "Angioneurotic edema produced by enalapril." Ann Pharmacother 29 (1995):  317|Gonzalo FE, Montagut LB, Vecina ST "Angioedema caused by ramipril." Ann Pharmacother 29 (1995):  431-2|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Forslund T, Tohmo H, Weckstrom G, Stenborg M, Jarvinen S "Angio-oedema induced by enalapril." J Intern Med 238 (1995):  179-81|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Gunkel AR, Thurner KH, Kanonier G, Sprinzl GM, Thumfart WF "Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors." Am J Otolaryngol 17 (1996):  87-91|O''Mara NB, O''Mara EM Jr "Delayed onset of andioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature." Pharmacotherapy 16 (1996):  675-9|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48751, 25195, 'Enalapril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Roberts JR, Wuerz RC "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema." Ann Emerg Med 20 (1991):  555-8|Jett GK "Captopril-induced angioedema ." Ann Emerg Med 13 (1984):  489-90|McElligott S, Perlroth M, Raish L "Angioedema after substituting lisinopril for captopril ." Ann Intern Med 116 (1992):  426-7|Hedner T, Samuelsson O, Lunde H, et al. "Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors." Br Med J 304 (1992):  941-6|Wood SM, Mann RD, Rawlins MD "Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors." Br Med J 294 (1987):  91-2|Seidman MD, Lewandowski CA, Sarpa JR, et al. "Angioedema related to angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 102 (1990):  727-31|Werber JL, Pincus RL "Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 101 (1989):  96-8|Jason DR "Fatal angioedema associated with captopril." J Forensic Sci 37 (1992):  1418-21|Gianos ME, Klaustermeyer WB, Kurohara M, et al. "Enalapril induced angioedema." Am J Emerg Med 8 (1990):  124-6|Gonnering RS, Hirsch SR "Delayed drug-induced periorbital angioedema ." Am J Ophthalmol 110 (1990):  566-8|Chin HL, Buchan DA "Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor ." Ann Intern Med 112 (1990):  312-3|Abidin MR, Eisele DW "Angioedema after long-term use of angiotensin-converting enzyme inhibitor ." Arch Otolaryngol Head Neck Surg 117 (1991):  1059|Orfan N, Patterson R, Dykewicz MS "Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema." JAMA 264 (1990):  1287-9|Gannon TH, Eby TL "Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction." Laryngoscope 100 (1990):  1156-60|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Soo Hoo GW, Dao HT, Klaustermeyer WB "Severe angioedema and respiratory distress associated with lisinopril use." West J Med 158 (1993):  412-7|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Frontera Y, Piecuch JF "Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor." J Am Dent Assoc 126 (1995):  217-20|Gimenez JC "Angioneurotic edema produced by enalapril." Ann Pharmacother 29 (1995):  317|Gonzalo FE, Montagut LB, Vecina ST "Angioedema caused by ramipril." Ann Pharmacother 29 (1995):  431-2|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Forslund T, Tohmo H, Weckstrom G, Stenborg M, Jarvinen S "Angio-oedema induced by enalapril." J Intern Med 238 (1995):  179-81|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Gunkel AR, Thurner KH, Kanonier G, Sprinzl GM, Thumfart WF "Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors." Am J Otolaryngol 17 (1996):  87-91|O''Mara NB, O''Mara EM Jr "Delayed onset of andioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature." Pharmacotherapy 16 (1996):  675-9|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48752, 25196, 'Enalapril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Roberts JR, Wuerz RC "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema." Ann Emerg Med 20 (1991):  555-8|Jett GK "Captopril-induced angioedema ." Ann Emerg Med 13 (1984):  489-90|McElligott S, Perlroth M, Raish L "Angioedema after substituting lisinopril for captopril ." Ann Intern Med 116 (1992):  426-7|Hedner T, Samuelsson O, Lunde H, et al. "Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors." Br Med J 304 (1992):  941-6|Wood SM, Mann RD, Rawlins MD "Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors." Br Med J 294 (1987):  91-2|Seidman MD, Lewandowski CA, Sarpa JR, et al. "Angioedema related to angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 102 (1990):  727-31|Werber JL, Pincus RL "Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 101 (1989):  96-8|Jason DR "Fatal angioedema associated with captopril." J Forensic Sci 37 (1992):  1418-21|Gianos ME, Klaustermeyer WB, Kurohara M, et al. "Enalapril induced angioedema." Am J Emerg Med 8 (1990):  124-6|Gonnering RS, Hirsch SR "Delayed drug-induced periorbital angioedema ." Am J Ophthalmol 110 (1990):  566-8|Chin HL, Buchan DA "Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor ." Ann Intern Med 112 (1990):  312-3|Abidin MR, Eisele DW "Angioedema after long-term use of angiotensin-converting enzyme inhibitor ." Arch Otolaryngol Head Neck Surg 117 (1991):  1059|Orfan N, Patterson R, Dykewicz MS "Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema." JAMA 264 (1990):  1287-9|Gannon TH, Eby TL "Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction." Laryngoscope 100 (1990):  1156-60|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Soo Hoo GW, Dao HT, Klaustermeyer WB "Severe angioedema and respiratory distress associated with lisinopril use." West J Med 158 (1993):  412-7|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Frontera Y, Piecuch JF "Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor." J Am Dent Assoc 126 (1995):  217-20|Gimenez JC "Angioneurotic edema produced by enalapril." Ann Pharmacother 29 (1995):  317|Gonzalo FE, Montagut LB, Vecina ST "Angioedema caused by ramipril." Ann Pharmacother 29 (1995):  431-2|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Forslund T, Tohmo H, Weckstrom G, Stenborg M, Jarvinen S "Angio-oedema induced by enalapril." J Intern Med 238 (1995):  179-81|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Gunkel AR, Thurner KH, Kanonier G, Sprinzl GM, Thumfart WF "Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors." Am J Otolaryngol 17 (1996):  87-91|O''Mara NB, O''Mara EM Jr "Delayed onset of andioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature." Pharmacotherapy 16 (1996):  675-9|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48753, 25871, 'Enalapril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Roberts JR, Wuerz RC "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema." Ann Emerg Med 20 (1991):  555-8|Jett GK "Captopril-induced angioedema ." Ann Emerg Med 13 (1984):  489-90|McElligott S, Perlroth M, Raish L "Angioedema after substituting lisinopril for captopril ." Ann Intern Med 116 (1992):  426-7|Hedner T, Samuelsson O, Lunde H, et al. "Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors." Br Med J 304 (1992):  941-6|Wood SM, Mann RD, Rawlins MD "Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors." Br Med J 294 (1987):  91-2|Seidman MD, Lewandowski CA, Sarpa JR, et al. "Angioedema related to angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 102 (1990):  727-31|Werber JL, Pincus RL "Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 101 (1989):  96-8|Jason DR "Fatal angioedema associated with captopril." J Forensic Sci 37 (1992):  1418-21|Gianos ME, Klaustermeyer WB, Kurohara M, et al. "Enalapril induced angioedema." Am J Emerg Med 8 (1990):  124-6|Gonnering RS, Hirsch SR "Delayed drug-induced periorbital angioedema ." Am J Ophthalmol 110 (1990):  566-8|Chin HL, Buchan DA "Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor ." Ann Intern Med 112 (1990):  312-3|Abidin MR, Eisele DW "Angioedema after long-term use of angiotensin-converting enzyme inhibitor ." Arch Otolaryngol Head Neck Surg 117 (1991):  1059|Orfan N, Patterson R, Dykewicz MS "Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema." JAMA 264 (1990):  1287-9|Gannon TH, Eby TL "Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction." Laryngoscope 100 (1990):  1156-60|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Soo Hoo GW, Dao HT, Klaustermeyer WB "Severe angioedema and respiratory distress associated with lisinopril use." West J Med 158 (1993):  412-7|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Frontera Y, Piecuch JF "Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor." J Am Dent Assoc 126 (1995):  217-20|Gimenez JC "Angioneurotic edema produced by enalapril." Ann Pharmacother 29 (1995):  317|Gonzalo FE, Montagut LB, Vecina ST "Angioedema caused by ramipril." Ann Pharmacother 29 (1995):  431-2|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Forslund T, Tohmo H, Weckstrom G, Stenborg M, Jarvinen S "Angio-oedema induced by enalapril." J Intern Med 238 (1995):  179-81|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Gunkel AR, Thurner KH, Kanonier G, Sprinzl GM, Thumfart WF "Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors." Am J Otolaryngol 17 (1996):  87-91|O''Mara NB, O''Mara EM Jr "Delayed onset of andioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature." Pharmacotherapy 16 (1996):  675-9|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48754, 25872, 'Enalapril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Roberts JR, Wuerz RC "Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema." Ann Emerg Med 20 (1991):  555-8|Jett GK "Captopril-induced angioedema ." Ann Emerg Med 13 (1984):  489-90|McElligott S, Perlroth M, Raish L "Angioedema after substituting lisinopril for captopril ." Ann Intern Med 116 (1992):  426-7|Hedner T, Samuelsson O, Lunde H, et al. "Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors." Br Med J 304 (1992):  941-6|Wood SM, Mann RD, Rawlins MD "Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors." Br Med J 294 (1987):  91-2|Seidman MD, Lewandowski CA, Sarpa JR, et al. "Angioedema related to angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 102 (1990):  727-31|Werber JL, Pincus RL "Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 101 (1989):  96-8|Jason DR "Fatal angioedema associated with captopril." J Forensic Sci 37 (1992):  1418-21|Gianos ME, Klaustermeyer WB, Kurohara M, et al. "Enalapril induced angioedema." Am J Emerg Med 8 (1990):  124-6|Gonnering RS, Hirsch SR "Delayed drug-induced periorbital angioedema ." Am J Ophthalmol 110 (1990):  566-8|Chin HL, Buchan DA "Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor ." Ann Intern Med 112 (1990):  312-3|Abidin MR, Eisele DW "Angioedema after long-term use of angiotensin-converting enzyme inhibitor ." Arch Otolaryngol Head Neck Surg 117 (1991):  1059|Orfan N, Patterson R, Dykewicz MS "Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema." JAMA 264 (1990):  1287-9|Gannon TH, Eby TL "Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction." Laryngoscope 100 (1990):  1156-60|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Soo Hoo GW, Dao HT, Klaustermeyer WB "Severe angioedema and respiratory distress associated with lisinopril use." West J Med 158 (1993):  412-7|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Frontera Y, Piecuch JF "Multiple episodes of angioedema associated with lisinopril, an ACE inhibitor." J Am Dent Assoc 126 (1995):  217-20|Gimenez JC "Angioneurotic edema produced by enalapril." Ann Pharmacother 29 (1995):  317|Gonzalo FE, Montagut LB, Vecina ST "Angioedema caused by ramipril." Ann Pharmacother 29 (1995):  431-2|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Forslund T, Tohmo H, Weckstrom G, Stenborg M, Jarvinen S "Angio-oedema induced by enalapril." J Intern Med 238 (1995):  179-81|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Gunkel AR, Thurner KH, Kanonier G, Sprinzl GM, Thumfart WF "Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors." Am J Otolaryngol 17 (1996):  87-91|O''Mara NB, O''Mara EM Jr "Delayed onset of andioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature." Pharmacotherapy 16 (1996):  675-9|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48755, 35, 'Enalapril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980):  927-8|Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982):  214-9|Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989):  187-8|Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984):  23-35|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Gavras I, Graff LG, Rose BD, et al. "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981):  58-9|Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989):  189-90|el-Makri A, Larabi MS, Kechrid C, et al. "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981):  277-8|Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985):  320-2|Shindo K, Matsuya F, Ura T, et al. "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984):  314-6|Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981):  166|Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980):  927-8|Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991):  399-400|Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985):  106-7|Hirakata H, Onoyama K, Iseki K, et al. "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984):  355-60|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990):  543-4|Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989):  s27-30|Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981):  508-16|Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983):  530-7|Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991):  199-205|Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988):  209-10|Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991):  461-2|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Materson BJ "Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril." Am J Cardiol 69 (1992):  c46-53|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995):  247-8|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48756, 36, 'Enalapril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980):  927-8|Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982):  214-9|Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989):  187-8|Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984):  23-35|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Gavras I, Graff LG, Rose BD, et al. "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981):  58-9|Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989):  189-90|el-Makri A, Larabi MS, Kechrid C, et al. "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981):  277-8|Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985):  320-2|Shindo K, Matsuya F, Ura T, et al. "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984):  314-6|Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981):  166|Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980):  927-8|Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991):  399-400|Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985):  106-7|Hirakata H, Onoyama K, Iseki K, et al. "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984):  355-60|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990):  543-4|Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989):  s27-30|Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981):  508-16|Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983):  530-7|Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991):  199-205|Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988):  209-10|Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991):  461-2|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Materson BJ "Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril." Am J Cardiol 69 (1992):  c46-53|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995):  247-8|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48757, 4167, 'Enalapril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980):  927-8|Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982):  214-9|Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989):  187-8|Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984):  23-35|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Gavras I, Graff LG, Rose BD, et al. "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981):  58-9|Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989):  189-90|el-Makri A, Larabi MS, Kechrid C, et al. "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981):  277-8|Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985):  320-2|Shindo K, Matsuya F, Ura T, et al. "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984):  314-6|Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981):  166|Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980):  927-8|Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991):  399-400|Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985):  106-7|Hirakata H, Onoyama K, Iseki K, et al. "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984):  355-60|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990):  543-4|Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989):  s27-30|Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981):  508-16|Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983):  530-7|Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991):  199-205|Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988):  209-10|Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991):  461-2|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Materson BJ "Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril." Am J Cardiol 69 (1992):  c46-53|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995):  247-8|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48758, 4588, 'Enalapril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980):  927-8|Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982):  214-9|Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989):  187-8|Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984):  23-35|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Gavras I, Graff LG, Rose BD, et al. "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981):  58-9|Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989):  189-90|el-Makri A, Larabi MS, Kechrid C, et al. "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981):  277-8|Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985):  320-2|Shindo K, Matsuya F, Ura T, et al. "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984):  314-6|Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981):  166|Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980):  927-8|Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991):  399-400|Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985):  106-7|Hirakata H, Onoyama K, Iseki K, et al. "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984):  355-60|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990):  543-4|Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989):  s27-30|Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981):  508-16|Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983):  530-7|Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991):  199-205|Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988):  209-10|Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991):  461-2|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Materson BJ "Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril." Am J Cardiol 69 (1992):  c46-53|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995):  247-8|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48759, 4591, 'Enalapril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980):  927-8|Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982):  214-9|Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989):  187-8|Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984):  23-35|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Gavras I, Graff LG, Rose BD, et al. "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981):  58-9|Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989):  189-90|el-Makri A, Larabi MS, Kechrid C, et al. "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981):  277-8|Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985):  320-2|Shindo K, Matsuya F, Ura T, et al. "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984):  314-6|Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981):  166|Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980):  927-8|Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991):  399-400|Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985):  106-7|Hirakata H, Onoyama K, Iseki K, et al. "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984):  355-60|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990):  543-4|Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989):  s27-30|Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981):  508-16|Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983):  530-7|Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991):  199-205|Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988):  209-10|Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991):  461-2|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Materson BJ "Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril." Am J Cardiol 69 (1992):  c46-53|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995):  247-8|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48760, 4605, 'Enalapril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980):  927-8|Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982):  214-9|Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989):  187-8|Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984):  23-35|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Gavras I, Graff LG, Rose BD, et al. "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981):  58-9|Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989):  189-90|el-Makri A, Larabi MS, Kechrid C, et al. "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981):  277-8|Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985):  320-2|Shindo K, Matsuya F, Ura T, et al. "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984):  314-6|Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981):  166|Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980):  927-8|Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991):  399-400|Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985):  106-7|Hirakata H, Onoyama K, Iseki K, et al. "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984):  355-60|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990):  543-4|Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989):  s27-30|Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981):  508-16|Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983):  530-7|Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991):  199-205|Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988):  209-10|Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991):  461-2|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Materson BJ "Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril." Am J Cardiol 69 (1992):  c46-53|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995):  247-8|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48761, 8030, 'Enalapril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980):  927-8|Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982):  214-9|Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989):  187-8|Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984):  23-35|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Gavras I, Graff LG, Rose BD, et al. "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981):  58-9|Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989):  189-90|el-Makri A, Larabi MS, Kechrid C, et al. "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981):  277-8|Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985):  320-2|Shindo K, Matsuya F, Ura T, et al. "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984):  314-6|Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981):  166|Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980):  927-8|Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991):  399-400|Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985):  106-7|Hirakata H, Onoyama K, Iseki K, et al. "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984):  355-60|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990):  543-4|Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989):  s27-30|Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981):  508-16|Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983):  530-7|Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991):  199-205|Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988):  209-10|Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991):  461-2|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Materson BJ "Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril." Am J Cardiol 69 (1992):  c46-53|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995):  247-8|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48762, 18295, 'Enalapril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980):  927-8|Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982):  214-9|Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989):  187-8|Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984):  23-35|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Gavras I, Graff LG, Rose BD, et al. "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981):  58-9|Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989):  189-90|el-Makri A, Larabi MS, Kechrid C, et al. "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981):  277-8|Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985):  320-2|Shindo K, Matsuya F, Ura T, et al. "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984):  314-6|Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981):  166|Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980):  927-8|Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991):  399-400|Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985):  106-7|Hirakata H, Onoyama K, Iseki K, et al. "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984):  355-60|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990):  543-4|Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989):  s27-30|Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981):  508-16|Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983):  530-7|Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991):  199-205|Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988):  209-10|Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991):  461-2|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Materson BJ "Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril." Am J Cardiol 69 (1992):  c46-53|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995):  247-8|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48763, 25189, 'Enalapril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980):  927-8|Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982):  214-9|Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989):  187-8|Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984):  23-35|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Gavras I, Graff LG, Rose BD, et al. "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981):  58-9|Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989):  189-90|el-Makri A, Larabi MS, Kechrid C, et al. "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981):  277-8|Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985):  320-2|Shindo K, Matsuya F, Ura T, et al. "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984):  314-6|Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981):  166|Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980):  927-8|Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991):  399-400|Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985):  106-7|Hirakata H, Onoyama K, Iseki K, et al. "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984):  355-60|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990):  543-4|Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989):  s27-30|Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981):  508-16|Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983):  530-7|Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991):  199-205|Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988):  209-10|Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991):  461-2|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Materson BJ "Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril." Am J Cardiol 69 (1992):  c46-53|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995):  247-8|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48764, 25190, 'Enalapril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980):  927-8|Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982):  214-9|Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989):  187-8|Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984):  23-35|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Gavras I, Graff LG, Rose BD, et al. "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981):  58-9|Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989):  189-90|el-Makri A, Larabi MS, Kechrid C, et al. "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981):  277-8|Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985):  320-2|Shindo K, Matsuya F, Ura T, et al. "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984):  314-6|Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981):  166|Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980):  927-8|Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991):  399-400|Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985):  106-7|Hirakata H, Onoyama K, Iseki K, et al. "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984):  355-60|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990):  543-4|Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989):  s27-30|Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981):  508-16|Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983):  530-7|Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991):  199-205|Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988):  209-10|Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991):  461-2|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Materson BJ "Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril." Am J Cardiol 69 (1992):  c46-53|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995):  247-8|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48765, 25195, 'Enalapril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980):  927-8|Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982):  214-9|Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989):  187-8|Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984):  23-35|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Gavras I, Graff LG, Rose BD, et al. "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981):  58-9|Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989):  189-90|el-Makri A, Larabi MS, Kechrid C, et al. "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981):  277-8|Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985):  320-2|Shindo K, Matsuya F, Ura T, et al. "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984):  314-6|Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981):  166|Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980):  927-8|Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991):  399-400|Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985):  106-7|Hirakata H, Onoyama K, Iseki K, et al. "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984):  355-60|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990):  543-4|Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989):  s27-30|Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981):  508-16|Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983):  530-7|Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991):  199-205|Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988):  209-10|Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991):  461-2|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Materson BJ "Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril." Am J Cardiol 69 (1992):  c46-53|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995):  247-8|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48766, 25196, 'Enalapril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980):  927-8|Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982):  214-9|Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989):  187-8|Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984):  23-35|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Gavras I, Graff LG, Rose BD, et al. "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981):  58-9|Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989):  189-90|el-Makri A, Larabi MS, Kechrid C, et al. "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981):  277-8|Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985):  320-2|Shindo K, Matsuya F, Ura T, et al. "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984):  314-6|Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981):  166|Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980):  927-8|Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991):  399-400|Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985):  106-7|Hirakata H, Onoyama K, Iseki K, et al. "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984):  355-60|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990):  543-4|Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989):  s27-30|Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981):  508-16|Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983):  530-7|Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991):  199-205|Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988):  209-10|Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991):  461-2|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Materson BJ "Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril." Am J Cardiol 69 (1992):  c46-53|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995):  247-8|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48767, 25871, 'Enalapril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980):  927-8|Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982):  214-9|Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989):  187-8|Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984):  23-35|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Gavras I, Graff LG, Rose BD, et al. "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981):  58-9|Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989):  189-90|el-Makri A, Larabi MS, Kechrid C, et al. "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981):  277-8|Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985):  320-2|Shindo K, Matsuya F, Ura T, et al. "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984):  314-6|Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981):  166|Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980):  927-8|Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991):  399-400|Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985):  106-7|Hirakata H, Onoyama K, Iseki K, et al. "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984):  355-60|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990):  543-4|Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989):  s27-30|Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981):  508-16|Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983):  530-7|Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991):  199-205|Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988):  209-10|Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991):  461-2|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Materson BJ "Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril." Am J Cardiol 69 (1992):  c46-53|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995):  247-8|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48768, 25872, 'Enalapril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980):  927-8|Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982):  214-9|Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989):  187-8|Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984):  23-35|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986):  336-8|Gavras I, Graff LG, Rose BD, et al. "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981):  58-9|Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989):  189-90|el-Makri A, Larabi MS, Kechrid C, et al. "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981):  277-8|Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985):  320-2|Shindo K, Matsuya F, Ura T, et al. "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984):  314-6|Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981):  166|Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980):  927-8|Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991):  399-400|Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985):  106-7|Hirakata H, Onoyama K, Iseki K, et al. "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984):  355-60|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990):  543-4|Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989):  s27-30|Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981):  508-16|Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983):  530-7|Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991):  199-205|Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988):  209-10|Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991):  461-2|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Materson BJ "Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril." Am J Cardiol 69 (1992):  c46-53|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995):  247-8|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48769, 35, 'Enalapril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, et al. "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group." N Engl J Med 333 (1995):  1670-6|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48770, 36, 'Enalapril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, et al. "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group." N Engl J Med 333 (1995):  1670-6|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48771, 4167, 'Enalapril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, et al. "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group." N Engl J Med 333 (1995):  1670-6|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48772, 4588, 'Enalapril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, et al. "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group." N Engl J Med 333 (1995):  1670-6|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48773, 4591, 'Enalapril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, et al. "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group." N Engl J Med 333 (1995):  1670-6|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48774, 4605, 'Enalapril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, et al. "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group." N Engl J Med 333 (1995):  1670-6|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48775, 8030, 'Enalapril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, et al. "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group." N Engl J Med 333 (1995):  1670-6|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48776, 18295, 'Enalapril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, et al. "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group." N Engl J Med 333 (1995):  1670-6|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48777, 25189, 'Enalapril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, et al. "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group." N Engl J Med 333 (1995):  1670-6|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48778, 25190, 'Enalapril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, et al. "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group." N Engl J Med 333 (1995):  1670-6|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48779, 25195, 'Enalapril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, et al. "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group." N Engl J Med 333 (1995):  1670-6|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48780, 25196, 'Enalapril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, et al. "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group." N Engl J Med 333 (1995):  1670-6|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48781, 25871, 'Enalapril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, et al. "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group." N Engl J Med 333 (1995):  1670-6|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48782, 25872, 'Enalapril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, et al. "A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group." N Engl J Med 333 (1995):  1670-6|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48783, 35, 'Enalapril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48784, 36, 'Enalapril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48785, 4167, 'Enalapril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48786, 4588, 'Enalapril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48787, 4591, 'Enalapril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48788, 4605, 'Enalapril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48789, 8030, 'Enalapril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48790, 18295, 'Enalapril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48791, 25189, 'Enalapril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48792, 25190, 'Enalapril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48793, 25195, 'Enalapril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48794, 25196, 'Enalapril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48795, 25871, 'Enalapril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48796, 25872, 'Enalapril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48797, 35, 'Enalapril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'Kindler J, Schunkert H, Gassmann M, Lahn W, Irmisch R, Debusmann ER, Ocon-Pujadas J, Ritz E, Sieberth HG "Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure." J Cardiovasc Pharmacol 13 (1989):  s55-8|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Tramonti G, Donadio C, Confessore N, Bianchi C "Antihypertensive activity and renal effects of benazepril in humans." Kidney Int (suppl 5) (1996):  s107-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48798, 36, 'Enalapril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'Kindler J, Schunkert H, Gassmann M, Lahn W, Irmisch R, Debusmann ER, Ocon-Pujadas J, Ritz E, Sieberth HG "Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure." J Cardiovasc Pharmacol 13 (1989):  s55-8|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Tramonti G, Donadio C, Confessore N, Bianchi C "Antihypertensive activity and renal effects of benazepril in humans." Kidney Int (suppl 5) (1996):  s107-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48799, 4167, 'Enalapril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'Kindler J, Schunkert H, Gassmann M, Lahn W, Irmisch R, Debusmann ER, Ocon-Pujadas J, Ritz E, Sieberth HG "Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure." J Cardiovasc Pharmacol 13 (1989):  s55-8|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Tramonti G, Donadio C, Confessore N, Bianchi C "Antihypertensive activity and renal effects of benazepril in humans." Kidney Int (suppl 5) (1996):  s107-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48800, 4588, 'Enalapril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'Kindler J, Schunkert H, Gassmann M, Lahn W, Irmisch R, Debusmann ER, Ocon-Pujadas J, Ritz E, Sieberth HG "Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure." J Cardiovasc Pharmacol 13 (1989):  s55-8|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Tramonti G, Donadio C, Confessore N, Bianchi C "Antihypertensive activity and renal effects of benazepril in humans." Kidney Int (suppl 5) (1996):  s107-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48801, 4591, 'Enalapril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'Kindler J, Schunkert H, Gassmann M, Lahn W, Irmisch R, Debusmann ER, Ocon-Pujadas J, Ritz E, Sieberth HG "Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure." J Cardiovasc Pharmacol 13 (1989):  s55-8|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Tramonti G, Donadio C, Confessore N, Bianchi C "Antihypertensive activity and renal effects of benazepril in humans." Kidney Int (suppl 5) (1996):  s107-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48802, 4605, 'Enalapril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'Kindler J, Schunkert H, Gassmann M, Lahn W, Irmisch R, Debusmann ER, Ocon-Pujadas J, Ritz E, Sieberth HG "Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure." J Cardiovasc Pharmacol 13 (1989):  s55-8|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Tramonti G, Donadio C, Confessore N, Bianchi C "Antihypertensive activity and renal effects of benazepril in humans." Kidney Int (suppl 5) (1996):  s107-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48803, 8030, 'Enalapril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'Kindler J, Schunkert H, Gassmann M, Lahn W, Irmisch R, Debusmann ER, Ocon-Pujadas J, Ritz E, Sieberth HG "Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure." J Cardiovasc Pharmacol 13 (1989):  s55-8|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Tramonti G, Donadio C, Confessore N, Bianchi C "Antihypertensive activity and renal effects of benazepril in humans." Kidney Int (suppl 5) (1996):  s107-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48804, 18295, 'Enalapril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'Kindler J, Schunkert H, Gassmann M, Lahn W, Irmisch R, Debusmann ER, Ocon-Pujadas J, Ritz E, Sieberth HG "Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure." J Cardiovasc Pharmacol 13 (1989):  s55-8|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Tramonti G, Donadio C, Confessore N, Bianchi C "Antihypertensive activity and renal effects of benazepril in humans." Kidney Int (suppl 5) (1996):  s107-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48805, 25189, 'Enalapril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'Kindler J, Schunkert H, Gassmann M, Lahn W, Irmisch R, Debusmann ER, Ocon-Pujadas J, Ritz E, Sieberth HG "Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure." J Cardiovasc Pharmacol 13 (1989):  s55-8|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Tramonti G, Donadio C, Confessore N, Bianchi C "Antihypertensive activity and renal effects of benazepril in humans." Kidney Int (suppl 5) (1996):  s107-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48806, 25190, 'Enalapril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'Kindler J, Schunkert H, Gassmann M, Lahn W, Irmisch R, Debusmann ER, Ocon-Pujadas J, Ritz E, Sieberth HG "Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure." J Cardiovasc Pharmacol 13 (1989):  s55-8|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Tramonti G, Donadio C, Confessore N, Bianchi C "Antihypertensive activity and renal effects of benazepril in humans." Kidney Int (suppl 5) (1996):  s107-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48807, 25195, 'Enalapril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'Kindler J, Schunkert H, Gassmann M, Lahn W, Irmisch R, Debusmann ER, Ocon-Pujadas J, Ritz E, Sieberth HG "Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure." J Cardiovasc Pharmacol 13 (1989):  s55-8|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Tramonti G, Donadio C, Confessore N, Bianchi C "Antihypertensive activity and renal effects of benazepril in humans." Kidney Int (suppl 5) (1996):  s107-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48808, 25196, 'Enalapril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'Kindler J, Schunkert H, Gassmann M, Lahn W, Irmisch R, Debusmann ER, Ocon-Pujadas J, Ritz E, Sieberth HG "Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure." J Cardiovasc Pharmacol 13 (1989):  s55-8|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Tramonti G, Donadio C, Confessore N, Bianchi C "Antihypertensive activity and renal effects of benazepril in humans." Kidney Int (suppl 5) (1996):  s107-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48809, 25871, 'Enalapril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'Kindler J, Schunkert H, Gassmann M, Lahn W, Irmisch R, Debusmann ER, Ocon-Pujadas J, Ritz E, Sieberth HG "Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure." J Cardiovasc Pharmacol 13 (1989):  s55-8|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Tramonti G, Donadio C, Confessore N, Bianchi C "Antihypertensive activity and renal effects of benazepril in humans." Kidney Int (suppl 5) (1996):  s107-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48810, 25872, 'Enalapril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'Kindler J, Schunkert H, Gassmann M, Lahn W, Irmisch R, Debusmann ER, Ocon-Pujadas J, Ritz E, Sieberth HG "Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure." J Cardiovasc Pharmacol 13 (1989):  s55-8|Moyses C, Higgins TJ "Safety of long-term use of lisinopril for congestive heart failure." Am J Cardiol 70 (1992):  c91-7|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfie "Adverse effects of enalapril in the studies of left ventricular dysfunction (SOLVD)." Am Heart J 131 (1996):  350-5|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Tramonti G, Donadio C, Confessore N, Bianchi C "Antihypertensive activity and renal effects of benazepril in humans." Kidney Int (suppl 5) (1996):  s107-8', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48811, 35, 'Enalapril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989):  389-95|Schoenberger JA, Testa M, Ross AD, et al. "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990):  301-6|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986):  539-40|Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989):  837-8|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|Cooper WD, Sheldon D, Brown D, et al. "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987):  346-9|Osterziel KJ, Karr M, Busch C, Dietz R "Comparison of the first-dose effect of captopril and lisinopril in heart failure." Am J Cardiol 70 (1992):  c137-9|MacNab M, Mallows S "Safety profile of benazepril in essential hypertension." Clin Cardiol 14 Suppl I (1991):  iv33-7|Balfour J, Goa K "Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure." Drugs 42 (1991):  511-39|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993):  577|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|Lang RM, Dibianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ "First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study." Am Heart J 128 (1994):  551-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Larochelle P, Haynes B, Maron N, Dugas S "A postmarketing surveillance evaluation of quinapril in 3742 canadian hypertensive patients - the ACCEPT study." Clin Ther 16 (1994):  838-53|Schmitt JK, Koch KS, Midha M "Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. case report." Paraplegia 32 (1994):  871-4|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48812, 36, 'Enalapril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989):  389-95|Schoenberger JA, Testa M, Ross AD, et al. "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990):  301-6|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986):  539-40|Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989):  837-8|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|Cooper WD, Sheldon D, Brown D, et al. "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987):  346-9|Osterziel KJ, Karr M, Busch C, Dietz R "Comparison of the first-dose effect of captopril and lisinopril in heart failure." Am J Cardiol 70 (1992):  c137-9|MacNab M, Mallows S "Safety profile of benazepril in essential hypertension." Clin Cardiol 14 Suppl I (1991):  iv33-7|Balfour J, Goa K "Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure." Drugs 42 (1991):  511-39|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993):  577|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|Lang RM, Dibianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ "First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study." Am Heart J 128 (1994):  551-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Larochelle P, Haynes B, Maron N, Dugas S "A postmarketing surveillance evaluation of quinapril in 3742 canadian hypertensive patients - the ACCEPT study." Clin Ther 16 (1994):  838-53|Schmitt JK, Koch KS, Midha M "Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. case report." Paraplegia 32 (1994):  871-4|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48813, 4167, 'Enalapril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989):  389-95|Schoenberger JA, Testa M, Ross AD, et al. "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990):  301-6|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986):  539-40|Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989):  837-8|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|Cooper WD, Sheldon D, Brown D, et al. "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987):  346-9|Osterziel KJ, Karr M, Busch C, Dietz R "Comparison of the first-dose effect of captopril and lisinopril in heart failure." Am J Cardiol 70 (1992):  c137-9|MacNab M, Mallows S "Safety profile of benazepril in essential hypertension." Clin Cardiol 14 Suppl I (1991):  iv33-7|Balfour J, Goa K "Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure." Drugs 42 (1991):  511-39|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993):  577|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|Lang RM, Dibianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ "First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study." Am Heart J 128 (1994):  551-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Larochelle P, Haynes B, Maron N, Dugas S "A postmarketing surveillance evaluation of quinapril in 3742 canadian hypertensive patients - the ACCEPT study." Clin Ther 16 (1994):  838-53|Schmitt JK, Koch KS, Midha M "Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. case report." Paraplegia 32 (1994):  871-4|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48814, 4588, 'Enalapril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989):  389-95|Schoenberger JA, Testa M, Ross AD, et al. "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990):  301-6|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986):  539-40|Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989):  837-8|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|Cooper WD, Sheldon D, Brown D, et al. "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987):  346-9|Osterziel KJ, Karr M, Busch C, Dietz R "Comparison of the first-dose effect of captopril and lisinopril in heart failure." Am J Cardiol 70 (1992):  c137-9|MacNab M, Mallows S "Safety profile of benazepril in essential hypertension." Clin Cardiol 14 Suppl I (1991):  iv33-7|Balfour J, Goa K "Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure." Drugs 42 (1991):  511-39|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993):  577|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|Lang RM, Dibianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ "First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study." Am Heart J 128 (1994):  551-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Larochelle P, Haynes B, Maron N, Dugas S "A postmarketing surveillance evaluation of quinapril in 3742 canadian hypertensive patients - the ACCEPT study." Clin Ther 16 (1994):  838-53|Schmitt JK, Koch KS, Midha M "Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. case report." Paraplegia 32 (1994):  871-4|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48815, 4591, 'Enalapril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989):  389-95|Schoenberger JA, Testa M, Ross AD, et al. "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990):  301-6|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986):  539-40|Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989):  837-8|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|Cooper WD, Sheldon D, Brown D, et al. "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987):  346-9|Osterziel KJ, Karr M, Busch C, Dietz R "Comparison of the first-dose effect of captopril and lisinopril in heart failure." Am J Cardiol 70 (1992):  c137-9|MacNab M, Mallows S "Safety profile of benazepril in essential hypertension." Clin Cardiol 14 Suppl I (1991):  iv33-7|Balfour J, Goa K "Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure." Drugs 42 (1991):  511-39|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993):  577|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|Lang RM, Dibianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ "First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study." Am Heart J 128 (1994):  551-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Larochelle P, Haynes B, Maron N, Dugas S "A postmarketing surveillance evaluation of quinapril in 3742 canadian hypertensive patients - the ACCEPT study." Clin Ther 16 (1994):  838-53|Schmitt JK, Koch KS, Midha M "Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. case report." Paraplegia 32 (1994):  871-4|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48816, 4605, 'Enalapril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989):  389-95|Schoenberger JA, Testa M, Ross AD, et al. "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990):  301-6|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986):  539-40|Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989):  837-8|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|Cooper WD, Sheldon D, Brown D, et al. "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987):  346-9|Osterziel KJ, Karr M, Busch C, Dietz R "Comparison of the first-dose effect of captopril and lisinopril in heart failure." Am J Cardiol 70 (1992):  c137-9|MacNab M, Mallows S "Safety profile of benazepril in essential hypertension." Clin Cardiol 14 Suppl I (1991):  iv33-7|Balfour J, Goa K "Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure." Drugs 42 (1991):  511-39|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993):  577|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|Lang RM, Dibianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ "First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study." Am Heart J 128 (1994):  551-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Larochelle P, Haynes B, Maron N, Dugas S "A postmarketing surveillance evaluation of quinapril in 3742 canadian hypertensive patients - the ACCEPT study." Clin Ther 16 (1994):  838-53|Schmitt JK, Koch KS, Midha M "Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. case report." Paraplegia 32 (1994):  871-4|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48817, 8030, 'Enalapril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989):  389-95|Schoenberger JA, Testa M, Ross AD, et al. "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990):  301-6|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986):  539-40|Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989):  837-8|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|Cooper WD, Sheldon D, Brown D, et al. "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987):  346-9|Osterziel KJ, Karr M, Busch C, Dietz R "Comparison of the first-dose effect of captopril and lisinopril in heart failure." Am J Cardiol 70 (1992):  c137-9|MacNab M, Mallows S "Safety profile of benazepril in essential hypertension." Clin Cardiol 14 Suppl I (1991):  iv33-7|Balfour J, Goa K "Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure." Drugs 42 (1991):  511-39|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993):  577|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|Lang RM, Dibianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ "First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study." Am Heart J 128 (1994):  551-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Larochelle P, Haynes B, Maron N, Dugas S "A postmarketing surveillance evaluation of quinapril in 3742 canadian hypertensive patients - the ACCEPT study." Clin Ther 16 (1994):  838-53|Schmitt JK, Koch KS, Midha M "Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. case report." Paraplegia 32 (1994):  871-4|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48818, 18295, 'Enalapril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989):  389-95|Schoenberger JA, Testa M, Ross AD, et al. "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990):  301-6|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986):  539-40|Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989):  837-8|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|Cooper WD, Sheldon D, Brown D, et al. "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987):  346-9|Osterziel KJ, Karr M, Busch C, Dietz R "Comparison of the first-dose effect of captopril and lisinopril in heart failure." Am J Cardiol 70 (1992):  c137-9|MacNab M, Mallows S "Safety profile of benazepril in essential hypertension." Clin Cardiol 14 Suppl I (1991):  iv33-7|Balfour J, Goa K "Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure." Drugs 42 (1991):  511-39|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993):  577|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|Lang RM, Dibianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ "First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study." Am Heart J 128 (1994):  551-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Larochelle P, Haynes B, Maron N, Dugas S "A postmarketing surveillance evaluation of quinapril in 3742 canadian hypertensive patients - the ACCEPT study." Clin Ther 16 (1994):  838-53|Schmitt JK, Koch KS, Midha M "Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. case report." Paraplegia 32 (1994):  871-4|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48819, 25189, 'Enalapril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989):  389-95|Schoenberger JA, Testa M, Ross AD, et al. "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990):  301-6|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986):  539-40|Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989):  837-8|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|Cooper WD, Sheldon D, Brown D, et al. "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987):  346-9|Osterziel KJ, Karr M, Busch C, Dietz R "Comparison of the first-dose effect of captopril and lisinopril in heart failure." Am J Cardiol 70 (1992):  c137-9|MacNab M, Mallows S "Safety profile of benazepril in essential hypertension." Clin Cardiol 14 Suppl I (1991):  iv33-7|Balfour J, Goa K "Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure." Drugs 42 (1991):  511-39|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993):  577|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|Lang RM, Dibianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ "First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study." Am Heart J 128 (1994):  551-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Larochelle P, Haynes B, Maron N, Dugas S "A postmarketing surveillance evaluation of quinapril in 3742 canadian hypertensive patients - the ACCEPT study." Clin Ther 16 (1994):  838-53|Schmitt JK, Koch KS, Midha M "Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. case report." Paraplegia 32 (1994):  871-4|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48820, 25190, 'Enalapril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989):  389-95|Schoenberger JA, Testa M, Ross AD, et al. "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990):  301-6|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986):  539-40|Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989):  837-8|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|Cooper WD, Sheldon D, Brown D, et al. "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987):  346-9|Osterziel KJ, Karr M, Busch C, Dietz R "Comparison of the first-dose effect of captopril and lisinopril in heart failure." Am J Cardiol 70 (1992):  c137-9|MacNab M, Mallows S "Safety profile of benazepril in essential hypertension." Clin Cardiol 14 Suppl I (1991):  iv33-7|Balfour J, Goa K "Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure." Drugs 42 (1991):  511-39|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993):  577|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|Lang RM, Dibianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ "First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study." Am Heart J 128 (1994):  551-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Larochelle P, Haynes B, Maron N, Dugas S "A postmarketing surveillance evaluation of quinapril in 3742 canadian hypertensive patients - the ACCEPT study." Clin Ther 16 (1994):  838-53|Schmitt JK, Koch KS, Midha M "Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. case report." Paraplegia 32 (1994):  871-4|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48821, 25195, 'Enalapril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989):  389-95|Schoenberger JA, Testa M, Ross AD, et al. "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990):  301-6|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986):  539-40|Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989):  837-8|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|Cooper WD, Sheldon D, Brown D, et al. "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987):  346-9|Osterziel KJ, Karr M, Busch C, Dietz R "Comparison of the first-dose effect of captopril and lisinopril in heart failure." Am J Cardiol 70 (1992):  c137-9|MacNab M, Mallows S "Safety profile of benazepril in essential hypertension." Clin Cardiol 14 Suppl I (1991):  iv33-7|Balfour J, Goa K "Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure." Drugs 42 (1991):  511-39|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993):  577|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|Lang RM, Dibianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ "First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study." Am Heart J 128 (1994):  551-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Larochelle P, Haynes B, Maron N, Dugas S "A postmarketing surveillance evaluation of quinapril in 3742 canadian hypertensive patients - the ACCEPT study." Clin Ther 16 (1994):  838-53|Schmitt JK, Koch KS, Midha M "Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. case report." Paraplegia 32 (1994):  871-4|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48822, 25196, 'Enalapril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989):  389-95|Schoenberger JA, Testa M, Ross AD, et al. "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990):  301-6|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986):  539-40|Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989):  837-8|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|Cooper WD, Sheldon D, Brown D, et al. "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987):  346-9|Osterziel KJ, Karr M, Busch C, Dietz R "Comparison of the first-dose effect of captopril and lisinopril in heart failure." Am J Cardiol 70 (1992):  c137-9|MacNab M, Mallows S "Safety profile of benazepril in essential hypertension." Clin Cardiol 14 Suppl I (1991):  iv33-7|Balfour J, Goa K "Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure." Drugs 42 (1991):  511-39|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993):  577|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|Lang RM, Dibianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ "First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study." Am Heart J 128 (1994):  551-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Larochelle P, Haynes B, Maron N, Dugas S "A postmarketing surveillance evaluation of quinapril in 3742 canadian hypertensive patients - the ACCEPT study." Clin Ther 16 (1994):  838-53|Schmitt JK, Koch KS, Midha M "Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. case report." Paraplegia 32 (1994):  871-4|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48823, 25871, 'Enalapril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989):  389-95|Schoenberger JA, Testa M, Ross AD, et al. "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990):  301-6|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986):  539-40|Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989):  837-8|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|Cooper WD, Sheldon D, Brown D, et al. "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987):  346-9|Osterziel KJ, Karr M, Busch C, Dietz R "Comparison of the first-dose effect of captopril and lisinopril in heart failure." Am J Cardiol 70 (1992):  c137-9|MacNab M, Mallows S "Safety profile of benazepril in essential hypertension." Clin Cardiol 14 Suppl I (1991):  iv33-7|Balfour J, Goa K "Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure." Drugs 42 (1991):  511-39|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993):  577|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|Lang RM, Dibianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ "First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study." Am Heart J 128 (1994):  551-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Larochelle P, Haynes B, Maron N, Dugas S "A postmarketing surveillance evaluation of quinapril in 3742 canadian hypertensive patients - the ACCEPT study." Clin Ther 16 (1994):  838-53|Schmitt JK, Koch KS, Midha M "Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. case report." Paraplegia 32 (1994):  871-4|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48824, 25872, 'Enalapril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992):  215-23|Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989):  389-95|Schoenberger JA, Testa M, Ross AD, et al. "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990):  301-6|Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987):  529-36|Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986):  539-40|Russell RM, Jones RM "Postoperative hypotension associated with enalapril." Anaesthesia 44 (1989):  837-8|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|Cooper WD, Sheldon D, Brown D, et al. "Post-marketing surveillance of enalapril: experience in 11,710 hypertensive patients in general practice." J R Coll Gen Pract 37 (1987):  346-9|Osterziel KJ, Karr M, Busch C, Dietz R "Comparison of the first-dose effect of captopril and lisinopril in heart failure." Am J Cardiol 70 (1992):  c137-9|MacNab M, Mallows S "Safety profile of benazepril in essential hypertension." Clin Cardiol 14 Suppl I (1991):  iv33-7|Balfour J, Goa K "Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure." Drugs 42 (1991):  511-39|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993):  577|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine CJ, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D "Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the studies of left ventricular dysfunction." Am Heart J 128 (1994):  358-64|Lang RM, Dibianco R, Broderick GT, Gottlieb SS, Kostis J, Lyle PA, Makris L, Rajfer SI, Rucinska EJ "First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study." Am Heart J 128 (1994):  551-6|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Larochelle P, Haynes B, Maron N, Dugas S "A postmarketing surveillance evaluation of quinapril in 3742 canadian hypertensive patients - the ACCEPT study." Clin Ther 16 (1994):  838-53|Schmitt JK, Koch KS, Midha M "Profound hypotension in a tetraplegic patient following angiotensin-converting enzyme inhibitor lisinopril. case report." Paraplegia 32 (1994):  871-4|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Kaplan NM "The CARE study: a postmarketing evaluation of ramipril in 11,100 patients." Clin Ther 18 (1996):  658-70|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48825, 35, 'Enalapril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48826, 36, 'Enalapril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48827, 4167, 'Enalapril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48828, 4588, 'Enalapril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48829, 4591, 'Enalapril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48830, 4605, 'Enalapril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48831, 8030, 'Enalapril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48832, 18295, 'Enalapril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48833, 25189, 'Enalapril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48834, 25190, 'Enalapril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48835, 25195, 'Enalapril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48836, 25196, 'Enalapril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48837, 25871, 'Enalapril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48838, 25872, 'Enalapril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', '"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Capoten (captopril)." Bristol-Myers Squibb  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48839, 35, 'Enalapril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Thind GS "Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis." J Clin Hypertens 1 (1985):  337-43|Champ JD "Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension." Am J Med Sci 305 (1993):  25-7|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|O''Donnell D "Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed." Med J Aust 148 (1988):  525-7|Heeg JE, de Jong PE, de Zeeuw D "Lisinopril and renal failure ." Lancet 1 (1989):  846|Thomson AH, Kelly JG, Whiting B "Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension." Br J Clin Pharmacol 27 (1989):  57-65|Sica DA, Cutler RE, Parmer RJ, Ford NF "Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency." Clin Pharmacokinet 20 (1991):  420-7|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|Frank GJ, Knapp LE, McLain RW "Overall tolerance and safety of quinapril in clinical trials." Angiology 40 (1989):  405-15|Cetnarowski-Cropp AB "Quinapril: a new second-generation ACE inhibitor." DICP 25 (1991):  499-504|Frank GJ, Knapp LE, Olson SC, Phelps MC, Quade MM, Rieger MM, Sedman AJ "Overview of quinapril, a new ACE inhibitor." J Cardiovasc Pharmacol 15 (1990):  s14-23|Murray BM, Venuto RC, Kohli R, Cunningham EE "Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine." Am J Kidney Dis 16 (1990):  66-9|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Moexipril: another ace inhibitor for hypertension." Med Lett Drugs Ther 37 (1995):  75-6|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Persson B, Stimpel M "Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients." Eur J Clin Pharmacol 50 (1996):  259-64|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135|Olivier PB, German ML, Carette BD, Millart HG, Trenque TC "Elevation of serum creatinine following fosinopril therapy." Ann Pharmacother 33 (1999):  382-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48840, 36, 'Enalapril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Thind GS "Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis." J Clin Hypertens 1 (1985):  337-43|Champ JD "Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension." Am J Med Sci 305 (1993):  25-7|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|O''Donnell D "Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed." Med J Aust 148 (1988):  525-7|Heeg JE, de Jong PE, de Zeeuw D "Lisinopril and renal failure ." Lancet 1 (1989):  846|Thomson AH, Kelly JG, Whiting B "Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension." Br J Clin Pharmacol 27 (1989):  57-65|Sica DA, Cutler RE, Parmer RJ, Ford NF "Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency." Clin Pharmacokinet 20 (1991):  420-7|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|Frank GJ, Knapp LE, McLain RW "Overall tolerance and safety of quinapril in clinical trials." Angiology 40 (1989):  405-15|Cetnarowski-Cropp AB "Quinapril: a new second-generation ACE inhibitor." DICP 25 (1991):  499-504|Frank GJ, Knapp LE, Olson SC, Phelps MC, Quade MM, Rieger MM, Sedman AJ "Overview of quinapril, a new ACE inhibitor." J Cardiovasc Pharmacol 15 (1990):  s14-23|Murray BM, Venuto RC, Kohli R, Cunningham EE "Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine." Am J Kidney Dis 16 (1990):  66-9|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Moexipril: another ace inhibitor for hypertension." Med Lett Drugs Ther 37 (1995):  75-6|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Persson B, Stimpel M "Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients." Eur J Clin Pharmacol 50 (1996):  259-64|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135|Olivier PB, German ML, Carette BD, Millart HG, Trenque TC "Elevation of serum creatinine following fosinopril therapy." Ann Pharmacother 33 (1999):  382-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48841, 4167, 'Enalapril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Thind GS "Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis." J Clin Hypertens 1 (1985):  337-43|Champ JD "Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension." Am J Med Sci 305 (1993):  25-7|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|O''Donnell D "Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed." Med J Aust 148 (1988):  525-7|Heeg JE, de Jong PE, de Zeeuw D "Lisinopril and renal failure ." Lancet 1 (1989):  846|Thomson AH, Kelly JG, Whiting B "Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension." Br J Clin Pharmacol 27 (1989):  57-65|Sica DA, Cutler RE, Parmer RJ, Ford NF "Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency." Clin Pharmacokinet 20 (1991):  420-7|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|Frank GJ, Knapp LE, McLain RW "Overall tolerance and safety of quinapril in clinical trials." Angiology 40 (1989):  405-15|Cetnarowski-Cropp AB "Quinapril: a new second-generation ACE inhibitor." DICP 25 (1991):  499-504|Frank GJ, Knapp LE, Olson SC, Phelps MC, Quade MM, Rieger MM, Sedman AJ "Overview of quinapril, a new ACE inhibitor." J Cardiovasc Pharmacol 15 (1990):  s14-23|Murray BM, Venuto RC, Kohli R, Cunningham EE "Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine." Am J Kidney Dis 16 (1990):  66-9|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Moexipril: another ace inhibitor for hypertension." Med Lett Drugs Ther 37 (1995):  75-6|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Persson B, Stimpel M "Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients." Eur J Clin Pharmacol 50 (1996):  259-64|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135|Olivier PB, German ML, Carette BD, Millart HG, Trenque TC "Elevation of serum creatinine following fosinopril therapy." Ann Pharmacother 33 (1999):  382-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48842, 4588, 'Enalapril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Thind GS "Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis." J Clin Hypertens 1 (1985):  337-43|Champ JD "Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension." Am J Med Sci 305 (1993):  25-7|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|O''Donnell D "Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed." Med J Aust 148 (1988):  525-7|Heeg JE, de Jong PE, de Zeeuw D "Lisinopril and renal failure ." Lancet 1 (1989):  846|Thomson AH, Kelly JG, Whiting B "Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension." Br J Clin Pharmacol 27 (1989):  57-65|Sica DA, Cutler RE, Parmer RJ, Ford NF "Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency." Clin Pharmacokinet 20 (1991):  420-7|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|Frank GJ, Knapp LE, McLain RW "Overall tolerance and safety of quinapril in clinical trials." Angiology 40 (1989):  405-15|Cetnarowski-Cropp AB "Quinapril: a new second-generation ACE inhibitor." DICP 25 (1991):  499-504|Frank GJ, Knapp LE, Olson SC, Phelps MC, Quade MM, Rieger MM, Sedman AJ "Overview of quinapril, a new ACE inhibitor." J Cardiovasc Pharmacol 15 (1990):  s14-23|Murray BM, Venuto RC, Kohli R, Cunningham EE "Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine." Am J Kidney Dis 16 (1990):  66-9|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Moexipril: another ace inhibitor for hypertension." Med Lett Drugs Ther 37 (1995):  75-6|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Persson B, Stimpel M "Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients." Eur J Clin Pharmacol 50 (1996):  259-64|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135|Olivier PB, German ML, Carette BD, Millart HG, Trenque TC "Elevation of serum creatinine following fosinopril therapy." Ann Pharmacother 33 (1999):  382-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48843, 4591, 'Enalapril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Thind GS "Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis." J Clin Hypertens 1 (1985):  337-43|Champ JD "Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension." Am J Med Sci 305 (1993):  25-7|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|O''Donnell D "Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed." Med J Aust 148 (1988):  525-7|Heeg JE, de Jong PE, de Zeeuw D "Lisinopril and renal failure ." Lancet 1 (1989):  846|Thomson AH, Kelly JG, Whiting B "Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension." Br J Clin Pharmacol 27 (1989):  57-65|Sica DA, Cutler RE, Parmer RJ, Ford NF "Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency." Clin Pharmacokinet 20 (1991):  420-7|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|Frank GJ, Knapp LE, McLain RW "Overall tolerance and safety of quinapril in clinical trials." Angiology 40 (1989):  405-15|Cetnarowski-Cropp AB "Quinapril: a new second-generation ACE inhibitor." DICP 25 (1991):  499-504|Frank GJ, Knapp LE, Olson SC, Phelps MC, Quade MM, Rieger MM, Sedman AJ "Overview of quinapril, a new ACE inhibitor." J Cardiovasc Pharmacol 15 (1990):  s14-23|Murray BM, Venuto RC, Kohli R, Cunningham EE "Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine." Am J Kidney Dis 16 (1990):  66-9|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Moexipril: another ace inhibitor for hypertension." Med Lett Drugs Ther 37 (1995):  75-6|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Persson B, Stimpel M "Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients." Eur J Clin Pharmacol 50 (1996):  259-64|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135|Olivier PB, German ML, Carette BD, Millart HG, Trenque TC "Elevation of serum creatinine following fosinopril therapy." Ann Pharmacother 33 (1999):  382-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48844, 4605, 'Enalapril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Thind GS "Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis." J Clin Hypertens 1 (1985):  337-43|Champ JD "Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension." Am J Med Sci 305 (1993):  25-7|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|O''Donnell D "Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed." Med J Aust 148 (1988):  525-7|Heeg JE, de Jong PE, de Zeeuw D "Lisinopril and renal failure ." Lancet 1 (1989):  846|Thomson AH, Kelly JG, Whiting B "Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension." Br J Clin Pharmacol 27 (1989):  57-65|Sica DA, Cutler RE, Parmer RJ, Ford NF "Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency." Clin Pharmacokinet 20 (1991):  420-7|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|Frank GJ, Knapp LE, McLain RW "Overall tolerance and safety of quinapril in clinical trials." Angiology 40 (1989):  405-15|Cetnarowski-Cropp AB "Quinapril: a new second-generation ACE inhibitor." DICP 25 (1991):  499-504|Frank GJ, Knapp LE, Olson SC, Phelps MC, Quade MM, Rieger MM, Sedman AJ "Overview of quinapril, a new ACE inhibitor." J Cardiovasc Pharmacol 15 (1990):  s14-23|Murray BM, Venuto RC, Kohli R, Cunningham EE "Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine." Am J Kidney Dis 16 (1990):  66-9|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Moexipril: another ace inhibitor for hypertension." Med Lett Drugs Ther 37 (1995):  75-6|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Persson B, Stimpel M "Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients." Eur J Clin Pharmacol 50 (1996):  259-64|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135|Olivier PB, German ML, Carette BD, Millart HG, Trenque TC "Elevation of serum creatinine following fosinopril therapy." Ann Pharmacother 33 (1999):  382-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48845, 8030, 'Enalapril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Thind GS "Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis." J Clin Hypertens 1 (1985):  337-43|Champ JD "Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension." Am J Med Sci 305 (1993):  25-7|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|O''Donnell D "Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed." Med J Aust 148 (1988):  525-7|Heeg JE, de Jong PE, de Zeeuw D "Lisinopril and renal failure ." Lancet 1 (1989):  846|Thomson AH, Kelly JG, Whiting B "Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension." Br J Clin Pharmacol 27 (1989):  57-65|Sica DA, Cutler RE, Parmer RJ, Ford NF "Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency." Clin Pharmacokinet 20 (1991):  420-7|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|Frank GJ, Knapp LE, McLain RW "Overall tolerance and safety of quinapril in clinical trials." Angiology 40 (1989):  405-15|Cetnarowski-Cropp AB "Quinapril: a new second-generation ACE inhibitor." DICP 25 (1991):  499-504|Frank GJ, Knapp LE, Olson SC, Phelps MC, Quade MM, Rieger MM, Sedman AJ "Overview of quinapril, a new ACE inhibitor." J Cardiovasc Pharmacol 15 (1990):  s14-23|Murray BM, Venuto RC, Kohli R, Cunningham EE "Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine." Am J Kidney Dis 16 (1990):  66-9|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Moexipril: another ace inhibitor for hypertension." Med Lett Drugs Ther 37 (1995):  75-6|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Persson B, Stimpel M "Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients." Eur J Clin Pharmacol 50 (1996):  259-64|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135|Olivier PB, German ML, Carette BD, Millart HG, Trenque TC "Elevation of serum creatinine following fosinopril therapy." Ann Pharmacother 33 (1999):  382-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48846, 18295, 'Enalapril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Thind GS "Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis." J Clin Hypertens 1 (1985):  337-43|Champ JD "Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension." Am J Med Sci 305 (1993):  25-7|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|O''Donnell D "Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed." Med J Aust 148 (1988):  525-7|Heeg JE, de Jong PE, de Zeeuw D "Lisinopril and renal failure ." Lancet 1 (1989):  846|Thomson AH, Kelly JG, Whiting B "Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension." Br J Clin Pharmacol 27 (1989):  57-65|Sica DA, Cutler RE, Parmer RJ, Ford NF "Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency." Clin Pharmacokinet 20 (1991):  420-7|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|Frank GJ, Knapp LE, McLain RW "Overall tolerance and safety of quinapril in clinical trials." Angiology 40 (1989):  405-15|Cetnarowski-Cropp AB "Quinapril: a new second-generation ACE inhibitor." DICP 25 (1991):  499-504|Frank GJ, Knapp LE, Olson SC, Phelps MC, Quade MM, Rieger MM, Sedman AJ "Overview of quinapril, a new ACE inhibitor." J Cardiovasc Pharmacol 15 (1990):  s14-23|Murray BM, Venuto RC, Kohli R, Cunningham EE "Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine." Am J Kidney Dis 16 (1990):  66-9|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Moexipril: another ace inhibitor for hypertension." Med Lett Drugs Ther 37 (1995):  75-6|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Persson B, Stimpel M "Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients." Eur J Clin Pharmacol 50 (1996):  259-64|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135|Olivier PB, German ML, Carette BD, Millart HG, Trenque TC "Elevation of serum creatinine following fosinopril therapy." Ann Pharmacother 33 (1999):  382-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48847, 25189, 'Enalapril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Thind GS "Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis." J Clin Hypertens 1 (1985):  337-43|Champ JD "Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension." Am J Med Sci 305 (1993):  25-7|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|O''Donnell D "Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed." Med J Aust 148 (1988):  525-7|Heeg JE, de Jong PE, de Zeeuw D "Lisinopril and renal failure ." Lancet 1 (1989):  846|Thomson AH, Kelly JG, Whiting B "Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension." Br J Clin Pharmacol 27 (1989):  57-65|Sica DA, Cutler RE, Parmer RJ, Ford NF "Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency." Clin Pharmacokinet 20 (1991):  420-7|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|Frank GJ, Knapp LE, McLain RW "Overall tolerance and safety of quinapril in clinical trials." Angiology 40 (1989):  405-15|Cetnarowski-Cropp AB "Quinapril: a new second-generation ACE inhibitor." DICP 25 (1991):  499-504|Frank GJ, Knapp LE, Olson SC, Phelps MC, Quade MM, Rieger MM, Sedman AJ "Overview of quinapril, a new ACE inhibitor." J Cardiovasc Pharmacol 15 (1990):  s14-23|Murray BM, Venuto RC, Kohli R, Cunningham EE "Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine." Am J Kidney Dis 16 (1990):  66-9|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Moexipril: another ace inhibitor for hypertension." Med Lett Drugs Ther 37 (1995):  75-6|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Persson B, Stimpel M "Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients." Eur J Clin Pharmacol 50 (1996):  259-64|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135|Olivier PB, German ML, Carette BD, Millart HG, Trenque TC "Elevation of serum creatinine following fosinopril therapy." Ann Pharmacother 33 (1999):  382-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48848, 25190, 'Enalapril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Thind GS "Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis." J Clin Hypertens 1 (1985):  337-43|Champ JD "Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension." Am J Med Sci 305 (1993):  25-7|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|O''Donnell D "Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed." Med J Aust 148 (1988):  525-7|Heeg JE, de Jong PE, de Zeeuw D "Lisinopril and renal failure ." Lancet 1 (1989):  846|Thomson AH, Kelly JG, Whiting B "Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension." Br J Clin Pharmacol 27 (1989):  57-65|Sica DA, Cutler RE, Parmer RJ, Ford NF "Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency." Clin Pharmacokinet 20 (1991):  420-7|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|Frank GJ, Knapp LE, McLain RW "Overall tolerance and safety of quinapril in clinical trials." Angiology 40 (1989):  405-15|Cetnarowski-Cropp AB "Quinapril: a new second-generation ACE inhibitor." DICP 25 (1991):  499-504|Frank GJ, Knapp LE, Olson SC, Phelps MC, Quade MM, Rieger MM, Sedman AJ "Overview of quinapril, a new ACE inhibitor." J Cardiovasc Pharmacol 15 (1990):  s14-23|Murray BM, Venuto RC, Kohli R, Cunningham EE "Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine." Am J Kidney Dis 16 (1990):  66-9|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Moexipril: another ace inhibitor for hypertension." Med Lett Drugs Ther 37 (1995):  75-6|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Persson B, Stimpel M "Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients." Eur J Clin Pharmacol 50 (1996):  259-64|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135|Olivier PB, German ML, Carette BD, Millart HG, Trenque TC "Elevation of serum creatinine following fosinopril therapy." Ann Pharmacother 33 (1999):  382-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48849, 25195, 'Enalapril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Thind GS "Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis." J Clin Hypertens 1 (1985):  337-43|Champ JD "Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension." Am J Med Sci 305 (1993):  25-7|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|O''Donnell D "Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed." Med J Aust 148 (1988):  525-7|Heeg JE, de Jong PE, de Zeeuw D "Lisinopril and renal failure ." Lancet 1 (1989):  846|Thomson AH, Kelly JG, Whiting B "Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension." Br J Clin Pharmacol 27 (1989):  57-65|Sica DA, Cutler RE, Parmer RJ, Ford NF "Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency." Clin Pharmacokinet 20 (1991):  420-7|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|Frank GJ, Knapp LE, McLain RW "Overall tolerance and safety of quinapril in clinical trials." Angiology 40 (1989):  405-15|Cetnarowski-Cropp AB "Quinapril: a new second-generation ACE inhibitor." DICP 25 (1991):  499-504|Frank GJ, Knapp LE, Olson SC, Phelps MC, Quade MM, Rieger MM, Sedman AJ "Overview of quinapril, a new ACE inhibitor." J Cardiovasc Pharmacol 15 (1990):  s14-23|Murray BM, Venuto RC, Kohli R, Cunningham EE "Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine." Am J Kidney Dis 16 (1990):  66-9|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Moexipril: another ace inhibitor for hypertension." Med Lett Drugs Ther 37 (1995):  75-6|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Persson B, Stimpel M "Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients." Eur J Clin Pharmacol 50 (1996):  259-64|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135|Olivier PB, German ML, Carette BD, Millart HG, Trenque TC "Elevation of serum creatinine following fosinopril therapy." Ann Pharmacother 33 (1999):  382-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48850, 25196, 'Enalapril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Thind GS "Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis." J Clin Hypertens 1 (1985):  337-43|Champ JD "Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension." Am J Med Sci 305 (1993):  25-7|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|O''Donnell D "Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed." Med J Aust 148 (1988):  525-7|Heeg JE, de Jong PE, de Zeeuw D "Lisinopril and renal failure ." Lancet 1 (1989):  846|Thomson AH, Kelly JG, Whiting B "Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension." Br J Clin Pharmacol 27 (1989):  57-65|Sica DA, Cutler RE, Parmer RJ, Ford NF "Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency." Clin Pharmacokinet 20 (1991):  420-7|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|Frank GJ, Knapp LE, McLain RW "Overall tolerance and safety of quinapril in clinical trials." Angiology 40 (1989):  405-15|Cetnarowski-Cropp AB "Quinapril: a new second-generation ACE inhibitor." DICP 25 (1991):  499-504|Frank GJ, Knapp LE, Olson SC, Phelps MC, Quade MM, Rieger MM, Sedman AJ "Overview of quinapril, a new ACE inhibitor." J Cardiovasc Pharmacol 15 (1990):  s14-23|Murray BM, Venuto RC, Kohli R, Cunningham EE "Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine." Am J Kidney Dis 16 (1990):  66-9|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Moexipril: another ace inhibitor for hypertension." Med Lett Drugs Ther 37 (1995):  75-6|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Persson B, Stimpel M "Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients." Eur J Clin Pharmacol 50 (1996):  259-64|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135|Olivier PB, German ML, Carette BD, Millart HG, Trenque TC "Elevation of serum creatinine following fosinopril therapy." Ann Pharmacother 33 (1999):  382-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48851, 25871, 'Enalapril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Thind GS "Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis." J Clin Hypertens 1 (1985):  337-43|Champ JD "Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension." Am J Med Sci 305 (1993):  25-7|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|O''Donnell D "Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed." Med J Aust 148 (1988):  525-7|Heeg JE, de Jong PE, de Zeeuw D "Lisinopril and renal failure ." Lancet 1 (1989):  846|Thomson AH, Kelly JG, Whiting B "Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension." Br J Clin Pharmacol 27 (1989):  57-65|Sica DA, Cutler RE, Parmer RJ, Ford NF "Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency." Clin Pharmacokinet 20 (1991):  420-7|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|Frank GJ, Knapp LE, McLain RW "Overall tolerance and safety of quinapril in clinical trials." Angiology 40 (1989):  405-15|Cetnarowski-Cropp AB "Quinapril: a new second-generation ACE inhibitor." DICP 25 (1991):  499-504|Frank GJ, Knapp LE, Olson SC, Phelps MC, Quade MM, Rieger MM, Sedman AJ "Overview of quinapril, a new ACE inhibitor." J Cardiovasc Pharmacol 15 (1990):  s14-23|Murray BM, Venuto RC, Kohli R, Cunningham EE "Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine." Am J Kidney Dis 16 (1990):  66-9|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Moexipril: another ace inhibitor for hypertension." Med Lett Drugs Ther 37 (1995):  75-6|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Persson B, Stimpel M "Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients." Eur J Clin Pharmacol 50 (1996):  259-64|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135|Olivier PB, German ML, Carette BD, Millart HG, Trenque TC "Elevation of serum creatinine following fosinopril therapy." Ann Pharmacother 33 (1999):  382-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48852, 25872, 'Enalapril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'Schwartz D, Averbuch M, Pines A, et al. "Renal toxicity of enalapril in very elderly patients with progressive, severe congestive heart failure." Chest 100 (1991):  1558-61|Forette B, Koen R, Vivaut E "Efficacy and safety of quinapril in the elderly hypertensive patient." Am Heart J 123 (1992):  1426-32|Ljungman S, Kjekshus J, Swedberg K "Renal function in severe congestive heart failure during treatment with enalapril." Am J Cardiol 70 (1992):  479-87|Thind GS "Renal insufficiency during angiotensin-converting enzyme inhibitor therapy in hypertensive patients with no renal artery stenosis." J Clin Hypertens 1 (1985):  337-43|Champ JD "Case report: azotemia secondary to enalapril and diuretic use and the diagnosis of renovascular hypertension." Am J Med Sci 305 (1993):  25-7|Inman WH, Rawson NS, Wilton LV, et al. "Postmarketing surveillance of enalapril. I: results of prescription-event monitoring." Br Med J 297 (1988):  826-9|O''Donnell D "Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed." Med J Aust 148 (1988):  525-7|Heeg JE, de Jong PE, de Zeeuw D "Lisinopril and renal failure ." Lancet 1 (1989):  846|Thomson AH, Kelly JG, Whiting B "Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension." Br J Clin Pharmacol 27 (1989):  57-65|Sica DA, Cutler RE, Parmer RJ, Ford NF "Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency." Clin Pharmacokinet 20 (1991):  420-7|Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990):  s47-55|Heintz B, Verho M, Brockmeier D, Kirsten R, Nelson K, Maigatter S, Lefevre G, Kierdorf H, Sieberth HG "Influence of ramipril on renal function in patients with chronic congestive heart failure." J Cardiovasc Pharmacol 18 (1991):  s174-9|Dietz R, Nagel F, Osterziel KJ "Angiotensin-converting enzyme inhibitors and renal function in heart failure." Am J Cardiol 70 (1992):  c119-25|Frank GJ, Knapp LE, McLain RW "Overall tolerance and safety of quinapril in clinical trials." Angiology 40 (1989):  405-15|Cetnarowski-Cropp AB "Quinapril: a new second-generation ACE inhibitor." DICP 25 (1991):  499-504|Frank GJ, Knapp LE, Olson SC, Phelps MC, Quade MM, Rieger MM, Sedman AJ "Overview of quinapril, a new ACE inhibitor." J Cardiovasc Pharmacol 15 (1990):  s14-23|Murray BM, Venuto RC, Kohli R, Cunningham EE "Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine." Am J Kidney Dis 16 (1990):  66-9|"Product Information. Lotensin (benazepril)." Ciba-Geigy Pharmaceuticals  (2002):|"Product Information. Vasotec (enalapril)." Merck & Co., Inc  (2002):|"Product Information. Prinivil (lisinopril)." Merck & Co., Inc  (2002):|"Product Information. Accupril (quinapril)." Parke-Davis  (2001):|"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb  (2001):|"Product Information. Altace (ramipril)." Hoechst Marion Roussel  (2001):|"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Univasc (moexipril)." Schwarz Pharma  (2001):|"Moexipril: another ace inhibitor for hypertension." Med Lett Drugs Ther 37 (1995):  75-6|Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995):  s11-6|Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996):  55-61|"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company  (2001):|Persson B, Stimpel M "Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients." Eur J Clin Pharmacol 50 (1996):  259-64|Howes LG, Nguyen T, Jackson B "Safety and efficacy of quinapril in hypertensive geriatric patients." J Am Geriatr Soc 44 (1996):  1135|Olivier PB, German ML, Carette BD, Millart HG, Trenque TC "Elevation of serum creatinine following fosinopril therapy." Ann Pharmacother 33 (1999):  382-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48853, 4460, 'Enfortumab vedotin', 'Hepatic Insufficiency', 'Avoid the use of enfortumab vedotin in patients with moderate or severe hepatic impairment as it has not been studied in these patients.  No adjustment in the starting dose is required when treating patients with mild hepatic impairment.', '3', '"Product Information. Padcev (enfortumab vedotin)." Seattle Genetics Inc  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48854, 4463, 'Enfortumab vedotin', 'Hepatic Insufficiency', 'Avoid the use of enfortumab vedotin in patients with moderate or severe hepatic impairment as it has not been studied in these patients.  No adjustment in the starting dose is required when treating patients with mild hepatic impairment.', '3', '"Product Information. Padcev (enfortumab vedotin)." Seattle Genetics Inc  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48855, 4460, 'Enfortumab vedotin', 'Hyperglycemia', 'Hyperglycemia occurred in patients treated with enfortumab vedotin, including death, and diabetic ketoacidosis (DKA) in those with and without preexisting-existing diabetes mellitus.  The incidence of Grade 3-4 hyperglycemia increased consistently in patients with higher body mass index and in patients with higher baseline A1C.  Closely monitor blood glucose levels in patients with, or at risk for, diabetes mellitus or hyperglycemia.  If blood glucose is elevated (>250 mg/dL), withhold treatment.', '2', '"Product Information. Padcev (enfortumab vedotin)." Seattle Genetics Inc  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48856, 4463, 'Enfortumab vedotin', 'Hyperglycemia', 'Hyperglycemia occurred in patients treated with enfortumab vedotin, including death, and diabetic ketoacidosis (DKA) in those with and without preexisting-existing diabetes mellitus.  The incidence of Grade 3-4 hyperglycemia increased consistently in patients with higher body mass index and in patients with higher baseline A1C.  Closely monitor blood glucose levels in patients with, or at risk for, diabetes mellitus or hyperglycemia.  If blood glucose is elevated (>250 mg/dL), withhold treatment.', '2', '"Product Information. Padcev (enfortumab vedotin)." Seattle Genetics Inc  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48857, 4460, 'Enfortumab vedotin', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy, predominantly sensory, occurred in 49% of the patients treated with enfortumab vedotin in clinical trials.  Peripheral neuropathy occurred in patients with or without preexisting peripheral neuropathy.  Monitor patients for symptoms of new or worsening peripheral neuropathy and consider dose interruption or dose reduction when peripheral neuropathy occurs.  Permanently discontinue treatment in patients that develop Grade >3 peripheral neuropathy.', '2', '"Product Information. Padcev (enfortumab vedotin)." Seattle Genetics Inc  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48858, 4463, 'Enfortumab vedotin', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy, predominantly sensory, occurred in 49% of the patients treated with enfortumab vedotin in clinical trials.  Peripheral neuropathy occurred in patients with or without preexisting peripheral neuropathy.  Monitor patients for symptoms of new or worsening peripheral neuropathy and consider dose interruption or dose reduction when peripheral neuropathy occurs.  Permanently discontinue treatment in patients that develop Grade >3 peripheral neuropathy.', '2', '"Product Information. Padcev (enfortumab vedotin)." Seattle Genetics Inc  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48859, 0, 'Enasidenib', 'Hyperbilirubinemia', 'The use of enasidenib may interfere with bilirubin metabolism through inhibition of UGT1A1.  It is recommended to advise patients to report any changes to the color of their skin or the whites of their eyes to their healthcare provider for further evaluation.  Evaluate for signs and symptoms of jaundice to rule out any conditions that may cause hyperbilirubinemia.', '2', '"Product Information. Idhifa (enasidenib)." Celgene Corporation  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48860, 0, 'Encorafenib', 'Hepatic Insufficiency', 'A recommended dose of encorafenib has not been established for patients with moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment.  Caution and monitoring is advised if used on these patients.  Dose adjustment for is not recommended in patients with mild hepatic impairment (Child-Pugh Class A).', '2', '"Product Information. Braftovi (encorafenib)." Array BioPharma Inc.  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48861, 0, 'Encorafenib', 'Long QT Syndrome', 'Encorafenib is associated with dose-dependent QTc interval prolongation in some patients.  Monitor patients who already have or who are at significant risk of developing QTc prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled heart failure and those taking other medicinal products associated with QT prolongation.  Correct hypokalemia and hypomagnesemia prior to and during therapy with encorafenib.  Withhold, reduce dose, or permanently discontinue for QTc > 500 ms.', '2', '"Product Information. Braftovi (encorafenib)." Array BioPharma Inc.  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48862, 0, 'Encorafenib', 'Kidney Diseases', 'A recommended dose of encorafenib has not been established for patients with severe renal impairment (CrCl < 30 mL/min).  Caution and monitoring is advised if used on these patients.  No dose adjustment is recommended for patients with mild to moderate renal impairment (CrCl 30 to < 90 mL/min).', '2', '"Product Information. Braftovi (encorafenib)." Array BioPharma Inc.  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48863, 2834, 'Entecavir', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48864, 11225, 'Entecavir', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48865, 11226, 'Entecavir', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48866, 14915, 'Entecavir', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48867, 14916, 'Entecavir', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48868, 15952, 'Entecavir', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48869, 16572, 'Entecavir', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48870, 18335, 'Entecavir', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48871, 18336, 'Entecavir', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48872, 18337, 'Entecavir', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48873, 20333, 'Entecavir', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48874, 20334, 'Entecavir', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48875, 22103, 'Entecavir', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48876, 22104, 'Entecavir', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48877, 27960, 'Entecavir', 'Liver Diseases', 'Hepatotoxicity including lactic acidosis, severe hepatomegaly with steatosis, fulminant hepatitis, and hepatic failure has been associated with the use of some nucleoside reverse transcriptase inhibitors (NRTIs) alone or in combination with other antiretroviral agents.  Therapy with NRTIs should be administered cautiously in patients with preexisting liver disease, a history of alcohol abuse, or hepatitis.  Therapy should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.  The use of abacavir is contraindicated in patients with moderate to severe hepatic impairment as its safety and efficacy has not been established on these patients.', '3', 'Yarchoan R, Mitsuya H, Pluda JM, et al. "The National Cancer Institute phase I study of 2'',3''-dideoxyinosine administration in adults with AIDS-related complex: analysis of activity and toxicity profiles." Rev Infect Dis 12 (1990):  s522-33|Dolin R, Lambert JS, Morse GD, et al. "2'',3''-dideoxyinosine in patients with AIDS or AIDS-related complex." Rev Infect Dis 12 (1990):  s540-51|Lai KK, Gang DL, Zawacki JK, Cooley TP "Fulminant hepatic failure associated with 2'',3''-dideoxyinosine (ddI)." Ann Intern Med 115 (1991):  283-4|Dubin G, Braffman MN "Zidovudine-induced hepatotoxicity." Ann Intern Med 110 (1989):  85-6|Shriner K, Goetz MB "Severe hepatoxicity in a patient receiving both acetaminophen and zidovudine." Am J Med 93 (1992):  94-6|Gradon JD, Chapnick EK, Sepkowitz DV "Zidovudine-induced hepatitis." J Intern Med 231 (1992):  317-8|Chen SC, Barker SM, Mitchell DH, et al. "Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection." Pathology 24 (1992):  109-11|"Product Information. Videx (didanosine)." Bristol-Myers Squibb  (2002):|"Product Information. HIVID (zalcitabine)." Roche Laboratories  (2001):|"Product Information. Retrovir (zidovudine)." Glaxo Wellcome  (2001):|Pike IM, Nicaise C "The didanosine Expanded Access Program: safety analysis." Clin Infect Dis 16 (1993):  S63-8|Shintaku M, Nasu K, Shimizu T "Fulminant hepatic failure in an AIDS patient: possible zidovudine- induced hepatotoxicity." Am J Gastroenterol 88 (1993):  464-6|Montaner JSG, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, Wainber "Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the canadian open ddi treatment program." J Acquir Immune Defic Syndr 7 (1994):  924-30|"Product Information. Epivir (lamivudine)." Glaxo Wellcome  (2001):|"Product Information. Ziagen (abacavir)." Glaxo Wellcome  (2001):|Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA "Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases." Ann Intern Med 133 (2000):  192-6|Lhouri S, Cushing H "Lactic acidosis secondary to nucleoside analog antiretroviral therapy." Infect Med 17 (2000):  547-54|Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000):  1135-40|Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC "Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens." Clin Infect Dis 31 (2000):  162-6|Kronenberg A, Riehle HM, Gunthard HF "Liver failure after long-term nucleoside antiretroviral therapy." Lancet 358 (2001):  759-601|Boubaker K, Flepp M, Sudre P, et al. "Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study." Clin Infect Dis 33 (2001):  1931-7|Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA "Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases." Clin Infect Dis 33 (2001):  1914-21|"Product Information. Viread (tenofovir)." Gilead Sciences  (2001):|"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48878, 2834, 'Entecavir', 'Diseases requiring hemodialysis', 'Entecavir is removed by hemodialysis.  Following a single 1 mg dose of entecavir administered two hours before the hemodialysis session, approximately 13% of the dose was removed over four hours of hemodialysis.  Entecavir should be administered after hemodialysis.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48879, 11225, 'Entecavir', 'Diseases requiring hemodialysis', 'Entecavir is removed by hemodialysis.  Following a single 1 mg dose of entecavir administered two hours before the hemodialysis session, approximately 13% of the dose was removed over four hours of hemodialysis.  Entecavir should be administered after hemodialysis.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48880, 11226, 'Entecavir', 'Diseases requiring hemodialysis', 'Entecavir is removed by hemodialysis.  Following a single 1 mg dose of entecavir administered two hours before the hemodialysis session, approximately 13% of the dose was removed over four hours of hemodialysis.  Entecavir should be administered after hemodialysis.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48881, 14915, 'Entecavir', 'Diseases requiring hemodialysis', 'Entecavir is removed by hemodialysis.  Following a single 1 mg dose of entecavir administered two hours before the hemodialysis session, approximately 13% of the dose was removed over four hours of hemodialysis.  Entecavir should be administered after hemodialysis.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48882, 14916, 'Entecavir', 'Diseases requiring hemodialysis', 'Entecavir is removed by hemodialysis.  Following a single 1 mg dose of entecavir administered two hours before the hemodialysis session, approximately 13% of the dose was removed over four hours of hemodialysis.  Entecavir should be administered after hemodialysis.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48883, 15952, 'Entecavir', 'Diseases requiring hemodialysis', 'Entecavir is removed by hemodialysis.  Following a single 1 mg dose of entecavir administered two hours before the hemodialysis session, approximately 13% of the dose was removed over four hours of hemodialysis.  Entecavir should be administered after hemodialysis.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48884, 16572, 'Entecavir', 'Diseases requiring hemodialysis', 'Entecavir is removed by hemodialysis.  Following a single 1 mg dose of entecavir administered two hours before the hemodialysis session, approximately 13% of the dose was removed over four hours of hemodialysis.  Entecavir should be administered after hemodialysis.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48885, 18335, 'Entecavir', 'Diseases requiring hemodialysis', 'Entecavir is removed by hemodialysis.  Following a single 1 mg dose of entecavir administered two hours before the hemodialysis session, approximately 13% of the dose was removed over four hours of hemodialysis.  Entecavir should be administered after hemodialysis.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48886, 18336, 'Entecavir', 'Diseases requiring hemodialysis', 'Entecavir is removed by hemodialysis.  Following a single 1 mg dose of entecavir administered two hours before the hemodialysis session, approximately 13% of the dose was removed over four hours of hemodialysis.  Entecavir should be administered after hemodialysis.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48887, 18337, 'Entecavir', 'Diseases requiring hemodialysis', 'Entecavir is removed by hemodialysis.  Following a single 1 mg dose of entecavir administered two hours before the hemodialysis session, approximately 13% of the dose was removed over four hours of hemodialysis.  Entecavir should be administered after hemodialysis.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48888, 20333, 'Entecavir', 'Diseases requiring hemodialysis', 'Entecavir is removed by hemodialysis.  Following a single 1 mg dose of entecavir administered two hours before the hemodialysis session, approximately 13% of the dose was removed over four hours of hemodialysis.  Entecavir should be administered after hemodialysis.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48889, 20334, 'Entecavir', 'Diseases requiring hemodialysis', 'Entecavir is removed by hemodialysis.  Following a single 1 mg dose of entecavir administered two hours before the hemodialysis session, approximately 13% of the dose was removed over four hours of hemodialysis.  Entecavir should be administered after hemodialysis.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48890, 22103, 'Entecavir', 'Diseases requiring hemodialysis', 'Entecavir is removed by hemodialysis.  Following a single 1 mg dose of entecavir administered two hours before the hemodialysis session, approximately 13% of the dose was removed over four hours of hemodialysis.  Entecavir should be administered after hemodialysis.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48891, 22104, 'Entecavir', 'Diseases requiring hemodialysis', 'Entecavir is removed by hemodialysis.  Following a single 1 mg dose of entecavir administered two hours before the hemodialysis session, approximately 13% of the dose was removed over four hours of hemodialysis.  Entecavir should be administered after hemodialysis.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48892, 27960, 'Entecavir', 'Diseases requiring hemodialysis', 'Entecavir is removed by hemodialysis.  Following a single 1 mg dose of entecavir administered two hours before the hemodialysis session, approximately 13% of the dose was removed over four hours of hemodialysis.  Entecavir should be administered after hemodialysis.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48893, 2834, 'Entecavir', 'Kidney Diseases', 'Entecavir is primarily eliminated by the kidney.  Compared to patients with normal renal function (CrCl above 80 mL/min), peak plasma concentration (Cmax) and systemic exposure (AUC) of a single 1 mg dose of entecavir increased by 30% and 150%, respectively, in patients with moderate renal dysfunction (CrCl 30 to 49 mL/min), and 89% and 422%, respectively, in patients with severe renal dysfunction (CrCl below 30 mL/min).  Systemic exposure was increased even further in patients with end-stage renal disease managed on dialysis.  These patients had an approximately 8-fold increase in entecavir AUC compared to patients with normal renal function.  Renal clearance of entecavir decreased by 65% and 89%, respectively, in patients with moderate and severe renal dysfunction.  Dosage adjustment of entecavir is recommended for patients with CrCl below 50 mL/min, including patients on dialysis, in accordance with the manufacturer''s product labeling.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48894, 11225, 'Entecavir', 'Kidney Diseases', 'Entecavir is primarily eliminated by the kidney.  Compared to patients with normal renal function (CrCl above 80 mL/min), peak plasma concentration (Cmax) and systemic exposure (AUC) of a single 1 mg dose of entecavir increased by 30% and 150%, respectively, in patients with moderate renal dysfunction (CrCl 30 to 49 mL/min), and 89% and 422%, respectively, in patients with severe renal dysfunction (CrCl below 30 mL/min).  Systemic exposure was increased even further in patients with end-stage renal disease managed on dialysis.  These patients had an approximately 8-fold increase in entecavir AUC compared to patients with normal renal function.  Renal clearance of entecavir decreased by 65% and 89%, respectively, in patients with moderate and severe renal dysfunction.  Dosage adjustment of entecavir is recommended for patients with CrCl below 50 mL/min, including patients on dialysis, in accordance with the manufacturer''s product labeling.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48895, 11226, 'Entecavir', 'Kidney Diseases', 'Entecavir is primarily eliminated by the kidney.  Compared to patients with normal renal function (CrCl above 80 mL/min), peak plasma concentration (Cmax) and systemic exposure (AUC) of a single 1 mg dose of entecavir increased by 30% and 150%, respectively, in patients with moderate renal dysfunction (CrCl 30 to 49 mL/min), and 89% and 422%, respectively, in patients with severe renal dysfunction (CrCl below 30 mL/min).  Systemic exposure was increased even further in patients with end-stage renal disease managed on dialysis.  These patients had an approximately 8-fold increase in entecavir AUC compared to patients with normal renal function.  Renal clearance of entecavir decreased by 65% and 89%, respectively, in patients with moderate and severe renal dysfunction.  Dosage adjustment of entecavir is recommended for patients with CrCl below 50 mL/min, including patients on dialysis, in accordance with the manufacturer''s product labeling.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48896, 14915, 'Entecavir', 'Kidney Diseases', 'Entecavir is primarily eliminated by the kidney.  Compared to patients with normal renal function (CrCl above 80 mL/min), peak plasma concentration (Cmax) and systemic exposure (AUC) of a single 1 mg dose of entecavir increased by 30% and 150%, respectively, in patients with moderate renal dysfunction (CrCl 30 to 49 mL/min), and 89% and 422%, respectively, in patients with severe renal dysfunction (CrCl below 30 mL/min).  Systemic exposure was increased even further in patients with end-stage renal disease managed on dialysis.  These patients had an approximately 8-fold increase in entecavir AUC compared to patients with normal renal function.  Renal clearance of entecavir decreased by 65% and 89%, respectively, in patients with moderate and severe renal dysfunction.  Dosage adjustment of entecavir is recommended for patients with CrCl below 50 mL/min, including patients on dialysis, in accordance with the manufacturer''s product labeling.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48897, 14916, 'Entecavir', 'Kidney Diseases', 'Entecavir is primarily eliminated by the kidney.  Compared to patients with normal renal function (CrCl above 80 mL/min), peak plasma concentration (Cmax) and systemic exposure (AUC) of a single 1 mg dose of entecavir increased by 30% and 150%, respectively, in patients with moderate renal dysfunction (CrCl 30 to 49 mL/min), and 89% and 422%, respectively, in patients with severe renal dysfunction (CrCl below 30 mL/min).  Systemic exposure was increased even further in patients with end-stage renal disease managed on dialysis.  These patients had an approximately 8-fold increase in entecavir AUC compared to patients with normal renal function.  Renal clearance of entecavir decreased by 65% and 89%, respectively, in patients with moderate and severe renal dysfunction.  Dosage adjustment of entecavir is recommended for patients with CrCl below 50 mL/min, including patients on dialysis, in accordance with the manufacturer''s product labeling.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48898, 15952, 'Entecavir', 'Kidney Diseases', 'Entecavir is primarily eliminated by the kidney.  Compared to patients with normal renal function (CrCl above 80 mL/min), peak plasma concentration (Cmax) and systemic exposure (AUC) of a single 1 mg dose of entecavir increased by 30% and 150%, respectively, in patients with moderate renal dysfunction (CrCl 30 to 49 mL/min), and 89% and 422%, respectively, in patients with severe renal dysfunction (CrCl below 30 mL/min).  Systemic exposure was increased even further in patients with end-stage renal disease managed on dialysis.  These patients had an approximately 8-fold increase in entecavir AUC compared to patients with normal renal function.  Renal clearance of entecavir decreased by 65% and 89%, respectively, in patients with moderate and severe renal dysfunction.  Dosage adjustment of entecavir is recommended for patients with CrCl below 50 mL/min, including patients on dialysis, in accordance with the manufacturer''s product labeling.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48899, 16572, 'Entecavir', 'Kidney Diseases', 'Entecavir is primarily eliminated by the kidney.  Compared to patients with normal renal function (CrCl above 80 mL/min), peak plasma concentration (Cmax) and systemic exposure (AUC) of a single 1 mg dose of entecavir increased by 30% and 150%, respectively, in patients with moderate renal dysfunction (CrCl 30 to 49 mL/min), and 89% and 422%, respectively, in patients with severe renal dysfunction (CrCl below 30 mL/min).  Systemic exposure was increased even further in patients with end-stage renal disease managed on dialysis.  These patients had an approximately 8-fold increase in entecavir AUC compared to patients with normal renal function.  Renal clearance of entecavir decreased by 65% and 89%, respectively, in patients with moderate and severe renal dysfunction.  Dosage adjustment of entecavir is recommended for patients with CrCl below 50 mL/min, including patients on dialysis, in accordance with the manufacturer''s product labeling.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48900, 18335, 'Entecavir', 'Kidney Diseases', 'Entecavir is primarily eliminated by the kidney.  Compared to patients with normal renal function (CrCl above 80 mL/min), peak plasma concentration (Cmax) and systemic exposure (AUC) of a single 1 mg dose of entecavir increased by 30% and 150%, respectively, in patients with moderate renal dysfunction (CrCl 30 to 49 mL/min), and 89% and 422%, respectively, in patients with severe renal dysfunction (CrCl below 30 mL/min).  Systemic exposure was increased even further in patients with end-stage renal disease managed on dialysis.  These patients had an approximately 8-fold increase in entecavir AUC compared to patients with normal renal function.  Renal clearance of entecavir decreased by 65% and 89%, respectively, in patients with moderate and severe renal dysfunction.  Dosage adjustment of entecavir is recommended for patients with CrCl below 50 mL/min, including patients on dialysis, in accordance with the manufacturer''s product labeling.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48901, 18336, 'Entecavir', 'Kidney Diseases', 'Entecavir is primarily eliminated by the kidney.  Compared to patients with normal renal function (CrCl above 80 mL/min), peak plasma concentration (Cmax) and systemic exposure (AUC) of a single 1 mg dose of entecavir increased by 30% and 150%, respectively, in patients with moderate renal dysfunction (CrCl 30 to 49 mL/min), and 89% and 422%, respectively, in patients with severe renal dysfunction (CrCl below 30 mL/min).  Systemic exposure was increased even further in patients with end-stage renal disease managed on dialysis.  These patients had an approximately 8-fold increase in entecavir AUC compared to patients with normal renal function.  Renal clearance of entecavir decreased by 65% and 89%, respectively, in patients with moderate and severe renal dysfunction.  Dosage adjustment of entecavir is recommended for patients with CrCl below 50 mL/min, including patients on dialysis, in accordance with the manufacturer''s product labeling.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48902, 18337, 'Entecavir', 'Kidney Diseases', 'Entecavir is primarily eliminated by the kidney.  Compared to patients with normal renal function (CrCl above 80 mL/min), peak plasma concentration (Cmax) and systemic exposure (AUC) of a single 1 mg dose of entecavir increased by 30% and 150%, respectively, in patients with moderate renal dysfunction (CrCl 30 to 49 mL/min), and 89% and 422%, respectively, in patients with severe renal dysfunction (CrCl below 30 mL/min).  Systemic exposure was increased even further in patients with end-stage renal disease managed on dialysis.  These patients had an approximately 8-fold increase in entecavir AUC compared to patients with normal renal function.  Renal clearance of entecavir decreased by 65% and 89%, respectively, in patients with moderate and severe renal dysfunction.  Dosage adjustment of entecavir is recommended for patients with CrCl below 50 mL/min, including patients on dialysis, in accordance with the manufacturer''s product labeling.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48903, 20333, 'Entecavir', 'Kidney Diseases', 'Entecavir is primarily eliminated by the kidney.  Compared to patients with normal renal function (CrCl above 80 mL/min), peak plasma concentration (Cmax) and systemic exposure (AUC) of a single 1 mg dose of entecavir increased by 30% and 150%, respectively, in patients with moderate renal dysfunction (CrCl 30 to 49 mL/min), and 89% and 422%, respectively, in patients with severe renal dysfunction (CrCl below 30 mL/min).  Systemic exposure was increased even further in patients with end-stage renal disease managed on dialysis.  These patients had an approximately 8-fold increase in entecavir AUC compared to patients with normal renal function.  Renal clearance of entecavir decreased by 65% and 89%, respectively, in patients with moderate and severe renal dysfunction.  Dosage adjustment of entecavir is recommended for patients with CrCl below 50 mL/min, including patients on dialysis, in accordance with the manufacturer''s product labeling.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48904, 20334, 'Entecavir', 'Kidney Diseases', 'Entecavir is primarily eliminated by the kidney.  Compared to patients with normal renal function (CrCl above 80 mL/min), peak plasma concentration (Cmax) and systemic exposure (AUC) of a single 1 mg dose of entecavir increased by 30% and 150%, respectively, in patients with moderate renal dysfunction (CrCl 30 to 49 mL/min), and 89% and 422%, respectively, in patients with severe renal dysfunction (CrCl below 30 mL/min).  Systemic exposure was increased even further in patients with end-stage renal disease managed on dialysis.  These patients had an approximately 8-fold increase in entecavir AUC compared to patients with normal renal function.  Renal clearance of entecavir decreased by 65% and 89%, respectively, in patients with moderate and severe renal dysfunction.  Dosage adjustment of entecavir is recommended for patients with CrCl below 50 mL/min, including patients on dialysis, in accordance with the manufacturer''s product labeling.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48905, 22103, 'Entecavir', 'Kidney Diseases', 'Entecavir is primarily eliminated by the kidney.  Compared to patients with normal renal function (CrCl above 80 mL/min), peak plasma concentration (Cmax) and systemic exposure (AUC) of a single 1 mg dose of entecavir increased by 30% and 150%, respectively, in patients with moderate renal dysfunction (CrCl 30 to 49 mL/min), and 89% and 422%, respectively, in patients with severe renal dysfunction (CrCl below 30 mL/min).  Systemic exposure was increased even further in patients with end-stage renal disease managed on dialysis.  These patients had an approximately 8-fold increase in entecavir AUC compared to patients with normal renal function.  Renal clearance of entecavir decreased by 65% and 89%, respectively, in patients with moderate and severe renal dysfunction.  Dosage adjustment of entecavir is recommended for patients with CrCl below 50 mL/min, including patients on dialysis, in accordance with the manufacturer''s product labeling.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48906, 22104, 'Entecavir', 'Kidney Diseases', 'Entecavir is primarily eliminated by the kidney.  Compared to patients with normal renal function (CrCl above 80 mL/min), peak plasma concentration (Cmax) and systemic exposure (AUC) of a single 1 mg dose of entecavir increased by 30% and 150%, respectively, in patients with moderate renal dysfunction (CrCl 30 to 49 mL/min), and 89% and 422%, respectively, in patients with severe renal dysfunction (CrCl below 30 mL/min).  Systemic exposure was increased even further in patients with end-stage renal disease managed on dialysis.  These patients had an approximately 8-fold increase in entecavir AUC compared to patients with normal renal function.  Renal clearance of entecavir decreased by 65% and 89%, respectively, in patients with moderate and severe renal dysfunction.  Dosage adjustment of entecavir is recommended for patients with CrCl below 50 mL/min, including patients on dialysis, in accordance with the manufacturer''s product labeling.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48907, 27960, 'Entecavir', 'Kidney Diseases', 'Entecavir is primarily eliminated by the kidney.  Compared to patients with normal renal function (CrCl above 80 mL/min), peak plasma concentration (Cmax) and systemic exposure (AUC) of a single 1 mg dose of entecavir increased by 30% and 150%, respectively, in patients with moderate renal dysfunction (CrCl 30 to 49 mL/min), and 89% and 422%, respectively, in patients with severe renal dysfunction (CrCl below 30 mL/min).  Systemic exposure was increased even further in patients with end-stage renal disease managed on dialysis.  These patients had an approximately 8-fold increase in entecavir AUC compared to patients with normal renal function.  Renal clearance of entecavir decreased by 65% and 89%, respectively, in patients with moderate and severe renal dysfunction.  Dosage adjustment of entecavir is recommended for patients with CrCl below 50 mL/min, including patients on dialysis, in accordance with the manufacturer''s product labeling.', '2', '"Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48908, 352, 'Enoxaparin', 'Hemophilia A', 'Anticoagulants should be given with extreme caution to patients with hemophilia or other congenital or acquired bleeding tendencies.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48909, 2752, 'Enoxaparin', 'Hemophilia A', 'Anticoagulants should be given with extreme caution to patients with hemophilia or other congenital or acquired bleeding tendencies.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48910, 7580, 'Enoxaparin', 'Hemophilia A', 'Anticoagulants should be given with extreme caution to patients with hemophilia or other congenital or acquired bleeding tendencies.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48911, 16504, 'Enoxaparin', 'Hemophilia A', 'Anticoagulants should be given with extreme caution to patients with hemophilia or other congenital or acquired bleeding tendencies.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48912, 16505, 'Enoxaparin', 'Hemophilia A', 'Anticoagulants should be given with extreme caution to patients with hemophilia or other congenital or acquired bleeding tendencies.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48913, 16507, 'Enoxaparin', 'Hemophilia A', 'Anticoagulants should be given with extreme caution to patients with hemophilia or other congenital or acquired bleeding tendencies.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48914, 19551, 'Enoxaparin', 'Hemophilia A', 'Anticoagulants should be given with extreme caution to patients with hemophilia or other congenital or acquired bleeding tendencies.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48915, 22078, 'Enoxaparin', 'Hemophilia A', 'Anticoagulants should be given with extreme caution to patients with hemophilia or other congenital or acquired bleeding tendencies.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48916, 30506, 'Enoxaparin', 'Hemophilia A', 'Anticoagulants should be given with extreme caution to patients with hemophilia or other congenital or acquired bleeding tendencies.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48917, 31856, 'Enoxaparin', 'Hemophilia A', 'Anticoagulants should be given with extreme caution to patients with hemophilia or other congenital or acquired bleeding tendencies.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48918, 352, 'Enoxaparin', 'Liver Diseases', 'Anticoagulants should be given with extreme caution to patients at increased risk for hemorrhage, including patients who have severe liver disease with impaired hemostasis.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48919, 2752, 'Enoxaparin', 'Liver Diseases', 'Anticoagulants should be given with extreme caution to patients at increased risk for hemorrhage, including patients who have severe liver disease with impaired hemostasis.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48920, 7580, 'Enoxaparin', 'Liver Diseases', 'Anticoagulants should be given with extreme caution to patients at increased risk for hemorrhage, including patients who have severe liver disease with impaired hemostasis.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48921, 16504, 'Enoxaparin', 'Liver Diseases', 'Anticoagulants should be given with extreme caution to patients at increased risk for hemorrhage, including patients who have severe liver disease with impaired hemostasis.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48922, 16505, 'Enoxaparin', 'Liver Diseases', 'Anticoagulants should be given with extreme caution to patients at increased risk for hemorrhage, including patients who have severe liver disease with impaired hemostasis.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48923, 16507, 'Enoxaparin', 'Liver Diseases', 'Anticoagulants should be given with extreme caution to patients at increased risk for hemorrhage, including patients who have severe liver disease with impaired hemostasis.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48924, 19551, 'Enoxaparin', 'Liver Diseases', 'Anticoagulants should be given with extreme caution to patients at increased risk for hemorrhage, including patients who have severe liver disease with impaired hemostasis.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48925, 22078, 'Enoxaparin', 'Liver Diseases', 'Anticoagulants should be given with extreme caution to patients at increased risk for hemorrhage, including patients who have severe liver disease with impaired hemostasis.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48926, 30506, 'Enoxaparin', 'Liver Diseases', 'Anticoagulants should be given with extreme caution to patients at increased risk for hemorrhage, including patients who have severe liver disease with impaired hemostasis.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48927, 31856, 'Enoxaparin', 'Liver Diseases', 'Anticoagulants should be given with extreme caution to patients at increased risk for hemorrhage, including patients who have severe liver disease with impaired hemostasis.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48928, 352, 'Enoxaparin', 'Peptic Ulcer', 'Anticoagulants are contraindicated in patients with active major bleeding or those patients at risk for hemorrhage.  Hemorrhage due to heparin derivatives may be treated with protamine sulfate 1%.  However, protamine sulfate may not completely neutralize the anti- Factor Xa activity.', '3', 'Oates JA, Wood AJJ "Heparin." N Engl J Med 324 (1991):  1565-74|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Walker AM, Jick H "Predictors of bleeding during heparin therapy." JAMA 244 (1980):  1209-12|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Breddin HK "Low molecular weight heparins and bleeding." Semin Thromb Hemost 15 (1989):  401-4|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Hirsh J, Fuster V "Guide to anticoagulant therapy. 1. Heparin." Circulation 89 (1994):  1449-68|Sugiyama T, Itoh M, Ohtawa M, Natsuga T "Study on neutralization of low molecular weight heparin (LHG) by  protamine sulfate and its neutralization characteristics." Thromb Res 68 (1992):  119-29|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48929, 2752, 'Enoxaparin', 'Peptic Ulcer', 'Anticoagulants are contraindicated in patients with active major bleeding or those patients at risk for hemorrhage.  Hemorrhage due to heparin derivatives may be treated with protamine sulfate 1%.  However, protamine sulfate may not completely neutralize the anti- Factor Xa activity.', '3', 'Oates JA, Wood AJJ "Heparin." N Engl J Med 324 (1991):  1565-74|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Walker AM, Jick H "Predictors of bleeding during heparin therapy." JAMA 244 (1980):  1209-12|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Breddin HK "Low molecular weight heparins and bleeding." Semin Thromb Hemost 15 (1989):  401-4|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Hirsh J, Fuster V "Guide to anticoagulant therapy. 1. Heparin." Circulation 89 (1994):  1449-68|Sugiyama T, Itoh M, Ohtawa M, Natsuga T "Study on neutralization of low molecular weight heparin (LHG) by  protamine sulfate and its neutralization characteristics." Thromb Res 68 (1992):  119-29|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48930, 7580, 'Enoxaparin', 'Peptic Ulcer', 'Anticoagulants are contraindicated in patients with active major bleeding or those patients at risk for hemorrhage.  Hemorrhage due to heparin derivatives may be treated with protamine sulfate 1%.  However, protamine sulfate may not completely neutralize the anti- Factor Xa activity.', '3', 'Oates JA, Wood AJJ "Heparin." N Engl J Med 324 (1991):  1565-74|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Walker AM, Jick H "Predictors of bleeding during heparin therapy." JAMA 244 (1980):  1209-12|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Breddin HK "Low molecular weight heparins and bleeding." Semin Thromb Hemost 15 (1989):  401-4|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Hirsh J, Fuster V "Guide to anticoagulant therapy. 1. Heparin." Circulation 89 (1994):  1449-68|Sugiyama T, Itoh M, Ohtawa M, Natsuga T "Study on neutralization of low molecular weight heparin (LHG) by  protamine sulfate and its neutralization characteristics." Thromb Res 68 (1992):  119-29|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48931, 16504, 'Enoxaparin', 'Peptic Ulcer', 'Anticoagulants are contraindicated in patients with active major bleeding or those patients at risk for hemorrhage.  Hemorrhage due to heparin derivatives may be treated with protamine sulfate 1%.  However, protamine sulfate may not completely neutralize the anti- Factor Xa activity.', '3', 'Oates JA, Wood AJJ "Heparin." N Engl J Med 324 (1991):  1565-74|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Walker AM, Jick H "Predictors of bleeding during heparin therapy." JAMA 244 (1980):  1209-12|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Breddin HK "Low molecular weight heparins and bleeding." Semin Thromb Hemost 15 (1989):  401-4|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Hirsh J, Fuster V "Guide to anticoagulant therapy. 1. Heparin." Circulation 89 (1994):  1449-68|Sugiyama T, Itoh M, Ohtawa M, Natsuga T "Study on neutralization of low molecular weight heparin (LHG) by  protamine sulfate and its neutralization characteristics." Thromb Res 68 (1992):  119-29|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48932, 16505, 'Enoxaparin', 'Peptic Ulcer', 'Anticoagulants are contraindicated in patients with active major bleeding or those patients at risk for hemorrhage.  Hemorrhage due to heparin derivatives may be treated with protamine sulfate 1%.  However, protamine sulfate may not completely neutralize the anti- Factor Xa activity.', '3', 'Oates JA, Wood AJJ "Heparin." N Engl J Med 324 (1991):  1565-74|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Walker AM, Jick H "Predictors of bleeding during heparin therapy." JAMA 244 (1980):  1209-12|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Breddin HK "Low molecular weight heparins and bleeding." Semin Thromb Hemost 15 (1989):  401-4|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Hirsh J, Fuster V "Guide to anticoagulant therapy. 1. Heparin." Circulation 89 (1994):  1449-68|Sugiyama T, Itoh M, Ohtawa M, Natsuga T "Study on neutralization of low molecular weight heparin (LHG) by  protamine sulfate and its neutralization characteristics." Thromb Res 68 (1992):  119-29|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48933, 16507, 'Enoxaparin', 'Peptic Ulcer', 'Anticoagulants are contraindicated in patients with active major bleeding or those patients at risk for hemorrhage.  Hemorrhage due to heparin derivatives may be treated with protamine sulfate 1%.  However, protamine sulfate may not completely neutralize the anti- Factor Xa activity.', '3', 'Oates JA, Wood AJJ "Heparin." N Engl J Med 324 (1991):  1565-74|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Walker AM, Jick H "Predictors of bleeding during heparin therapy." JAMA 244 (1980):  1209-12|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Breddin HK "Low molecular weight heparins and bleeding." Semin Thromb Hemost 15 (1989):  401-4|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Hirsh J, Fuster V "Guide to anticoagulant therapy. 1. Heparin." Circulation 89 (1994):  1449-68|Sugiyama T, Itoh M, Ohtawa M, Natsuga T "Study on neutralization of low molecular weight heparin (LHG) by  protamine sulfate and its neutralization characteristics." Thromb Res 68 (1992):  119-29|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48934, 19551, 'Enoxaparin', 'Peptic Ulcer', 'Anticoagulants are contraindicated in patients with active major bleeding or those patients at risk for hemorrhage.  Hemorrhage due to heparin derivatives may be treated with protamine sulfate 1%.  However, protamine sulfate may not completely neutralize the anti- Factor Xa activity.', '3', 'Oates JA, Wood AJJ "Heparin." N Engl J Med 324 (1991):  1565-74|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Walker AM, Jick H "Predictors of bleeding during heparin therapy." JAMA 244 (1980):  1209-12|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Breddin HK "Low molecular weight heparins and bleeding." Semin Thromb Hemost 15 (1989):  401-4|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Hirsh J, Fuster V "Guide to anticoagulant therapy. 1. Heparin." Circulation 89 (1994):  1449-68|Sugiyama T, Itoh M, Ohtawa M, Natsuga T "Study on neutralization of low molecular weight heparin (LHG) by  protamine sulfate and its neutralization characteristics." Thromb Res 68 (1992):  119-29|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48935, 22078, 'Enoxaparin', 'Peptic Ulcer', 'Anticoagulants are contraindicated in patients with active major bleeding or those patients at risk for hemorrhage.  Hemorrhage due to heparin derivatives may be treated with protamine sulfate 1%.  However, protamine sulfate may not completely neutralize the anti- Factor Xa activity.', '3', 'Oates JA, Wood AJJ "Heparin." N Engl J Med 324 (1991):  1565-74|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Walker AM, Jick H "Predictors of bleeding during heparin therapy." JAMA 244 (1980):  1209-12|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Breddin HK "Low molecular weight heparins and bleeding." Semin Thromb Hemost 15 (1989):  401-4|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Hirsh J, Fuster V "Guide to anticoagulant therapy. 1. Heparin." Circulation 89 (1994):  1449-68|Sugiyama T, Itoh M, Ohtawa M, Natsuga T "Study on neutralization of low molecular weight heparin (LHG) by  protamine sulfate and its neutralization characteristics." Thromb Res 68 (1992):  119-29|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48936, 30506, 'Enoxaparin', 'Peptic Ulcer', 'Anticoagulants are contraindicated in patients with active major bleeding or those patients at risk for hemorrhage.  Hemorrhage due to heparin derivatives may be treated with protamine sulfate 1%.  However, protamine sulfate may not completely neutralize the anti- Factor Xa activity.', '3', 'Oates JA, Wood AJJ "Heparin." N Engl J Med 324 (1991):  1565-74|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Walker AM, Jick H "Predictors of bleeding during heparin therapy." JAMA 244 (1980):  1209-12|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Breddin HK "Low molecular weight heparins and bleeding." Semin Thromb Hemost 15 (1989):  401-4|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Hirsh J, Fuster V "Guide to anticoagulant therapy. 1. Heparin." Circulation 89 (1994):  1449-68|Sugiyama T, Itoh M, Ohtawa M, Natsuga T "Study on neutralization of low molecular weight heparin (LHG) by  protamine sulfate and its neutralization characteristics." Thromb Res 68 (1992):  119-29|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48937, 31856, 'Enoxaparin', 'Peptic Ulcer', 'Anticoagulants are contraindicated in patients with active major bleeding or those patients at risk for hemorrhage.  Hemorrhage due to heparin derivatives may be treated with protamine sulfate 1%.  However, protamine sulfate may not completely neutralize the anti- Factor Xa activity.', '3', 'Oates JA, Wood AJJ "Heparin." N Engl J Med 324 (1991):  1565-74|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Walker AM, Jick H "Predictors of bleeding during heparin therapy." JAMA 244 (1980):  1209-12|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Breddin HK "Low molecular weight heparins and bleeding." Semin Thromb Hemost 15 (1989):  401-4|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Hirsh J, Fuster V "Guide to anticoagulant therapy. 1. Heparin." Circulation 89 (1994):  1449-68|Sugiyama T, Itoh M, Ohtawa M, Natsuga T "Study on neutralization of low molecular weight heparin (LHG) by  protamine sulfate and its neutralization characteristics." Thromb Res 68 (1992):  119-29|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48938, 352, 'Enoxaparin', 'Diabetic Retinopathy', 'The use of anticoagulants may increase the risk of bleeding in patients with hypertensive or diabetic retinopathy.  Therapy with anticoagulants should be administered with extreme caution in such patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48939, 2752, 'Enoxaparin', 'Diabetic Retinopathy', 'The use of anticoagulants may increase the risk of bleeding in patients with hypertensive or diabetic retinopathy.  Therapy with anticoagulants should be administered with extreme caution in such patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48940, 7580, 'Enoxaparin', 'Diabetic Retinopathy', 'The use of anticoagulants may increase the risk of bleeding in patients with hypertensive or diabetic retinopathy.  Therapy with anticoagulants should be administered with extreme caution in such patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48941, 16504, 'Enoxaparin', 'Diabetic Retinopathy', 'The use of anticoagulants may increase the risk of bleeding in patients with hypertensive or diabetic retinopathy.  Therapy with anticoagulants should be administered with extreme caution in such patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48942, 16505, 'Enoxaparin', 'Diabetic Retinopathy', 'The use of anticoagulants may increase the risk of bleeding in patients with hypertensive or diabetic retinopathy.  Therapy with anticoagulants should be administered with extreme caution in such patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48943, 16507, 'Enoxaparin', 'Diabetic Retinopathy', 'The use of anticoagulants may increase the risk of bleeding in patients with hypertensive or diabetic retinopathy.  Therapy with anticoagulants should be administered with extreme caution in such patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48944, 19551, 'Enoxaparin', 'Diabetic Retinopathy', 'The use of anticoagulants may increase the risk of bleeding in patients with hypertensive or diabetic retinopathy.  Therapy with anticoagulants should be administered with extreme caution in such patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48945, 22078, 'Enoxaparin', 'Diabetic Retinopathy', 'The use of anticoagulants may increase the risk of bleeding in patients with hypertensive or diabetic retinopathy.  Therapy with anticoagulants should be administered with extreme caution in such patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48946, 30506, 'Enoxaparin', 'Diabetic Retinopathy', 'The use of anticoagulants may increase the risk of bleeding in patients with hypertensive or diabetic retinopathy.  Therapy with anticoagulants should be administered with extreme caution in such patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48947, 31856, 'Enoxaparin', 'Diabetic Retinopathy', 'The use of anticoagulants may increase the risk of bleeding in patients with hypertensive or diabetic retinopathy.  Therapy with anticoagulants should be administered with extreme caution in such patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48948, 352, 'Enoxaparin', 'Endocarditis, Subacute Bacterial', 'Anticoagulants should be given with extreme caution to patients with subacute bacterial endocarditis.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48949, 2752, 'Enoxaparin', 'Endocarditis, Subacute Bacterial', 'Anticoagulants should be given with extreme caution to patients with subacute bacterial endocarditis.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48950, 7580, 'Enoxaparin', 'Endocarditis, Subacute Bacterial', 'Anticoagulants should be given with extreme caution to patients with subacute bacterial endocarditis.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48951, 16504, 'Enoxaparin', 'Endocarditis, Subacute Bacterial', 'Anticoagulants should be given with extreme caution to patients with subacute bacterial endocarditis.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48952, 16505, 'Enoxaparin', 'Endocarditis, Subacute Bacterial', 'Anticoagulants should be given with extreme caution to patients with subacute bacterial endocarditis.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48953, 16507, 'Enoxaparin', 'Endocarditis, Subacute Bacterial', 'Anticoagulants should be given with extreme caution to patients with subacute bacterial endocarditis.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48954, 19551, 'Enoxaparin', 'Endocarditis, Subacute Bacterial', 'Anticoagulants should be given with extreme caution to patients with subacute bacterial endocarditis.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48955, 22078, 'Enoxaparin', 'Endocarditis, Subacute Bacterial', 'Anticoagulants should be given with extreme caution to patients with subacute bacterial endocarditis.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48956, 30506, 'Enoxaparin', 'Endocarditis, Subacute Bacterial', 'Anticoagulants should be given with extreme caution to patients with subacute bacterial endocarditis.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48957, 31856, 'Enoxaparin', 'Endocarditis, Subacute Bacterial', 'Anticoagulants should be given with extreme caution to patients with subacute bacterial endocarditis.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48958, 352, 'Enoxaparin', 'Hemorrhage', 'The use of heparin is contraindicated in patients with uncontrollable active bleeding, except when the bleeding is due to disseminated intravascular coagulation.  Hemorrhage can occur at virtually any site in patients receiving heparin.  An unexplained drop in hematocrit or blood pressure, or any other unexplained symptom, should lead to serious consideration of a hemorrhagic event.  Therapy with heparin should be used with extreme caution in patients with known bleeding disorders or disease states that may predispose to hemorrhage during heparin administration, including hemophilia, thrombocytopenia, certain vascular purpuras, ulcerative gastrointestinal lesions, diverticulitis, ulcerative colitis, severe liver disease, subacute bacterial endocarditis, severe hypertension, myeloproliferative disorders, and threatened abortion.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  There is usually no need to monitor coagulation parameters in patients receiving low-dose heparin, except in patients undergoing major surgery.  For low molecular weight heparin (LMWH), coagulation tests such as prothrombin time (PT) and aPTT are relatively insensitive measures of LMWH activity and not suitable for routine monitoring.  Anti-Factor Xa may be used to monitor the anticoagulant effect of LMWH in patients with significant renal impairment, abnormal coagulation parameters, or bleeding during therapy.', '3', 'Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48959, 2752, 'Enoxaparin', 'Hemorrhage', 'The use of heparin is contraindicated in patients with uncontrollable active bleeding, except when the bleeding is due to disseminated intravascular coagulation.  Hemorrhage can occur at virtually any site in patients receiving heparin.  An unexplained drop in hematocrit or blood pressure, or any other unexplained symptom, should lead to serious consideration of a hemorrhagic event.  Therapy with heparin should be used with extreme caution in patients with known bleeding disorders or disease states that may predispose to hemorrhage during heparin administration, including hemophilia, thrombocytopenia, certain vascular purpuras, ulcerative gastrointestinal lesions, diverticulitis, ulcerative colitis, severe liver disease, subacute bacterial endocarditis, severe hypertension, myeloproliferative disorders, and threatened abortion.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  There is usually no need to monitor coagulation parameters in patients receiving low-dose heparin, except in patients undergoing major surgery.  For low molecular weight heparin (LMWH), coagulation tests such as prothrombin time (PT) and aPTT are relatively insensitive measures of LMWH activity and not suitable for routine monitoring.  Anti-Factor Xa may be used to monitor the anticoagulant effect of LMWH in patients with significant renal impairment, abnormal coagulation parameters, or bleeding during therapy.', '3', 'Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48960, 7580, 'Enoxaparin', 'Hemorrhage', 'The use of heparin is contraindicated in patients with uncontrollable active bleeding, except when the bleeding is due to disseminated intravascular coagulation.  Hemorrhage can occur at virtually any site in patients receiving heparin.  An unexplained drop in hematocrit or blood pressure, or any other unexplained symptom, should lead to serious consideration of a hemorrhagic event.  Therapy with heparin should be used with extreme caution in patients with known bleeding disorders or disease states that may predispose to hemorrhage during heparin administration, including hemophilia, thrombocytopenia, certain vascular purpuras, ulcerative gastrointestinal lesions, diverticulitis, ulcerative colitis, severe liver disease, subacute bacterial endocarditis, severe hypertension, myeloproliferative disorders, and threatened abortion.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  There is usually no need to monitor coagulation parameters in patients receiving low-dose heparin, except in patients undergoing major surgery.  For low molecular weight heparin (LMWH), coagulation tests such as prothrombin time (PT) and aPTT are relatively insensitive measures of LMWH activity and not suitable for routine monitoring.  Anti-Factor Xa may be used to monitor the anticoagulant effect of LMWH in patients with significant renal impairment, abnormal coagulation parameters, or bleeding during therapy.', '3', 'Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48961, 16504, 'Enoxaparin', 'Hemorrhage', 'The use of heparin is contraindicated in patients with uncontrollable active bleeding, except when the bleeding is due to disseminated intravascular coagulation.  Hemorrhage can occur at virtually any site in patients receiving heparin.  An unexplained drop in hematocrit or blood pressure, or any other unexplained symptom, should lead to serious consideration of a hemorrhagic event.  Therapy with heparin should be used with extreme caution in patients with known bleeding disorders or disease states that may predispose to hemorrhage during heparin administration, including hemophilia, thrombocytopenia, certain vascular purpuras, ulcerative gastrointestinal lesions, diverticulitis, ulcerative colitis, severe liver disease, subacute bacterial endocarditis, severe hypertension, myeloproliferative disorders, and threatened abortion.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  There is usually no need to monitor coagulation parameters in patients receiving low-dose heparin, except in patients undergoing major surgery.  For low molecular weight heparin (LMWH), coagulation tests such as prothrombin time (PT) and aPTT are relatively insensitive measures of LMWH activity and not suitable for routine monitoring.  Anti-Factor Xa may be used to monitor the anticoagulant effect of LMWH in patients with significant renal impairment, abnormal coagulation parameters, or bleeding during therapy.', '3', 'Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48962, 16505, 'Enoxaparin', 'Hemorrhage', 'The use of heparin is contraindicated in patients with uncontrollable active bleeding, except when the bleeding is due to disseminated intravascular coagulation.  Hemorrhage can occur at virtually any site in patients receiving heparin.  An unexplained drop in hematocrit or blood pressure, or any other unexplained symptom, should lead to serious consideration of a hemorrhagic event.  Therapy with heparin should be used with extreme caution in patients with known bleeding disorders or disease states that may predispose to hemorrhage during heparin administration, including hemophilia, thrombocytopenia, certain vascular purpuras, ulcerative gastrointestinal lesions, diverticulitis, ulcerative colitis, severe liver disease, subacute bacterial endocarditis, severe hypertension, myeloproliferative disorders, and threatened abortion.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  There is usually no need to monitor coagulation parameters in patients receiving low-dose heparin, except in patients undergoing major surgery.  For low molecular weight heparin (LMWH), coagulation tests such as prothrombin time (PT) and aPTT are relatively insensitive measures of LMWH activity and not suitable for routine monitoring.  Anti-Factor Xa may be used to monitor the anticoagulant effect of LMWH in patients with significant renal impairment, abnormal coagulation parameters, or bleeding during therapy.', '3', 'Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48963, 16507, 'Enoxaparin', 'Hemorrhage', 'The use of heparin is contraindicated in patients with uncontrollable active bleeding, except when the bleeding is due to disseminated intravascular coagulation.  Hemorrhage can occur at virtually any site in patients receiving heparin.  An unexplained drop in hematocrit or blood pressure, or any other unexplained symptom, should lead to serious consideration of a hemorrhagic event.  Therapy with heparin should be used with extreme caution in patients with known bleeding disorders or disease states that may predispose to hemorrhage during heparin administration, including hemophilia, thrombocytopenia, certain vascular purpuras, ulcerative gastrointestinal lesions, diverticulitis, ulcerative colitis, severe liver disease, subacute bacterial endocarditis, severe hypertension, myeloproliferative disorders, and threatened abortion.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  There is usually no need to monitor coagulation parameters in patients receiving low-dose heparin, except in patients undergoing major surgery.  For low molecular weight heparin (LMWH), coagulation tests such as prothrombin time (PT) and aPTT are relatively insensitive measures of LMWH activity and not suitable for routine monitoring.  Anti-Factor Xa may be used to monitor the anticoagulant effect of LMWH in patients with significant renal impairment, abnormal coagulation parameters, or bleeding during therapy.', '3', 'Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48964, 19551, 'Enoxaparin', 'Hemorrhage', 'The use of heparin is contraindicated in patients with uncontrollable active bleeding, except when the bleeding is due to disseminated intravascular coagulation.  Hemorrhage can occur at virtually any site in patients receiving heparin.  An unexplained drop in hematocrit or blood pressure, or any other unexplained symptom, should lead to serious consideration of a hemorrhagic event.  Therapy with heparin should be used with extreme caution in patients with known bleeding disorders or disease states that may predispose to hemorrhage during heparin administration, including hemophilia, thrombocytopenia, certain vascular purpuras, ulcerative gastrointestinal lesions, diverticulitis, ulcerative colitis, severe liver disease, subacute bacterial endocarditis, severe hypertension, myeloproliferative disorders, and threatened abortion.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  There is usually no need to monitor coagulation parameters in patients receiving low-dose heparin, except in patients undergoing major surgery.  For low molecular weight heparin (LMWH), coagulation tests such as prothrombin time (PT) and aPTT are relatively insensitive measures of LMWH activity and not suitable for routine monitoring.  Anti-Factor Xa may be used to monitor the anticoagulant effect of LMWH in patients with significant renal impairment, abnormal coagulation parameters, or bleeding during therapy.', '3', 'Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48965, 22078, 'Enoxaparin', 'Hemorrhage', 'The use of heparin is contraindicated in patients with uncontrollable active bleeding, except when the bleeding is due to disseminated intravascular coagulation.  Hemorrhage can occur at virtually any site in patients receiving heparin.  An unexplained drop in hematocrit or blood pressure, or any other unexplained symptom, should lead to serious consideration of a hemorrhagic event.  Therapy with heparin should be used with extreme caution in patients with known bleeding disorders or disease states that may predispose to hemorrhage during heparin administration, including hemophilia, thrombocytopenia, certain vascular purpuras, ulcerative gastrointestinal lesions, diverticulitis, ulcerative colitis, severe liver disease, subacute bacterial endocarditis, severe hypertension, myeloproliferative disorders, and threatened abortion.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  There is usually no need to monitor coagulation parameters in patients receiving low-dose heparin, except in patients undergoing major surgery.  For low molecular weight heparin (LMWH), coagulation tests such as prothrombin time (PT) and aPTT are relatively insensitive measures of LMWH activity and not suitable for routine monitoring.  Anti-Factor Xa may be used to monitor the anticoagulant effect of LMWH in patients with significant renal impairment, abnormal coagulation parameters, or bleeding during therapy.', '3', 'Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48966, 30506, 'Enoxaparin', 'Hemorrhage', 'The use of heparin is contraindicated in patients with uncontrollable active bleeding, except when the bleeding is due to disseminated intravascular coagulation.  Hemorrhage can occur at virtually any site in patients receiving heparin.  An unexplained drop in hematocrit or blood pressure, or any other unexplained symptom, should lead to serious consideration of a hemorrhagic event.  Therapy with heparin should be used with extreme caution in patients with known bleeding disorders or disease states that may predispose to hemorrhage during heparin administration, including hemophilia, thrombocytopenia, certain vascular purpuras, ulcerative gastrointestinal lesions, diverticulitis, ulcerative colitis, severe liver disease, subacute bacterial endocarditis, severe hypertension, myeloproliferative disorders, and threatened abortion.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  There is usually no need to monitor coagulation parameters in patients receiving low-dose heparin, except in patients undergoing major surgery.  For low molecular weight heparin (LMWH), coagulation tests such as prothrombin time (PT) and aPTT are relatively insensitive measures of LMWH activity and not suitable for routine monitoring.  Anti-Factor Xa may be used to monitor the anticoagulant effect of LMWH in patients with significant renal impairment, abnormal coagulation parameters, or bleeding during therapy.', '3', 'Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48967, 31856, 'Enoxaparin', 'Hemorrhage', 'The use of heparin is contraindicated in patients with uncontrollable active bleeding, except when the bleeding is due to disseminated intravascular coagulation.  Hemorrhage can occur at virtually any site in patients receiving heparin.  An unexplained drop in hematocrit or blood pressure, or any other unexplained symptom, should lead to serious consideration of a hemorrhagic event.  Therapy with heparin should be used with extreme caution in patients with known bleeding disorders or disease states that may predispose to hemorrhage during heparin administration, including hemophilia, thrombocytopenia, certain vascular purpuras, ulcerative gastrointestinal lesions, diverticulitis, ulcerative colitis, severe liver disease, subacute bacterial endocarditis, severe hypertension, myeloproliferative disorders, and threatened abortion.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  There is usually no need to monitor coagulation parameters in patients receiving low-dose heparin, except in patients undergoing major surgery.  For low molecular weight heparin (LMWH), coagulation tests such as prothrombin time (PT) and aPTT are relatively insensitive measures of LMWH activity and not suitable for routine monitoring.  Anti-Factor Xa may be used to monitor the anticoagulant effect of LMWH in patients with significant renal impairment, abnormal coagulation parameters, or bleeding during therapy.', '3', 'Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48968, 352, 'Enoxaparin', 'Hypertension', 'Heparin should be used with extreme caution in patients with uncontrolled or severe hypertension as these conditions may predispose the patient to hemorrhage during heparin administration.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  Clinical monitoring of blood pressure is recommended.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48969, 2752, 'Enoxaparin', 'Hypertension', 'Heparin should be used with extreme caution in patients with uncontrolled or severe hypertension as these conditions may predispose the patient to hemorrhage during heparin administration.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  Clinical monitoring of blood pressure is recommended.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48970, 7580, 'Enoxaparin', 'Hypertension', 'Heparin should be used with extreme caution in patients with uncontrolled or severe hypertension as these conditions may predispose the patient to hemorrhage during heparin administration.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  Clinical monitoring of blood pressure is recommended.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48971, 16504, 'Enoxaparin', 'Hypertension', 'Heparin should be used with extreme caution in patients with uncontrolled or severe hypertension as these conditions may predispose the patient to hemorrhage during heparin administration.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  Clinical monitoring of blood pressure is recommended.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48972, 16505, 'Enoxaparin', 'Hypertension', 'Heparin should be used with extreme caution in patients with uncontrolled or severe hypertension as these conditions may predispose the patient to hemorrhage during heparin administration.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  Clinical monitoring of blood pressure is recommended.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48973, 16507, 'Enoxaparin', 'Hypertension', 'Heparin should be used with extreme caution in patients with uncontrolled or severe hypertension as these conditions may predispose the patient to hemorrhage during heparin administration.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  Clinical monitoring of blood pressure is recommended.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48974, 19551, 'Enoxaparin', 'Hypertension', 'Heparin should be used with extreme caution in patients with uncontrolled or severe hypertension as these conditions may predispose the patient to hemorrhage during heparin administration.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  Clinical monitoring of blood pressure is recommended.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48975, 22078, 'Enoxaparin', 'Hypertension', 'Heparin should be used with extreme caution in patients with uncontrolled or severe hypertension as these conditions may predispose the patient to hemorrhage during heparin administration.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  Clinical monitoring of blood pressure is recommended.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48976, 30506, 'Enoxaparin', 'Hypertension', 'Heparin should be used with extreme caution in patients with uncontrolled or severe hypertension as these conditions may predispose the patient to hemorrhage during heparin administration.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  Clinical monitoring of blood pressure is recommended.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48977, 31856, 'Enoxaparin', 'Hypertension', 'Heparin should be used with extreme caution in patients with uncontrolled or severe hypertension as these conditions may predispose the patient to hemorrhage during heparin administration.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  Clinical monitoring of blood pressure is recommended.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48978, 352, 'Enoxaparin', 'Kidney Diseases', 'Systemic exposure and the risk of bleeding may be increased when heparin is used in the presence of severe renal impairment.  Therapy with heparin should be administered cautiously in patients with significantly impaired renal function.  A reduction in dosage may be necessary.', '3', 'Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48979, 2752, 'Enoxaparin', 'Kidney Diseases', 'Systemic exposure and the risk of bleeding may be increased when heparin is used in the presence of severe renal impairment.  Therapy with heparin should be administered cautiously in patients with significantly impaired renal function.  A reduction in dosage may be necessary.', '3', 'Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48980, 7580, 'Enoxaparin', 'Kidney Diseases', 'Systemic exposure and the risk of bleeding may be increased when heparin is used in the presence of severe renal impairment.  Therapy with heparin should be administered cautiously in patients with significantly impaired renal function.  A reduction in dosage may be necessary.', '3', 'Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48981, 16504, 'Enoxaparin', 'Kidney Diseases', 'Systemic exposure and the risk of bleeding may be increased when heparin is used in the presence of severe renal impairment.  Therapy with heparin should be administered cautiously in patients with significantly impaired renal function.  A reduction in dosage may be necessary.', '3', 'Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48982, 16505, 'Enoxaparin', 'Kidney Diseases', 'Systemic exposure and the risk of bleeding may be increased when heparin is used in the presence of severe renal impairment.  Therapy with heparin should be administered cautiously in patients with significantly impaired renal function.  A reduction in dosage may be necessary.', '3', 'Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48983, 16507, 'Enoxaparin', 'Kidney Diseases', 'Systemic exposure and the risk of bleeding may be increased when heparin is used in the presence of severe renal impairment.  Therapy with heparin should be administered cautiously in patients with significantly impaired renal function.  A reduction in dosage may be necessary.', '3', 'Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48984, 19551, 'Enoxaparin', 'Kidney Diseases', 'Systemic exposure and the risk of bleeding may be increased when heparin is used in the presence of severe renal impairment.  Therapy with heparin should be administered cautiously in patients with significantly impaired renal function.  A reduction in dosage may be necessary.', '3', 'Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48985, 22078, 'Enoxaparin', 'Kidney Diseases', 'Systemic exposure and the risk of bleeding may be increased when heparin is used in the presence of severe renal impairment.  Therapy with heparin should be administered cautiously in patients with significantly impaired renal function.  A reduction in dosage may be necessary.', '3', 'Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48986, 30506, 'Enoxaparin', 'Kidney Diseases', 'Systemic exposure and the risk of bleeding may be increased when heparin is used in the presence of severe renal impairment.  Therapy with heparin should be administered cautiously in patients with significantly impaired renal function.  A reduction in dosage may be necessary.', '3', 'Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48987, 31856, 'Enoxaparin', 'Kidney Diseases', 'Systemic exposure and the risk of bleeding may be increased when heparin is used in the presence of severe renal impairment.  Therapy with heparin should be administered cautiously in patients with significantly impaired renal function.  A reduction in dosage may be necessary.', '3', 'Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48988, 352, 'Enoxaparin', 'Thrombocytopenia', 'The use of heparin is contraindicated in patients with severe thrombocytopenia.  Acute thrombocytopenia can occur in patients receiving heparin, with a reported incidence of up to 30%.  Platelet counts should be obtained before and periodically during heparin administration, including regular and repeated use of heparin flush solutions if given for longer than 5 days.  Mild thrombocytopenia with counts above 100,000/mm3 may remain stable or reverse despite continued heparin administration.  However, thrombocytopenia of any degree should be closely monitored.  Therapy should be discontinued if the count falls below 100,000/mm3 or if recurrent thrombosis develops, and an alternative, nonheparin anticoagulant (e.g., argatroban, bivalirudin, lepirudin) administered if necessary.  Heparin-induced thrombocytopenia (HIT) is a serious antibody-mediated reaction resulting from irreversible aggregation of platelets.  HIT may progress to the development of venous and arterial thromboses, a condition referred to as heparin-induced thrombocytopenia and thrombosis (HITT).  Thrombotic events may also be the initial presentation for HITT, and may include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, mesenteric thrombosis, renal artery thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death.  Both HIT and HITT can occur up to several weeks after the discontinuation of heparin therapy.  Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT.  Following an episode, any future use of heparin should be avoided, and use of low-molecular weight heparin should consider the potential for cross-reactivity with the HIT antibody and approached with extreme caution, if not otherwise contraindicated.', '3', 'Bell WR, Royall RM "Heparin-associated thrombocytopenia: a comparison of three heparin preparations." N Engl J Med 303 (1980):  902-7|Cines DB, Kaywin P, Bina M, et al. "Heparin-associated thrombocytopenia." N Engl J Med 303 (1980):  788-95|Kelton JG, Sheridan D, Santos A, et al. "Heparin-induced thrombocytopenia: laboratory studies." Blood 72 (1988):  925-30|Chong BH "Heparin-induced thrombocytopenia." Aust N Z J Med 22 (1992):  145-52|Warkentin TE, Hayward CP, Smith CA, et al. "Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia." J Lab Clin Med 120 (1992):  371-9|Bleasel JF, Rasko JE, Rickard KA, Richards G "Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome." Med J Aust 157 (1992):  192-3|Sandler RM, Seifer DB, Morgan K, Pockros PJ, Wypych J, Weiss LM, Schiffman S "Heparin-induced thrombocytopenia and thrombosis: detection and specificity of a platelet-aggregating IgG." Am J Clin Pathol 83 (1985):  760-4|Platell CF, Tan EG "Hypersensitivity reactions to heparin: delayed onset thrombocytopenia and necrotizing skin lesions." Aust N Z J Surg 56 (1986):  621-3|Gruel Y, Lang M, Darnige L, Pacouret G, Dreyfus X, Leroy J, Charbonnier B "Fatal effect of re-exposure to heparin after previous heparin- associated thrombocytopenia and thrombosis ." Lancet 336 (1990):  1077-8|Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A "Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia." Eur J Clin Pharmacol 37 (1989):  415-8|Lecompte T, Luo SK, Stieltjes N, Lecrubier C, et al. "Thrombocytopenia associated with low-molecular-weight heparin." Lancet 338 (1991):  1217|Eichinger S, Kyrle PA, Brenner B, Wagner B, Kapiotis S, Lechner K, Korninger HC "Thrombocytopenia associated with low-molecular-weight heparin" Lancet 337 (1991):  1425-6|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|Kikta MJ, Keller MP, Humphrey PW, Silver D, Towne JB, Tsapogas M "Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?" Surgery 114 (1993):  705-10|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Balestra B, Quadri P, Biasiutti FD, Furlan M, Lammle B "Low molecular weight heparin-induced thrombocytopenia and skin necrosis distant from injection sites." Eur J Haematol 53 (1994):  61-3|Tezcan AZ, Tezcan H, Gastineau DA, Armitage JO, Haire WD "Heparin-induced thrombocytopenia after bone marrow transplantation: report of two cases." Bone Marrow Transplant 14 (1994):  487-90|Munver R, Schulman IC, Wolf DJ, Rosengart TK "Heparin-induced thrombocytopenia and thrombosis: presentation after cardiopulmonary bypass." Ann Thorac Surg 58 (1994):  1764-6|Kleinschmidt S, Seyfert UT "Heparin-associated thrombocytopenia (HAT) - still a diagnostic and therapeutical problem in clinical practice." Angiology 46 (1995):  37-44|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG "Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin." N Engl J Med 332 (1995):  1330-5|Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Anguenot T, Bernard Y, Bassand JP "Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia." Am J Hematol 50 (1995):  20-5|Shumate MJ "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1006-7|Hougardy N, Machiels JP, Ravoet C "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Warkentin TE, Hirsh J, Kelton JG "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Ramakrishna R, Manoharan A, Kwan YL, Kyle PW "Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (fragmin) and heparinoid, danaparoid (orgaran)." Br J Haematol 91 (1995):  736-8|Force RW "Heparin-induced thrombocytopenia." Am J Health Syst Pharm 52 (1995):  2528|Luzzatto G, Cordiano I, Patrassi G, Fabris F "Heparin-induced thrombocytopenia: discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use." Thromb Haemost 75 (1996):  211-2|Peters FPJ, Doevendans PAFM, Erdkamp FLG, Vanderent FWC, Deheer F "Low molecular weight heparin-induced thrombocytopenia and thrombosis." Eur J Haematol 56 (1996):  329-30|Slocum MM, Adams JG, Teel R, Spadone DP, Silver D "Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome." J Vasc Surg 23 (1996):  839-43|Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T "Heparin-induced thrombocytopenia in hemodialysis patients." Am J Kidney Dis 28 (1996):  82-5|Rizzieri DA, Wong WM, Gockerman JP "Thrombocytosis associated with low-molecular-weight heparin." Ann Intern Med 125 (1996):  157|Chong BH, Magnani HN "Orgaran in heparin-induced thrombocytopenia." Haemostasis 22 (1992):  85-91|Magnani HN "Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172) [published erratum appears in Thromb Haemost 1993 Dec 20;70(6):1072]." Thromb Haemost 70 (1993):  554-61|Rice P, Dace S, Mcmullin MF, Clements WDB "Heparin induced thrombocytopenia causing life-threatening postoperative haemorrhage." Br J Clin Pract 50 (1996):  404-5|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48989, 2752, 'Enoxaparin', 'Thrombocytopenia', 'The use of heparin is contraindicated in patients with severe thrombocytopenia.  Acute thrombocytopenia can occur in patients receiving heparin, with a reported incidence of up to 30%.  Platelet counts should be obtained before and periodically during heparin administration, including regular and repeated use of heparin flush solutions if given for longer than 5 days.  Mild thrombocytopenia with counts above 100,000/mm3 may remain stable or reverse despite continued heparin administration.  However, thrombocytopenia of any degree should be closely monitored.  Therapy should be discontinued if the count falls below 100,000/mm3 or if recurrent thrombosis develops, and an alternative, nonheparin anticoagulant (e.g., argatroban, bivalirudin, lepirudin) administered if necessary.  Heparin-induced thrombocytopenia (HIT) is a serious antibody-mediated reaction resulting from irreversible aggregation of platelets.  HIT may progress to the development of venous and arterial thromboses, a condition referred to as heparin-induced thrombocytopenia and thrombosis (HITT).  Thrombotic events may also be the initial presentation for HITT, and may include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, mesenteric thrombosis, renal artery thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death.  Both HIT and HITT can occur up to several weeks after the discontinuation of heparin therapy.  Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT.  Following an episode, any future use of heparin should be avoided, and use of low-molecular weight heparin should consider the potential for cross-reactivity with the HIT antibody and approached with extreme caution, if not otherwise contraindicated.', '3', 'Bell WR, Royall RM "Heparin-associated thrombocytopenia: a comparison of three heparin preparations." N Engl J Med 303 (1980):  902-7|Cines DB, Kaywin P, Bina M, et al. "Heparin-associated thrombocytopenia." N Engl J Med 303 (1980):  788-95|Kelton JG, Sheridan D, Santos A, et al. "Heparin-induced thrombocytopenia: laboratory studies." Blood 72 (1988):  925-30|Chong BH "Heparin-induced thrombocytopenia." Aust N Z J Med 22 (1992):  145-52|Warkentin TE, Hayward CP, Smith CA, et al. "Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia." J Lab Clin Med 120 (1992):  371-9|Bleasel JF, Rasko JE, Rickard KA, Richards G "Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome." Med J Aust 157 (1992):  192-3|Sandler RM, Seifer DB, Morgan K, Pockros PJ, Wypych J, Weiss LM, Schiffman S "Heparin-induced thrombocytopenia and thrombosis: detection and specificity of a platelet-aggregating IgG." Am J Clin Pathol 83 (1985):  760-4|Platell CF, Tan EG "Hypersensitivity reactions to heparin: delayed onset thrombocytopenia and necrotizing skin lesions." Aust N Z J Surg 56 (1986):  621-3|Gruel Y, Lang M, Darnige L, Pacouret G, Dreyfus X, Leroy J, Charbonnier B "Fatal effect of re-exposure to heparin after previous heparin- associated thrombocytopenia and thrombosis ." Lancet 336 (1990):  1077-8|Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A "Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia." Eur J Clin Pharmacol 37 (1989):  415-8|Lecompte T, Luo SK, Stieltjes N, Lecrubier C, et al. "Thrombocytopenia associated with low-molecular-weight heparin." Lancet 338 (1991):  1217|Eichinger S, Kyrle PA, Brenner B, Wagner B, Kapiotis S, Lechner K, Korninger HC "Thrombocytopenia associated with low-molecular-weight heparin" Lancet 337 (1991):  1425-6|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|Kikta MJ, Keller MP, Humphrey PW, Silver D, Towne JB, Tsapogas M "Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?" Surgery 114 (1993):  705-10|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Balestra B, Quadri P, Biasiutti FD, Furlan M, Lammle B "Low molecular weight heparin-induced thrombocytopenia and skin necrosis distant from injection sites." Eur J Haematol 53 (1994):  61-3|Tezcan AZ, Tezcan H, Gastineau DA, Armitage JO, Haire WD "Heparin-induced thrombocytopenia after bone marrow transplantation: report of two cases." Bone Marrow Transplant 14 (1994):  487-90|Munver R, Schulman IC, Wolf DJ, Rosengart TK "Heparin-induced thrombocytopenia and thrombosis: presentation after cardiopulmonary bypass." Ann Thorac Surg 58 (1994):  1764-6|Kleinschmidt S, Seyfert UT "Heparin-associated thrombocytopenia (HAT) - still a diagnostic and therapeutical problem in clinical practice." Angiology 46 (1995):  37-44|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG "Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin." N Engl J Med 332 (1995):  1330-5|Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Anguenot T, Bernard Y, Bassand JP "Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia." Am J Hematol 50 (1995):  20-5|Shumate MJ "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1006-7|Hougardy N, Machiels JP, Ravoet C "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Warkentin TE, Hirsh J, Kelton JG "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Ramakrishna R, Manoharan A, Kwan YL, Kyle PW "Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (fragmin) and heparinoid, danaparoid (orgaran)." Br J Haematol 91 (1995):  736-8|Force RW "Heparin-induced thrombocytopenia." Am J Health Syst Pharm 52 (1995):  2528|Luzzatto G, Cordiano I, Patrassi G, Fabris F "Heparin-induced thrombocytopenia: discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use." Thromb Haemost 75 (1996):  211-2|Peters FPJ, Doevendans PAFM, Erdkamp FLG, Vanderent FWC, Deheer F "Low molecular weight heparin-induced thrombocytopenia and thrombosis." Eur J Haematol 56 (1996):  329-30|Slocum MM, Adams JG, Teel R, Spadone DP, Silver D "Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome." J Vasc Surg 23 (1996):  839-43|Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T "Heparin-induced thrombocytopenia in hemodialysis patients." Am J Kidney Dis 28 (1996):  82-5|Rizzieri DA, Wong WM, Gockerman JP "Thrombocytosis associated with low-molecular-weight heparin." Ann Intern Med 125 (1996):  157|Chong BH, Magnani HN "Orgaran in heparin-induced thrombocytopenia." Haemostasis 22 (1992):  85-91|Magnani HN "Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172) [published erratum appears in Thromb Haemost 1993 Dec 20;70(6):1072]." Thromb Haemost 70 (1993):  554-61|Rice P, Dace S, Mcmullin MF, Clements WDB "Heparin induced thrombocytopenia causing life-threatening postoperative haemorrhage." Br J Clin Pract 50 (1996):  404-5|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48990, 7580, 'Enoxaparin', 'Thrombocytopenia', 'The use of heparin is contraindicated in patients with severe thrombocytopenia.  Acute thrombocytopenia can occur in patients receiving heparin, with a reported incidence of up to 30%.  Platelet counts should be obtained before and periodically during heparin administration, including regular and repeated use of heparin flush solutions if given for longer than 5 days.  Mild thrombocytopenia with counts above 100,000/mm3 may remain stable or reverse despite continued heparin administration.  However, thrombocytopenia of any degree should be closely monitored.  Therapy should be discontinued if the count falls below 100,000/mm3 or if recurrent thrombosis develops, and an alternative, nonheparin anticoagulant (e.g., argatroban, bivalirudin, lepirudin) administered if necessary.  Heparin-induced thrombocytopenia (HIT) is a serious antibody-mediated reaction resulting from irreversible aggregation of platelets.  HIT may progress to the development of venous and arterial thromboses, a condition referred to as heparin-induced thrombocytopenia and thrombosis (HITT).  Thrombotic events may also be the initial presentation for HITT, and may include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, mesenteric thrombosis, renal artery thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death.  Both HIT and HITT can occur up to several weeks after the discontinuation of heparin therapy.  Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT.  Following an episode, any future use of heparin should be avoided, and use of low-molecular weight heparin should consider the potential for cross-reactivity with the HIT antibody and approached with extreme caution, if not otherwise contraindicated.', '3', 'Bell WR, Royall RM "Heparin-associated thrombocytopenia: a comparison of three heparin preparations." N Engl J Med 303 (1980):  902-7|Cines DB, Kaywin P, Bina M, et al. "Heparin-associated thrombocytopenia." N Engl J Med 303 (1980):  788-95|Kelton JG, Sheridan D, Santos A, et al. "Heparin-induced thrombocytopenia: laboratory studies." Blood 72 (1988):  925-30|Chong BH "Heparin-induced thrombocytopenia." Aust N Z J Med 22 (1992):  145-52|Warkentin TE, Hayward CP, Smith CA, et al. "Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia." J Lab Clin Med 120 (1992):  371-9|Bleasel JF, Rasko JE, Rickard KA, Richards G "Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome." Med J Aust 157 (1992):  192-3|Sandler RM, Seifer DB, Morgan K, Pockros PJ, Wypych J, Weiss LM, Schiffman S "Heparin-induced thrombocytopenia and thrombosis: detection and specificity of a platelet-aggregating IgG." Am J Clin Pathol 83 (1985):  760-4|Platell CF, Tan EG "Hypersensitivity reactions to heparin: delayed onset thrombocytopenia and necrotizing skin lesions." Aust N Z J Surg 56 (1986):  621-3|Gruel Y, Lang M, Darnige L, Pacouret G, Dreyfus X, Leroy J, Charbonnier B "Fatal effect of re-exposure to heparin after previous heparin- associated thrombocytopenia and thrombosis ." Lancet 336 (1990):  1077-8|Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A "Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia." Eur J Clin Pharmacol 37 (1989):  415-8|Lecompte T, Luo SK, Stieltjes N, Lecrubier C, et al. "Thrombocytopenia associated with low-molecular-weight heparin." Lancet 338 (1991):  1217|Eichinger S, Kyrle PA, Brenner B, Wagner B, Kapiotis S, Lechner K, Korninger HC "Thrombocytopenia associated with low-molecular-weight heparin" Lancet 337 (1991):  1425-6|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|Kikta MJ, Keller MP, Humphrey PW, Silver D, Towne JB, Tsapogas M "Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?" Surgery 114 (1993):  705-10|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Balestra B, Quadri P, Biasiutti FD, Furlan M, Lammle B "Low molecular weight heparin-induced thrombocytopenia and skin necrosis distant from injection sites." Eur J Haematol 53 (1994):  61-3|Tezcan AZ, Tezcan H, Gastineau DA, Armitage JO, Haire WD "Heparin-induced thrombocytopenia after bone marrow transplantation: report of two cases." Bone Marrow Transplant 14 (1994):  487-90|Munver R, Schulman IC, Wolf DJ, Rosengart TK "Heparin-induced thrombocytopenia and thrombosis: presentation after cardiopulmonary bypass." Ann Thorac Surg 58 (1994):  1764-6|Kleinschmidt S, Seyfert UT "Heparin-associated thrombocytopenia (HAT) - still a diagnostic and therapeutical problem in clinical practice." Angiology 46 (1995):  37-44|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG "Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin." N Engl J Med 332 (1995):  1330-5|Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Anguenot T, Bernard Y, Bassand JP "Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia." Am J Hematol 50 (1995):  20-5|Shumate MJ "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1006-7|Hougardy N, Machiels JP, Ravoet C "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Warkentin TE, Hirsh J, Kelton JG "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Ramakrishna R, Manoharan A, Kwan YL, Kyle PW "Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (fragmin) and heparinoid, danaparoid (orgaran)." Br J Haematol 91 (1995):  736-8|Force RW "Heparin-induced thrombocytopenia." Am J Health Syst Pharm 52 (1995):  2528|Luzzatto G, Cordiano I, Patrassi G, Fabris F "Heparin-induced thrombocytopenia: discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use." Thromb Haemost 75 (1996):  211-2|Peters FPJ, Doevendans PAFM, Erdkamp FLG, Vanderent FWC, Deheer F "Low molecular weight heparin-induced thrombocytopenia and thrombosis." Eur J Haematol 56 (1996):  329-30|Slocum MM, Adams JG, Teel R, Spadone DP, Silver D "Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome." J Vasc Surg 23 (1996):  839-43|Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T "Heparin-induced thrombocytopenia in hemodialysis patients." Am J Kidney Dis 28 (1996):  82-5|Rizzieri DA, Wong WM, Gockerman JP "Thrombocytosis associated with low-molecular-weight heparin." Ann Intern Med 125 (1996):  157|Chong BH, Magnani HN "Orgaran in heparin-induced thrombocytopenia." Haemostasis 22 (1992):  85-91|Magnani HN "Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172) [published erratum appears in Thromb Haemost 1993 Dec 20;70(6):1072]." Thromb Haemost 70 (1993):  554-61|Rice P, Dace S, Mcmullin MF, Clements WDB "Heparin induced thrombocytopenia causing life-threatening postoperative haemorrhage." Br J Clin Pract 50 (1996):  404-5|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48991, 16504, 'Enoxaparin', 'Thrombocytopenia', 'The use of heparin is contraindicated in patients with severe thrombocytopenia.  Acute thrombocytopenia can occur in patients receiving heparin, with a reported incidence of up to 30%.  Platelet counts should be obtained before and periodically during heparin administration, including regular and repeated use of heparin flush solutions if given for longer than 5 days.  Mild thrombocytopenia with counts above 100,000/mm3 may remain stable or reverse despite continued heparin administration.  However, thrombocytopenia of any degree should be closely monitored.  Therapy should be discontinued if the count falls below 100,000/mm3 or if recurrent thrombosis develops, and an alternative, nonheparin anticoagulant (e.g., argatroban, bivalirudin, lepirudin) administered if necessary.  Heparin-induced thrombocytopenia (HIT) is a serious antibody-mediated reaction resulting from irreversible aggregation of platelets.  HIT may progress to the development of venous and arterial thromboses, a condition referred to as heparin-induced thrombocytopenia and thrombosis (HITT).  Thrombotic events may also be the initial presentation for HITT, and may include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, mesenteric thrombosis, renal artery thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death.  Both HIT and HITT can occur up to several weeks after the discontinuation of heparin therapy.  Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT.  Following an episode, any future use of heparin should be avoided, and use of low-molecular weight heparin should consider the potential for cross-reactivity with the HIT antibody and approached with extreme caution, if not otherwise contraindicated.', '3', 'Bell WR, Royall RM "Heparin-associated thrombocytopenia: a comparison of three heparin preparations." N Engl J Med 303 (1980):  902-7|Cines DB, Kaywin P, Bina M, et al. "Heparin-associated thrombocytopenia." N Engl J Med 303 (1980):  788-95|Kelton JG, Sheridan D, Santos A, et al. "Heparin-induced thrombocytopenia: laboratory studies." Blood 72 (1988):  925-30|Chong BH "Heparin-induced thrombocytopenia." Aust N Z J Med 22 (1992):  145-52|Warkentin TE, Hayward CP, Smith CA, et al. "Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia." J Lab Clin Med 120 (1992):  371-9|Bleasel JF, Rasko JE, Rickard KA, Richards G "Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome." Med J Aust 157 (1992):  192-3|Sandler RM, Seifer DB, Morgan K, Pockros PJ, Wypych J, Weiss LM, Schiffman S "Heparin-induced thrombocytopenia and thrombosis: detection and specificity of a platelet-aggregating IgG." Am J Clin Pathol 83 (1985):  760-4|Platell CF, Tan EG "Hypersensitivity reactions to heparin: delayed onset thrombocytopenia and necrotizing skin lesions." Aust N Z J Surg 56 (1986):  621-3|Gruel Y, Lang M, Darnige L, Pacouret G, Dreyfus X, Leroy J, Charbonnier B "Fatal effect of re-exposure to heparin after previous heparin- associated thrombocytopenia and thrombosis ." Lancet 336 (1990):  1077-8|Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A "Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia." Eur J Clin Pharmacol 37 (1989):  415-8|Lecompte T, Luo SK, Stieltjes N, Lecrubier C, et al. "Thrombocytopenia associated with low-molecular-weight heparin." Lancet 338 (1991):  1217|Eichinger S, Kyrle PA, Brenner B, Wagner B, Kapiotis S, Lechner K, Korninger HC "Thrombocytopenia associated with low-molecular-weight heparin" Lancet 337 (1991):  1425-6|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|Kikta MJ, Keller MP, Humphrey PW, Silver D, Towne JB, Tsapogas M "Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?" Surgery 114 (1993):  705-10|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Balestra B, Quadri P, Biasiutti FD, Furlan M, Lammle B "Low molecular weight heparin-induced thrombocytopenia and skin necrosis distant from injection sites." Eur J Haematol 53 (1994):  61-3|Tezcan AZ, Tezcan H, Gastineau DA, Armitage JO, Haire WD "Heparin-induced thrombocytopenia after bone marrow transplantation: report of two cases." Bone Marrow Transplant 14 (1994):  487-90|Munver R, Schulman IC, Wolf DJ, Rosengart TK "Heparin-induced thrombocytopenia and thrombosis: presentation after cardiopulmonary bypass." Ann Thorac Surg 58 (1994):  1764-6|Kleinschmidt S, Seyfert UT "Heparin-associated thrombocytopenia (HAT) - still a diagnostic and therapeutical problem in clinical practice." Angiology 46 (1995):  37-44|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG "Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin." N Engl J Med 332 (1995):  1330-5|Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Anguenot T, Bernard Y, Bassand JP "Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia." Am J Hematol 50 (1995):  20-5|Shumate MJ "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1006-7|Hougardy N, Machiels JP, Ravoet C "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Warkentin TE, Hirsh J, Kelton JG "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Ramakrishna R, Manoharan A, Kwan YL, Kyle PW "Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (fragmin) and heparinoid, danaparoid (orgaran)." Br J Haematol 91 (1995):  736-8|Force RW "Heparin-induced thrombocytopenia." Am J Health Syst Pharm 52 (1995):  2528|Luzzatto G, Cordiano I, Patrassi G, Fabris F "Heparin-induced thrombocytopenia: discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use." Thromb Haemost 75 (1996):  211-2|Peters FPJ, Doevendans PAFM, Erdkamp FLG, Vanderent FWC, Deheer F "Low molecular weight heparin-induced thrombocytopenia and thrombosis." Eur J Haematol 56 (1996):  329-30|Slocum MM, Adams JG, Teel R, Spadone DP, Silver D "Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome." J Vasc Surg 23 (1996):  839-43|Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T "Heparin-induced thrombocytopenia in hemodialysis patients." Am J Kidney Dis 28 (1996):  82-5|Rizzieri DA, Wong WM, Gockerman JP "Thrombocytosis associated with low-molecular-weight heparin." Ann Intern Med 125 (1996):  157|Chong BH, Magnani HN "Orgaran in heparin-induced thrombocytopenia." Haemostasis 22 (1992):  85-91|Magnani HN "Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172) [published erratum appears in Thromb Haemost 1993 Dec 20;70(6):1072]." Thromb Haemost 70 (1993):  554-61|Rice P, Dace S, Mcmullin MF, Clements WDB "Heparin induced thrombocytopenia causing life-threatening postoperative haemorrhage." Br J Clin Pract 50 (1996):  404-5|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48992, 16505, 'Enoxaparin', 'Thrombocytopenia', 'The use of heparin is contraindicated in patients with severe thrombocytopenia.  Acute thrombocytopenia can occur in patients receiving heparin, with a reported incidence of up to 30%.  Platelet counts should be obtained before and periodically during heparin administration, including regular and repeated use of heparin flush solutions if given for longer than 5 days.  Mild thrombocytopenia with counts above 100,000/mm3 may remain stable or reverse despite continued heparin administration.  However, thrombocytopenia of any degree should be closely monitored.  Therapy should be discontinued if the count falls below 100,000/mm3 or if recurrent thrombosis develops, and an alternative, nonheparin anticoagulant (e.g., argatroban, bivalirudin, lepirudin) administered if necessary.  Heparin-induced thrombocytopenia (HIT) is a serious antibody-mediated reaction resulting from irreversible aggregation of platelets.  HIT may progress to the development of venous and arterial thromboses, a condition referred to as heparin-induced thrombocytopenia and thrombosis (HITT).  Thrombotic events may also be the initial presentation for HITT, and may include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, mesenteric thrombosis, renal artery thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death.  Both HIT and HITT can occur up to several weeks after the discontinuation of heparin therapy.  Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT.  Following an episode, any future use of heparin should be avoided, and use of low-molecular weight heparin should consider the potential for cross-reactivity with the HIT antibody and approached with extreme caution, if not otherwise contraindicated.', '3', 'Bell WR, Royall RM "Heparin-associated thrombocytopenia: a comparison of three heparin preparations." N Engl J Med 303 (1980):  902-7|Cines DB, Kaywin P, Bina M, et al. "Heparin-associated thrombocytopenia." N Engl J Med 303 (1980):  788-95|Kelton JG, Sheridan D, Santos A, et al. "Heparin-induced thrombocytopenia: laboratory studies." Blood 72 (1988):  925-30|Chong BH "Heparin-induced thrombocytopenia." Aust N Z J Med 22 (1992):  145-52|Warkentin TE, Hayward CP, Smith CA, et al. "Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia." J Lab Clin Med 120 (1992):  371-9|Bleasel JF, Rasko JE, Rickard KA, Richards G "Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome." Med J Aust 157 (1992):  192-3|Sandler RM, Seifer DB, Morgan K, Pockros PJ, Wypych J, Weiss LM, Schiffman S "Heparin-induced thrombocytopenia and thrombosis: detection and specificity of a platelet-aggregating IgG." Am J Clin Pathol 83 (1985):  760-4|Platell CF, Tan EG "Hypersensitivity reactions to heparin: delayed onset thrombocytopenia and necrotizing skin lesions." Aust N Z J Surg 56 (1986):  621-3|Gruel Y, Lang M, Darnige L, Pacouret G, Dreyfus X, Leroy J, Charbonnier B "Fatal effect of re-exposure to heparin after previous heparin- associated thrombocytopenia and thrombosis ." Lancet 336 (1990):  1077-8|Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A "Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia." Eur J Clin Pharmacol 37 (1989):  415-8|Lecompte T, Luo SK, Stieltjes N, Lecrubier C, et al. "Thrombocytopenia associated with low-molecular-weight heparin." Lancet 338 (1991):  1217|Eichinger S, Kyrle PA, Brenner B, Wagner B, Kapiotis S, Lechner K, Korninger HC "Thrombocytopenia associated with low-molecular-weight heparin" Lancet 337 (1991):  1425-6|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|Kikta MJ, Keller MP, Humphrey PW, Silver D, Towne JB, Tsapogas M "Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?" Surgery 114 (1993):  705-10|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Balestra B, Quadri P, Biasiutti FD, Furlan M, Lammle B "Low molecular weight heparin-induced thrombocytopenia and skin necrosis distant from injection sites." Eur J Haematol 53 (1994):  61-3|Tezcan AZ, Tezcan H, Gastineau DA, Armitage JO, Haire WD "Heparin-induced thrombocytopenia after bone marrow transplantation: report of two cases." Bone Marrow Transplant 14 (1994):  487-90|Munver R, Schulman IC, Wolf DJ, Rosengart TK "Heparin-induced thrombocytopenia and thrombosis: presentation after cardiopulmonary bypass." Ann Thorac Surg 58 (1994):  1764-6|Kleinschmidt S, Seyfert UT "Heparin-associated thrombocytopenia (HAT) - still a diagnostic and therapeutical problem in clinical practice." Angiology 46 (1995):  37-44|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG "Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin." N Engl J Med 332 (1995):  1330-5|Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Anguenot T, Bernard Y, Bassand JP "Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia." Am J Hematol 50 (1995):  20-5|Shumate MJ "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1006-7|Hougardy N, Machiels JP, Ravoet C "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Warkentin TE, Hirsh J, Kelton JG "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Ramakrishna R, Manoharan A, Kwan YL, Kyle PW "Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (fragmin) and heparinoid, danaparoid (orgaran)." Br J Haematol 91 (1995):  736-8|Force RW "Heparin-induced thrombocytopenia." Am J Health Syst Pharm 52 (1995):  2528|Luzzatto G, Cordiano I, Patrassi G, Fabris F "Heparin-induced thrombocytopenia: discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use." Thromb Haemost 75 (1996):  211-2|Peters FPJ, Doevendans PAFM, Erdkamp FLG, Vanderent FWC, Deheer F "Low molecular weight heparin-induced thrombocytopenia and thrombosis." Eur J Haematol 56 (1996):  329-30|Slocum MM, Adams JG, Teel R, Spadone DP, Silver D "Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome." J Vasc Surg 23 (1996):  839-43|Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T "Heparin-induced thrombocytopenia in hemodialysis patients." Am J Kidney Dis 28 (1996):  82-5|Rizzieri DA, Wong WM, Gockerman JP "Thrombocytosis associated with low-molecular-weight heparin." Ann Intern Med 125 (1996):  157|Chong BH, Magnani HN "Orgaran in heparin-induced thrombocytopenia." Haemostasis 22 (1992):  85-91|Magnani HN "Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172) [published erratum appears in Thromb Haemost 1993 Dec 20;70(6):1072]." Thromb Haemost 70 (1993):  554-61|Rice P, Dace S, Mcmullin MF, Clements WDB "Heparin induced thrombocytopenia causing life-threatening postoperative haemorrhage." Br J Clin Pract 50 (1996):  404-5|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48993, 16507, 'Enoxaparin', 'Thrombocytopenia', 'The use of heparin is contraindicated in patients with severe thrombocytopenia.  Acute thrombocytopenia can occur in patients receiving heparin, with a reported incidence of up to 30%.  Platelet counts should be obtained before and periodically during heparin administration, including regular and repeated use of heparin flush solutions if given for longer than 5 days.  Mild thrombocytopenia with counts above 100,000/mm3 may remain stable or reverse despite continued heparin administration.  However, thrombocytopenia of any degree should be closely monitored.  Therapy should be discontinued if the count falls below 100,000/mm3 or if recurrent thrombosis develops, and an alternative, nonheparin anticoagulant (e.g., argatroban, bivalirudin, lepirudin) administered if necessary.  Heparin-induced thrombocytopenia (HIT) is a serious antibody-mediated reaction resulting from irreversible aggregation of platelets.  HIT may progress to the development of venous and arterial thromboses, a condition referred to as heparin-induced thrombocytopenia and thrombosis (HITT).  Thrombotic events may also be the initial presentation for HITT, and may include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, mesenteric thrombosis, renal artery thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death.  Both HIT and HITT can occur up to several weeks after the discontinuation of heparin therapy.  Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT.  Following an episode, any future use of heparin should be avoided, and use of low-molecular weight heparin should consider the potential for cross-reactivity with the HIT antibody and approached with extreme caution, if not otherwise contraindicated.', '3', 'Bell WR, Royall RM "Heparin-associated thrombocytopenia: a comparison of three heparin preparations." N Engl J Med 303 (1980):  902-7|Cines DB, Kaywin P, Bina M, et al. "Heparin-associated thrombocytopenia." N Engl J Med 303 (1980):  788-95|Kelton JG, Sheridan D, Santos A, et al. "Heparin-induced thrombocytopenia: laboratory studies." Blood 72 (1988):  925-30|Chong BH "Heparin-induced thrombocytopenia." Aust N Z J Med 22 (1992):  145-52|Warkentin TE, Hayward CP, Smith CA, et al. "Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia." J Lab Clin Med 120 (1992):  371-9|Bleasel JF, Rasko JE, Rickard KA, Richards G "Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome." Med J Aust 157 (1992):  192-3|Sandler RM, Seifer DB, Morgan K, Pockros PJ, Wypych J, Weiss LM, Schiffman S "Heparin-induced thrombocytopenia and thrombosis: detection and specificity of a platelet-aggregating IgG." Am J Clin Pathol 83 (1985):  760-4|Platell CF, Tan EG "Hypersensitivity reactions to heparin: delayed onset thrombocytopenia and necrotizing skin lesions." Aust N Z J Surg 56 (1986):  621-3|Gruel Y, Lang M, Darnige L, Pacouret G, Dreyfus X, Leroy J, Charbonnier B "Fatal effect of re-exposure to heparin after previous heparin- associated thrombocytopenia and thrombosis ." Lancet 336 (1990):  1077-8|Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A "Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia." Eur J Clin Pharmacol 37 (1989):  415-8|Lecompte T, Luo SK, Stieltjes N, Lecrubier C, et al. "Thrombocytopenia associated with low-molecular-weight heparin." Lancet 338 (1991):  1217|Eichinger S, Kyrle PA, Brenner B, Wagner B, Kapiotis S, Lechner K, Korninger HC "Thrombocytopenia associated with low-molecular-weight heparin" Lancet 337 (1991):  1425-6|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|Kikta MJ, Keller MP, Humphrey PW, Silver D, Towne JB, Tsapogas M "Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?" Surgery 114 (1993):  705-10|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Balestra B, Quadri P, Biasiutti FD, Furlan M, Lammle B "Low molecular weight heparin-induced thrombocytopenia and skin necrosis distant from injection sites." Eur J Haematol 53 (1994):  61-3|Tezcan AZ, Tezcan H, Gastineau DA, Armitage JO, Haire WD "Heparin-induced thrombocytopenia after bone marrow transplantation: report of two cases." Bone Marrow Transplant 14 (1994):  487-90|Munver R, Schulman IC, Wolf DJ, Rosengart TK "Heparin-induced thrombocytopenia and thrombosis: presentation after cardiopulmonary bypass." Ann Thorac Surg 58 (1994):  1764-6|Kleinschmidt S, Seyfert UT "Heparin-associated thrombocytopenia (HAT) - still a diagnostic and therapeutical problem in clinical practice." Angiology 46 (1995):  37-44|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG "Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin." N Engl J Med 332 (1995):  1330-5|Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Anguenot T, Bernard Y, Bassand JP "Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia." Am J Hematol 50 (1995):  20-5|Shumate MJ "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1006-7|Hougardy N, Machiels JP, Ravoet C "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Warkentin TE, Hirsh J, Kelton JG "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Ramakrishna R, Manoharan A, Kwan YL, Kyle PW "Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (fragmin) and heparinoid, danaparoid (orgaran)." Br J Haematol 91 (1995):  736-8|Force RW "Heparin-induced thrombocytopenia." Am J Health Syst Pharm 52 (1995):  2528|Luzzatto G, Cordiano I, Patrassi G, Fabris F "Heparin-induced thrombocytopenia: discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use." Thromb Haemost 75 (1996):  211-2|Peters FPJ, Doevendans PAFM, Erdkamp FLG, Vanderent FWC, Deheer F "Low molecular weight heparin-induced thrombocytopenia and thrombosis." Eur J Haematol 56 (1996):  329-30|Slocum MM, Adams JG, Teel R, Spadone DP, Silver D "Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome." J Vasc Surg 23 (1996):  839-43|Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T "Heparin-induced thrombocytopenia in hemodialysis patients." Am J Kidney Dis 28 (1996):  82-5|Rizzieri DA, Wong WM, Gockerman JP "Thrombocytosis associated with low-molecular-weight heparin." Ann Intern Med 125 (1996):  157|Chong BH, Magnani HN "Orgaran in heparin-induced thrombocytopenia." Haemostasis 22 (1992):  85-91|Magnani HN "Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172) [published erratum appears in Thromb Haemost 1993 Dec 20;70(6):1072]." Thromb Haemost 70 (1993):  554-61|Rice P, Dace S, Mcmullin MF, Clements WDB "Heparin induced thrombocytopenia causing life-threatening postoperative haemorrhage." Br J Clin Pract 50 (1996):  404-5|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48994, 19551, 'Enoxaparin', 'Thrombocytopenia', 'The use of heparin is contraindicated in patients with severe thrombocytopenia.  Acute thrombocytopenia can occur in patients receiving heparin, with a reported incidence of up to 30%.  Platelet counts should be obtained before and periodically during heparin administration, including regular and repeated use of heparin flush solutions if given for longer than 5 days.  Mild thrombocytopenia with counts above 100,000/mm3 may remain stable or reverse despite continued heparin administration.  However, thrombocytopenia of any degree should be closely monitored.  Therapy should be discontinued if the count falls below 100,000/mm3 or if recurrent thrombosis develops, and an alternative, nonheparin anticoagulant (e.g., argatroban, bivalirudin, lepirudin) administered if necessary.  Heparin-induced thrombocytopenia (HIT) is a serious antibody-mediated reaction resulting from irreversible aggregation of platelets.  HIT may progress to the development of venous and arterial thromboses, a condition referred to as heparin-induced thrombocytopenia and thrombosis (HITT).  Thrombotic events may also be the initial presentation for HITT, and may include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, mesenteric thrombosis, renal artery thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death.  Both HIT and HITT can occur up to several weeks after the discontinuation of heparin therapy.  Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT.  Following an episode, any future use of heparin should be avoided, and use of low-molecular weight heparin should consider the potential for cross-reactivity with the HIT antibody and approached with extreme caution, if not otherwise contraindicated.', '3', 'Bell WR, Royall RM "Heparin-associated thrombocytopenia: a comparison of three heparin preparations." N Engl J Med 303 (1980):  902-7|Cines DB, Kaywin P, Bina M, et al. "Heparin-associated thrombocytopenia." N Engl J Med 303 (1980):  788-95|Kelton JG, Sheridan D, Santos A, et al. "Heparin-induced thrombocytopenia: laboratory studies." Blood 72 (1988):  925-30|Chong BH "Heparin-induced thrombocytopenia." Aust N Z J Med 22 (1992):  145-52|Warkentin TE, Hayward CP, Smith CA, et al. "Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia." J Lab Clin Med 120 (1992):  371-9|Bleasel JF, Rasko JE, Rickard KA, Richards G "Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome." Med J Aust 157 (1992):  192-3|Sandler RM, Seifer DB, Morgan K, Pockros PJ, Wypych J, Weiss LM, Schiffman S "Heparin-induced thrombocytopenia and thrombosis: detection and specificity of a platelet-aggregating IgG." Am J Clin Pathol 83 (1985):  760-4|Platell CF, Tan EG "Hypersensitivity reactions to heparin: delayed onset thrombocytopenia and necrotizing skin lesions." Aust N Z J Surg 56 (1986):  621-3|Gruel Y, Lang M, Darnige L, Pacouret G, Dreyfus X, Leroy J, Charbonnier B "Fatal effect of re-exposure to heparin after previous heparin- associated thrombocytopenia and thrombosis ." Lancet 336 (1990):  1077-8|Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A "Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia." Eur J Clin Pharmacol 37 (1989):  415-8|Lecompte T, Luo SK, Stieltjes N, Lecrubier C, et al. "Thrombocytopenia associated with low-molecular-weight heparin." Lancet 338 (1991):  1217|Eichinger S, Kyrle PA, Brenner B, Wagner B, Kapiotis S, Lechner K, Korninger HC "Thrombocytopenia associated with low-molecular-weight heparin" Lancet 337 (1991):  1425-6|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|Kikta MJ, Keller MP, Humphrey PW, Silver D, Towne JB, Tsapogas M "Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?" Surgery 114 (1993):  705-10|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Balestra B, Quadri P, Biasiutti FD, Furlan M, Lammle B "Low molecular weight heparin-induced thrombocytopenia and skin necrosis distant from injection sites." Eur J Haematol 53 (1994):  61-3|Tezcan AZ, Tezcan H, Gastineau DA, Armitage JO, Haire WD "Heparin-induced thrombocytopenia after bone marrow transplantation: report of two cases." Bone Marrow Transplant 14 (1994):  487-90|Munver R, Schulman IC, Wolf DJ, Rosengart TK "Heparin-induced thrombocytopenia and thrombosis: presentation after cardiopulmonary bypass." Ann Thorac Surg 58 (1994):  1764-6|Kleinschmidt S, Seyfert UT "Heparin-associated thrombocytopenia (HAT) - still a diagnostic and therapeutical problem in clinical practice." Angiology 46 (1995):  37-44|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG "Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin." N Engl J Med 332 (1995):  1330-5|Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Anguenot T, Bernard Y, Bassand JP "Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia." Am J Hematol 50 (1995):  20-5|Shumate MJ "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1006-7|Hougardy N, Machiels JP, Ravoet C "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Warkentin TE, Hirsh J, Kelton JG "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Ramakrishna R, Manoharan A, Kwan YL, Kyle PW "Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (fragmin) and heparinoid, danaparoid (orgaran)." Br J Haematol 91 (1995):  736-8|Force RW "Heparin-induced thrombocytopenia." Am J Health Syst Pharm 52 (1995):  2528|Luzzatto G, Cordiano I, Patrassi G, Fabris F "Heparin-induced thrombocytopenia: discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use." Thromb Haemost 75 (1996):  211-2|Peters FPJ, Doevendans PAFM, Erdkamp FLG, Vanderent FWC, Deheer F "Low molecular weight heparin-induced thrombocytopenia and thrombosis." Eur J Haematol 56 (1996):  329-30|Slocum MM, Adams JG, Teel R, Spadone DP, Silver D "Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome." J Vasc Surg 23 (1996):  839-43|Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T "Heparin-induced thrombocytopenia in hemodialysis patients." Am J Kidney Dis 28 (1996):  82-5|Rizzieri DA, Wong WM, Gockerman JP "Thrombocytosis associated with low-molecular-weight heparin." Ann Intern Med 125 (1996):  157|Chong BH, Magnani HN "Orgaran in heparin-induced thrombocytopenia." Haemostasis 22 (1992):  85-91|Magnani HN "Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172) [published erratum appears in Thromb Haemost 1993 Dec 20;70(6):1072]." Thromb Haemost 70 (1993):  554-61|Rice P, Dace S, Mcmullin MF, Clements WDB "Heparin induced thrombocytopenia causing life-threatening postoperative haemorrhage." Br J Clin Pract 50 (1996):  404-5|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48995, 22078, 'Enoxaparin', 'Thrombocytopenia', 'The use of heparin is contraindicated in patients with severe thrombocytopenia.  Acute thrombocytopenia can occur in patients receiving heparin, with a reported incidence of up to 30%.  Platelet counts should be obtained before and periodically during heparin administration, including regular and repeated use of heparin flush solutions if given for longer than 5 days.  Mild thrombocytopenia with counts above 100,000/mm3 may remain stable or reverse despite continued heparin administration.  However, thrombocytopenia of any degree should be closely monitored.  Therapy should be discontinued if the count falls below 100,000/mm3 or if recurrent thrombosis develops, and an alternative, nonheparin anticoagulant (e.g., argatroban, bivalirudin, lepirudin) administered if necessary.  Heparin-induced thrombocytopenia (HIT) is a serious antibody-mediated reaction resulting from irreversible aggregation of platelets.  HIT may progress to the development of venous and arterial thromboses, a condition referred to as heparin-induced thrombocytopenia and thrombosis (HITT).  Thrombotic events may also be the initial presentation for HITT, and may include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, mesenteric thrombosis, renal artery thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death.  Both HIT and HITT can occur up to several weeks after the discontinuation of heparin therapy.  Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT.  Following an episode, any future use of heparin should be avoided, and use of low-molecular weight heparin should consider the potential for cross-reactivity with the HIT antibody and approached with extreme caution, if not otherwise contraindicated.', '3', 'Bell WR, Royall RM "Heparin-associated thrombocytopenia: a comparison of three heparin preparations." N Engl J Med 303 (1980):  902-7|Cines DB, Kaywin P, Bina M, et al. "Heparin-associated thrombocytopenia." N Engl J Med 303 (1980):  788-95|Kelton JG, Sheridan D, Santos A, et al. "Heparin-induced thrombocytopenia: laboratory studies." Blood 72 (1988):  925-30|Chong BH "Heparin-induced thrombocytopenia." Aust N Z J Med 22 (1992):  145-52|Warkentin TE, Hayward CP, Smith CA, et al. "Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia." J Lab Clin Med 120 (1992):  371-9|Bleasel JF, Rasko JE, Rickard KA, Richards G "Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome." Med J Aust 157 (1992):  192-3|Sandler RM, Seifer DB, Morgan K, Pockros PJ, Wypych J, Weiss LM, Schiffman S "Heparin-induced thrombocytopenia and thrombosis: detection and specificity of a platelet-aggregating IgG." Am J Clin Pathol 83 (1985):  760-4|Platell CF, Tan EG "Hypersensitivity reactions to heparin: delayed onset thrombocytopenia and necrotizing skin lesions." Aust N Z J Surg 56 (1986):  621-3|Gruel Y, Lang M, Darnige L, Pacouret G, Dreyfus X, Leroy J, Charbonnier B "Fatal effect of re-exposure to heparin after previous heparin- associated thrombocytopenia and thrombosis ." Lancet 336 (1990):  1077-8|Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A "Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia." Eur J Clin Pharmacol 37 (1989):  415-8|Lecompte T, Luo SK, Stieltjes N, Lecrubier C, et al. "Thrombocytopenia associated with low-molecular-weight heparin." Lancet 338 (1991):  1217|Eichinger S, Kyrle PA, Brenner B, Wagner B, Kapiotis S, Lechner K, Korninger HC "Thrombocytopenia associated with low-molecular-weight heparin" Lancet 337 (1991):  1425-6|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|Kikta MJ, Keller MP, Humphrey PW, Silver D, Towne JB, Tsapogas M "Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?" Surgery 114 (1993):  705-10|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Balestra B, Quadri P, Biasiutti FD, Furlan M, Lammle B "Low molecular weight heparin-induced thrombocytopenia and skin necrosis distant from injection sites." Eur J Haematol 53 (1994):  61-3|Tezcan AZ, Tezcan H, Gastineau DA, Armitage JO, Haire WD "Heparin-induced thrombocytopenia after bone marrow transplantation: report of two cases." Bone Marrow Transplant 14 (1994):  487-90|Munver R, Schulman IC, Wolf DJ, Rosengart TK "Heparin-induced thrombocytopenia and thrombosis: presentation after cardiopulmonary bypass." Ann Thorac Surg 58 (1994):  1764-6|Kleinschmidt S, Seyfert UT "Heparin-associated thrombocytopenia (HAT) - still a diagnostic and therapeutical problem in clinical practice." Angiology 46 (1995):  37-44|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG "Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin." N Engl J Med 332 (1995):  1330-5|Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Anguenot T, Bernard Y, Bassand JP "Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia." Am J Hematol 50 (1995):  20-5|Shumate MJ "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1006-7|Hougardy N, Machiels JP, Ravoet C "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Warkentin TE, Hirsh J, Kelton JG "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Ramakrishna R, Manoharan A, Kwan YL, Kyle PW "Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (fragmin) and heparinoid, danaparoid (orgaran)." Br J Haematol 91 (1995):  736-8|Force RW "Heparin-induced thrombocytopenia." Am J Health Syst Pharm 52 (1995):  2528|Luzzatto G, Cordiano I, Patrassi G, Fabris F "Heparin-induced thrombocytopenia: discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use." Thromb Haemost 75 (1996):  211-2|Peters FPJ, Doevendans PAFM, Erdkamp FLG, Vanderent FWC, Deheer F "Low molecular weight heparin-induced thrombocytopenia and thrombosis." Eur J Haematol 56 (1996):  329-30|Slocum MM, Adams JG, Teel R, Spadone DP, Silver D "Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome." J Vasc Surg 23 (1996):  839-43|Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T "Heparin-induced thrombocytopenia in hemodialysis patients." Am J Kidney Dis 28 (1996):  82-5|Rizzieri DA, Wong WM, Gockerman JP "Thrombocytosis associated with low-molecular-weight heparin." Ann Intern Med 125 (1996):  157|Chong BH, Magnani HN "Orgaran in heparin-induced thrombocytopenia." Haemostasis 22 (1992):  85-91|Magnani HN "Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172) [published erratum appears in Thromb Haemost 1993 Dec 20;70(6):1072]." Thromb Haemost 70 (1993):  554-61|Rice P, Dace S, Mcmullin MF, Clements WDB "Heparin induced thrombocytopenia causing life-threatening postoperative haemorrhage." Br J Clin Pract 50 (1996):  404-5|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48996, 30506, 'Enoxaparin', 'Thrombocytopenia', 'The use of heparin is contraindicated in patients with severe thrombocytopenia.  Acute thrombocytopenia can occur in patients receiving heparin, with a reported incidence of up to 30%.  Platelet counts should be obtained before and periodically during heparin administration, including regular and repeated use of heparin flush solutions if given for longer than 5 days.  Mild thrombocytopenia with counts above 100,000/mm3 may remain stable or reverse despite continued heparin administration.  However, thrombocytopenia of any degree should be closely monitored.  Therapy should be discontinued if the count falls below 100,000/mm3 or if recurrent thrombosis develops, and an alternative, nonheparin anticoagulant (e.g., argatroban, bivalirudin, lepirudin) administered if necessary.  Heparin-induced thrombocytopenia (HIT) is a serious antibody-mediated reaction resulting from irreversible aggregation of platelets.  HIT may progress to the development of venous and arterial thromboses, a condition referred to as heparin-induced thrombocytopenia and thrombosis (HITT).  Thrombotic events may also be the initial presentation for HITT, and may include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, mesenteric thrombosis, renal artery thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death.  Both HIT and HITT can occur up to several weeks after the discontinuation of heparin therapy.  Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT.  Following an episode, any future use of heparin should be avoided, and use of low-molecular weight heparin should consider the potential for cross-reactivity with the HIT antibody and approached with extreme caution, if not otherwise contraindicated.', '3', 'Bell WR, Royall RM "Heparin-associated thrombocytopenia: a comparison of three heparin preparations." N Engl J Med 303 (1980):  902-7|Cines DB, Kaywin P, Bina M, et al. "Heparin-associated thrombocytopenia." N Engl J Med 303 (1980):  788-95|Kelton JG, Sheridan D, Santos A, et al. "Heparin-induced thrombocytopenia: laboratory studies." Blood 72 (1988):  925-30|Chong BH "Heparin-induced thrombocytopenia." Aust N Z J Med 22 (1992):  145-52|Warkentin TE, Hayward CP, Smith CA, et al. "Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia." J Lab Clin Med 120 (1992):  371-9|Bleasel JF, Rasko JE, Rickard KA, Richards G "Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome." Med J Aust 157 (1992):  192-3|Sandler RM, Seifer DB, Morgan K, Pockros PJ, Wypych J, Weiss LM, Schiffman S "Heparin-induced thrombocytopenia and thrombosis: detection and specificity of a platelet-aggregating IgG." Am J Clin Pathol 83 (1985):  760-4|Platell CF, Tan EG "Hypersensitivity reactions to heparin: delayed onset thrombocytopenia and necrotizing skin lesions." Aust N Z J Surg 56 (1986):  621-3|Gruel Y, Lang M, Darnige L, Pacouret G, Dreyfus X, Leroy J, Charbonnier B "Fatal effect of re-exposure to heparin after previous heparin- associated thrombocytopenia and thrombosis ." Lancet 336 (1990):  1077-8|Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A "Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia." Eur J Clin Pharmacol 37 (1989):  415-8|Lecompte T, Luo SK, Stieltjes N, Lecrubier C, et al. "Thrombocytopenia associated with low-molecular-weight heparin." Lancet 338 (1991):  1217|Eichinger S, Kyrle PA, Brenner B, Wagner B, Kapiotis S, Lechner K, Korninger HC "Thrombocytopenia associated with low-molecular-weight heparin" Lancet 337 (1991):  1425-6|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|Kikta MJ, Keller MP, Humphrey PW, Silver D, Towne JB, Tsapogas M "Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?" Surgery 114 (1993):  705-10|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Balestra B, Quadri P, Biasiutti FD, Furlan M, Lammle B "Low molecular weight heparin-induced thrombocytopenia and skin necrosis distant from injection sites." Eur J Haematol 53 (1994):  61-3|Tezcan AZ, Tezcan H, Gastineau DA, Armitage JO, Haire WD "Heparin-induced thrombocytopenia after bone marrow transplantation: report of two cases." Bone Marrow Transplant 14 (1994):  487-90|Munver R, Schulman IC, Wolf DJ, Rosengart TK "Heparin-induced thrombocytopenia and thrombosis: presentation after cardiopulmonary bypass." Ann Thorac Surg 58 (1994):  1764-6|Kleinschmidt S, Seyfert UT "Heparin-associated thrombocytopenia (HAT) - still a diagnostic and therapeutical problem in clinical practice." Angiology 46 (1995):  37-44|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG "Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin." N Engl J Med 332 (1995):  1330-5|Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Anguenot T, Bernard Y, Bassand JP "Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia." Am J Hematol 50 (1995):  20-5|Shumate MJ "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1006-7|Hougardy N, Machiels JP, Ravoet C "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Warkentin TE, Hirsh J, Kelton JG "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Ramakrishna R, Manoharan A, Kwan YL, Kyle PW "Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (fragmin) and heparinoid, danaparoid (orgaran)." Br J Haematol 91 (1995):  736-8|Force RW "Heparin-induced thrombocytopenia." Am J Health Syst Pharm 52 (1995):  2528|Luzzatto G, Cordiano I, Patrassi G, Fabris F "Heparin-induced thrombocytopenia: discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use." Thromb Haemost 75 (1996):  211-2|Peters FPJ, Doevendans PAFM, Erdkamp FLG, Vanderent FWC, Deheer F "Low molecular weight heparin-induced thrombocytopenia and thrombosis." Eur J Haematol 56 (1996):  329-30|Slocum MM, Adams JG, Teel R, Spadone DP, Silver D "Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome." J Vasc Surg 23 (1996):  839-43|Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T "Heparin-induced thrombocytopenia in hemodialysis patients." Am J Kidney Dis 28 (1996):  82-5|Rizzieri DA, Wong WM, Gockerman JP "Thrombocytosis associated with low-molecular-weight heparin." Ann Intern Med 125 (1996):  157|Chong BH, Magnani HN "Orgaran in heparin-induced thrombocytopenia." Haemostasis 22 (1992):  85-91|Magnani HN "Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172) [published erratum appears in Thromb Haemost 1993 Dec 20;70(6):1072]." Thromb Haemost 70 (1993):  554-61|Rice P, Dace S, Mcmullin MF, Clements WDB "Heparin induced thrombocytopenia causing life-threatening postoperative haemorrhage." Br J Clin Pract 50 (1996):  404-5|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48997, 31856, 'Enoxaparin', 'Thrombocytopenia', 'The use of heparin is contraindicated in patients with severe thrombocytopenia.  Acute thrombocytopenia can occur in patients receiving heparin, with a reported incidence of up to 30%.  Platelet counts should be obtained before and periodically during heparin administration, including regular and repeated use of heparin flush solutions if given for longer than 5 days.  Mild thrombocytopenia with counts above 100,000/mm3 may remain stable or reverse despite continued heparin administration.  However, thrombocytopenia of any degree should be closely monitored.  Therapy should be discontinued if the count falls below 100,000/mm3 or if recurrent thrombosis develops, and an alternative, nonheparin anticoagulant (e.g., argatroban, bivalirudin, lepirudin) administered if necessary.  Heparin-induced thrombocytopenia (HIT) is a serious antibody-mediated reaction resulting from irreversible aggregation of platelets.  HIT may progress to the development of venous and arterial thromboses, a condition referred to as heparin-induced thrombocytopenia and thrombosis (HITT).  Thrombotic events may also be the initial presentation for HITT, and may include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, mesenteric thrombosis, renal artery thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death.  Both HIT and HITT can occur up to several weeks after the discontinuation of heparin therapy.  Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT.  Following an episode, any future use of heparin should be avoided, and use of low-molecular weight heparin should consider the potential for cross-reactivity with the HIT antibody and approached with extreme caution, if not otherwise contraindicated.', '3', 'Bell WR, Royall RM "Heparin-associated thrombocytopenia: a comparison of three heparin preparations." N Engl J Med 303 (1980):  902-7|Cines DB, Kaywin P, Bina M, et al. "Heparin-associated thrombocytopenia." N Engl J Med 303 (1980):  788-95|Kelton JG, Sheridan D, Santos A, et al. "Heparin-induced thrombocytopenia: laboratory studies." Blood 72 (1988):  925-30|Chong BH "Heparin-induced thrombocytopenia." Aust N Z J Med 22 (1992):  145-52|Warkentin TE, Hayward CP, Smith CA, et al. "Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia." J Lab Clin Med 120 (1992):  371-9|Bleasel JF, Rasko JE, Rickard KA, Richards G "Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome." Med J Aust 157 (1992):  192-3|Sandler RM, Seifer DB, Morgan K, Pockros PJ, Wypych J, Weiss LM, Schiffman S "Heparin-induced thrombocytopenia and thrombosis: detection and specificity of a platelet-aggregating IgG." Am J Clin Pathol 83 (1985):  760-4|Platell CF, Tan EG "Hypersensitivity reactions to heparin: delayed onset thrombocytopenia and necrotizing skin lesions." Aust N Z J Surg 56 (1986):  621-3|Gruel Y, Lang M, Darnige L, Pacouret G, Dreyfus X, Leroy J, Charbonnier B "Fatal effect of re-exposure to heparin after previous heparin- associated thrombocytopenia and thrombosis ." Lancet 336 (1990):  1077-8|Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A "Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia." Eur J Clin Pharmacol 37 (1989):  415-8|Lecompte T, Luo SK, Stieltjes N, Lecrubier C, et al. "Thrombocytopenia associated with low-molecular-weight heparin." Lancet 338 (1991):  1217|Eichinger S, Kyrle PA, Brenner B, Wagner B, Kapiotis S, Lechner K, Korninger HC "Thrombocytopenia associated with low-molecular-weight heparin" Lancet 337 (1991):  1425-6|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|Kikta MJ, Keller MP, Humphrey PW, Silver D, Towne JB, Tsapogas M "Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?" Surgery 114 (1993):  705-10|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Balestra B, Quadri P, Biasiutti FD, Furlan M, Lammle B "Low molecular weight heparin-induced thrombocytopenia and skin necrosis distant from injection sites." Eur J Haematol 53 (1994):  61-3|Tezcan AZ, Tezcan H, Gastineau DA, Armitage JO, Haire WD "Heparin-induced thrombocytopenia after bone marrow transplantation: report of two cases." Bone Marrow Transplant 14 (1994):  487-90|Munver R, Schulman IC, Wolf DJ, Rosengart TK "Heparin-induced thrombocytopenia and thrombosis: presentation after cardiopulmonary bypass." Ann Thorac Surg 58 (1994):  1764-6|Kleinschmidt S, Seyfert UT "Heparin-associated thrombocytopenia (HAT) - still a diagnostic and therapeutical problem in clinical practice." Angiology 46 (1995):  37-44|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG "Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin." N Engl J Med 332 (1995):  1330-5|Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Anguenot T, Bernard Y, Bassand JP "Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia." Am J Hematol 50 (1995):  20-5|Shumate MJ "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1006-7|Hougardy N, Machiels JP, Ravoet C "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Warkentin TE, Hirsh J, Kelton JG "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Ramakrishna R, Manoharan A, Kwan YL, Kyle PW "Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (fragmin) and heparinoid, danaparoid (orgaran)." Br J Haematol 91 (1995):  736-8|Force RW "Heparin-induced thrombocytopenia." Am J Health Syst Pharm 52 (1995):  2528|Luzzatto G, Cordiano I, Patrassi G, Fabris F "Heparin-induced thrombocytopenia: discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use." Thromb Haemost 75 (1996):  211-2|Peters FPJ, Doevendans PAFM, Erdkamp FLG, Vanderent FWC, Deheer F "Low molecular weight heparin-induced thrombocytopenia and thrombosis." Eur J Haematol 56 (1996):  329-30|Slocum MM, Adams JG, Teel R, Spadone DP, Silver D "Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome." J Vasc Surg 23 (1996):  839-43|Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T "Heparin-induced thrombocytopenia in hemodialysis patients." Am J Kidney Dis 28 (1996):  82-5|Rizzieri DA, Wong WM, Gockerman JP "Thrombocytosis associated with low-molecular-weight heparin." Ann Intern Med 125 (1996):  157|Chong BH, Magnani HN "Orgaran in heparin-induced thrombocytopenia." Haemostasis 22 (1992):  85-91|Magnani HN "Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172) [published erratum appears in Thromb Haemost 1993 Dec 20;70(6):1072]." Thromb Haemost 70 (1993):  554-61|Rice P, Dace S, Mcmullin MF, Clements WDB "Heparin induced thrombocytopenia causing life-threatening postoperative haemorrhage." Br J Clin Pract 50 (1996):  404-5|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48998, 352, 'Enoxaparin', 'Premature Birth', 'Some preparations (i.e., multiple-dose vials) of low molecular weight heparin (LMWH) contain benzyl alcohol as a preservative.  Benzyl alcohol in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions has been associated with fatalities and severe respiratory and metabolic complications in low-birthweight premature infants.  Symptoms include a striking onset of gasping respiration, hypotension, bradycardia, and cardiovascular collapse.  The manufacturers recommend that use of these products be avoided in all neonates whenever possible.  Nevertheless, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  LMWHs are not approved for use in pediatric patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (48999, 2752, 'Enoxaparin', 'Premature Birth', 'Some preparations (i.e., multiple-dose vials) of low molecular weight heparin (LMWH) contain benzyl alcohol as a preservative.  Benzyl alcohol in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions has been associated with fatalities and severe respiratory and metabolic complications in low-birthweight premature infants.  Symptoms include a striking onset of gasping respiration, hypotension, bradycardia, and cardiovascular collapse.  The manufacturers recommend that use of these products be avoided in all neonates whenever possible.  Nevertheless, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  LMWHs are not approved for use in pediatric patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (49000, 7580, 'Enoxaparin', 'Premature Birth', 'Some preparations (i.e., multiple-dose vials) of low molecular weight heparin (LMWH) contain benzyl alcohol as a preservative.  Benzyl alcohol in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions has been associated with fatalities and severe respiratory and metabolic complications in low-birthweight premature infants.  Symptoms include a striking onset of gasping respiration, hypotension, bradycardia, and cardiovascular collapse.  The manufacturers recommend that use of these products be avoided in all neonates whenever possible.  Nevertheless, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  LMWHs are not approved for use in pediatric patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);